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Karen Sagomonyants, D.M.D.

University of Connecticut, 2014

Odontoblast differentiation and reparative dentinogenesis are dependent on multiple signaling
molecules, including members of Fibroblast Growth Factor (FGF) family. Previous studies have
demonstrated both positive and negative effects of FGFs on odontoblast differentiation in dental
pulp. However, the underlying cellular and molecular mechanisms of these opposite effects are
unclear. Therefore, the overall goal of the studies outlined in this dissertation was to gain insight

into the cellular and molecular mechanisms of the effects of FGF signaling on mineralization and
dentinogenesis of pulp cells. To approach this goal, we used dental pulp cultures derived from the
coronal portion of unerupted molars from various transgenic mice, which display stage-specific
activation of transgenes during odontoblast differentiation. Our observations showed that exposure of
progenitors and cells at early stages of odontoblast differentiation stimulated/accelerated their
differentiation into functional odontoblasts, expressing high levels of Dmp1 and DMP1-GFP, and
low levels of Dspp and DSPP-Cerulean. Additional exposure maintained cells as functional
odontoblasts and prevented their differentiation into mature odontoblasts, expressing high levels of
Dspp and DSPP-Cerulean and producing mineralized matrix. Withdrawal of FGF2 resulted in

Karen Sagomonyants, University of Connecticut, 2014

complete recovery of mineralization and differentiation of functional odontoblasts into mature
odontoblasts. Analysis of FACS-sorted 2.3-GFP– (progenitors) and 2.3-GFP+ (cells at early stages of
differentiation) cells confirmed that FGF2 stimulated/accelerated their differentiation into functional
odontoblasts, while prevented their differentiation into fully differentiated odontoblasts. Finally, our
results showed that stimulatory effects of FGF2 were mediated by activation of the FGFR,
MEK/Erk1/2 and BMP/BMPR signaling pathways, whereas inhibitory effects were mediated by reactivation of the FGFR and MEK/Erk1/2 pathways with negative roles in odontoblast differentiation.
Taken together, our results demonstrated the stage-specificity of the effects of FGF2 on odontoblast
differentiation, suggesting that FGF2 is a viable growth factor for dentin regeneration.
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CHAPTER I

INTRODUCTION.
Tooth Development and Odontoblast Differentiation.

Odontoblast differentiation during in vivo tooth development is a complex and multistep
process, involving epithelial-mesenchymal interactions (1-5). During early stages of
dentinogenesis, cells originating from the neural crest migrate toward the paraxial mesenchyme
of the first branchial arch, where they contribute to the formation of tooth buds. These neural
crest-derived dental papilla cells receive signals from dental epithelium and become
preodontoblasts. Preodontoblasts undergo the minimum number of cell cycles before they
become competent to respond to external stimuli, such as growth factors. This allows
preodontoblasts to reach the periphery of the dental pulp, where they are located roughly parallel
to the basement membrane. The final mitosis is asymmetric and occurs perpendicularly to the
basement membrane, resulting in generation of two daughter cells. The one adjacent to the
basement membrane receives inductive signals to differentiate into more mature odontoblasts,
whereas the other cell stays underneath this layer and remains undifferentiated. This latter
daughter cell forms subodontoblastic layer of Höhl, which serves as a reservoir of cells with
dentinogenic potential and is thought to play an important role during reparative dentinogenesis
(6-9).
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In contrast, the daughter cells in contact with the basement membrane stop proliferating
and undergo specific morphological changes upon receiving the inductive signals (10, 11). These
cells are called polarizing odontoblasts. In addition to morphological changes, these cells
undergo functional changes, as they are the first cells within the odontoblast lineage to secrete
Type I collagen (as well as Types V and VI collagen), a major component of unmineralized
predentin (10). In vivo studies demonstrated that the process of secretion of Type I collagen is
intense, as injection of 3H-thymidine-labeled proline resulted in its extensive appearance in
predentin after 1-6 hrs (12, 13).

During

further

differentiation,

polarizing

odontoblasts

differentiate

into

functional/secretory odontoblasts, which in addition to Type I collagen start secreting various
non-collagenous components of unmineralized predentin, including members of the SIBLING
family, such as BSP, DMP1 and DSPP (will be discussed below). Functional odontoblasts
eventually become fully differentiated/mature odontoblasts secreting mineralized dentin matrix
(9, 11, 14).

In the teeth, odontoblasts form a layer of cells on the periphery of the pulp and a cell
process extending into the dentin. The number of dentinal tubules corresponds to the number of
odontoblasts, and is estimated to be in the range of 60.000-75.000/mm2 in coronal dentin and
20.000-30.000/mm2 in root dentin. In addition, odontoblasts in the crown are larger and
columnar, whereas they become smaller and flatter towards the root (11, 15). Since mature
odontoblasts are postmitotic cells, their life span is believed to be equal to that of the tooth (15).
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Dentin is defined as a mineralized tissue resulting from the formation of a specific
extracellular matrix (ECM) by the highly polarized postmitotic odontoblasts located at the
periphery of the dental pulp (16). Dentin is first deposited as a layer of unmineralized matrix
called predentin, which lines its innermost (pulpal) portion. Predentin is composed primarily of
Type I collagen and is biochemically similar to osteoid in bone. Predentin gradually undergoes
mineralization, as various non-collagenous proteins (NCPs) are incorporated into the
mineralization front, forming mineralized dentin matrix (15). This is a matrix-controlled process,
which requires the presence of Type I collagen serving as a scaffold for NCPs (11).

Dentin formation starts with the formation of the pulp chamber immediately prior to
formation of enamel, and continues as long as the pulp chamber remains intact. In murine teeth,
two types of dentin are distinguished: developmental dentin, which is formed during
development as a result of embryonic interactions (primary dentin), and physiologic dentin,
which is formed as a result of responses to environmental stimuli (secondary and tertiary dentin).

In addition, three types of dentin can be recognized based on the stage of tooth
development and origin of odontoblasts secreting it. Most of the tooth is formed by primary
dentin, which is secreted by primary odontoblasts prior to termination of root development
(before and during tooth eruption).

Secondary dentin is secreted as a continuation of the primary dentin and is formed by the
same primary odontoblasts, but when root development is completed and teeth come into
occlusion. Histologically and physiologically, formation of secondary dentin is achieved
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essentially the same way as that of primary dentin, though at a much slower rate (~10 times), and
it is higher in the areas subjected to more intense stimuli. The major difference between primary
and secondary dentin is the S-curve of the dentinal tubules, which is more pronounced in the
secondary dentin, where odontoblasts located at the periphery of a withdrawing pulp become
gradually restricted in space (11). Another difference is the morphology of odontoblasts
themselves engaged in the production of primary and secondary dentin (17).

Tertiary dentin is formed at specific sites of the tooth in response to irritation or injury
(trauma, attrition, restorative procedure, deep caries, etc.), and is aimed to restore structural
integrity of a tooth. Unlike primary and secondary dentin that is formed along the entire dentinpulp border, tertiary dentin is secreted only by the cells, which are directly affected by the stimuli.
Two types of tertiary dentin are distinguished based on the intensity and duration of stimuli:
reactionary and reparative (18). Reactionary dentin is formed by pre-existing postmitotic
primary odontoblasts in response to mild and short stimuli, which do not lead to cell death
(odontoblast-mediated tertiary dentinogenesis). Typically, formation of reactionary dentin
represents the upregulation of the secretory activity of odontoblasts during mild adverse stimuli
to the tooth (19, 20). Reactionary dentin appears either as a layer of osteodentin, or as a tubular
or atubular orthodentin, depending on the speed and severity of the stimuli, the progression of
the reaction and the age of the patient (11). On the other hand, reparative dentin is formed by
newly differentiated odontoblast-like cells following the death of the original cells. Reparative
dentin is formed by so-called secondary (or repairing) odontoblasts in response to severe stimuli
resulted in the death of primary odontoblasts (21). Secondary odontoblasts are newly formed
odontoblast-like cells differentiated from odontoprogenitor cells (progenitor-mediated tertiary
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dentinogenesis), however the exact origin of these progenitor cells remains unclear. Formation of
reparative dentin occurs at a much slower rate than that of primary or secondary dentin.
Furthermore, tertiary dentin is more irregular and amorphous, and contains fewer dentinal
tubules. In addition to its particular structural organization, the chemical composition of tertiary
dentin is also distinctive: during its formation, production of Type I collagen, dentin sialoprotein
(DSP) and dentin matrix protein 1 (DMP1) appears to be downregulated, whereas that of bone
sialoprotein (BSP) and osteopontin is upregulated (15, 22, 23), thus resembling the chemical
composition of bone. In the clinical conditions tertiary dentin formed at the dentin-pulp interface
often comprises both reactionary and reparative dentin (24). So, reparative dentinogenesis
represents a much more complex sequence of biological events, involving recruitment and
differentiation of odontoprogenitor cells as well as upregulation of secretory activity of
odontoblasts, as compared to reactionary dentin (19).

Although reparative dentinogenesis during pulp healing requires recruitment of
progenitor cells and their differentiation into odontoblast-like cells, it is still unclear (1) which
cell type contributes to formation of newly formed odontoblast-like cells, and (2) which cellular
and molecular mechanisms are involved in this regulation. Since primary odontoblasts are
postmitotic cells, they are unable to regenerate by cell division upon damage. This suggests that
the cells other than mature odontoblasts are involved in this process. Although the origin of these
cells still remains unclear, it is suggested that formation of newly formed odontoblast-like cells
results from proliferation and differentiation of a population of stem/progenitor cells residing
within the dental pulp (presumably cells of the Höhl layer) (9, 15, 19). Some studies have also
suggested that dental pulp cells at the apex of the roots can serve as an important source of cells
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involved in reparative dentinogenesis (25). In addition, other cell types, such as undifferentiated
mesenchymal cells in the pulp core or perivascular progenitors/pericytes, could be involved in
this process (8, 15, 26). As embryonic derivation of these progenitor/stem cells is different, this
can possibly affect the resulting cell phenotype and its relationship to that of the odontoblast (27).

Chemical Composition of Dentin.

Mature dentin is composed of approximately 70% inorganic (mineral) material, 20%
organic material and 10% water by weight (40-45%, 30% and 20-25% by volume, respectively).
This makes dentin slightly harder than bone and softer than enamel (11, 15).

Inorganic component of dentin is primarily represented by hydroxyapatite (HA)
[Ca5(PO4)3OH] (15). The mineral phase appears first within the matrix vesicles as single crystals
seeded by phospholipids of the vesicle membrane. These crystals grow rapidly and later fuse
with adjacent crystals to form a continuous layer of the mineralized matrix. Following mineral
seeding, NCPs produced by odontoblasts regulate mineral deposition (15).

Organic component consists primarily of Type I collagen, which constitutes
approximately 90% of all dentin proteins, and is one of the earliest markers of odontoblast
differentiation (11, 15). The assembly of α1 and α2 pro-collagen peptides is initiated within the
rough endoplasmic reticulum, but their chemical modification (glycosylation and sulphatation)
occurs in the Golgi apparatus. Maturation of these peptides occurs in secretory vesicles, which
are transported into the ECM, where the peptides are cleaved by various pro-collagen peptidases
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(11). In the ECM, two α1 chains and one α2 chain (89%) or three α1 chains (11%) self-aggregate
into filamentous triple helix molecules stabilized by intra- and intermolecular cross-links (11, 15,
28). L-ascorbic acid serves as an essential cofactor for lysyl hydroxylase and prolyl hydroxylase
enzymes, which are essential for collagen biosynthesis (29). The importance of the correct
collagen structure in dentin is clearly seen in patients with dentinogenesis imperfecta (DGI) type
I caused by mutations in the Type I collagen gene, which clinically resemble DGI type II and III
caused by Dspp mutations (15, 30-32)

Type I collagen by itself does not induce mineralization, however it serves as an organic
scaffold to further retain NCPs and accommodate a large proportion (~56%) of the mineral in the
holes and pores of the fibrils (15, 28, 33). In addition to Type I collagen, small amounts of Types
III and V collagen (~3%) are also present in dentin of very young animals or during defective
collagen synthesis (11).

SIBLING Proteins.

Besides Type I collagen, dentin contains various NCPs, including proteoglycans,
glycoproteins, serum proteins, enzymes and growth factors. However, a family of so-called
SIBLING (Small Integrin-Binding Ligand N-linked Glycoprotein) proteins represents the most
abundant group of NCPs. The SIBLING proteins themselves are a part of a larger family called
secretory calcium-binding phosphoproteins (SCPPs), which are involved directly in binding of
calcium ions. There are five members in the SIBLING family: dentin sialophosphoprotein (Dspp,
encoding DSPP protein), dentin matrix protein 1 (Dmp1, encoding DMP1 protein), integrin-
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binding sialoprotein (Ibsp, encoding BSP protein), secreted phosphoprotein 1 (Spp1, encoding
Osteopontin protein) and matrix extracellular glycophosphoprotein (Mepe, encoding MEPE
protein) (34). These genes are clustered within a 375.000 bp region on the human chromosome
4q21 and the mouse chromosome 5 (35-37). This clustering most likely reflects their apparent
common evolutionary heritage, as recent studies have shown that these genes arose from the
early common progenitor gene by gene duplication or divergence (37, 38). It is therefore
surprising that the SIBLING proteins are poorly conserved (36, 38, 39). Besides common genetic
features, these proteins also share some structural and biochemical features, such as highly acidic
nature due to abundance of acidic amino acid residues, multiple phosphorylation sites, the
presence of an arginine-glycine-aspartic acid (RGD) integrin binding site, similar types of posttranslational modifications (e.g. phosphorylation and glycosylation) and the presence of a
proteolytic-resistant acidic serine–aspartate-rich MEPE-associated (ASARM) motifs (35, 38, 40).
Although these proteins regulate various biological properties of cells, they are different in terms
of the expression in different cell types, stage of cell differentiation and functional activity.

Among SIBLING proteins, DSPP and DMP1 play the most significant roles during
odontoblast differentiation and dentin formation. Below is the summary of the patterns of their
expression and roles during dentinogenesis and odontoblast differentiation.

Dspp. For a long time Dspp has been considered to be the only dentin-specific gene, as it
was found only in odontoblasts, predentin and dentin (41), however more recent studies localized
Dspp to many other tissues. Expression of Dspp has been detected in bone and cementum,
however levels of its expression in these tissues are dramatically lower as compared to those in
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dentin (42-45). In addition, Dspp expression has been transiently detected in preameloblasts (46,
47) as well as in various non-mineralized tissues and organs, including those where epithelialmesenchymal interactions play an essential role during their development (salivary glands, hair
follicles) (48-52). Therefore, although Dspp expression is not restricted to odontoblasts, high
levels of its expression are specific to odontoblasts. In the odontoblast lineage, expression of
Dspp is first detected at low levels in functional/secretory odontoblasts and levels of its
expression increase further in fully differentiated/mature odontoblasts (53).

Dspp gene encodes a single large precursor protein DSPP (54-56). In the mineralized
tissues, DSPP protein undergoes proteolytic cleavage by bone morphogenetic protein 1 (BMP1)
proteinase (57, 58) forming two fragments: 53-kDa dentin sialoprotein (DSP) representing the Nterminus of DSPP (11, 59-61) and 53-155-kDa dentin phosphoprotein (DPP) representing the Cterminus of DSPP (11, 54, 61-63). Very minor amounts of the uncleaved native DSPP protein
can still be present in the extracellular space (64). Cleavage of DSPP protein is a critical and
initial step to trigger a cascade of events promoting mineralization (64). In addition to DSP and
DPP, a 19-kDa proteoglycan form of DSP called dentin glycoprotein (DGP, sometimes called
DSP-PG) has recently been discovered, although due to its abundance it probably represents a
functional form of DSP in the process of biomineralization (11, 65-67). Gene knockout studies
have demonstrated that Dspp–/– mice display enlarged pulp chambers, reduced thickness of
dentin and its hypomineralization, disrupted dentinal tubules and widened predentin with
irregular mineralization front resulting in frequent pulp exposure (68-70). In humans, multiple
heterozygous Dspp mutations have been linked to the two most common hereditary disorders
affecting dentin: DGI-II and -III, and dentin dysplasia (15, 30, 71, 72). Due to defective dentin,
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enamel in these patients has a tendency to fracture during mastication, leaving the exposed
dentin vulnerable to excessive wear and caries (72).

Although DSP and DPP are fragments of a single DSPP protein, their roles in the process
of biomineralization are very different due to substantial differences in their chemical structures
(31, 70, 73). DPP (sometimes called phosphophoryn or DMP2) is the most abundant NCP in
dentin representing approximately 50% of this fraction (54). DPP protein has been isolated and
characterized from cells of different species, and although these DPPs are somewhat different in
the molecular weight, they all share very similar physical and chemical properties (54, 74, 75).
Interestingly, DPP is absent in some toothless animals (76). The strong affinity of DPP to
calcium ions is due to its high degree of phosphorylation and extreme anionic character (15, 54,
63, 74). This makes DPP the most acidic protein discovered so far (63).

Several studies have demonstrated that DPP has a high affinity to Type I collagen, which
together with its highly acidic nature suggests that it can act as an effective nucleator of
mineralization and is essential for converting unmineralized predentin to mineralized dentin (63,
68). However, the ability of DPP to promote mineral deposition in vitro and in vivo depends on
the degree of its phosphorylation. For example, phosphorylated DPP promotes nucleation of
plate-like apatite crystals in the in vitro mineralization system, whereas unphosphorylated DPP
fails to do so, forming only very amorphous mineral depositions (77-79). In vivo studies suggest
that DPP is secreted in the mineralization front, where it binds to Type I collagen fibrils of
unmineralized predentin and initiates formation of apatite crystals, therefore forming mineralized

10

dentin matrix. As this process continues, apatite crystals grow in an oriented manner, therefore
converting more predentin into dentin (32, 69, 74, 80, 81).

As compared to DPP, DSP is much less abundant in the dentin (~10 times less abundant)
(74, 82). In addition, DSP contains very few, if any, phosphorylated amino acids and has no
effect on in vitro mineralization (82). It is thought that DSP is secreted in the predentin but is not
present in the mineralized dentin matrix, as its extraction demonstrated that DSP is present only
in the organic phase of dentin extracts (i.e. predentin and odontoblasts) but not in the inorganic
phase (apatite crystals) (32). This suggests that high amounts of DSP in predentin act as an
inhibitor of mineralization, preventing premature or too rapid conversion of predentin into dentin.
To date, very few reports on the role of DSP (and DGP) in regulation of in vivo mineralization
have been published. Dspp–/–/DSPTg mice exhibit remarkably large pulp chambers, extremely
thin and porous dentin with very few dentinal tubules, and dramatically expanded predentin,
which almost completely replaced the entire predentin-dentin complex, a phenotype which was
worse as compared to Dspp–/– mice (69). These data suggest that in contrast to DPP, high
amounts of DSP may have an inhibitory role on formation of mineralized matrix in order to
appropriately control this complex process. Overall, these studies clearly demonstrate important
roles of Dspp in regulation of biomineralization of dentin, and, to a much less extent, of bone.

Taken together, these studies demonstrated important roles of Dspp in regulation of
dentin formation and mineralization. It regulates these processes by formation of DSP and DPP
fragments with differential roles: DSP being mainly involved in regulation of matrix formation,
and DPP mainly involved in initiation and maturation of the matrix.
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Dmp1. Similar to DPP, DMP1 is a highly acidic phosphoprotein, which was originally
thought to be present specifically in the dentin matrix (83). However further studies have
demonstrated that it is expressed in enamel (84, 85), bone (86, 87), cementum (84), cartilage (88)
and some non-mineralized tissues (brain, kidneys, pancreas, liver, muscle) (89). In the
odontoblast lineage, DMP1 is first expressed by functional odontoblasts, whereas levels of its
expression decrease in fully differentiated odontoblasts (90). In contrast to Dspp, low levels of
Dmp1 expression have been detected in undifferentiated dental pulp cells both in vivo and in
vitro (84, 90). In the osteoblast lineage, Dmp1 is expressed by late osteoblasts and osteocytes (86,
87). In addition, in contrast to Dspp, levels of Dmp1 are much higher in bone than in dentin (91).
To date, two Dmp1 mRNA transcripts have been identified: one with all six exons (more
predominant in mice), whereas the second one misses exon 5 (more predominant in humans),
although functional differences between these two forms are not exactly clear (91). Interestingly,
although DMP1 sequences among different species are quite divergent, one of the most
conserved DMP1 regions is localized at the cleavage site, which suggests that cleavage of DMP1
is essential for its functions (92).

A unique feature of the DMP1 protein is the presence of multiple acidic domains,
suggesting that DMP1 is involved in regulation of mineralization (91, 93). Similar to DSPP, the
~90-kDa DMP1 protein is cleaved by BMP1 proteinase upon its release into the ECM into two
fragments: a less phosphorylated 37-kDa N-terminal fragment and a more phosphorylated 57kDa C-terminal fragment (92, 94). In addition, more recent studies have demonstrated that in
addition to existence as a phosphoprotein, the N-terminal fragment also exists in a proteoglycan
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form when bound to chondroitin sulfate (DMP1-PG) (95). Although almost all DMP1 molecules
are being cleaved in the ECM, some minor amounts of full-length DMP1 protein are still present
in bone and dentin (93). Studies have demonstrated that both N- and C-terminal fragments are
localized to unmineralized and mineralized tissues of the bone and teeth, respectively. In bone,
N-terminal fragment is localized to proliferative and hypertrophic zones of the growth plate,
whereas C-terminal fragment is localized to the ossification zone. In teeth, N-terminal fragment
is located in predentin, whereas the C-terminal fragment is localized to mineralized dentin. This
differential localization of both fragments suggests their differential roles in mineralization. This
is supported by studies which have demonstrated that both full-length and C-terminal fragment
of DMP1 are able to promote nucleation of hydroxyapatite, whereas N-terminal fragment
inhibits this process (96). Similar to N- and C-fragments of DSPP, counterbalancing effects of Nand C-fragments of DMP1 may have an important role in inhibition of early or too rapid
mineralization (97). Interestingly, some studies have demonstrated that the release of Ca2+ ions
from the endoplasmic reticulum triggers the transport of DMP1 into the ECM (98), which
suggests that release of Ca2+ ions may be an important inductor signal for functions of DMP1 in
the extracellular space.

An important role of DMP1 during mineralization has clearly been demonstrated in
various transgenic animal models. Deletion of Dmp1 in Dmp1–/– mice does not affect growth and
development of embryos or newborn pups, which suggests that Dmp1 is not essential for early
development of mineralized tissues (84). However, during postnatal development these mice
develop increased thickness of predentin, decreased thickness and mineralization of dentin and
its irregular structure, enlarged pulp chamber, and delayed development or absence of a third
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molar (85). This phenotype is very close to that observed in Dspp–/– mice (68, 69). Interestingly,
levels of Dspp were decreased in Dmp1 knockout mice as compared to wild-type littermates,
suggesting that Dmp1 can act as a positive regulator of Dspp expression (85). This is also
supported by partial rescuing of the odontoblast phenotype of Dmp1 knockout mice by breeding
them with mice expressing Dspp under the control of a 3.6-kb rat Col1a1 promoter (99). In vitro
experiments have shown that overexpression of Dmp1 in undifferentiated C3H10T1/2 cells
stimulates expression of Dspp (100). Furthermore, DMP1 has been shown to bind to the Dspp
promoter region, therefore supporting previous findings, which suggest that DMP1 acts as a
transcriptional regulator of Dspp (101).

Overall, these studies clearly demonstrate the importance of Dmp1 in regulation of
mineralization of bone and dentin.

Dental Pulp.

Dental pulp is a connective tissue that resides within the pulp chamber of a tooth. Dentin
is an immediate tissue that contacts the dental pulp cells. Due to slow but continuous secretion of
physiological secondary dentin, the space occupied by pulp is gradually reduced. Thus, the
communication between pulp and periapical tissues occurs only via the apical foramen, which
contains blood vessels and nerves (6). Although dental pulp shares many properties with other
connective tissues in the body, its unique localization imposes several special constrains on its
development, maintenance and response to injury (102).
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Several zones within the pulp can be distinguished based on their location. Subjacent to
the layer of odontoblasts is the cell-free zone (also called zone of Weil), which is the area that is
relatively free of cells. More deeply, there is a cell-rich zone, which is relatively rich in cells
(fibroblasts, undifferentiated mesenchymal cells, immune cells, etc.) and blood capillaries. Due
to the presence of undifferentiated cells that are frequently occupying the perivascular area, this
zone is presumably the source of cells that will give rise to newly formed odontoblast-like cells
after injury or death of primary odontoblasts. Finally, pulp proper (or pulp core) is also rich in
cells (fibroblasts, undifferentiated mesenchymal cells, immune cells) and blood vessels (102).
Decreased numbers of pulp cells are observed with aging in humans and rodents (6).

Besides cells and blood vessels, dental pulp contains extracellular matrix, which typically
includes various proteins, such as collagen, glycosaminoglycans, proteoglycans and fibronectin
(6, 102). Important feature of dental pulp is the lack of DSP and DPP proteins, suggesting the
lack of mature odontoblasts (6).

The considerable capacity of dental pulp for dentin regeneration and repair and
identification of stem/progenitor cells in dental pulp capable of giving rise to new odontoblastlike cells makes dental pulp cells a valuable model for examining the mechanisms regulating the
sequential steps involved in odontoblast differentiation.

Growth Factors and Reparative Dentinogenesis.
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Epithelial-mesenchymal interactions are critical for proper tooth formation and
odontoblast differentiation during in vivo tooth development. Many of these interactions are
mediated by growth factors, which diffuse between epithelial and mesenchymal compartments of
the tooth germ. During the late bell stage of tooth development, inner dental epithelium secretes
various growth factors, which act on neighboring cells in a paracrine manner, and thus signal the
peripheral cells of the dental papilla to differentiate into odontoblasts. Growth factors mediate
signal transduction through many cell layers and act at very low concentrations, therefore they
are important regulators of proper tooth development (103). Considering these mechanisms of
odontoblast differentiation during tooth development, it has been suggested that similar
processes occur during reparative dentinogenesis. However, mature teeth lack dental epithelium,
and since formation of reparative odontoblasts cannot be induced by dental epithelium, inductive
stimuli are likely to come from other signaling mechanisms (23, 104, 105).

It is well known that besides collagen and NCPs, dentin matrix contains trace amounts of
various growth factors, including fibroblast growth factors (FGFs) (106), TGFβ1 (107-110),
bone morphogenetic proteins (BMPs) (111, 112), platelet-derived growth factor (PDGF) (106),
vascular endothelial growth factor (VEGF) (106), epidermal growth factor (EGF) (106), insulinlike growth factors (IGFs) (110), hepatocyte growth factor (HGF) (113) and others. FGFs (114119), IGFs (119, 120), BMPs (121, 122) and EGF (123, 124) are associated with the onset of
odontoblast differentiation in developing teeth in vivo. They are secreted into the ECM of
predentin and dentin and sequestrated with the matrix during the mineralization process.
Therefore, it is believed that upon severe dentin injury leading to the death of primary
odontoblasts and pulp exposure, these growth factors are released and can affect undifferentiated
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progenitors in the pulp (23). Since some growth factors, such as FGF2, induce cell migration and
proliferation (125, 126), it is therefore possible that when the odontoblast layer is destroyed,
progenitors from the underlying pulp migrate to the site of injury where they proliferate and
further differentiate into odontoblast-like cells engaged in deposition of dentin matrix. Thus, in
the presence of growth factors dental mesenchyme behaves as if dental epithelium is present, i.e.
growth factors mimic actions of dental epithelium on mesenchyme (20). It has also been
suggested that odontoblasts can also be stimulated by growth factors released from dentinal
matrix as a result of its demineralization by acidic acids released by bacteria (19, 110). All these
studies may suggest that growth factors released upon dentin injury can play an essential role
during reparative dentinogenesis.

Multiple previous studies have demonstrated that various growth factors can modulate
the process of reparative dentinogenesis (19). The first study to report successful application of
growth factors for stimulation of reparative dentinogenesis was by Nakashima, who
demonstrated that BMP stimulated formation of tubular-like tertiary dentin in partially
amputated pulps of adult canine teeth (127). Combination of inactivated and demineralized
dentin matrix powder with either BMP2 or BMP4 results in stimulation of reparative
dentinogenesis in canine teeth (128). Capping of tooth cavity with calcium phosphate cement
containing polylactic-co-glycolic acid (PLGA) loaded with TGFβ1 results in enhanced formation
of tertiary dentin in goat incisors (129). Implantation of beads loaded with 100 ng/ml TGFβ1 at
the sites of mechanically exposed dental pulp of canine teeth leads to formation of numerous
polarized cells and later to deposition of tubular mineralized matrix. In contrast, beads loaded
with 100 ng/ml FGF2 lead to formation of numerous groups of polarized cells without deposition
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of mineralized matrix; whereas beads loaded with 500 ng/ml IGF-II do not stimulate cell
polarization or deposition of mineralized matrix (130). Active formation of reparative dentin is
observed in the areas of implantation of scaffolds loaded with BMP7 in exposed pulp cavities in
rats or miniature pigs (131-133). In contrast, no significant formation of reparative dentin in
mechanically exposed pulp cavities of canine teeth has been observed (134). More intense and
frequent (~80% cases) formation of reparative dentin in exposed rat teeth is observed in response
to recombinant human (rh)-IGF-I as compared to control (~30% cases) (135). Hu et al. have
demonstrated the formation of mineralized tissue in the area of pulp exposure in response to
TGFβ1, FGF2, EGF and PDGF, however only TGFβ1 stimulates formation of mineralized tissue
containing dentinal tubules (136). More recent study has showed that implantation of FGF2loaded beads at the site of pulp exposure leads to formation of calcified bridge, which is DSP+
and DMP1+ matrix but does not include cells expressing Nestin, shown to be expressed by
odontoblasts and not by osteoblasts (137), indicating the formation of osteodentin.

Successful dentin regeneration requires absence of severe inflammatory environment at
the dentin-pulp interface. Persistent inflammatory processes may result in early formation of socalled fibrodentin with osteotypic appearance at the traumatized area, which however does not
represent a guided natural regeneration at the dentin-pulp border. In addition, it cannot provide
the necessary barrier effect to protect the pulp from exogenous destructive stimuli (24).
Therefore, regulation of inflammatory processes is important for successful formation of tertiary
dentin.
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Interestingly, in addition to roles of growth factors in stimulation of formation of tertiary
dentin by affecting odontoblasts or undifferentiated pulp cells, they play an important role in
regulation of inflammatory processes in the body (138-142), which in general are similar to these
occurring during the cavity preparation or pulp exposure. Increased expression of various growth
factors, including TGFβ (143) and HGF (144), during dental pulp inflammation/carious injury
has been demonstrated. In addition, exposure of inflamed human dental pulp cells to FGF2
increased their migration, viability, proliferation and colony-forming-unit capabilities as
compared to control (145). Recent studies using stem cells from inflamed primary teeth (iSHFD)
showed that FGF2 increases their proliferation and migration potential (146). Taken together,
these studies suggest that increased activity of these and other growth factors could be involved
in regulation of inflammatory response during pulp inflammation and contribute to better pulp
healing and/or increased reparative dentinogenesis.

Overall, results of these studies suggest that growth factors can play an important role
during the reparative dentinogenesis through stimulated migration of undifferentiated cells to the
site of injury, their proliferation and further differentiation into odontoblast-like cells, which
secrete mineralized dentin-like matrix. Therefore, better understanding of the underlying
molecular and cellular mechanisms is important for the development of improved treatments for
vital pulp therapy and dentin regeneration. Development of new capping materials for delivery of
growth factors to the site of dental pulp/dentin injury will broaden application of growth factors
for clinical applications in the future.

Fibroblast Growth Factors (FGFs).
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In our studies we focused on examination of the effects of FGF signaling on
mineralization and odontoblast differentiation in primary murine dental pulp cultures.

Description and classification:
First FGF-like mitogenic effects in the culture were observed in 1939 (147), however first
FGFs (FGF1 and 2) were isolated from the bovine pituitary as mitogen factors for cultured
BALB/C3T3 fibroblasts only in the 1970s (148-150). FGFs are widely expressed during
vertebrate development and are implicated in various biological processes, and their deregulation
causes several congenital diseases and some types of cancer (151-154). In addition to their role
during proliferation, FGFs are also involved in regulation of cell migration, differentiation and
apoptosis by inducing distinct downstream signaling pathways (154).

FGF ligands are small polypeptides, which have been identified in both invertebrates and
vertebrates (155). In vertebrates, currently 22 members of the FGF family have been identified,
and they constitute one of the largest and well-studied families of polypeptide growth factors.
Most recent studies suggest that no other FGF genes could be identified in the complete human
genome sequence (156). In humans and mice, FGFs are found scattered throughout the genome,
however some of them (FGF3, 4, and 19, or FGF6 and 23) are clustered. These findings suggest
that during evolution most of the FGFs were generated by chromosomal translocation or
duplication, but not by local duplication events (155, 157).
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Vertebrate FGFs can be classified into several subfamilies based on their evolutionary,
biochemical and functional properties. Based on the phylogenetic analysis (i.e. evolutionary
relationship), all FGFs are grouped into seven evolutionary divergent subfamilies according to
their sequence homology and function: FGF A (FGF1 and 2), FGF B (FGF3, 7, 10 and 22), FGF
C (FGF4, 5 and 6), FGF D (FGF8, 17 and 18), FGF E (FGF9, 16 and 20), FGF F (FGF11-14)
and FGF G (FGF15, 19, 21 and 23) (153, 156-158). Human FGF15 and mouse FGF19 have not
been identified (155, 156). By the mechanisms of their action, all vertebrate FGFs can be
classified into canonical FGFs (FGF1/2/5, FGF3/4/6, FGF7/10/22, FGF8/17/18, and
FGF9/16/20), fibroblast homologous factors (FHFs, FGF11/12/13/14) and hormone-like FGFs
(hFGFs, FGF15 or 19/21/23) (153, 159, 160).

All FGFs exert their biological effects through interaction with a family of tyrosine
kinase receptors, the FGF receptors (FGFRs), and the mechanisms of these interactions and
signaling pathways downstream of FGF/FGFR will be discussed in details later. However,
although the FHFs (FGF11-14) share a high degree of sequence homology with other FGFs and
bind heparin with high affinity (will be discussed later), they do not activate FGFRs and
therefore are largely unrelated to the FGF family (161). Currently, it is believed that FHFs act in
an FGFR-independent manner and primarily interact with intracellular domains of voltage-gated
sodium channels and with the neuronal MAPK scaffold protein, islet-brain-2 (153, 160).
Therefore, FHF mutations in humans are involved in the development of cerebellar ataxia, and in
mice they result in development of various neurological abnormalities (153). In addition,
although most of FGFs act as paracrine factors, the hormone-like FGFs have been shown to act
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in the endocrine manner, and dependent on the presence of Klotho cofactors in their target
tissues (153, 162).

Expression of FGF ligands has been detected in virtually all tissues and organs. However,
many of them have a unique pattern of their expression and stage of development (embryonic vs.
postnatal). For example, some FGFs (FGF3, 4, 8, 15, 17 and 19) are expressed only during
embryonic development, whereas others (FGF1, 2, 5-7, 9-14, 16, 18, 20-23) are expressed during
both embryonic and postnatal development (155). Specific patterns of FGFs’ expression in
certain types of tissue (for example, epithelial vs. mesenchymal) could also be due to the
interaction with FGF receptors expressed exclusively in a specific type of the tissue. Functions of
various FGFs during development and the phenotypes of their loss in vertebrates have been
discussed in details in several review papers (151, 153, 156, 163).

Among FGFs, in our studies we have focused on FGF2, as it is one of the most abundant
FGFs in the dentin matrix. The human genome has only one copy of the Fgf2 gene, which is
located on the chromosome 4q 26-27.3. The size of the gene is 40.000 bp, and the coding
sequence consists of three exons, which are interrupted by two introns (155, 164). However,
FGF2 is unique among other FGFs. In humans FGF2 occurs in five different isoforms: a low
molecular weight (LMW) 18-kDa isoform and four high molecular weight (HMW) 22-, 22.5-,
24-, and 34-kDa isoforms. Three FGF2 isoforms have been described in rodents (18-, 21- and
23-kDa) and in chicken (18.5-, 20- and 21.5-kDa) (164). These different isoforms are generated
by alternative initiation of translation of the Fgf2 gene (165). LMW FGF2 is translated from the
conventional AUG codon in a 5’-cap-dependent manner and consists of 155 amino acids
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representing the core sequence common to all FGF2 isoforms (164-166). In contrast, HMW
FGF2 isoforms (except 34-kDa isoform) are generated by the alternative translations initiating
from different in-frame CUG codons upstream of the AUG codon under the control of internal
ribosome entry site (IRES) (164, 167-169). This results in the formation of the extensive Nterminus that contains an additional nuclear localization sequence (170, 171).

Differences in the structure of FGF2 isoforms result in their different cellular localization
and mode of action and, as consequence, determine their functional diversity (164, 166).
Although HMW FGF2 isoforms sometimes can be released from the cells (172), they are
predominantly localized in the nucleus, where they co-localize with chromosomes (170), thus
acting in the FGFR-independent (intracrine) manner. In the nucleus, HMW FGF2 isoforms
regulate various transcription factors and ribosomal proteins and mediate a wide variety of
biological effects (164, 173). In contrast, LMW FGF2 is localized predominantly in the cytosol
and ECM (although a fraction of LMW FGF2 can also translocate to the nucleus) (174, 175), and
it acts through binding to FGF receptors (164). Thus, pleiotropic roles of FGF2 could be, at least
in part, explained by the existence of its multiple isoforms.

Structure:
FGFs contain a partially conserved core of 120–130 amino acids (~17-34 kDa in
vertebrates), and in humans they share ~30-60% homology (176). In 1991, several independent
laboratories revealed three-dimensional structure of FGF2 (177-179). These studies have
demonstrated that FGF2 is composed entirely of the β-trefoil structure that contains fourstranded β-sheets arranged in a pattern with approximate threefold internal symmetry
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(resembling trigonal pyramid), and linked with each other by hydrogen bonds. Two β-strands (βstrands 10 and 11) contain several basic amino-acid residues that form the primary heparinbinding site of FGF2. Other 10 β-strands are involved in interaction with FGF receptors and
nuclear translocation (155, 180). Although FGF2 contains four cysteine residues in its amino
sequence, biochemical analyses have demonstrated that they do not form intramolecular disulfide
bonds (181). In addition, two inverse arginine-glycine-aspartate (RGD) sequences are identified
within FGF2, and they are shown to be important for FGF2-mediated cell adhesion and
proliferation (182).

Secretion:
Several review papers have summarized the current knowledge about secretion of various
FGF ligands (155, 156, 183, 184). Most of FGFs are typical growth factors, which are
synthesized in the cells and then released into the extracellular space to mediate their biological
effects through binding to FGF receptors on the surface of their own (autocrine) and/or
neighboring (paracrine) cells. A majority of FGFs (FGFs 3-8, 10, 15, 17-19, and 21-23) contain
signal peptides within their N-terminus, which allows them to get secreted through the
endoplasmic reticulum (ER)/Golgi and later translocate into the extracellular space, where they
function as conventional growth factors by binding to FGFRs. Although FGF9, 16 and 20 lack
the N-terminal signal peptide, they are nevertheless secreted through the ER/Golgi pathway (due
to their non-cleaved N-terminal hydrophobic sequence). In contrast, LMW FGF2 (as well as
FGF1 and FHFs) does not have signal peptides, and is not secreted. Nevertheless, FGF2
mediates its signaling through binding to the transmembrane FGF receptors, suggesting that
FGF2 should be translocated to the extracellular space. For a long time, it has been considered
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that FGF2 is stored in the cytosol and can be released from the damaged cells. However, more
recent studies have demonstrated that FGF2 can also be released from intact cells by
unconventional ER/Golgi-independent mechanisms. In addition, transport of FGF2 into the
extracellular space can be mediated by heparan sulphate proteoglycans (HSPGs) (185). Possible
mechanisms of FGF2 secretion into the extracellular space have been discussed in details by
Nickel (186).

In contrast to LMW FGF2, the additional N-terminal sequence in HMW FGF2 contains
nuclear-localization signals, which allows them to translocate to the nucleus (155, 183).

FGF Receptors.

Paracrine FGF ligands trigger cascades of intracellular events regulating various cell
functions through interaction with transmembrane FGF receptors (184). To date four FGFR
transmembrane tyrosine kinase receptors (FGFR1, FGFR2, FGFR3 and FGFR4), which share a
high degree of homology, have been identified in humans and mice (159, 184, 187, 188). A fifth
related receptor, FGFR5 (also known as FGFRL1), is soluble and although it can bind FGFs, it
has no tyrosine kinase domain (189-191).

The full-length FGFRs (~800 amino acids), like other typical tyrosine kinase receptors,
consist of an extracellular ligand-biding domain, a single-pass transmembrane domain and a split
intracellular tyrosine kinase domain. The extracellular region consists of a signal peptide and
three immunoglobulin-like domains (IgI, IgII, IgIII). A unique feature of FGFRs is the presence
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of an acidic, serine-rich domain in the linker between IgI and IgII, termed the acid box (AB)
domain. Cysteine residues present within each Ig-like domain form an intramolecular disulfide
bond to maintain the tertiary structure of the receptor (153). Ig-like domains play various but
distinct roles during interactions with FGF ligands. The IgI and AB domains are thought to play
a role in receptor autoinhibition, whereas the IgII and IgIII domains are necessary and sufficient
for ligand binding and specificity (153).

The diversity of FGF receptors is enhanced by the existence of multiple alternative splice
sites that can result in the generation of numerous isoforms. Alternative mRNA splicing of the
second half of the IgIII domain of Fgfr1-Fgfr3 genes specifies the sequence of the C-terminus of
IgIII domain, resulting in either the IIIb or the IIIc isoform of the FGFR with different ligandreceptor binding specificity. In contrast, no alternative mRNA splicing of Fgfr4 gene has been
demonstrated (153), however two Fgfr4 isoforms resulted from alternative splicing of intron 17
have been described (192). Thus, in vertebrates seven FGFR proteins (FGFR1IIIb, FGFR1IIIc,
FGFR2IIIb, FGFR2IIIc, FGFR3IIIb, FGFR3IIIc and FGFR4) differing in their ligand-binding
speciﬁcity are generated from four Fgfr genes (153, 159).

Interestingly, although the IIIa isoform of FGF receptors has been described, it encodes a
secreted extracellular FGF-binding protein with no known signaling capability (193, 194). Thus,
the alternative splicing that generates IIIb and IIIc isoforms is an essential determinant of ligand
binding specificity (193-196).

High affinity of FGF ligands to specific FGF receptors suggests that different splicing
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isoforms of FGFRs may have a tissue-specific pattern of expression and/or developmental stagespecific functions. For example, Fgfr1 is expressed predominantly in cells and tissues of the
mesenchymal origin, whereas Fgfr2 is expressed predominantly in tissues of ectodermal origin
(197, 198). Expression of Fgfr3 is localized to the epithelium of the neural tube during early
mouse development and later is detected in various regions of the brain and central nervous
system and at very high levels in the cartilage rudiments of developing bone (199). Expression of
Fgfr4 is detected in the endoderm of the developing gut at E14.5 of mouse development (200).

FGF ligands produced in either epithelial or mesenchymal tissue generally activate
receptors of the opposite tissue specificity, thus resulting in directional epithelial-mesenchymal
signaling (153, 194, 201, 202). For example, FGF2, 4, 5, 6, 8, 9, 17, 19 and 20 bind to the IIIc
isoform with much higher affinity as compared to the IIIb isoform (194, 203). In contrast, FGF3,
7, 10 and 22 bind to the IIIb isoform with much higher affinity as compared to the IIIc isoform
(194, 203). Although almost all FGF ligands bind to epithelial or mesenchymal FGFRs with
different affinity, certain ligands, for example FGF1, bind to both IIIb and IIIc isoforms with the
same affinity (153, 194, 203). Although splicing of the extracellular domain controls ligand
specificity, no evidence that this affects intracellular signaling exists (154).

Importance of binding specificity of FGF ligands to FGF receptors has been revealed in
multiple studies in humans and other vertebrates, which showed that loss of this specificity
resulted in development of various syndromes and cancers. More detailed description of various
syndromes resulted from deregulated activity of FGF receptors will be presented in later parts of
this chapter.
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Interactions with heparin or heparan sulfate proteoglycans (HSPGs):
An important feature of paracrine FGFs is the interaction between FGFs and heparin or
heparan sulfate proteoglycans (HSPGs). It has been established that heparin is required for FGF
ligands to effectively activate FGFR in cells deficient in HSPGs or unable to synthesize them, or
in cells pretreated with heparin/HSPG-degrading enzymes. Additional studies have shown that
these interactions stabilize FGFs to thermal denaturation and proteolysis, thus facilitating binding
of FGFs to FGFRs and increasing the half-life of the FGF-FGFR complex (155). Indeed,
interactions between FGF and FGFR in the absence of HSPGs are not sufficient for stabilizing
FGFR dimers at the cell surface under normal physiological conditions (204).

In the presence of heparan sulfate, paracrine FGFs stably bind to FGFRs in a 2:2:2 ratio
(205, 206). Incorporation of HSPGs into the binding complex requires the presence of the AB
domain of the FGFRs, whereas IgI domain inhibits this incorporation (151). In contrast to
paracrine FGFs, the endocrine FGFs have low-afﬁnity heparin-binding sites and have been found
to act in an endocrine manner (159).

The importance of HSPGs for FGF/FGFR signaling has first been demonstrated by
studies, which show that mutations of Sgl and Sfl, genes essential for biosynthesis and
modification of HSPGs, greatly decrease the ability of FGF signaling to activate MAPK (207).
These and other studies have demonstrated that a unique feature of FGF-FGFR interactions is
that FGFs are unable to activate FGFRs without cooperation of HSPGs (208). The identification
of heparin/HSPGs as an active and essential component of FGF/FGFR signaling complex
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suggests that FGF activity and specificity can be modulated not only at the transcriptional and
translational levels, but also at the level of “bioavailability” (180). In the latter case, FGF2 is
retained locally by binding to HSPGs at the ECM and at the cell surface. It is believed that thus
retained FGF2 becomes available for interaction and activation of cell receptors after specific
stimuli (such as injury) release it from its “storage sites” (209). Released FGFs subsequently
bind to cell surface HPSGs (154).

Activation:
Binding of FGFs to the FGFRs results in their dimerization and autophosphorylation, and
triggers a cascade of intracellular events, including recruitment of docking and signaling proteins
at the plasma membrane (151, 159). Upon binding to FGF ligands, FGF receptors undergo
complex changes leading to their activation. After binding of FGF ligand and HSPGs, FGF
receptors undergo dimerization, which results in conformational changes in their structure,
activation of the intracellular kinase domain and subsequent phosphorylation of the tyrosine
kinase domains and intracellular C-terminus (154).

The two main intracellular substrates of FGFR are FGFR substrate 2 (FRS2) and
phospholipase Cγ1 (PLCγ1, also known as FRS1). FRS2 is largely specific, however not unique,
to FGFRs, as it can also bind other tyrosine kinase receptors. Phosphorylation of the C-terminus
of FGFRs creates a binding site for the SH2 domain of PLCγ1 and is required for activation and
phosphorylation of PLCγ1. In contrast, FRS2 associates constitutively with the JM domain of the
FGFR (154).
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The activated FGFRs phosphorylate FRS2, thus allowing the recruitment of the adaptor
proteins son of sevenless (SoS) and growth factor receptor-bound protein 2 (GRb2) to activate
RAS and the downstream mitogen-activated protein kinase (MAPK) signaling pathway, which
includes MEK/Erk, JNK and p38 subpathways. A separate complex involving GRb2-associated
binding protein 1 (GAb1) recruits a complex, which includes phosphoinositide 3-kinase (PI3K),
and this activates the Akt-dependent antiapoptotic pathway. Independently of FRS2, Src
homology 2 (SH2) domain of phospholipase Cγ (PLCγ) binds to a phosphotyrosine residue
towards the carboxyl terminus. After PLCγ is activated, it hydrolyses phosphatidylinositol 4,5
bisphosphate (PIP2) to phosphatidylinositol 3,4,5 trisphosphate (PIP3) and diacylglycerol (DAG),
activating the protein kinase C (PKC) signaling pathway (154).

Several other pathways activated by FGFRs include signal transducer and activator of
transcription (STAT) signaling and ribosomal protein S6 kinase 2 (RSK2) (154). In addition,
FGFs are also known to function in the cytosol cell nuclei, both through endocytosis of activated
FGF–FGFR complexes and through endogenous sources of a ligand (153).

Furthermore, interactions between the FGF and other signaling pathways, including BMP
(210-219) and Wnt (220-231), during skeletal and tooth development have been well
documented. Thus, activated FGF/FGFR signaling triggers a cascade of multiple intracellular
events, which regulate various cell functions.

Effects of FGF/FGFR Signaling on Bone.
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FGF/FGFR signaling is triggered by binding of FGF ligands to specific FGF receptors.
Therefore, the effects of FGF/FGFR signaling on osteoblasts and bone formation could be
divided into the effects of FGF ligands and FGF receptors.

Among the FGF members, in our study we have focused on FGF2. FGF2 is one of the
most abundant FGFs in the body, and its importance for bone formation and regulation of
biomineralization has been demonstrated in numerous in vivo and in vitro studies. However,
these studies have revealed both positive and negative effects of FGF2 on these processes. Here
we will summarize the current knowledge about the effects of FGF2 on bone formation and
mineralization, and try to find explanation for the conflicting results reported in the literature.

First, we will look at the gene deletion/activation studies. Fgf2–/– mice exhibit a
significant reduction in bone formation in vivo and in vitro, and decreased expression of markers
of mineralization (Type I collagen, Osteocalcin) in cultured BMSCs in vitro (231-233). These
decreases are in part due to the decreased number of osteoprogenitors (232). In addition, Fgf2–/–
mice display significantly impaired anabolic effects of PTH on osteoblast proliferation,
differentiation and apoptosis (234, 235). BMSCs isolated from Fgf2–/– mice have a substantially
decreased capacity to form mineralized nodules in vitro, and these decreases are completely
reversed by exogenous FGF2 (236).

Transgenic mice constitutively overexpressing human Fgf2, which encodes all FGF2
isoforms, display various skeletal alterations, including dwarfism, shortening of long bones (~2030% reduction), severe chondrodysplasia (237, 238), markedly decreased proliferation of the
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growth plate chondrocytes, and increased apoptosis of chondrocytes and calvarial osteoblasts
(238). Further studies have demonstrated that these mice have significantly decreased bone
formation in vivo and mineralization in BMSC cultures in vitro (239). However, transgenic mice
overexpressing Fgf2 under the control of the Col3.6 promoter (Col3.6–18-kDa FGF2-IRESGFPsaph mice) exhibit significantly increased bone formation in vivo (233). BMSC cultures
derived from transgenic mice overexpressing high molecular weight (HMW) Fgf2 under the
control of the 3.6-kb Col1a1 promoter (Col3.6-HMWFgf2) display increased osteogenic
differentiation during early stages of their differentiation (1 week), however display significantly
decreased osteogenic differentiation during later stages of the culture (2-3 weeks) (240).
Inhibition of FGFR signaling by SU5402 at these later time points significantly increases the
extent of mineralization and levels of expression of markers of mineralization (240).

These studies have demonstrated the importance of detailed analysis of activation or
deletion of Fgf2 for bone formation. It appears that the initial discrepancy between the results
can be due to 1) deletion/activation of Fgf2 in cells at different stages of their differentiation, 2)
deletion/activation of LMW vs. HMW FGF2, which have different localization and trigger a
different set of receptors, and 3) the effects on chondrocytes and cartilage formation affecting
bone formation.

In vivo and in vitro studies involved exogenous FGF2 are also contradictory and show
both positive and negative effects of FGF2 on bone formation that could be attributed to 1)
differentiation stage of osteoblasts and duration of exposure FGF2, 2) concentration of FGF2, 3)
mode of FGF2 delivery to the tissues, and 4) age of animals.
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Stage-specific effects and effects of duration of exposure to FGF2.

Multiple studies have demonstrated that exposure of cells at different stages of their
differentiation to FGF2 can result in opposite effects of FGF2 on mineralization and bone
formation.

In vivo studies have shown that implantation of FGF2 and demineralized bone scaffolds
results in increased bone formation 3 weeks after surgery, however no further stimulatory effects
are observed at 4-6 weeks after surgery (241). This suggests that initial exposure of less
differentiated cells to FGF2 stimulates cell differentiation, however further exposure of more
mature cells results in the absence of stimulation.

In vitro studies have shown that continuous exposure of calvarial osteoblasts to FGF2
markedly decreases the extent of mineralization, ALP activity and synthesis of Type I collagen
(213, 242). Continuous exposure of adipose-tissue-derived stromal cells (ADSCs) to FGF2
markedly decreases the extent of mineralization and expression of markers of mineralization
(211, 212). Overexpression of Fgf2 in ADSC cultures completely inhibits mineralization and
expression of Osteocalcin (243). Similarly, continuous exposure of differentiating MLO-Y4
osteocyte-like cells (244), MC3T3-E1 cells (245) or BMSC cells (246-248) to FGF2 results in
marked inhibition of mineralization. In addition to decreased mineralization, continuous
exposure to FGF2 completely inhibits expression of 3.6-GFP and 2.3-GFP transgenes in BMSC
cultures, which is reversed by withdrawal of FGF2 (248). Overall, these studies have
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demonstrated that continuous exposure of osteoprogenitor cells to FGF2 negatively regulates
mineralization and expression of various markers of mineralization.

Exposure during the proliferation phase of in vitro growth (prior to induction of
differentiation). Exposure of primary osteoblast cultures to FGF2 markedly increases the extent
of mineralization (249) and expression of markers of mineralization (249, 250). Exposure of
human BMSCs to FGF2 markedly increases ALP activity (251). Exposure of human BMSCs to
FGF2 markedly increases the extent of mineralized tissue in vitro and after their implantation on
the back of the mice in vivo (252). Early and transient (between days 1-2) exposure of MC3T3E1 cells to FGF2 results in slightly increased formation of mineralized tissue (245).

Various studies using primary BMSCs or osteoblast cell lines have demonstrated rapid
stimulatory effects of FGF2 on expression of markers of mineralization. Exposure of rat
ROS17/2.8 osteoblast-like cells to FGF2 induces rapid upregulation of Bsp mRNA and Runx2
protein via activation of the Erk1/2 – AP-1 signaling pathway (253). Exposure of MC-4
osteoblast-like cells or BMSCs to FGF2 markedly increases expression levels of Dmp1 and other
osteocyte-associated markers (E11, Cx43, Phex, Sost), but decreases the expression of Alp and
ALP activity (254). Exposure of MLO-Y4 osteocyte-like cells to FGF2 rapidly (within ~ 8 hrs
after exposure) stimulates expression of Dmp1 and other osteoblast/osteocyte-associated genes
(Mgp, Slc20a1) (244). FGF2 rapidly (~12 hrs after exposure) increases expression of Osteocalcin
mRNA in MC-4 osteoblast-like cells (243).
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Using microarray and qPCR analysis, Nakayama et al. have demonstrated that exposure
of confluent cells to FGF2 for 6 hrs increases expression of Wnt5b and Bmp2 (~3.4-fold) in
human Saos2 osteoblast-like cells, and markedly increases expression of Dmp1 (~130-fold), Ank
(~13-fold), c-Fos (~7-fold), jun-B (~4-fold) and Axin2 (~5-fold) in rat ROS17/2.8 osteoblast-like
cells (255).

These stimulatory effects of FGF2 on osteogenic differentiation are mediated, at least in
part, by the enrichment of these cultures with osteoprogenitors prior to induction of their
osteogenic differentiation. Stimulatory effects of FGF2 on proliferation of osteoprogenitor cells
have been demonstrated in multiple studies (242, 252, 256-261). In addition, several studies have
demonstrated anti-apoptotic effects of FGF2 on osteoprogenitor cells (262, 263), suggesting that
promoting of cell survival could also be an important mechanism of the enrichment of cultures
with osteoprogenitors.

These results correlate with the high levels of Fgf2 expression in the mesenchymal
progenitor cells of the developing mouse calvaria and low levels of expression in the calvarial
bone (264). This suggests that FGF2 may be required for commitment of undifferentiated
progenitors towards the osteoblast lineage, however its downregulation is required for maturation
of osteoblasts.

Exposure during the differentiation/mineralization phase of in vitro growth (after
induction of mineralization). Exposure of BMSC cultures to FGF2 decreases expression of
markers of mineralization (256) and the extent of mineralization (265, 266). Similar inhibitory
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effects of FGF2 on mineralization and expression of markers of mineralization are observed in
osteoblast cultures (267). Exposure of MC3T3-E1 osteoblast-like cells to FGF2 rapidly decreases
expression of Osteonectin, an essential regulator of bone formation, in a concentration-dependent
manner (268). Exposure of differentiating C3H10T1/2, C2C12 and BMSC cultures to FGF2
inhibits BMP9-induced ALP activity in a concentration-dependent manner (269).

These studies suggest that the exposure of osteoprogenitor cells to FGF2 during the
differentiation/mineralization phase of in vitro growth negatively regulates mineralization and
expression of various markers of mineralization.

Overall, these results suggest that early exposure to FGF2 (during the proliferation phase
of in vitro growth) increases the osteogenic potential of osteoprogenitor cells. However since
both continuous (during both proliferation and differentiation/mineralization phase of in vitro
growth) and late (during the differentiation/mineralization phase of in vitro growth only)
exposure results in inhibition of osteogenic differentiation, this suggests that as cells progress
through the lineage, they display restricted responses to FGF2.

Concentration-dependent Effects of FGF2 on Bone Formation.

In addition to stage-specific effects of FGF2 on mineralization, results of several studies
suggest that effects of FGF2 on osteogenesis may be concentration-dependent.

In vivo:
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Combination of FGF2 and demineralized bone stimulates formation of newly formed
bone using ~17 µg/cm2 FGF2, however a marked decrease in the amount of the newly formed
bone is observed using 2100 µg/cm2 FGF2 (270). Stimulation of bone formation is observed
using ~3.4-84 µg/cm2 FGF2, however 2100 µg/cm2 FGF2 has a profound inhibitory effect (241).
Using a critical size defect model, Maus et al. have demonstrated that application of FGF2 with
TCP cement (200 µg/cm2 FGF2) decreases the amount of newly formed bone as compared to the
TCP alone (271). Implantation of bone matrix powder followed by local injections of FGF2 into
the site of implantation does not affect the area of heterotopic bone formation by lower
concentrations of FGF2 (1-100 ng/ml), however it is markedly decreased by higher
concentrations of FGF2 (1-10 µg) (272). By using bone conduction chambers, it has been
demonstrated that lower concentrations of FGF2 (8-200 ng) stimulate bone ingrowth into the
chamber, whereas very low (0.3 ng) or very high (1000 ng) concentrations of FGF2 have no
stimulatory effect (273).

In vitro and ex vivo:
Hurley et al. have demonstrated that FGF2 significantly decreases levels of Type I
collagen in MC3T3-E1 osteoblast-like cells in a concentration-dependent manner (258).
Exposure of rat BMSCs to a relatively low concentration of FGF2 (2.5 ng/ml) after induction of
differentiation significantly increases the extent of mineralization (274). Fetal rat metatarsal bone
organ culture exposed to FGF2 (100 ng/ml) exhibits increased longitudinal bone growth,
however higher concentrations of FGF2 (1000 ng/ml) dramatically decrease bone growth (260).
Similarly, lower concentrations of FGF2 (1 and 10 ng) stimulate expression of Bmpr-1a and
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Bmpr-1b mRNA, whereas a higher concentration of FGF2 (100 ng) negatively regulates their
expression (275).

Interestingly, even continuous exposure of human BMSCs to a relatively low
concentration of FGF2 (3 ng/ml) for 28 days significantly increases the extent of mineralized
matrix (257). Similarly, rat BMSCs grown on the collagen hydrogel with incorporated low
concentrations of FGF2 significantly increases/accelerates expression of Type I collagen,
Osteocalcin and Bsp during the differentiation phase of in vitro growth (276). Overall, these
studies suggest that low concentrations of FGF2, in general, have a stimulatory effect on
mineralization and expression of markers of osteogenic differentiation.

Mode of FGF2 delivery to the tissues.

Mode of FGF2 delivery is important for its short-term or continuous and gradual release
from the scaffold material. This can affect the concentration of released FGF2 and the duration
of exposure of targeted cells. To address this issue, a wide variety of scaffold biomaterials have
been developed for controlled release of FGF2 in different target tissues (277).

Age-specific effects of FGF2 on bone formation.

In general, cells gradually loose their mitogenic and differentiation potentials with aging.
This has been well established in multiple in vivo studies, which demonstrated the reduced bone
mass in elderly patients as compared to the younger ones in humans (278, 279) and rodents (280).
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In addition, proliferation and differentiation of osteoblasts cultured on various surfaces and
implant materials also decreases with the age of the cell donor (281).

Recent studies have demonstrated that although FGF2 has positive effects on
proliferation of osteoblasts from ageing patients, the extent of this proliferation is lower as
compared to the cultures derived from younger individuals. Exposure of primary human
osteoblasts isolated from young (21-35 years old) and older (56-74 years old) females to FGF2
increases their proliferation and viability in a concentration-dependent manner (261). It has been
demonstrated that stimulatory effects of FGF2 on mitogenic and differentiation potentials of
osteoblasts isolated from young (2-3-day-old) rats are greatly impaired in osteoblasts from older
(60-day-old) animals (250, 282). In addition, calvarial osteoblasts derived from aged (10-monthold) rats exhibit markedly decreased proliferative and differential responsiveness to FGF2 as
compared to fetal osteoblasts (283).

Overall, these results suggest that cells isolated from older animals may have greatly
decreased responsiveness to FGF2, which can affect the interpretation of experimental results.

FGFR and Bone Formation.

An important role of FGFR in skeletal formation has been demonstrated in multiple
studies, as mutations in each of the FGF receptors are associated with various pathological
syndromes (151, 153, 284-287).

39

FGFR1. Expression of Fgfr1 is localized to the mesenchymal cells of limb buds,
precartilage blastema of the vertebrae, mandible and long bones, hypertrophic chondrocytes,
mesenchymal cells of cranial sutures, osteoblasts and osteocytes (288-290). This suggests an
important role of Fgfr1 during skeletal development.

In humans, mutations of Fgfr1 lead to development of several syndromes affecting
multiple tissues and organs, including skeletal elements. Proline-to-arginine gain-of-function
mutation (P252R) in the Fgfr1 gene (topologically equivalent ‘linker’ residue to Fgfr2 P253R)
results in the development of Pfeiffer syndrome characterized by craniosynostosis (291, 292). In
addition, loss-of-function P252R mutation results in development of Kallmann syndrome (293)
characterized by cleft palate (294), spine and limb malformations, and oligodactyly (295). In
addition, cysteine-to-arginine (C379R) mutation of Fgfr1 leads to the development of
osteoglophonic dysplasia (296) characterized by severe dwarfism and craniofacial abnormalities,
craniosynostosis and midface hypoplasia (296-298). These results demonstrate that inactivating
mutations of Fgfr1 negatively regulate bone formation.

Mice carrying P252R mutation of Fgfr1 (orthologous to a mild form of Pfeiffer syndrome
in humans) display craniofacial abnormalities (premature suture fusion, facial asymmetry) but no
other skeletal abnormalities. In addition, these mice display increased osteoblast proliferation,
increased expression of BSP and OCN proteins and Runx2 mRNA, leading to
accelerated/increased bone formation and increased amounts of mineralization of calvarial bones
(299). In the calvarial bones of the developing mouse embryos (E16), expression of Fgfr1
mRNA is localized to newly differentiated osteoblasts of the osteoid, which co-express
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Osteonectin (but not Osteopontin) (300). Silencing of Fgfr1 in fetal mouse osteoblasts greatly
decreases their mineralization potential (301). Exposure of human mesenchymal stem cells
(hMSCs) to DJ-1 protein led to increased levels of phospho-FGFR1 and osteogenic
differentiation of human hMSCs, which are reverted by SU5402 (302). Increased expression of
markers of osteoblast differentiation (Alp, Type I collagen, Osteocalcin, Runx2) in chick calvaria
osteoblast cultures correlates with the increased expression of Fgfr1 (213). In differentiating
ADSC cells, expression of Fgfr1 is relatively low prior to induction of differentiation, however it
markedly increases in more mature cells (303). Thus, similar to the human studies, rodent studies
demonstrate that inactivating mutations of Fgfr1 negatively regulate bone formation.

FGFR2. Expression of Fgfr2 is localized to the mesenchymal cells of cranial sutures,
periosteum and perichondrium (286, 288, 290). This suggests that Fgfr2 plays an important role
during bone formation.

In humans, activating mutations of Fgfr2 lead to development of multiple syndromes,
which in addition to other tissues and organs affect axial and appendicular skeleton development
(craniosynostosis and other skeletal abnormalities). These syndromes include Apert syndrome
(304, 305) Crouzon syndrome (306, 307), Pfeiffer syndrome (292, 308), Jackson-Weiss
syndrome (307), bent bone dysplasia (309) and others.

Previous studies have demonstrated that the Ser252Trp (S252W) and Pro253Arg (P253R)
mutations of FGFR2 are the most common mutations in patients with Apert syndrome;
Cys342Tyr (C342Y) is commonly found in patients with Crouzon syndrome, and Cys342Arg
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(C342R) is commonly found in patients with Pfeiffer syndrome (304, 305, 310-312).
Biochemical and crystallographic analyses have demonstrated that S243Y mutation affects a
highly conserved linker region located between the IgII and IgIII of FGFR2, and disrupts the
structure of IgIII domain. Since Cys342, which normally forms an intramolecular disulfide bond
with Cys278, is mutated, Cys278 becomes unpaired and forms a disulfide bond with Cys278 of a
neighboring similarly mutated FGFR2. Disruption of the disulfide bonds within these domains
receptor-dimerization leads to formation of constitutively active homodimers, which however are
unable to bind FGF ligands (311, 313-317).

Mice with the germline Pro253Arg (P253R) mutation of Fgfr2 are smaller in size and
exhibit craniofacial abnormalities (craniosynostosis, reduced cranial length) (318). Similarly,
BALB/c Fgfr2C342Y/+ mice exhibit somatic growth deficiency, midface hypoplasia, and reduced
bone volume and density in neural-crest-derived frontal bones (but not in mesoderm-derived
parietal bones) (319).

Similarly, mice with germline Ser250Trp (S250W) mutation of

Fgfr2 (equivalent to the human Apert mutation S252W) exhibit severely reduced body size and
severe craniofacial abnormalities, including craniosynostosis and markedly decreased cranial
length. Further analysis has demonstrated that this mutation does not affect osteoblast
proliferation or differentiation but induces apoptosis in cells of the cranial sutures (320).
However, some other studies have associated activating mutations of Fgfr2 with the
increased/accelerated proliferation and differentiation of osteoprogenitor cells during the process
of cranial suture growth and closure, which results in premature suture closure and smaller size
of the skull (321, 322).
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Recent studies have also demonstrated that Fgfr2S252W/+ mice display markedly reduced
body size, decreased growth and mineralization of the mandible due to decreased number of
osteoblasts and increased number of osteoclasts, suggesting the role of FGF receptors in
osteoclastogenesis (323).

In vitro studies have demonstrated conflicting (both positive and negative) effects of
Fgfr2 in osteogenic differentiation of osteoblasts. Expression of Fgfr2 is increased in confluent
osteoblast cultures, and its transfection into C3H10T1/2 pluripotent cells leads to increased
mineralization and expression of osteogenic markers (Runx2, Type I collagen, Osteocalcin) (324).
Similarly, osteoblasts derived from Apert patients and cultured under mineralization-inducing
conditions display markedly increased/accelerated osteogenic differentiation (325) and increased
expression of osteogenic markers (Alp, Type I collagen and Osteocalcin) (326). Dominantnegative Fgfr2 (DN-FGFR2) greatly decreases the number of proliferating osteoblasts,
suggesting that Fgfr2 is important for cell proliferation and can be downregulated in postmitotic
cells (213). Overall, these results suggest that Fgfr2 acts as a positive regulator of bone
formation.

In contrast, it has demonstrated that OB-1 osteoblasts expressing C342Y (Crouzon)
mutation of Fgfr2 are able to produce extracellular matrix, however failed to mineralize it (327).
Similarly, transfection of chicken calvaria osteoblasts with viruses carrying dominant-negative
Fgfr2 markedly decreases cell proliferation, but increases the amount of mineralization and Alp
expression. In contrast, viruses carrying activating P253R (Apert) or C278F (Pfeiffer and
Crouzon) mutations of Fgfr2 display increased cell proliferation and greatly decreased extent of
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mineralization (215). Primary BMSC cultures derived from Fgfr2C342Y/+ mice exhibit increased
expression of markers of osteogenic differentiation (Runx2, Bsp, Type I collagen, Osteocalcin) at
early stages of cell differentiation, however levels of their expression is decreased during late
stages of cell differentiation. In addition, when implanted subcutaneously, these cells produce
markedly lower amounts of the mineralized tissue as compared to cells derived from wild-type
control animals (328). Cultured calvaria osteoblasts isolated from frontal bones of these mice
displayed noticeably decreased amounts of mineralization as compared to the wild-type control
(319). Increased expression of markers of osteoblast differentiation (Alp, Type I collagen,
Osteocalcin, Runx2) in chick calvaria osteoblast cultures correlates with the decreased
expression of Fgfr2 (213). Expression of Fgfr2c in differentiating ADSC cells peaks in
undifferentiated cells and decreases substantially after induction of mineralization (303).

Roles of FGFR Signaling in Dentinogenesis.

Expression of Fgf2 during mouse embryonic development is localized to the dental
mesenchyme and dental papilla cells (115). In the developing mouse root structures, FGF2 is
localized to the differentiating odontoblasts (114). Intense expression of FGF2 protein is
observed in the layer of odontoblasts, dentin matrix and dental papilla cells immediately below
the odontoblast layer (118). These results indicate that FGF2 may be important during various
stages of odontoblast differentiation, especially in early odontoprogenitors.

Previous studies have demonstrated a specific pattern of expression of FGFRs in cells at
early and more advanced stages of their differentiation. Similar to cells of the osteoblast lineage,
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expression of Fgfr1c increases from undifferentiated dental pulp cells and preodontoblasts to
postmitotic secretory/functional odontoblasts, however Fgfr2c is expressed in dental follicle but
not in odontoblasts (117). Expression of Fgfr3 is primarily localized to the dental papilla cells
but not to more mature cells (117). Overall, these studies demonstrate a differential pattern of
FGFR1 and FGFR2 expression during odontoblast differentiation in vivo and suggest that they
act as important regulators of intracellular signaling in undifferentiated cells and cells committed
to the odontoblast lineage.

In contrast to multiple studies on the effects of Fgf2 deletion or overexpression on bone
formation, very little information is available on dentinogenesis.

In addition, studies on the effects of FGF/FGFR signaling on dentinogenesis are not well
understood, as most of studies have examined the tissue-specific deletions of Fgf2 and/or Fgfrs
only in the epithelial tissues. Conditional inactivation of Fgfr1 under the control of a Keratin 14
promoter (K14-Cre;Fgfr1fl/fl mice) leads to abnormal ameloblast structure and enamel defects in
both molars and incisors by 8 weeks of age, whereas odontoblasts appear to be unaffected (329).
Tissue-specific inactivation of Fgfr2 in the epithelium results in markedly decreased levels of
DMP1 and DSP proteins (330). Conditional inactivation of Fgfr2IIIb in the dental epithelium
using Nkx3.1-Cre results in the defects in enamel, impaired odontoblast organization and reduced
expression levels of Dmp1 and Dspp (330). Injections of BMS-645737, an inhibitor of both
FGFR and VEGFR2, lead to degeneration and necrosis of odontoblasts and formation of thinner
dentin in rat incisors (331).
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Transgenic mice expressing a dominant-negative chimeric FGFR2 protein (dnFGFR-HFc
mice) display lack of tooth buds by E18.5 (332), whereas homozygous mice lacking the IIIbspecific isoform of Fgfr2 (Fgfr2IIIb−/− mice) display arrest in tooth development beyond the bud
stage (E13.5) (333). Targeted inactivation of the IIIb-specific isoform of Fgfr2 in Fgfr2IIIb–/–lacZ
mice display tooth agenesis by E16.5 (334). Specific deletion of Fgfr2 in the dental epithelium in
K14-Cre;Fgfr2fl/fl mice resulted in a delay in tooth formation at the bud stage, most likely due to
the decreased proliferation of dental epithelium cells (335). Similarly, targeted deletion of
Fgfr2IIIb from the mouse germline using Cre recombinase results in the arrest of tooth
development at the bud stage (333).

Overall, these results have demonstrated that FGFRs are important for tooth development,
however the exact role of FGF/FGFR signaling in regulation of odontoblast differentiation
during tooth development is still largely unclear.

Roles of FGFR Signaling in Reparative Dentinogenesis.

Both dentin matrix and dental pulp cells contain FGF2, and its large amounts can be
released from the dental pulp fibroblasts or endothelial cells upon their injury (106, 126, 336,
337).

Beads loaded with FGF2 led to formation of numerous groups of polarized cells without
deposition of mineralized matrix (130). In other studies, the formation of mineralized tissue in
the area of pulp exposure in response to FGF2 has been observed, however this mineralized
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tissue does not contain dentinal tubules, suggesting formation of osteodentin (136). More recent
studies have expanded our understanding of the role of FGF2 in dentin regeneration. Using
FGF2-carrying gelatin hydrogel microspheres and collagen sponges as a scaffold, Kikuchi et al.
demonstrated formation of DSP+ mineralized tissue in the area of pulp exposure 21 days after
surgery (338). However, authors conclude that the regenerated dentin-like tissue is a porous
aggregate composed of dentin-like particles, whereas physiological tertiary dentin is non-porous.
Using the same model, formation of DMP1+/Nestin– osteodentin on the surface of the
regenerated pulp by FGF2 has been demonstrated, whereas no effect is observed at lower
concentrations (137). Overall, these observations suggest that the controlled release of FGF2 can
induce formation of reparative dentin in vivo, however further studies are needed to optimize the
concentrations of FGF2, duration of exposure and scaffold materials for more controlled release
of FGF2.

Similar to the studies on bone, reports on the effects of FGF2 on odontoblast differentiation
also showed conflicting (both positive and negative) effects.

Dental pulp cells isolated from different species display marked increases in proliferation
upon treatment with FGF2, suggesting that it stimulated odontoprogenitor cells (339-343).
Similarly, FGF2-soaked beads markedly increase cell proliferation of E11 dental mesenchyme ex
vivo (117). Concentration-dependent increases in cell proliferation in response to FGF2 have also
been demonstrated (126, 344).
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Rat incisor pulp cells cultured on Type I collagen-coated gel culture exhibit a pronounced
increase in the expression of Dspp (343). Continuous exposure of hTERT-immortalized human
pulp cells to FGF2 between days 0-14 stimulates their dentinogenic differentiation and increases
expression of Dmp1 and Dspp (345).

In addition, some ex vivo studies suggest that FGF2 in combination with other growth
factors can be involved in regulation of odontoblast polarization and functional activity.
Combination of FGF2 and BMP4 potentiates FGF2-induced increases in the expression of Dspp
(343). Cultured mouse dental papillae (E17 bell stage) exposed to FGF2 or TGFβ1 alone for 6
days do not exhibit visible morphological changes or predentin secretion. However combination
of these growth factors induces cell polarization and leads to intense secretion of extracellular
matrix, suggesting stimulation of functional differentiation of odontoblasts (346, 347).

In contrast to these the positive effects, several studies have shown the negative effects of
FGF2 on dentinogenesis. Continuous exposure of dental pulp cells isolated from various species
to FGF2 increases proliferation and significantly decreased mineralization, ALP activity and
expression of various markers of dentinogenesis, including Dspp (126, 339-342, 344, 348).
Continuous exposure of immortalized pulp cells to 50 ng/ml FGF2 inhibited their dentinogenic
differentiation while lower concentrations of FGF2 (1-10 ng/ml) positively regulate expression
of Dmp1 and Dspp in these cells (345), further raising a possibility of a concentration-dependent
effects of FGF2 on dentinogenesis.
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Although extended exposure of differentiating human dental pulp cells to FGF2 greatly
decreases the extent of mineralization, withdrawal of FGF2 almost completely reverses this
inhibitory effect (126). This suggests that cells continuously exposed to FGF2 do not dedifferentiate or die, but retain their dentinogenic potential and are capable of differentiating into
mature odontoblasts upon withdrawal of FGF2.

Mouse tooth germs (E17 bell stage) exposed to FGF2 for 4 days display marked
decreases in dentin formation and expression of Dspp and Alp, whereas Fgf2-specific antisense
oligodeoxynucleotides exerted an opposite effect. Interestingly, authors noted that the same
treatment of the tooth germs isolated at the earlier stage of their development (E15 cap stage)
results in some stimulatory effects on expression of Dspp and Alp. This may suggest that FGF2
stimulates dentinogenic differentiation of less mature odontoblasts and inhibits dentinogenic
differentiation of more mature odontoblasts (349).

Overall, these results suggest that FGF2 exerts both positive and negative effects on
dentinogenic differentiation of dental pulp cells. It is important to note that cells continuously
exposed to FGF2 remain capable of differentiating into mature odontoblasts, suggesting that
FGF2 prevents terminal differentiation of odontoprogenitor cells. However, studies
demonstrating stage-specific effects of FGF2 on odontoprogenitor cells have not been reported.

49

CHAPTER II

SPECIFIC AIMS.

Specific Aim #1: To Examine the Effects of Continuous Exposure of Primary Dental
Pulp Cultures to FGF2 on Dentinogenesis.

A. Examine the effects of continuous exposure to FGF2 on mineralization, expression of
markers of mineralization and dentinogenesis, expression of various transgenes (Col1a1GFP, DMP1-GFP and DSPP-Cerulean) in unsorted (whole) primary dental pulp cultures.
B. Examine the effects of continuous exposure to FGF2 on mineralization, expression of
markers of mineralization and dentinogenesis in FACS-sorted 2.3-GFP– (progenitors)
and 2.3-GFP+ (cells at early stages of differentiation) subpopulations.
C. Compare the effects of continuous exposure to FGF2 on mineralization, expression of
markers of mineralization and dentinogenesis, expression of various GFP transgenes
(Col1a1-GFP and DMP1-GFP) in primary dental pulp and bone marrow stromal cell
cultures.

Specific Aim #2: To Examine the Effects of FGF2 on Progenitors and Cells at Early
Stages of Differentiation (Early Exposure).
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A. Examine the effects of early exposure to FGF2 on mineralization, expression of markers
of mineralization and dentinogenesis, expression of various transgenes (Col1a1-GFP,
DMP1-GFP and DSPP-Cerulean) in unsorted (whole) primary dental pulp cultures.
B. Examine the signaling pathways involved in mediating the effects of early exposure to
FGF2 on dentinogenic differentiation in unsorted (whole) primary dental pulp cultures.
C. Examine the effects of early exposure to FGF2 on proliferation, mineralization,
expression of markers of mineralization and dentinogenesis in FACS-sorted 2.3-GFP–
(progenitors) and 2.3-GFP+ (cells at early stages of differentiation) subpopulations.

Specific Aim #3: To Examine the Effects of FGF2 on Cells at More Advanced Stages of
Differentiation (Late Exposure).

A. Examine the effects of late exposure to FGF2 on mineralization, expression of markers of

mineralization and dentinogenesis, expression of various transgenes (Col1a1-GFP,
DMP1-GFP and DSPP-Cerulean) in unsorted (whole) primary dental pulp cultures.
B. Examine the signaling pathways involved in mediating the effects of late exposure to

FGF2 on dentinogenic differentiation in unsorted (whole) primary dental pulp cultures.
C. Examine the effects of late exposure to FGF2 on mineralization and expression of

markers of mineralization and dentinogenesis in FACS-sorted 2.3-GFP– (progenitors)
and 2.3-GFP+ (cells at early stages of differentiation) subpopulations.
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CHAPTER III

MATERIALS AND METHODS.

CELL CULTURES:
Primary dental pulp cultures. The coronal portions of the pulps from first and second
molars were isolated from 5-7-day-old hemizygous pOBCol3.6GFP (referred to as 3.6-GFP),
pOBCol2.3GFP (referred to as 2.3-GFP), DMP1-GFP, DSPP-Cerulean and non-transgenic pups
as described previously (350, 351). All mice were maintained in the CD1 background. After
isolation, 8.75×104 cells/cm2 were grown first in Dulbecco's modified Eagle’s medium (DMEM),
20% fetal bovine serum (FBS), 2 mM L-glutamine, 40 U/ml penicillin, 40 µg/ml streptomycin
and 0.1 µg/ml Fungizone (Invitrogen). Three days later, the medium was changed to DMEM
containing 5% FBS. At day 7, mineralization was induced by addition of medium containing
Minimum Essential Medium alpha (αMEM), 5% FBS, with 50 µg/ml fresh ascorbic acid and 4
mM β-glycerophosphate. Medium was changed every other day.

Primary bone marrow stromal cell (BMSC) cultures. BMSCs were prepared from
femurs and tibiae of 5-7-day-old pups as described before (352). Briefly, single cell suspension
was prepared from flushed marrows, plated at a density of 6.5×105 cells/cm2 and grown in
αMEM containing 10% FBS, 40 U/ml penicillin and 40 µg/ml streptomycin. Three days later,
the medium was changed to the medium containing αMEM and 5% FBS. At day 7, when the
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cells became confluent, the medium was switched to the mineralization-inducing medium
containing αMEM, 5% FBS, with 50 µg/ml fresh ascorbic acid and 4 mM β-glycerophosphate.
Medium was changed every other day.

FGF2 treatment of primary cultures. To examine the effects of FGF2, low molecular
weight (18 kDa) bovine FGF2 (R&D systems, Inc., Minneapolis, MN) was added to these
cultures every other day at different time points: during both proliferation and
differentiation/mineralization phases of in vitro growth (between days 3-21, referred to as
continuous exposure); during only proliferation phase of in vitro growth (between days 3-7,
referred to as early exposure); and during only differentiation/mineralization phase of in vitro
growth (between days 7-21, referred to as late exposure). For all experiments, vehicle (VH, 0.1%
BSA fraction V in PBS) served as a control.

Detection and quantification of mineralization in primary cultures. Mineralization in
live cultures was examined by Xylenol Orange (XO) staining as described previously (352, 353).
The mean epifluorescence intensity of XO staining was measured using a multidetection
monochromator microplate reader (Safire2, Tecan, Research Triangle Park, NC) as described
previously (354) with minor modifications. Fluorometric measurements were performed at
570/610 nm wavelength (excitation/emission) and gain of 80. The entire area of each well was
read at a scan density of 6×6 regions (high sensitivity flash mode). Background fluorescence for
XO was measured using cultures from preodontoblastic Q705 cell line (355) that lacks a
mineralization potential. The background fluorescence values were subtracted from respective
XO measurements.
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Mineralization in fixed cultures was examined using a modified von Kossa silver nitrate
staining protocol as described previously (352). After staining, cultures were rinsed and images
were acquired using a scanner. The area of mineralization (black precipitate) in each well was
quantified using NIH ImageJ software and is represented as the percentage of total area analyzed
as described before (352).

Immunocytochemistry. Pulp cells were processed for immunocytochemistry as
described previously (356) with minor modifications. Cells were fixed with 3.7% formaldehyde
in PBS for 4 minutes at room temperature (RT), incubated with 0.5% Triton X in PBS for 10
minutes at RT and blocked with 3% milk for 1 hr at RT. For detection of DSPP-Cerulean,
cultures were incubated with 1:1000 dilution of anti-GFP Alexa Fluor 488 conjugated antibody
(Invitrogen) in 0.3% Triton X in PBS overnight at +4°C. In these cultures, the anti-GFP antibody
binds specifically to the Cerulean fluorescent protein to enhance its visualization.

Percentage of DSPP-Cerulean+ odontoblasts in cultures was calculated as the ratio of
cells stained with anti-GFP antibody (DSPP-Cerulean+ odontoblasts) to the total number of
Hoechst+ cells. Approximately 20,000-50,000 Hoechst+ cells were counted from 20-60 different
representative areas of the culture. Negative controls included primary BMSC cultures derived
from DSPP-Cerulean littermates and stained with anti-GFP antibody and primary dental pulp
cultures derived from DSPP-Cerulean littermates without addition of anti-GFP antibody.
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For detection of phospho-Erk1/2, cultures were incubated with 1:200 dilution of rabbit
anti-mouse phospho-Erk1/2 primary antibody (Cell Signaling, Boston, MA) and then with 1:400
secondary Alexa Fluor 488 goat anti-rabbit antibody (Invitrogen) for 1 hr at RT. The nuclei were
stained with 1.0 µg/ml Hoechst 33342 dye (Molecular Probes, Invitrogen) for 15 minutes at RT.
After staining, coverslips were mounted using Dako Fluorescent Mounting Medium (Dako North
America, Inc., Carpinteria, CA) and visualized under the microscope.

Digital imaging and epifluorescence analysis of primary cultures. GFP expression in
cell cultures at various time points was examined using Zeiss AxioObserver Z.1 microscope
equipped with AxioCam MRc digital camera and appropriate filters. Exposure times were
adjusted for optimum imaging, and kept consistent for each time point of the culture. Panoramic
images of larger areas of the cultures were obtained using a computer-controlled motorized
imaging workstation and Zeiss AxioObserver Z.1 microscope.

Epifluorescence intensity of GFP. The mean epifluorescence intensity of GFP
transgenes in each well was measured as described for XO staining. Fluorometric measurement
was performed at 483/525 nm wavelength (excitation/emission) for the 2.3-GFP transgene and at
500/540 nm wavelength for the 3.6-GFP and DMP1-GFP transgenes (gain 80 for all transgenes).
Background fluorescence for GFP was measured using dental pulp cultures from non-transgenic
littermates, and these values were subtracted from respective GFP measurements.

Fluorometric measurements were also obtained in DSPP-Cerulean cultures stained with
anti-GFP antibody (500/540 nm wavelength and gain 80) and Hoechst 33342 dye (343/483 nm
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wavelength and gain 70). Background fluorescence for GFP was measured using BMSC cultures
from DSPP-Cerulean littermates stained with anti-GFP antibody, and these values were
subtracted from respective GFP measurements.

RNA ANALYSIS:
RNA extraction and quantitative PCR (qPCR) analysis. Total RNA was isolated
using TRIzol reagent (Life Technologies, Carlsbad, CA) according to the manufacturer's
protocol and treated with RNase-free DNase to eliminate genomic DNA. Isolated RNA was
reverse transcribed by Superscript II Reverse Transcriptase with Oligo(dT)12–18 primers (Life
Technologies, Grand Island, NY). Gene expression in the cultures was examined by qPCR
analysis using the 2-ΔΔCT method as described previously (357-359). For TaqMan qPCR reactions,
9 ng of cDNA was combined with 5 µl TaqMan Universal PCR Master Mix (Applied
Biosystems, Branchburg, NJ), 2.5 µl H2O and 0.5 µl TaqMan primers (total 10 µl). TaqMan
primers for Bsp, Dmp1, Dspp, Gapdh, Osteocalcin, Osterix (Osx), Phex, Runx2 and Type I
collagen were purchased from Applied Biosystems (Table 1). For SYBR Green qPCR, 9 ng
cDNA was combined with 5 µl SYBR Green PCR Master Mix (Applied Biosystems, Warrington,
UK), 0.5 µl SYBR Green primers (2 µM forward and reverse) and 2.5 µl H2O (total 10 µl). All
qPCR reactions were run using 7900HT Fast Real-Time PCR System (Applied Biosystems)
under the following conditions: 50°C for 2 min, 95°C for 10 min, and 40 cycles with
denaturation at 95°C for 15 s and extension at 60°C for 1 min. SYBR Green primers for
Ameloblastin (Ambn), Ank, Bmp2, Bono1, Dkk3, Dlx5, Fgfr1c, Fgfr2c, Gapdh, Msx2, Nkd2,
Phex, Tnap, Wisp2 and Wnt10a (Table 2) were designed using MacVectorTM 12.7.5 software
(MacVector, Inc., Cary, NC) and tested to ensure high specificity. Melting curves confirmed the
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amplification of only one specific PCR product (Figure 1A) and its size was confirmed by gel
electrophoresis on 2% agarose gel (Figure 1B). Amplification efficiency was determined using
internal standard curves derived from a purified amplicon, diluted 2-fold (0.14 - 9.0 ng), and was
close to 100% for all qPCR reactions. We defined the acceptable range of CT values representing
gene expression to be between 10 and 35 cycles, according to manufacturer’s recommendations
(Applied Biosystems).

Reverse-transcriptase (RT)-PCR. Expression of Dmp1, Dspp, Fgfr1c, Fgfr2c and
Gapdh was examined using RT-PCR analysis. Primers were designed using MacVectorTM 12.7.5
software (MacVector, Inc., Cary, NC) and demonstrated specific amplification of only one target
gene. For all RT-PCR reactions, 2 µl (100 ng) of cDNA was combined with 48 µl of Master Mix
(8 µl 1.25 mM dNTP (Qiagen), 5 µl 10x PCR buffer (Invitrogen), 1.5 µl 50 mM MgCl2
(Invitrogen), 2 µl forward and reverse primers each, and 0.5 µl recombinant Taq DNA
Polymerase (Invitrogen) and 31 µl H2O). All reactions were performed using a 2720 Thermal
Cycler (Applied Biosystems, Foster City, CA) under the conditions described in Table 3. The
RT-PCR products were analyzed by gel electrophoresis on 1% agarose gel with addition of
ethidium bromide for 45 min at 100 V in 1x UltraPure Tris–borate–EDTA (TBE) buffer (Life
Technologies). The DNA bands were visualized under the UV light at 395 nm.

Cell cycle analysis. Pulp cultures were established from the 2.3-GFP transgenic mice as
described above. Cells were treated with VH or FGF2 starting day 3 (0 hrs) and processed for
cell cycle analysis 24-96 hrs after treatment (days 4-7 of the culture). Cell cycle and rate of
proliferation in the 2.3-GFP– and 2.3-GFP+ populations were examined by FACS-based cell
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cycle analysis using Hoechst 33342 nuclear dye. Cultures were detached by trypsin/EDTA,
resuspended in the staining medium (1x HBSS, 2% FBS, 10 mM HEPES, in distilled H2O, pH
7.2), and incubated at 37°C for 90 minutes in the dark with 1 µg/ml propidium iodide (PI) and
Hoechst 33342 (400 µl of 7.5 µg/ml solution per 500,000 cells) (Molecular Probes, Invitrogen,
USA). Cells were strained through a 70 µm strainer to obtain single-cell suspension. Negative
controls included (i) pulp cultures from non-transgenic littermates stained with PI, (ii) pulp
cultures from non-transgenic littermates stained with Hoechst, and (iii) 2.3-GFP+ cells without
PI and Hoechst. Approximately 50,000-70,000 cells/sample were analyzed in a BD LSRII flow
cytometer (BD Biosciences, San Jose, CA) with a blue laser (excitation 488 nm at 20 mW;
collected emission at 515-545 nm at 20 mW). Samples were analyzed by single-cell gating.
Percentages of the 2.3-GFP− and 2.3-GFP+ cells at G0/G1, S, G2/M and S+G2/M cell cycle
phases were determined using ModFit LT cell-cycle analysis software (Verity Software House,
Topsham, ME).

WST-1 cell proliferation assay. Cell proliferation was examined by WST-1 rapid cell
proliferation assay according to manufacturer’s instructions (EMD Millipore Corporation,
Billerica, MA). The assay is based on the cleavage of the tetrazolium salt, WST-1, to formazan
by cellular mitochondrial dehydrogenases. Increases in the number of viable cells result in
increases in the amount of formazan dye formed. Pulp cells were cultured in a 96-well microtiter
plate (17×103 cells/cm2), treated with VH or FGF2 starting day 3 (0 hrs) and processed for WST1 assay at 24, 48, 72 and 96 hrs after treatment. The amount of the formazan dye produced was
quantified by the optical density (OD) at 450 nm using a Synergy™ HT Multi-detection
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microplate reader and analyzed using Gen5TM 1.09 Data Analysis Software (BioTek Instruments,
Winooski, VT).

FLOW CYTOMETRY:
Flow cytometric (FACS) analysis and sorting. Cells were processed for FACS analysis
between days 4-7 (24-96 hrs of treatment) by mild 0.05% trypsin/EDTA (Invitrogen, USA)
digestion followed by centrifugation at 4°C. Cells were then resuspended in 300-400 µl of the
staining medium containing 1.0 µg/ml PI, and strained through a 70 µm strainer to obtain singlecell suspension. Approximately 50,000-100,000 cells/sample were collected by a BDTM LSR-II
FACS cytometer (BD Biosciences, San Jose, CA) using a blue laser (excitation 488 nm at 20
mW; collected emission at 515-545 nm). Percentages of GFP+ and GFP– cells were determined
using BD FACSDiva™ 6.2 software. Pulp cells from non-transgenic littermates served as a
negative control for GFP expression in all experiments.

For FACS sorting, pulp cells from 2.3-GFP transgenic mice were grown either with VH
or FGF2 for 7 days. At day 7, cultures were prepared by mild 0.05% trypsin/EDTA digestion
followed by centrifugation at 4°C. FACS based on GFP expression was performed on 2.5×106
cells/ml by UCHC FACS facility using a BD FACSAriaTM II cell sorter (130 µm nozzle at 12
PSI) (BD Biosciences, San Jose, CA). GFP was excited at 488 nm with an argon laser and a
550/30 emission filter was utilized. Upon separation, reanalysis confirmed that the purity of 2.3GFP– and 2.3-GFP+ sorted populations was higher than 98%. Live GFP– and GFP+ cells were
collected into DMEM with 20% FBS, recounted and replated at the same density as the primary
cultures (8.75×104 cells/cm2). Cultures were grown in the absence or presence of FGF2 between
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days 3-14 (continuous exposure), 3-7 (early exposure) or 7-14 (late exposure), and processed for
various analyses as described for unsorted cultures.

Inhibition of signaling pathways. The FGFR inhibitor SU5402 (360, 361) (Santa Cruz
Biotechnology, Santa Cruz, CA) and the MEK/Erk1/2 inhibitor U0126 (362, 363) (Promega
Corporation, Madison, WI) were dissolved in DMSO (5 µM stock solution). Each inhibitor was
added to the cultures at various concentrations (5, 10 and 20 µM). The BMP/BMPR inhibitor
noggin (PeproTech, Rocky Hill, NJ) (364-366) was dissolved in 0.1% BSA fraction V in PBS
(50 µg/ml, or 1.08 pM, stock solution), and added to the cultures at final concentrations of 100,
200 and 300 ng/ml (2.16, 4.32 and 6.47 pM, respectively).

Bioinformatics analysis. Complete sequences of Dmp1 (chromosome 5:104,202,617104,214,102) and Dspp (chromosome 5: 104,170,712-104,180,127) genes, as well as the
sequences corresponding to their respective transcription start codons, were obtained from
Ensembl genome browser (www.ensembl.org). Mapping of potential AP-1, CRE and CRE-like
binding elements was performed in the region within 25.000 bp upstream of the transcription
start using MacVectorTM 12.7 software (MacVector, Inc., Cary, NC).

Statistical analysis. Statistical analysis was performed by GraphPad Prism 6 software
using one-way ANOVA analysis with the Bonferroni’s multiple comparison post-test or
unpaired two-tailed Student t-test. In all experiments values represent mean ± SEM of at least
three independent experiments, and a *p-value ≤ 0.05 was considered statistically significant.
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Figures.
A.

B.

Figure 1. Melting curves and gel electrophoresis for products amplified during SYBR
Green qPCR reactions. A. SYBR Green qPCR reactions were run using control culture sample
at day 14. Reaction products were analyzed to ensure primer specificity and amplification of
only a single amplicon. All melting curves demonstrate the amplification of only a single target
gene evidenced by a single peak. B. Products of the SYBR Green qPCR reactions were run on a
1.5% agarose gel to verify that the single amplicon in each reaction is of predicted size (see
Table 2). Gel electrophoresis demonstrated that amplified products are of a predicted size
ensuring the specificity of SYBR Green qPCR reactions. Lane 1. 10 bp DNA ladder; Lane 2.
Ambn; Lane 3. Ank; Lane 4. Bmp2; Lane 5. Bono1; Lane 6. Dkk3; Lane 7. Dlx5; Lane 8.
Fgfr1c; Lane 9. Fgfr2c; Lane 10. Gapdh; Lane 11. Phex; Lane 12. Msx2; Lane 13. Nkd2; Lane
14. Tnap; Lane 15. Wisp2; Lane 16. Wnt10a.
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Tables.
Gene ID
Bsp
Dmp1
Dspp
Gapdh
Osteocalcin
Osx
Phex
Runx2
Type I collagen

Assay ID
Mm01208381_g1
Mm00803831_m1
Mm00515666_m1
Mm99999915_g1
Mm03413826_mH
Mm00504574_m1
Mm00448119_m1
Mm03003491_m1
Mm00801666_g1

Table 1. Primers used for TaqMan qPCR reactions.
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Gene
Ambn
Ank
Bmp2
Bono-1
Dkk3
Dlx5
Enpp1
Fgfr1c
Fgfr2c
Gapdh
Msx2
Nkd2
Phex
Tnap
Wisp2
Wnt10a

Product size
(bp)

Primer sequence
5' TCAGACACGAAGGAGGTGAGGGCG 3'
5' GGGACCGATAAGGGAGGGGCAGAG 3'
5' GGGCTACTACAGGAACATCCACGAC 3'
5' GGACACGAAGAGGTTGACAATGGG 3'
5' GTTGCTGCTCCAGGTCCCTCGGA 3'
5' CCCGGCCCGTGTCCTCTACCTTTAG 3'
5' CCAGCACCATCACCCCAACCTGAAG 3'
5' CGCACACACACACCAGCATCACCTC 3'
5' TGGGGGTTCGTCTCACTGGGGTAAG 3'
5' TCAGCAAAAGTCTGGGTGGGTAGCC 3'
5' CCCCTTCTTTTCCCTCCCAACCC 3'
5' CCAACTCCCTTCAGTCCCCTCGG 3’
5' CCCCTTCTTTTCCCTCCCAACCC 3'
5' CCAACTCCCTTCAGTCCCCTCGG 3’
5’ TCCATCCCCGCTGACTCTGGC 3’
5’ CAGGCCTACGGTTTGGTTTGGTGTT 3’
5' GGTCAGCTGGGGGCGCTTCA 3'
5' CGGGGGCAACCACGTACGCTT 3'
5' GGAGAGTGTTTCCTCGTCCCGTAG 3'
5' TGCCGTGAGTGGAGTCATACTGG 3'
5' GCGGTGACTTGTTTTCGTCGGATG 3'
5' GAGACCTTGACCCTGCGTTCCTCTG 3'
5' GCCCTTGTCTCACCTCCTCTTGCC 3'
5' TTGCTGCCTTCTCCCCATCATCTG 3'
5’ TGGAGACTGGAAAGGGGACCAACC 3’
5’ TGATGGCAGCAGCGGCTTCTATG 3’
5' ACAGACCCTCCCCACGAGTGC 3'
5' ACCCTGAGATTCGTCCCTCGC 3'
5' CCCACGCCCCAGGAGAATACAGG 3'
5' TTCCCCGCACTCACTCACCTTGG 3'
5' CAAGGCACTGGGATGACTGGCAGAG 3'
5' GGCAGACAGGGGAGGATGAGAGGAG 3'

Annealing
temperature,°C

108

56.2

160

60.2

120

59.4

116

56.4

117

58.6

120

59.8

200

59.2

181

60.7

161

59.5

186

58.7

109

61.8

112

58.9

174

59.0

122

59.5

119

61.6

116

58.8

Table 2. Primers, conditions and expected product sizes for SYBR Green qPCR reactions.
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Gene
Dmp1
Dspp
Fgfr1c
Fgfr2c
Gapdh

Primer sequence
5' TTTGGCTGGGTCACCACCACC 3'
5' ACCTCCCACCCGCTGTTCCTC 3'
5’ GGCATAATCAAAACACCGCTGC 3’
5’ GGGGAAATAGGGAAATGACAAAGG 3’
5’ TCCATCCCCGCTGACTCTGGC 3’
5’ CAGGCCTACGGTTTGGTTTGGTGTT 3’
5' GGTCAGCTGGGGGCGCTTCA 3'
5' CGGGGGCAACCACGTACGCTT 3'
5’ TGAAGGTCGGTGTGAACGGATTTGGC 3’
5’ CATGTAGGCCATGAGGTCCACCAC 3’

Product size (bp)/
Number of cycles

Ta,°C

466/25

61.9

556/35

56.8

181/30

60.7

161/30

59.5

983/20

55.0

Table 3. Primers, conditions and expected product sizes for RT-PCR reactions.
For Dmp1 reactions, samples were incubated at 95°C for 10 min followed by 25 cycles at 95°C
for 30 s, 55°C for 1 min, 72°C for 1 min, and extension at 72°C for 10 min. For Dspp reactions,
samples were incubated at 95°C for 10 min followed by 35 cycles at 95°C for 30 s, 55°C for 1
min, 72°C for 1 min, and extension at 72°C for 10 min. For Fgfr1c and Fgfr2c reactions, samples
were incubated at 95°C for 10 min followed by 30 cycles at 95°C for 30 s, 60°C for 1 min, 72°C
for 1 min, and extension at 72°C for 10 min. For Gapdh, which served as a housekeeping gene,
samples were incubated at 95°C for 10 min followed by 20 cycles at 95°C for 30 s, 55°C for 1
min, 72°C for 1 min, and extension at 72°C for 10 min. All primers were designed to amplify a
single specific product. Ta = annealing temperature. All the primers, except for Gapdh, were
designed to span an intron to avoid and/or identify amplifying of contaminating genomic DNA,
which could result in generation of a larger size product.
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CHAPTER IV

EFFECTS OF CONTINUOUS EXPOSURE OF PRIMARY DENTAL PULP CULTURES
TO FGF2 ON DENTINOGENESIS.

Abstract.

Reparative dentinogenesis is a complex and multistep process, which is regulated by
various growth factors, including members of the Fibroblast Growth Factor (FGF) family.
However, both positive and negative effects of FGFs on dentinogenesis have been reported but
the underlying mechanisms of these conflicting results are still unclear. In the present study we
used dental pulp cells obtained from various transgenic mice in which the fluorescent protein
expression identifies cells at different stages of odontoblast differentiation to gain better insight
on the role of FGF2 on mineralization and dentinogenesis. Our results showed that continuous
exposure of pulp cells to FGF2 during both proliferation and differentiation/mineralization
phases of in vitro growth resulted in marked decreases in the extent of mineralization, and
exerted biphasic effects on the expression of markers of mineralization and dentinogenesis and
expression of various transgenes. Exposure of dental pulp cells to FGF2 during the proliferation
phase of in vitro growth resulted in increased levels of expression of markers of mineralization
and dentinogenesis and expression of DMP1-GFP transgene. Additional exposure of these cells
to FGF2 during the differentiation/mineralization phase of in vitro growth resulted in decreases
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in the extent of mineralization, expression of markers of mineralization and dentinogenesis, and
expression of DMP1-GFP and DSPP-Cerulean transgenes. Recovery experiments showed that
the inhibitory effects of FGF2 on mineralization and dentinogenesis were related to the lack of
differentiation of cells into mature odontoblasts. Additional experiments using bone marrow
stromal cell cultures showed differences between the effects of FGF2 on osteoprogenitors and
odontoprogenitors. These observations together show the stage-specific effects of FGF2 on the
expression of Dmp1 and Dspp in dental pulp cells and provide critical information for the
development of improved treatments for vital pulp therapy and dentin regeneration.

66

Introduction.

Fibroblast growth factors (FGFs) are a family of signaling molecules shown to play
essential roles in development, repair and regeneration of damaged skeletal tissues including
cartilage, bone and dentin (151, 156, 277, 367, 368). Currently, the FGF family contains 22
members, which elicit their effects through interaction with four highly conserved
transmembrane tyrosine kinase receptors (FGFR1, FGFR2, FGFR3, and FGFR4) in concert with
heparin or heparan sulfate proteoglycans (184, 367). FGFRs contain an extracellular ligandbinding domain with three immunoglobulin-like domains (IgI, II and III), a transmembrane
domain and a split intracellular tyrosine kinase domain (151, 184). Three major downstream
pathways, which mediate effects of FGF/FGFR signaling on cellular processes, include MAPK,
PI3K/Akt and PLCγ (151, 277).

Previous studies have revealed important roles of FGF signaling in osteogenesis and
dentinogenesis (151, 368). Among FGFs, FGF2 is widely expressed in the cells of odontoblast
and osteoblast lineages and has been identified as a potent regulator of mineralization in vivo and
in vitro (114, 115, 118, 369, 370).

Several studies have shown positive effects of FGF2 on osteogenesis in vivo and in vitro.
Transgenic mice overexpressing 18-kDa isoform of FGF2 under the control of the 3.6-kb
fragment of Type I collagen promoter displayed significantly increased bone mass in vivo and
increased mineralization in bone marrow stromal cell (BMSC) cultures in vitro (233). On the
other hand, deletion of either 18-kDa FGF2 or all FGF2 isoforms decreased osteoblast
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proliferation and mineralization (232, 233). Injection of FGF2 for 7 days resulted in significant
increases in endosteal osteogenesis in rats (371). Transient exposure of BMSC or osteoblast
cultures to FGF2 during the proliferation phase of in vitro growth stimulated proliferation,
expression of markers of mineralization and the amount of mineralized matrix (249, 252, 258,
261, 327).

In contrast, other studies have shown negative effects of FGF2 on osteogenesis. These
studies have demonstrated that despite the stimulatory effects on osteoblast proliferation,
constitutive overexpression of all FGF2 isoforms led to chondrodysplasia (237) and significantly
decreased the extent of mineralization in vitro and bone mass in vivo (239). Continuous exposure
of BMSCs to FGF2 decreased synthesis of Type I collagen, inhibited mineralization and the
expression of markers of mineralization (248, 258, 372). FGF2 also inhibited mineralization and
the expression of markers of mineralization in ADSC cultures (212).

With regard to the effects of FGF2 on dental pulp cells, several studies showed the
mitogenic effect of FGF2 on these cells (126, 339, 341-343, 348). Recent study showed the
stimulatory effects of FGF2 in a 3D collagen gel on homing and migration of dental pulp cells,
resulting in recellularization of dental pulp (125). FGF2 increased the expression of markers of
mesenchymal stem cells Oct4, Nanog and Rex1 (344, 348) and the percentage of STRO-1+ cells
in the dental pulp (342, 348). Recent studies using stem cells from inflamed primary teeth
(iSHFD) showed that FGF2 increased their proliferation and migration potential (146).

Similarly, available literature cites both positive and negative effects of FGF2 on
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dentinogenesis and mineralization. Several studies reported inhibitory effects of FGF2 on
dentinogenesis and the expression of Dspp (126, 146, 339-341, 345, 349). On the other hand,
others have shown stimulatory effects of FGF2 on the formation of osteodentin in vivo (137, 146,
338) and expression of Dspp in vitro (345).

The mechanisms underlying the positive and negative effects of FGF signaling on
dentinogenesis are not well understood and most likely involve multiple intra- and extracellular
mediators and differential responses of various cell populations (373).

Most of the published results are based on observations in whole primary dental pulp
cultures, which are composed of a heterogeneous population of cells including fibroblasts,
macrophages, endothelial cells and lymphocytes, and contain nodules at various stages of
differentiation/mineralization (90, 351, 352, 374). Furthermore, most of the techniques used in
these studies have been endpoint assays that require the termination of cultures at different time
points. Thus, the mechanisms underlying the positive and negative effects of FGF signaling on
odontoblast differentiation are not well understood. This is partially due to the lack of
availability of stage-specific molecular markers for cell lineage studies and the inability to
identify and isolate relatively pure populations of cells from dental pulp during progression into
the odontoblast lineage.

During the past few years we have used a series of GFP reporter transgenic mice, which
display stage-specific activation of transgenes during odontoblast differentiation in vivo and in
vitro, to gain a better understanding of the progression of progenitor cells in the odontoblast
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lineage (90, 351, 375). These studies showed that during odontoblast differentiation, 3.6-GFP
and 2.3-GFP transgenes were activated at early stages in polarizing odontoblasts, i.e. prior to
initiation of mineralization and expression of Dmp1 and Dspp (351). Using DMP1-GFP
transgenic mice we showed that DMP1-GFP transgene was not expressed at early stages of
differentiation, and was first activated in functional/secretory odontoblasts expressing Dmp1 and
low levels of Dspp (90). We also showed that 3.6-GFP, 2.3-GFP and DMP1-GFP transgenes
were expressed at high levels in fully differentiated/mature odontoblasts, and their temporal and
spatial patterns of expression mimicked those of endogenous transcripts and proteins (90, 351,
375).

In addition, we have recently generated new transgenic mice using the bacterial artificial
chromosome (BAC), which directs expression of the DSPP-Cerulean transgene, thus making it a
useful marker for identification of functional and fully differentiated odontoblasts (manuscript in
preparation). Our in vivo studies showed that expression of DSPP-Cerulean transgene was
limited to odontoblasts and correlated closely with the expression of endogenous Dspp. In vitro
studies using primary dental pulp cultures demonstrated that DSPP-Cerulean transgene was not
expressed during the proliferation phase of in vitro growth, and appeared after activation of
DMP1-GFP transgene in a few cells within the mineralized nodules around day 10. The
advancing stages of differentiation were associated with increases in the number of DSPPCerulean+ odontoblasts in the mineralized nodules and increases in the intensity of this
transgene. Overall, these results demonstrated that temporal and spatial patterns of the expression
of DSPP-Cerulean transgene mimicked those of endogenous Dspp and could be used to identify
functional and fully differentiated odontoblasts in the heterogeneous pulp cultures. In addition,
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the availability of these transgenic animals and the utilization of FACS-mediated cell isolation
and enrichment have provided powerful experimental tools for our studies on odontoblast lineage
(90, 351).

Therefore, in this chapter we have used dental pulp cells from various transgenic mice,
which display stage-specific activation of transgenes during odontoblast differentiation, to gain
insight into effects of FGF2 on mineralization and dentinogenesis of dental pulp cells.
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Results.

Effects of continuous exposure to FGF2 on mineralization and dentinogenesis in primary
dental pulp cultures.

Previous studies in our laboratory showed that when placed in primary culture, pulp cells
from unerupted molars proliferated rapidly and reached confluence around day 7 (proliferation
phase of in vitro growth). Following addition of the mineralization-inducing medium at day 7,
these cells underwent differentiation and gave rise to an extensive amount of mineralized matrix
(differentiation/mineralization phase of in vitro growth). The first sign of mineralization
appeared around day 10 with significant increases in the extent of mineralization thereafter. At
day 21 almost the entire culture dish was covered with a sheet of mineralized tissue (352).

Using this well-characterized dental pulp culture system, we examined the effects of FGF2
on mineralization and dentinogenesis. In these experiments, primary pulp cultures were exposed
to

VH

(control)

or

FGF2

between

days

3-21

(during

both

proliferation

and

differentiation/mineralization phases of in vitro growth, referred to as continuous exposure).

Xylenol Orange (XO) (Figure 2A-C and Table 4) and von Kossa (Figure 2D) staining
showed concentration-dependent decreases (up to ~7-fold) in the extent of mineralization in
FGF2-treated cultures as compared to control at all time points. The inhibitory effects of FGF2
on mineralization were not related to marked differences in the cellularity of the cultures
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evidenced by the lack of detectable differences in the intensity of crystal violet staining (Figure
2E).

Quantitative PCR analysis showed continuous increases in the expression of markers of
mineralization and dentinogenesis in control cultures between days 7-21 (Figure 3 and Table 5).
In contrast, FGF2 decreased levels of expression of Type I collagen, Runx2, Bsp, Osteocalcin
and Dmp1 in a concentration-dependent manner at days 10-21 as compared to control (Figure 3
and Table 5). Similarly, expression of Dspp, a marker of odontoblast differentiation, was
markedly inhibited in cultures exposed to 20 ng/ml of FGF2 at days 14-21 (Figure 3 and Table 5).
However, at days 10 and 14 lower concentrations of FGF2 (5 and 10 ng/ml) increased levels of
Dspp as compared to control (Figure 3 and Table 5).

Despite these inhibitory effects at days 10-21, cultures exposed to FGF2 showed transient
and concentration-dependent increases in the levels of expression of all markers of
mineralization and dentinogenesis at day 7 as compared to control (Figure 3 and Table 5). The
most marked increases at day 7 were observed in the expression of Dmp1 (up to ~310-fold)
followed by ~2-fold increases in the expression of Bsp and Osteocalcin (Figure 2). In addition,
although no Dspp expression was detected in the control cultures at day 7, its expression was
stimulated by all concentrations of FGF2 (Figure 3 and Table 5).

These observations showed that continuous exposure of primary dental pulp cultures to
FGF2 resulted in decreased mineralization and biphasic effects on the expression of markers of
mineralization and dentinogenesis. During the proliferation phase of in vitro growth, FGF2
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increased levels of expression of markers of mineralization and dentinogenesis. These increases
were transient and followed by decreases in the expression of these markers and the extent of
mineralization during the differentiation/mineralization phase of in vitro growth. These
observations suggested that the effects of FGF2 on dental pulp cells are stage-specific. As the
most consistent inhibitory effects were observed in cultures exposed to 20 ng/ml FGF2, all
further experiments in this and other chapters of this dissertation were performed using this
concentration.

Effects of continuous exposure to FGF2 on expression of various GFP transgenes in
primary dental pulp cultures.

To gain further insight into underlying mechanisms of the biphasic effects of FGF2, we
examined the effects of FGF2 on pulp cells from a series of GFP reporter transgenic mice that
display stage-specific activation of transgenes during odontoblast differentiation in vivo and in
vitro (90, 351, 375). In these studies 3.6-GFP and 2.3-GFP transgenes were used as markers for
cells at early stages of odontoblast differentiation (polarizing odontoblasts that lack expression of
Dmp1 and Dspp) (351). DMP1-GFP (90) and DSPP-Cerulean (manuscript in preparation)
transgenes were used as markers for cells at later stages of odontoblast differentiation (functional
and fully differentiated odontoblasts). Functional odontoblasts were also identified by high levels
of expression of Dmp1 and low levels of Dspp (90), and fully differentiated odontoblasts by high
levels of Dspp expression.
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In these experiments primary pulp cultures from each transgenic mouse were exposed
continuously to VH or FGF2 between days 3-14.

Epifluorescence analysis of cultures from 3.6-GFP and 2.3-GFP transgenic mice showed
slight increases in the intensity of these transgenes at day 7 followed by marked decreases at
days 10 and 14 in FGF2-treated cultures as compared to the respective controls (Figures 4A-C
and Table 6).

Analysis of cultures from DMP1-GFP transgenic mice showed marked (~38-fold)
increases in the intensity of DMP1-GFP transgene in FGF2-treated cultures as compared to
control at day 7 (Figures 4A-C and Table 6). FACS analysis at day 7 showed that FGF2 did not
affect the percentage of 3.6-GFP+ and 2.3-GFP+ cells, but markedly increased the percentage of
DMP1-GFP+ cells (35.40 ± 2.98%) as compared to control (5.40 ± 0.27%). This indicates that
increases in the intensity of DMP1-GFP transgene and Dmp1 in FGF2-treated cultures at day 7
were at least partially related to increases in the number of DMP1-GFP+ cells. The increases in
the intensity of DMP1-GFP transgene were also followed by marked decreases at days 10 and 14
in FGF2-treated cultures as compared to control. However, despite the changes in the intensity of
expression of DMP1-GFP relative to control, the intensity of DMP1-GFP transgene in FGF2treated cultures between days 7-14 remained relatively constant.

Analysis of FGF2-treated pulp cultures at day 14 showed ~2.3- and 2.6-fold decreases in
the percentage of DSPP-Cerulean+ odontoblasts and intensity of DSPP-Cerulean transgene
expression as compared to control, respectively (Table 7). The percentage of DSPP-Cerulean+
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odontoblasts in cultures exposed to FGF2 was less than half of that in the control cultures,
indicating that reduced levels of Dspp were also at least partially related to the reduced number
of fully differentiated odontoblasts.

The marked increases in the percentage of DMP1-GFP+ cells in FGF2-treated cultures
relative to control at day 7 suggested that FGF2 initially increased the number of functional
odontoblasts in pulp cultures. The decreases in the expression of all transgenes and percentage of
DSPP-Cerulean+ odontoblasts at later time points in FGF2-treated cultures relative to control
indicated that despite the transient increases in the percentage of DMP1-GFP+ cells, continuous
exposure to FGF2 led to inhibition of further mineralization and dentinogenesis in pulp cultures.

Recovery of differentiation of FGF2-treated cells.

Next we examined the reversibility of the inhibitory effects of FGF2 on differentiation of
pulp cells. In these experiments, pulp cells were exposed to FGF2 between days 3-14 and then
grown under the control culture conditions (without FGF2) for additional 7 days till day 21. The
effects of withdrawal of FGF2 on the extent of mineralization and dentinogenesis in these
cultures were examined and compared to those in control cultures (never exposed to FGF2) and
cultures continuously exposed to FGF2 between days 3-21.

XO and von Kossa staining demonstrated that withdrawal of FGF2 for 7 days allowed
almost complete (~90%) recovery of mineralization (Figure 6A and Table 8). Quantitative PCR
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analysis demonstrated that these increases were reflected in the increased expression of various
markers of mineralization and dentinogenesis (Figure 7 and Table 9).

The intensity of XO staining and the extent of mineralization measured by von Kossa
staining at day 21 in these cultures were similar to those in control cultures (Figure 6A and Table
8). Levels of expression of Type I collagen, Bsp and Osteocalcin in these cultures at day 21 were
higher than those in cultures continuously exposed to FGF2, but did not reach those in control
cultures (Figure 7 and Table 9). On the other hand, the levels of Dmp1 in the cultures following
withdrawal of FGF2 were similar to those in control, and levels of Dspp were ~3.2-fold higher
than those in control cultures (Figure 7 and Table 9).

Rapid recovery of mineralization and expression of markers of mineralization and
dentinogenesis in the cultures following withdrawal of FGF2 indicated that continuous exposure
of pulp cells to FGF2 prevented their further differentiation.

Expression of various GFP transgenes after recovery of differentiation of FGF2-treated
cells.

Using pulp cultures from 3.6-GFP, 2.3-GFP, DMP1-GFP and DSPP-Cerulean transgenic
mice we also examined the effects of withdrawal of FGF2 on expression of the respective
transgenes (Figures 6B-D and 8, and Table 10). At day 21, 7 days following the withdrawal of
FGF2, the intensity of expression of 3.6-GFP and 2.3-GFP transgenes reached that in the
respective controls. On the other hand, the intensity of DMP1-GFP and DSPP-Cerulean
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transgenes was higher than that in the respective controls. The percentage of DSPP-Cerulean+
odontoblasts following withdrawal of FGF2 was also higher (~1.2-fold) than that in the control,
indicating the presence of the increased number of fully differentiated odontoblasts (Figures 8A
and 8B).

The increases in the number of DSPP-Cerulean+ odontoblasts and increases in the levels of
Dmp1, Dspp and DMP1-GFP transgene after withdrawal of FGF2 suggested that continuous
exposure of dental pulp to FGF2 increased the number of functional odontoblasts, which upon
withdrawal of FGF2, gave rise to fully differentiated odontoblasts.

Effects of continuous exposure to FGF2 on FACS-sorted 2.3-GFP+ and 2.3-GFP–
populations.

To further confirm stage-specificity of the effects of FGF2 and to gain insight into specific
cell populations responsive to FGF2, we utilized FACS-mediated cell isolation and enrichment
shown to be a powerful experimental tool for lineage studies. Our previous observations on
FACS-sorted populations showed that 2.3-GFP+ population represented proliferative cells
enriched in polarizing odontoblasts, whereas DMP1-GFP+ population represented postmitotic
functional odontoblasts (90, 351).

Based on these observations, we examined the effects of FGF2 on 2.3-GFP+ and 2.3-GFP–
populations. In these experiments, primary pulp cultures from the 2.3-GFP transgenic mice were
first grown in culture conditions supporting their proliferation and expansion in the absence of
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FGF2. At day 7, FACS was used to separate relatively homogeneous populations of 2.3-GFP+
and 2.3-GFP– cells, and reanalysis demonstrated a high (≥ 98%) purity of isolated populations
(Figure 9). Both populations were replated at the same density as unsorted cells and cultured in
the absence or presence of FGF2 between days 3-14 as described for unsorted cultures.

In cultures established from the 2.3-GFP+ population, GFP expression was detected
initially and was maintained throughout the entire culture period (Figure 10). The first sign of
mineralization was around day 10 with significant increases thereafter (Figure 10). In these
cultures low levels of Bsp, Osteocalcin and Dmp1 were detected around day 7, whereas
expression of Dspp was detected around day 10. Expression of these markers of mineralization
and dentinogenesis increased with more advanced stages of culture differentiation (Figure 11 and
Table 11).

Continuous exposure of 2.3-GFP+ cultures to FGF2 resulted in modest increases in Bsp
and Osteocalcin and marked increases in the expression of Dmp1 at day 7 as compared to control.
Analysis at days 10 and 14 showed decreases in the intensity of 2.3-GFP expression, extent of
mineralization and expression of Bsp, Osteocalcin, Dmp1 and Dspp as compared to control
(Figures 10 and 11, and Table 11). Thus, continuous exposure of the 2.3-GFP+ population to
FGF2 resulted in transient increases in the expression of Bsp, Osteocalcin, Dmp1 and Dspp
followed by decreases in their expression and reduced mineralization.

Our analysis of cultures established from the 2.3-GFP– population showed that expression
of GFP was not detected initially, but appeared at day 7 in a few isolated cuboidal cells and
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increased thereafter (Figure 10). In these cultures low levels of Bsp, Osteocalcin and Dmp1 were
detected at day 7, and mineralization and expression of Dspp were detected only at day 14
(Figures 10 and 11, and Table 11), indicating delayed differentiation as compared to the 2.3GFP+ population. In these cultures mineralization was not over the entire culture dish and had a
nodular pattern. The extent of mineralization and levels of expression of Bsp, Osteocalcin, Dmp1
and Dspp in these cultures were markedly lower than those in the cultures established from the
2.3-GFP+ population (Figures 10 and 11), indicating that the 2.3-GFP– population contained less
differentiated cells.

Continuous exposure of the 2.3-GFP– population to FGF2 resulted in a delayed, but similar
outcome as compared to that of the 2.3-GFP+ population. Exposure to FGF2 resulted in
decreases in the expression of Bsp and Osteocalcin and increases in the expression of Dmp1 at
days 7 and 10 followed by decreases at day 14 as compared to control (Figure 11 and Table 11).
Expression of Dspp in FGF2-treated 2.3-GFP– cultures was detected only at day 14 and at lower
levels as compared to control (Figure 11 and Table 11).

The effects of FGF2 on both these populations are similar to the effects of FGF2 on
unsorted cultures and indicate that FGF2 initially stimulated the expression of Dmp1 in both
undifferentiated progenitors and cells at early stages of differentiation. FGF2 was able to
stimulate the expression of Dspp in the 2.3-GFP+ but not in the 2.3-GFP– population. However,
additional exposure to FGF2 prevented further differentiation of cells into mature odontoblasts.

Effects of continuous exposure to FGF2 on primary BMSC cultures.
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Our previous studies showed that primary dental pulp cultures from unerupted molars
contained progenitors capable of giving rise to both osteoblasts and odontoblasts (352). This
makes it difficult to distinguish the effects of FGF2 on cells of osteogenic vs. dentinogenic
lineages, and raises the possibility that some of the effects of FGF2 on dental pulp cultures were
due to its effects on osteoblasts rather than on osteoblasts.

To distinguish between the effects of FGF2 on cells of these lineages, we examined the
effects of FGF2 on BMSC cultures, as they do not contain odontoprogenitors and are used
routinely to examine mineralization and osteoblast differentiation in vitro.

BMSCs were cultured under conditions described in the Materials and Methods and
exposed to VH or FGF2 continuously between days 3-14. Our results showed that FGF2
completely inhibited mineralization (Figure 12) and greatly decreased expression of markers of
early and late stages of osteoblast differentiation at days 10 and 14 (evidenced by qPCR analysis,
Figure 13). Expression of Dspp was not detected in the control or FGF2-treated cultures at any
time point (Figure 13 and Table 12).

Analysis at day 7 showed a transient and significant increase (~35-fold) in the levels of
Dmp1 but not other markers of mineralization in FGF2-treated cultures as compared to control
(Figure 13 and Table 12).
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We also examined the effects of FGF2 on the expression of various transgenes in BMSC
cultures. Previous studies showed that in the osteogenic lineage 3.6-GFP transgene was activated
in preosteoblasts, 2.3-GFP transgene in early osteoblasts (376) and DMP1-GFP transgene in late
osteoblasts and osteocytes (86).

BMSC cultures from 3.6-GFP and 2.3-GFP transgenic mice showed that FGF2 completely
inhibited the expression of both 3.6-GFP and 2.3-GFP transgenes at all time points as compared
to control (Figures 14A and 14B). These effects were observed as early as day 7, and are
consistent with results of previous studies (248), indicating that FGF2 blocked the onset of
preosteoblast differentiation.

Analysis of BMSC cultures from DMP1-GFP transgenic mice showed the increased
number of DMP1-GFP+ cells in FGF2-treated cultures as compared to control at day 7. However,
despite these transient increases, the expression of DMP1-GFP transgene in FGF2-treated BMSC
cultures was markedly decreased at days 10 and 14 as compared to control (Figures 14A and
14B).

82

Discussion.

Members of the FGF family of growth factors play essential roles in various functions of
dental pulp cells during reparative dentinogenesis, including proliferation, migration,
differentiation and self-renewal of dental pulp stem and progenitor cells (125, 126, 339, 341-344,
348). However, the effects of FGF2 on cell differentiation and dentinogenesis remain unclear, as
both stimulatory and inhibitory effects of FGF2 on dentinogenesis have been reported.

It has been shown that continuous exposure of primary dental pulp cultures to FGF2
decreased expression of various markers of mineralization and dentinogenesis, including Dmp1
and Dspp (339, 344), alkaline phosphatase activity and mineral content (339-341, 344, 348).
Similarly, exposure of tooth organ cultures to FGF2 for 4 days decreased expression of
endogenous Dspp and Alp (349).

On the other hand, other studies have shown that in dental pulp cultures FGF2 increased
expression of Dmp1 and Dspp as early as 24 hrs after exposure (345). In vitro exposure of dental
pulp cells grown in collagen type I gel cultures, but not plate-coated collagen type I, to FGF2
increased expression of Dspp (343). Exposure of immortalized human dental pulp cells to FGF2
stimulated expression of Dmp1 and Dspp (345). Exposure of E15 (cap stage) tooth germ to FGF2
stimulated dentinogenesis and Dspp expression (349). Inhibition of FGF2 signaling in tooth
organ cultures by specific antisense oligonucleotides increased expression of endogenous Alp
and Dspp (349).
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Several studies have suggested that the differences in the differentiation response of pulp
cells to FGF2 are related to dosage and duration of FGF2 treatment as well as the stage of
differentiation of the responding cells (344, 345).

Our results are consistent with previous observations, which showed that continuous
exposure of primary dental pulp cultures to FGF2 inhibited mineralization and dentinogenesis. In
addition we showed biphasic effects of FGF2 on the expression of markers of mineralization and
dentinogenesis, suggesting a stage-specific response of pulp cultures to FGF2. Our study showed
that exposure of pulp cells to FGF2 during the proliferation phase of in vitro growth increased
levels of Dmp1 (up to ~310-fold) and Dspp, whereas additional exposure to FGF2 during the
differentiation/mineralization phase of in vitro growth resulted in marked decreases in the
expression of all markers of mineralization and dentinogenesis as compared to control.

Our further analysis of the effects of FGF2 on pulp cultures from a series of GFP reporter
transgenic mice that display stage-specific activation of transgenes during odontoblast
differentiation (90, 351) provided additional evidence of the stage-specific effects of FGF2 on
cells of the odontoblast lineage.

Our analysis of pulp cultures from 3.6-GFP and 2.3-GFP transgenic mice at day 7 showed
that exposure to FGF2 during the proliferation phase of in vitro growth did not affect the
expression of these transgenes, shown to be markers of cells at early stages of odontoblast
differentiation (90, 351). On the other hand, FGF2 markedly increased intensity (~38-fold) of
DMP1-GFP transgene, shown to be activated in functional odontoblasts (351).
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Our studies on FACS-separated populations showed that FGF2 stimulated expression of
Dmp1 at day 7 in both undifferentiated/progenitor cells (2.3-GFP–) and polarizing odontoblasts
(2.3-GFP+). On the other hand, FGF2 stimulated the expression of Dspp only in the 2.3-GFP+
population at day 7. These observations suggested that the exposure of pulp cells to FGF2
initially resulted in stimulated/accelerated differentiation in both populations. In the 2.3-GFP+
population FGF2 stimulated the differentiation into functional odontoblasts producing
unmineralized predentin-like matrix and expressing low levels of Dmp1 and Dspp. In the 2.3GFP– population that contains undifferentiated population, FGF2 the formation of cells
expressing Dmp1.

Our analysis at later time points (days 10-21) showed that despite these early stimulatory
effects, additional exposure of pulp cells to FGF2 reduced mineralization and dentinogenesis,
decreased the intensity of expression of all transgenes and the number of DSPP-Cerulean+
odontoblasts as compared to the respective controls. The percentage of DSPP-Cerulean+
odontoblasts in cultures exposed to FGF2 was less than half of that in the control. Our studies on
FACS-sorted populations showed that FGF2 decreased the expression of Dmp1 and Dspp in both
2.3-GFP– and 2.3-GFP+ populations.

In addition, our results showed that the inhibitory effects of FGF2 on dentinogenesis were
primarily related to its negative effects on the final stages of odontoblast differentiation. Our
results showed rapid and almost complete recovery of mineralization, expression of markers of
mineralization and dentinogenesis and the expression of various GFP transgenes 7 days after
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withdrawal of FGF2. Furthermore, increases in the intensity of the DMP1-GFP and DSPPCerulean transgenes, percentage of DSPP-Cerulean+ odontoblasts and expression of Dspp in
cultures following withdrawal of FGF2 as compared to the respective controls indicated
increased dentinogenesis in these cultures. These observations suggest that after initial
stimulation of formation of functional odontoblasts at day 7, additional exposure to FGF2
prevented their further differentiation.

Taken together, these results show stage-specific effects of FGF2 on differentiation of cells
in the odontoblast lineage and suggest positive roles of FGF2 on the formation of functional
odontoblasts and negative roles on the further differentiation of these cells. These observations
suggest that limited and early exposure of pulp cells to FGF2 may lead to increases in
dentinogenesis. Additional experiments are in progress to examine the underlying mechanisms
mediating the stimulatory and inhibitory effects of FGF2 on pulp cells. Taken together, these
observations provide insight into conflicting results from other laboratories reporting both
positive and negative effects of FGF2 on mineralization and dentinogenesis.

Effects of FGF2 on primary BMSC cultures reveal differences between the effects of FGF2
on osteoprogenitors and odontoprogenitors.

The formation of both bone-like and dentin-like tissues in primary pulp cultures (352)
raises the possibility that some of the effects of FGF2 on dental pulp cultures may be related to
its effects on cells of the osteoblast lineage. However, the differences between the early and later
effects of FGF2 on BMSC and pulp cultures in our study suggest that the effects of FGF2 in pulp
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cultures are primarily on cells in the odontoblast lineage.

Our results are consistent with those reported by others (211-213, 243, 245, 247, 248, 259,
261, 377) that showed that continuous exposure of BMSCs to FGF2 completely inhibited
mineralization and significantly decreased expression of markers of early and late stages of
osteoblast differentiation. FGF2-induced decreases in osteogenesis have been attributed to the
preservation of the undifferentiated state of osteoprogenitors and mesenchymal stem cells
leading to a higher pool of progenitors and possibly promoting differentiation in the long term
(247, 248).

Our analysis showed differences in the early effects of FGF2 on BMSC and pulp cultures.
At day 7, FGF2-treated BMSC cultures showed significant decreases in the expression of Type I
collagen, Bsp and Osteocalcin but not Dmp1 as compared to control. Furthermore, consistent
with previous results (248), we showed that FGF2 completely inhibited expression of 3.6-GFP
and 2.3-GFP transgenes in BMSC cultures, indicating that the inhibition of osteogenesis by
FGF2 was mediated by blocking the onset of preosteoblast differentiation.

These results are different from the effects of FGF2 on pulp cultures, in which FGF2
induced transient increases in the expression of all markers of mineralization and dentinogenesis
at day 7. Furthermore, exposure of dental pulp cells to FGF2 reduced (but did not eliminate)
expression of 3.6-GFP and 2.3-GFP transgenes.
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In addition, rapid and almost complete recovery of mineralization in pulp cultures after
withdrawal of FGF2 in our study is different from that in BMSC cultures. Upon withdrawal of
FGF2 from BMSC cultures, full osteoblast differentiation and mineralization did not appear in
vitro and was detected only after subcutaneous implantation of FGF2-treated cells in SCID/Beige
mice in vivo (248).

These observations suggest significant differences in the response of odontoprogenitors and
osteoprogenitors to FGF2 and/or differences in osteoprogenitors residing in the dental pulp vs.
BMSC.

Similar to the pulp cultures, exposure of BMSC cultures to FGF2 during the proliferation
phase of in vitro growth resulted in a transient increase in the expression of Dmp1 (~35-fold) and
formation of DMP1-GFP+ cells. Although the effects of FGF2 on DMP1-GFP+ cells in
osteogenic cultures have not been reported before, stimulatory effects of FGF2 on expression of
Dmp1 in our study are in agreement with previous studies using BMSCs and various
osteoblast/osteocyte cell lines. Exposure of osteoblast-like cells (ROS17/2.8 and MC-4),
osteocyte-like cells (MLO-Y4) and BMSC cells to FGF2 during the proliferation phase of in
vitro growth resulted in rapid and marked increases in the expression of Dmp1 and other
osteocyte-associated markers (E11, Cx43, Phex) (244, 255). Although the underlying
mechanisms of the stimulatory effects of FGF2 on Dmp1 are not fully understood, available
evidence suggests the involvement of FGFR/MEK/Erk1/2 in this regulation (244).
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Summary and conclusions.

In conclusion, our results demonstrated biphasic effects of FGF2 on dental pulp cells,
including stimulatory effects on the expression of Dmp1, Dspp and DMP1-GFP+ cells. These
transient stimulatory effects were followed by inhibitory effects on further differentiation and
maturation of cells of the odontoblast lineage.

We provided in vitro evidence that FGF2 stimulated formation of functional odontoblasts,
but inhibited their further differentiation and maturation into mature odontoblasts. Functional
odontoblasts in our study were identified by high levels of expression of Dmp1 and DMP1-GFP
transgene and by low levels of expression of Dspp and DSPP-Cerulean transgene.

Overall, our data suggest an intriguing mechanism to explain conflicting effects of FGF
signaling on dentinogenesis previously reported in the literature. These findings provide critical
information for the development of improved treatments for vital pulp therapy and dentin
regeneration.
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Figures.

Figure 2. Concentration-dependent effects of continuous exposure to FGF2 on the extent of
mineralization in primary dental pulp cultures. Primary dental pulp cultures derived from 57-day-old pups were established and grown in the absence (0 ng/ml) or presence of 5, 10 and 20
ng/ml FGF2 between days 3-21 as described in the Materials and Methods.
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A. Images of the same areas in cultures analyzed under brightfield (upper row), and
epifluorescent light using TRITC Red filter for detection of XO staining (lower row) at different
time points. Scale bar is 200 µm. Area of each individual 10x image is 5.67×10-3 cm2 (0.14% of
the total area of the well, which is 4.0 cm2).
B. Representative scanned composite 5x images of a larger area of the well. Scanned area is 0.55
cm2 (13.8% of the total area of the well). Scale bar is 2 mm.
C. The intensity of fluorescence of XO staining at various time points.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point.
D. Images of wells of cultured cells after von Kossa staining at different time points.
E. Images of wells of cultured cells after crystal violet staining at different time points.
FGF2 decreased the extent of mineralization in a concentration-dependent manner as compared
to control at all time points. The inhibitory effects of FGF2 on mineralization were not related to
marked differences in the cellularity of the cultures evidenced by the lack of detectable
differences in the intensity of crystal violet staining
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Figure 3. Concentration-dependent effects of continuous exposure to FGF2 on the
expression of markers of mineralization and dentinogenesis in primary dental pulp
cultures. Primary dental pulp cultures derived from 5-7-day-old pups were established and
grown in the absence (0 ng/ml) or presence of 5, 10 and 20 ng/ml FGF2 between days 3-21 as
described in the Materials and Methods. At various time points cells were harvested and
processed for RNA isolation and qPCR analysis. Expression levels of all genes except Dspp
were normalized to VH at day 7, which is arbitrarily set to 1 and is indicated by the dashed line.
The expression of Dspp was normalized to VH at day 10, which is arbitrarily set to 1 and is
indicated by the dashed line. Results represent mean ± SEM of at least three independent
experiments; *p ≤ 0.05 relative to control at each time point.
N.D. = not detected.
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FGF2 decreased the expression of markers of mineralization and dentinogenesis between days
10-14 as compared to control. These decreases were preceded by transient increases in the
expression of all these markers at day 7 as compared to control.
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Figure 4. Effects of continuous exposure to FGF2 on the expression of GFP transgenes in
primary dental pulp cultures. Cultures were established from 3.6-GFP, 2.3-GFP and DMP1GFP transgenic mice as described in the Materials and Methods and grown in the absence (VH)
or presence of FGF2 between days 3-14.
A. Each panel represents images of the same area in cultures at different time points analyzed
under brightfield (upper rows) and epifluorescent light using GFPtpz filter for detection of 3.6GFP and DMP1-GFP, and GFPemd filter for detection of 2.3-GFP (lower rows). Scale bar is 200
µm.
B. Representative scanned composite 5x images of a larger area of the well. Scanned area is 2.0
cm2 (50% of the total area of the well). Scale bar is 4 mm.
C. The intensity of GFP fluorescence at various time points. The dashed line indicates levels of
epifluorescence intensity of GFP in VH at day 7.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point.
Epifluorescence analysis of cultures from 3.6-GFP and 2.3-GFP transgenic mice showed slight
increases in their intensity at day 7 followed by marked decreases at days 10 and 14 in FGF295

treated cultures as compared to the respective controls. Analysis of cultures from DMP1-GFP
transgenic mice showed that decreases in the intensity of DMP1-GFP in FGF2-treated cultures at
days 10 and 14 relative to control were preceded by marked increases at day 7.
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Figure 5. Effects of continuous exposure to FGF2 on distribution of GFP+ and GFP– cells
in primary dental pulp cultures. Primary dental pulp cultures derived from 3.6-GFP, 2.3-GFP
and DMP1-GFP transgenic mice were grown in the absence (VH) or presence of FGF2 between
days 3-7, and processed for FACS analysis using BD FACSDivaTM 6.0 software (BD
Biosciences, San Jose, CA). Dot plots were gated on live cells based on their forward (FSC) and
side (SSC) scatters properties and exclusion of PI.
P4 represents population of GFP– cells, P5 represents population with intermediate levels of
GFP, and P6 represents population with high levels of GFP expression. Cells from nontransgenic littermates served as the negative control (neg. control).
Reanalysis demonstrated that the purity of FACS-sorted 2.3-GFP+ and 2.3-GFP– populations
was higher than 98%.
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Figure 6. Effects of withdrawal of FGF2 on the extent of mineralization and expression of
GFP transgenes in primary dental pulp cultures. Cultures were established from 3.6-GFP,
2.3-GFP and DMP1-GFP transgenic mice and grown in the absence (VH) or presence of FGF2
between days 3-14. At day 14 FGF2 was withdrawn and cells were grown under the control
culture conditions (without FGF2) for additional 7 days till day 21.
A. Images of the same areas in cultures at different time points analyzed under brightfield (upper
row) and epifluorescent light using TRITC Red filter for detection of XO staining (middle row).
Scale bar is 200 µm. The lower row in panel A represents scanned wells processed for von Kossa
staining.
B. Images of the same areas in cultures at different time points analyzed under brightfield (upper
row) and epifluorescent light using GFPtpz filter for detection of 3.6-GFP (middle and lower
rows). Scale bar is 200 µm. Lower row is representative scanned composite 5x images of a larger
area of the well. Scanned area is 0.93 cm2 (23% of the total area of the well). Scale bar is 4 mm.
Graph represents the intensity of 3.6-GFP transgene at various time points.
C. Images of the same areas in cultures at different time points analyzed under brightfield (upper
row) and epifluorescent light using GFPemd filter for detection of 2.3-GFP (middle and lower
rows). Scale bar is 200 µm. Lower row is representative scanned composite 5x images of a larger
area of the well. Scanned area is 0.93 cm2 (23% of the total area of the well). Scale bar is 4 mm.
Graph represents the intensity of 2.3-GFP transgene at various time points.
D. Images of the same areas in cultures at different time points analyzed under brightfield (upper
row) and epifluorescent light using GFPtpz filters for detection of DMP1-GFP (middle and lower
rows). Scale bar is 200 µm. Lower row is representative scanned composite 5x images of a larger
area of the well. Scanned area is 0.93 cm2 (23% of the total area of the well). Scale bar is 4 mm.
Graph represents the intensity of DMP1-GFP transgene at various time points.
Results in all graphs represent mean ± SEM of at least three independent experiments; *p ≤ 0.05
relative to control at each time point. The dashed line in all panels indicates the level of
epifluorescence intensity of GFP in VH at day 14.
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Withdrawal of FGF2 resulted in almost complete recovery of the extent of mineralization and
expression of 3.6-GFP, 2.3-GFP and DMP1-GFP transgenes as compared to control.
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Figure 7. Effects of withdrawal of FGF2 on expression of markers of mineralization and
dentinogenesis in primary dental pulp cultures. Cultures were treated with VH or FGF2
between days 3-14. At day 14 FGF2 was withdrawn and cells were grown under the control
culture conditions for additional 7 days till day 21. Expression of Type I collagen, Bsp,
Osteocalcin, Dmp1 and Dspp was determined by qPCR analysis at days 14 and 21.
Results represent mean ± SEM of values from at least three independent experiments; *p ≤ 0.05
relative to control at each time point. Expression levels of all genes were normalized to VH at
day 14, which is arbitrarily set to 1 and is indicated by the dashed line.
Withdrawal of FGF2 recovered expression of all markers of mineralization and dentinogenesis,
except Osteocalcin. Expression of Dspp exceeded that in the control cultures.
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Figure 8. Effects of withdrawal of FGF2 on the percentage of DSPP-Cerulean+
odontoblasts in primary dental pulp cultures. Cultures derived from DSPP-Cerulean
transgenic mice were treated with VH or FGF2 between days 3-14. At day 14 FGF2 was
withdrawn and the cells were grown under the control culture conditions for additional 7 days till
day 21. Cells were processed for immunocytochemical analysis using anti-GFP antibody at days
14 and 21. To visualize nuclei, cells were stained with 1.0 µg/ml Hoechst 33342 dye prior to
mounting.
A. Representative images of the same areas in cultures analyzed under brightfield (upper rows),
epifluorescent light using GFPtpz filter for detection of DSPP-Cerulean (middle row) and
overlaid images (Hoechst/GFP) filters. Hoechst staining was visualized using DAPI filters. Scale
bar is 200 µm.
Numbers represent mean ± SEM of the percentage of DSPP-Cerulean+ odontoblasts in at least
three independent experiments. Percentage of DSPP-Cerulean+ odontoblasts was calculated as a
ratio between DSPP-Cerulean+ odontoblasts and the total number of Hoechst+ cells. Negative
controls included BMSC cultures derived from DSPP-Cerulean transgenic mice and stained with
anti-GFP antibody (BMSC), and dental pulp cultures derived from DSPP-Cerulean transgenic
mice processed for immunocytochemistry with omission of antibody (Dental pulp, without Ab).
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B. Representative scanned composite 5x images of a larger area of the well at days 14 and 21.
Scanned area is 0.93 cm2 (23% of the total area of the well). Scale bar is 4 mm.
Withdrawal of FGF2 increased the percentage of DSPP-Cerulean+ odontoblasts as compared to
control.
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Figure 9. Isolation of 2.3-GFP– and 2.3-GFP+ populations by FACS. Primary dental pulp
cultures derived from 2.3-GFP transgenic mice were grown under control culture conditions till
day 7. At day 7 cells were subjected to GFP-based FACS sorting to separate relatively
homogeneous populations of GFP– and GFP+ cells. Cells were gated based on FSC and SSC, PI
and GFP.
Reanalysis demonstrated a high (≥ 98%) purity of isolated populations of 2.3-GFP− (Reanalysis
Q3) and 2.3-GFP+ cells (Reanalysis Q4).
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Figure 10. Effects of continuous exposure to FGF2 on the extent of mineralization and
expression of 2.3-GFP transgene in FACS-sorted 2.3-GFP+ and 2.3-GFP– populations.
Primary pulp cultures from the 2.3-GFP transgenic mice were grown under control culture
conditions and processed for FACS to separate relatively homogeneous 2.3-GFP+ and 2.3-GFP–
populations. Separated populations were exposed to VH or FGF2 between days 3-14 as
described in the Materials and Methods.
Each panel represents images of the same areas in cultures at different time points analyzed
under brightfield (upper row) and epifluorescent light using GFPemd and TRITC Red filters for
detection of GFP (middle row) and XO (lower row), respectively. Scale bar is 200 µm.
Continuous exposure to FGF2 decreased the extent of mineralization and expression of 2.3-GFP
in both 2.3-GFP+ and 2.3-GFP– populations as compared to respective controls.
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Figure 11. Effects of continuous exposure to FGF2 on expression of markers of
mineralization and dentinogenesis in FACS-sorted 2.3-GFP+ and 2.3-GFP– populations.
Cultures were established and treated with VH or FGF2 between days 3-14 as described in
Materials and Methods. At various time points cells were harvested and processed for RNA
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isolation and qPCR analysis. Expression levels of Bsp, Osteocalcin and Dmp1 in both 2.3-GFP+
and 2.3-GFP– populations were normalized to GFP+ VH at day 7, which is arbitrarily set to 1
and is indicated by the dashed line. Expression levels of Dspp in both 2.3-GFP+ and 2.3-GFP–
populations were normalized to GFP+ VH at day 10, which is arbitrarily set to 1 and is indicated
by the dashed line.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point.
N.D. = not detected.
In the 2.3-GFP+ population, expression of Bsp, Dmp1 and Dspp was higher in FGF2-treated
cultures relative to control at day 7, but was lower relative to control at later time points. In the
2.3-GFP– population, expression of Dmp1 was higher in FGF2-treated cultures relative to
control, and Dmp1 and all other markers were lower relative to control at later time points.
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Figure 12. Effects of continuous exposure to FGF2 on the extent of mineralization in
primary BMSC cultures. Primary BMSC cultures derived from 5-7-day-old pups were grown
in the presence of VH or FGF2 at days 3-14 as described in the Materials and Methods. Images
of the same areas in cultures at different time points analyzed under brightfield (upper row), and
epifluorescent light using TRITC Red filter for detection of XO staining (second row). Scale bar
is 200 µm. Representative scanned composite 5x images of a larger area of the well (third row).
Scanned area is 0.55 cm2 (14% of the total area of the well). Scale bar is 2 mm. Cultures
processed for von Kossa at different time points were scanned (lower row).
Continuous exposure of BMSC cultures to FGF2 completely inhibited formation of the
mineralized matrix.
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Figure 13. Effects of continuous exposure to FGF2 on expression of markers of
mineralization and dentinogenesis in primary BMSC cultures. BMSC cultures were
established and grown in the absence (VH) or presence of FGF2 as described in Materials and
Methods. At various time points cells were harvested and processed for RNA isolation and qPCR
analysis. Expression of Type I collagen, Bsp, Osteocalcin and Dmp1 was normalized to VH at
day 7, which is arbitrarily set to 1 and is indicated by the dashed line. Results represent mean ±
SEM of at least three independent experiments. *p ≤ 0.05 relative to control at each time point.
N.D. = not detected.
Expression of markers of mineralization was markedly decreased by continuous exposure to
FGF2 at all time points as compared to control (except Dmp1 at day 7).
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Figure 14. Effects of continuous exposure to FGF2 on expression of various GFP
transgenes in primary BMSC cultures. BMSC cultures were established and grown in the
absence or presence of FGF2 between days 3-14 as described in the Materials and Methods.
A. Representative scanned composite 5x images of a larger area of the well. Scanned area is 2.0
cm2 (50% of the total area of the well). Scale bar is 2 mm.
B. Each panel represents images of the same areas in cultures at different time points analyzed
under brightfield (upper row) and epifluorescent light using filters for GFPtpz and GFPemd for
detection of GFP (lower row). Scale bar is 200 µm.
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Continuous exposure to FGF2 completely inhibited expression of 3.6-GFP and 2.3-GFP
transgenes at all time points and as early day 7. FGF2 increased expression of DMP1-GFP at day
7 as compared to control, but at later time points it decreased relative to control.
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Tables.
Table 4. Concentration-dependent effects of continuous exposure to FGF2 on
epifluorescence intensity of Xylenol Orange staining in primary dental pulp cultures.

10
20

FGF2 (ng/ml)

5

Control

Treatment

Day of
culture

Epifluorescence
intensity

Fold change

7

N.D.

–

10

161.00 ± 8.74

1

14

352.75 ± 41.86

1

21

803.13 ± 39.03

1

7

N.D.

–

10

73.00 ± 12.17*

~0.45

14

147.71 ± 12.10*

~0.42

21

370.43 ± 51.67*

~0.46

7

N.D.

–

10

53.33 ± 11.98*

~0.33

14

94.67 ± 7.89*

~0.27

21

290.33 ± 26.08*

~0.36

7

N.D.

–

10

21.67 ± 6.36*

~0.13

14

46.43 ± 13.45*

~0.13

21

179.83 ± 19.33*

~0.22

Results represent mean ± SEM of at least three independent experiments. *p ≤ 0.05 relative to
the control at each time point. Fold changes represent the FGF2 value divided by the control
value for each time point.
N.D. = not detected.
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Table 5. Concentration-dependent effects of continuous exposure to FGF2 on the
expression of markers of mineralization and dentinogenesis in primary dental pulp
cultures.
CT

ΔCT

-ΔΔCT

Fold change

19.82 ± 0.37
16.10 ± 0.25
28.04 ± 0.44
26.03 ± 0.54
31.08 ± 0.25
22.68 ± 0.45
37.19 ± 0.82

−
-4.14 ± 0.16
7.80 ± 0.18
5.83 ± 0.53
11.24 ± 0.48
2.45 ± 0.54
17.03 ± 0.84

−
0
0
0
0
0
−

−
1
1
1
1
1
N.D.

Day 10

Gapdh
Type I collagen
Runx2
Bsp
Dmp1
Osteocalcin
Dspp

19.97 ± 0.44
14.39 ± 0.22
27.01 ± 0.32
19.70 ± 0.27
22.67 ± 0.28
19.99 ± 0.82
31.10 ± 0.54

−
-6.17 ± 0.22
6.45 ± 0.34
-0.86 ± 0.22
2.68 ± 0.64
-0.57 ± 0.78
11.13 ± 0.78

−
2.03 ± 0.26
1.35 ± 0.24
6.68 ± 0.48
8.56 ± 0.44
3.01 ± 0.45
0

−
4.47 ± 0.92
2.73 ± 1.08
136.52 ± 49.27
516.13 ± 158.90
10.00 ± 2.67
1

Day 14

Gapdh
Type I collagen
Runx2
Bsp
Dmp1
Osteocalcin
Dspp

20.84 ± 0.31
13.17 ± 0.22
26.80 ± 0.24
16.89 ± 0.49
21.75 ± 0.50
17.70 ± 0.57
29.27 ± 0.41

−
-7.67 ± 0.14
5.96 ± 0.31
-3.95 ± 0.28
0.94 ± 0.40
0.84 ± 0.40
8.43 ± 0.44

−
3.53 ± 0.23
1.84 ± 0.19
9.51 ± 0.40
9.89 ± 0.19
5.59 ± 0.42
1.42 ± 0.50

−
12.47 ± 2.56
3.73 ± 1.11
892.88 ± 264.05
992.67 ± 135.93
60.97 ± 21.21
6.26 ± 2.53

Gapdh
Type I collagen
Runx2
Bsp
Dmp1
Osteocalcin
Dspp

20.84 ± 0.20
11.24 ± 0.32
26.82 ± 0.09
15.57 ± 0.12
20.50 ± 0.17
16.20 ± 0.37
26.33 ± 0.21

−
-9.60 ± 0.14
5.98 ± 0.19
-5.27 ± 0.29
-0.34 ± 0.30
0.21 ± 0.17
5.49 ± 0.22

−
5.46 ± 0.14
1.82 ± 0.19
11.10 ± 0.29
11.58 ± 0.30
7.08 ± 0.17
5.65 ± 0.22

ΔCT

-ΔΔCT

Fold change

−
-4.22 ± 0.13
8.43 ± 0.21
4.09 ± 0.11
8.13 ± 0.47

−
-0.19 ± 0.05
-0.36 ± 0.02
0.39 ± 0.05
2.33 ± 0.75

−
0.88 ± 0.03
0.78 ± 0.01
1.31 ± 0.04
6.21 ± 2.22

Control

Day 7

Gene
Gapdh
Type I collagen
Runx2
Bsp
Dmp1
Osteocalcin
Dspp

Day 21

Control

Day 7

FGF2 (5
ng/ml)

FGF2-treated (5 ng/ml between days 3-21)
Gene
CT
20.33 ± 0.10
Gapdh
16.11 ± 0.14
Type I collagen
28.76 ± 0.29
Runx2
24.42 ± 0.19
Bsp
28.52 ± 0.52
Dmp1
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−
44.38 ± 4.35
3.60 ± 0.82
2285.60 ± 482.46
3195.65 ± 659.43
137.45 ± 16.04
51.25 ± 7.13

Osteocalcin
Dspp

21.20 ± 0.11
30.44 ± 1.02

0.88 ± 0.02
10.11 ± 0.92

0.51 ± 0.25
0.53 ± 0.18

1.46 ± 0.24
1.47 ± 0.18

Day 10

Gapdh
Type I collagen
Runx2
Bsp
Dmp1
Osteocalcin
Dspp

20.50 ± 0.07
15.40 ± 0.13
27.56 ± 0.04
22.53 ± 0.34
22.50 ± 0.21
18.42 ± 0.27
30.05 ± 0.83

−
-5.11 ± 0.19
7.06 ± 0.10
2.03 ± 0.27
2.00 ± 0.28
0.42 ± 0.33
9.55 ± 0.89

−
0.70 ± 0.14
1.02 ± 0.12
2.45 ± 0.30
8.45 ± 0.57
3.47 ± 0.11
1.10 ± 0.17

−
1.65 ± 0.17
2.04 ± 0.18
5.70 ± 1.15
399.96 ± 121.81
11.13 ± 0.85
2.17 ± 0.25

Day 14

Gapdh
Type I collagen
Runx2
Bsp
Dmp1
Osteocalcin
Dspp

20.95 ± 0.08
14.20 ± 0.07
28.07 ± 0.20
21.49 ± 0.11
22.25 ± 0.11
18.23 ± 0.29
27.56 ± 0.46

−
-6.75 ± 0.09
7.12 ± 0.28
0.54 ± 0.05
1.38 ± 0.12
0.29 ± 0.23
6.61 ± 0.49

−
2.35 ± 0.22
0.96 ± 0.29
3.94 ± 0.20
9.07 ± 0.21
4.11 ± 0.48
4.03 ± 0.29

−
5.22 ± 0.72
2.02 ± 0.38
15.65 ± 2.25
549.75 ± 78.83
19.23 ± 6.26
17.08 ± 3.51

Day 21

Gapdh
Type I collagen
Runx2
Bsp
Dmp1
Osteocalcin
Dspp

20.80 ± 0.32
15.05 ± 0.01
26.99 ± 0.09
16.20 ± 0.11
22.22 ± 0.61
17.54 ± 0.50
28.93 ± 0.36

−
-5.75 ± 0.31
6.18 ± 0.23
-4.61 ± 0.34
1.42 ± 0.85
0.35 ± 0.28
8.13 ± 0.05

−
1.61 ± 0.31
2.25 ± 0.28
10.43 ± 0.34
9.82 ± 0.85
5.71 ± 0.28
3.01 ± 0.05

−
3.20 ± 0.63*
4.88 ± 0.72
1462.63 ± 340.22
1297.32 ± 776.24
54.38 ± 9.62*
8.05 ± 0.29*

ΔCT

-ΔΔCT

Fold change

−
-4.46 ± 0.06
7.79 ± 0.34
3.75 ± 0.23
5.42 ± 0.42
0.78 ±0 .11
8.99 ± 0.90

−
0.06 ± 0.12
0.28 ± 0.18
0.74 ± 0.15
5.04 ± 0.70
0.60 ± 0.35
1.66 ± 0.25

−
1.05 ± 0.09
1.23 ± 0.16
1.68 ± 0.19
39.79 ± 13.69
1.61 ± 0.37
3.25 ± 0.59*

Gapdh
Type I collagen
Runx2
Bsp
Dmp1
Osteocalcin
Dspp

20.84 ± 0.06
15.83 ± 0.09
28.20 ± 0.06
22.69 ± 0.04
23.14 ± 0.74
19.59 ± 0.18
29.79 ± 0.80

−
-5.01 ± 0.04
7.36 ± 0.06
1.85 ± 0.02
2.34 ± 0.78
0.28 ± 0.22
8.99 ± 0.31

−
0.61 ± 0.11
0.72 ± 0.16
2.63 ± 0.15
8.12 ± 1.07
2.64 ± 0.20
1.70 ± 0.16

−
1.53 ± 0.11
1.66 ± 0.20
6.25 ± 0.67
416.18 ± 191.40
6.34 ± 0.88
3.28 ± 0.38

Gapdh

20.73 ± 0.02

−

−

−

1
4

Day 10

D
a
y

FGF2 (10 ng/ml)

Day 7

FGF2-treated (10 ng/ml between days 3-21)
Gene
CT
20.42 ± 0.11
Gapdh
15.96 ± 0.07
Type I collagen
28.21 ± 0.41
Runx2
24.17 ± 0.20
Bsp
25.88 ± 0.51
Dmp1
21.20 ± 0.06
Osteocalcin
29.41 ± 1.01
Dspp
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Day 21

Type I collagen
Runx2
Bsp
Dmp1
Osteocalcin
Dspp

14.88 ± 0.09
28.17 ± 0.29
22.03 ± 0.05
23.14 ± 0.74
18.08 ± 0.34
27.66 ± 0.33

-5.86 ± 0.08
7.43 ± 0.28
1.30 ± 0.03
1.64 ± 0.09
-2.66 ± 0.33
6.93 ± 0.34

1.46 ± 0.20
0.64 ± 0.41
3.18 ± 0.16
8.82 ± 0.31
4.44 ± 0.56
3.72 ± 0.44

2.79 ± 0.36*
1.68 ± 0.40
9.17 ± 0.97
471.96 ± 89.43
19.28 ± 7.80
14.51 ± 4.73

Gapdh
Type I collagen
Runx2
Bsp
Dmp1
Osteocalcin
Dspp

20.63 ± 0.03
15.09 ± 0.03
26.92 ± 0.15
16.85 ± 0.41
22.53 ± 0.09
17.52 ± 0.41
29.02 ± 0.13

−
-5.54 ± 0.03
6.29 ± 0.18
-3.78 ± 0.45
1.89 ± 0.06
0.47 ± 0.37
8.39 ± 0.12

−
1.40 ± 0.03
1.51 ± 0.18
9.61 ± 0.45
9.35 ± 0.06
5.56 ± 0.37
2.75 ± 0.12

−
2.65 ± 0.06*
2.88 ± 0.33
850.84 ± 218.47
652.90 ± 27.79*
50.45 ± 13.47*
6.76 ± 0.56*

ΔCT

-ΔΔCT

Fold change

−
-4.57 ± 0.18
7.17 ± 0.20
4.74 ± 0.56
2.98 ± 0.53
1.69 ± 0.47
10.49 ± 0.86

−
0.43 ± 0.13
0.63 ± 0.25
1.09 ± 0.23
8.17 ± 0.24
0.76 ± 0.31
0.65 ± 0.53

−
1.38 ± 0.14*
1.68 ± 0.35
2.28 ± 0.33*
314.07 ± 55.64*
1.92 ± 0.44
2.39 ± 0.67*

Day 10

Gapdh
Type I collagen
Runx2
Bsp
Dmp1
Osteocalcin
Dspp

19.86 ± 0.38
15.82 ± 0.51
27.58 ± 0.04
23.57 ± 0.15
23.57 ± 0.79
20.14 ± 0.14
32.10 ± 0.91

−
-4.05 ± 0.34
7.72 ± 0.04
3.71 ± 0.16
3.69 ± 0.86
0.43 ± 0.26
12.54 ± 1.21

−
-0.22 ± 0.47
0.31 ± 0.16
1.35 ± 0.47
7.42 ± 0.61
1.43 ± 0.19
-0.15 ± 1.04

−
0.63 ± 0.40*
1.26 ± 0.17
3.04 ± 1.15
209.06 ± 56.20
2.49 ± 0.37
1.63 ± 0.68

Day 14

Gapdh
Type I collagen
Runx2
Bsp
Dmp1
Osteocalcin
Dspp

20.59 ± 0.18
16.78 ± 0.62
28.76 ± 0.23
24.04 ± 0.13
23.88 ± 0.23
20.76 ± 0.37
32.16 ± 1.16

−
-3.81 ± 0.78
8.02 ± 0.19
3.45 ± 0.29
3.30 ± 0.39
0.17 ± 0.46
11.57 ± 1.29

−
-1.95 ± 1.23
0.005 ± 0.29
1.61 ± 0.29
7.81 ± 0.32
1.18 ± 0.47
0.12 ± 1.23

−
0.52 ± 0.24*
1.06 ± 0.19
3.26 ± 0.75*
243.21 ± 62.88*
2.59 ± 0.64
1.43 ± 0.57

Day 21

FGF2 (20 ng/ml)

Day 7

FGF2-treated (20 ng/ml between days 3-21)
Gene
CT
19.77
± 0.39
Gapdh
15.73 ± 0.16
Type I collagen
27.47 ± 0.28
Runx2
24.87 ± 0.33
Bsp
22.95 ± 0.25
Dmp1
21.98 ± 0.21
Osteocalcin
30.69 ± 0.65
Dspp

Gapdh
Type I collagen
Runx2
Bsp

20.82 ± 0.12
15.48 ± 0.14
27.01 ± 0.15
18.47 ± 0.08

−
-5.34 ± 0.08
6.19 ± 0.27
-2.35 ± 0.20

−
1.20 ± 0.08
0.99 ± 0.27
8.17 ± 0.20

−
2.30 ± 0.13*
2.05 ± 0.30
294.44 ± 39.75*
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Dmp1
Osteocalcin
Dspp

23.54 ± 0.11
18.05 ± 0.37
28.57 ± 0.08

2.71 ± 0.23
0.36 ± 0.27
7.75 ± 0.09

8.52 ± 0.23
5.22 ± 0.27
3.38 ± 0.09

377.29 ± 59.50*
38.37 ± 6.39*
10.45 ± 0.64*

ΔCT = CTgene - CTGapdh; -ΔΔCT = -(ΔCTsample – ΔCTcontrol).
Positive –ΔΔCT value = increased gene expression relative to VH at day 7.
Negative –ΔΔCT value = decreased gene expression relative to VH at day 7.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
the control at each time point.
All fold changes are relative to VH at day 7, except Dspp, which is relative to VH at day 10.
N.D. = not detected.
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Table 6. The effects of continuous exposure to FGF2 on the epifluorescence intensity of
GFP transgenes in primary dental pulp cultures.
Transgene
(wavelength)
3.6-GFP
(500 nm)

2.3-GFP
(483 nm)

DMP1-GFP
(500 nm)

DSPP-Cerulean
(500 nm)

Day of
culture

Control

7

5348.6 ± 158.1

6311.4 ± 231.6*

~1.18

10

16227.3 ± 1015.4

11980.8 ± 340.0*

~0.74

14

33184.1 ± 630.6

25126.4 ± 689.9*

~0.76

7

3022.2 ± 245.0

4444.0 ± 275.3*

~1.47

10

16352.1 ± 1806.2

8780.0 ± 1314.9*

~0.54

14

28268.2 ± 1070.6

15679.7 ± 805.4*

~0.56

7

69.0 ± 12.6

2579.1 ± 156.7*

~37.38

10

9590.4 ± 614.3

5256.6 ± 193.5*

~0.55

14

19207.8 ± 549.0

4719.3 ± 684.7*

~0.25

14

4.20 ± 0.29

1.63 ± 0.12*

~0.39

FGF2

Fold changes

Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point. Fold changes represent FGF2 value divided by the control value for
each time point.
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Table 7. The effects of FGF2 on the distribution of GFP+ and GFP– populations in
primary dental pulp cultures.
Transgene
3.6-GFP

2.3-GFP

DMP1-GFP

DSPP-Cerulean

Cell
population

VH (%)

FGF2 (%)

Fold
changes

GFP–

17.31 ± 0.19

15.62 ± 0.35*

~ 0.90

GFP+

82.69 ± 0.14

84.38 ± 0.40*

~ 1.02

GFP–

15.10 ± 0.80

12.57 ± 0.64*

~ 0.83

GFP+

84.90 ± 0.77

87.43 ± 0.66*

~ 1.03

GFP–

94.60 ± 0.27

64.60 ± 2.98*

~ 0.68

GFP+

5.40 ± 0.27

35.40 ± 2.98*

~ 6.56

Cerulean+

6.57 ± 0.18

2.92 ± 0.15

~ 0.44

Cultures derived from 3.6-GFP, 2.3-GFP and DMP1-GFP transgenic mice were established and
treated with VH or FGF2 between days 3-7 as described in the Materials and Methods. At day 7
cells were subjected to GFP-based FACS analysis to determine the percentages of the GFP+ and
GFP– cells.
For immunocytochemical analysis, cultures derived from the DSPP-Cerulean transgenic mice
were treated with VH or FGF2 between days 3-14. At day 14 cultures were processed for
immunocytochemical analysis using anti-GFP antibody. To visualize nuclei, cells were stained
with 1.0 µg/ml Hoechst 33342 dye prior to mounting. Numbers represent mean ± SEM of the
percentage of DSPP-Cerulean+ odontoblasts in at least three independent experiments.
Percentage of DSPP-Cerulean+ odontoblasts was calculated as a ratio between Cerulean+ cells
and the total number of Hoechst+ cells. Fold changes represent FGF2 value divided by the
control value for each time point.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point.
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Table 8. Effects of withdrawal of FGF2 on mineralization in primary dental pulp cultures.

21

14

Day of
culture

Parameter
Xylenol Orange
(570 nm)
von Kossa
(mm2)
Xylenol Orange
(570 nm)
von Kossa
(mm2)

VH

FGF2
(3-21)

FGF2
(3-14)

369.2 ± 31.6

52.5 ± 10.2*

207.8 ± 11.8

Fold changes
FGF2
(3-21)

FGF2
(3-14)

52.5 ± 10.2*

~0.14

~0.14

40.8 ± 2.8*

40.8 ± 2.8*

~0.20

~0.20

796.3 ± 28.9

179.8 ± 19.3*

706.0 ± 45.6#

~0.23

~0.89

334.1 ± 5.1

62.3 ± 7.8*

322.3 ± 16.3#

~0.19

~0.96

Cultures were treated with VH or FGF2 between days 3-14. At day 14 FGF2 was withdrawn and
cells were grown under the control culture conditions (without FGF2) for additional 7 days till
day 21.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point. Fold changes represent FGF2 value divided by the control value for
each time point.
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Table 9. Effects of withdrawal of FGF2 on expression of markers of mineralization and
dentinogenesis in primary dental pulp cultures.

CT

ΔCT

-ΔΔCT

Fold change

14

Gapdh
Type I collagen
Bsp
Osteocalcin
Dmp1
Dspp

20.84 ± 0.31
13.17 ± 0.22
16.89 ± 0.49
17.70 ± 0.57
21.75 ± 0.50
29.27 ± 0.41

−
-7.67 ± 0.14
-3.95 ± 0.28
-3.14 ± 0.41
3.27 ± 0.40
8.43 ± 0.44

−
0
0
0
0
0

−
1
1
1
1
1

21

Control
Day of
culture

Gene

Gapdh
Type I collagen
Bsp
Osteocalcin
Dmp1
Dspp

20.84 ± 0.20
11.24 ± 0.32
15.57 ± 0.12
16.20 ± 0.37
20.50 ± 0.17
26.33 ± 0.21

−
-9.60 ± 0.14
-5.27 ± 0.29
-4.63 ± 0.17
-0.34 ± 0.30
5.49 ± 0.22

−
1.93 ± 0.14
1.32 ± 0.29
1.50 ± 0.17
3.61 ± 0.30
2.95 ± 0.22

−
3.84 ± 0.38
3.22 ± 0.47
2.64 ± 0.38
14.47 ± 3.03
9.00 ± 0.05

Fold change

CT

ΔCT

-ΔΔCT

20.59 ± 0.18
16.78 ± 0.62
24.04 ± 0.13
20.76 ± 0.12
25.13 ± 0.81
32.16 ± 1.16

−
-3.81 ± 0.78
3.45 ± 0.29
0.17 ± 0.46
4.54 ± 0.97
11.57 ± 1.29

−
-3.72 ± 0.63
-7.72 ± 0.29
-3.62 ± 0.49
-3.47 ± 0.40
-1.29 ± 1.65

−
0.10 ± 0.03*
0.005 ± 0.001*
0.09 ± 0.03
0.10 ± 0.03*
0.59 ± 0.42

Gapdh
Type I collagen
Bsp
Osteocalcin
Dmp1
Dspp

20.82 ± 0.41
15.48 ± 0.14
18.47 ± 0.08
18.05 ± 0.37
23.54 ± 0.11
28.57 ± 0.08

−
-5.34 ± 0.08
-2.35 ± 0.20
-2.77 ± 0.27
2.72 ± 0.23
7.75 ± 0.09

−
-2.33 ± 0.08
-1.60 ± 0.20
-0.37 ± 0.27
0.55 ± 0.23
0.68 ± 0.09

−
0.20 ± 0.01*
0.34 ± 0.05*
0.80 ± 0.13*
1.66 ± 0.27*
1.07 ± 0.10*

CT

ΔCT

-ΔΔCT

Fold change

20.59 ± 0.18
16.78 ± 0.62
24.04 ± 0.13
20.76 ± 0.12
25.13 ± 0.81

−
-3.81 ± 0.78
3.45 ± 0.29
0.17 ± 0.46
4.54 ± 0.97

−
-3.72 ± 0.63
-7.72 ± 0.29
-3.62 ± 0.49
-3.47 ± 0.40

−
0.10 ± 0.03*
0.005 ± 0.001*
0.09 ± 0.03
0.10 ± 0.03*

21

14

FGF2 (3-21)
Day of
Gene
culture
Gapdh
Type I collagen
Bsp
Osteocalcin
Dmp1
Dspp

14

FGF2 (3-14)
Day of
Gene
culture
Gapdh
Type I collagen
Bsp
Osteocalcin
Dmp1
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Dspp

32.16 ± 1.16

11.57 ± 1.29

-1.29 ± 1.65

0.59 ± 0.42

Gapdh
Type I collagen
Bsp
Osteocalcin
Dmp1
Dspp

20.04 ± 0.38
11.47 ± 0.09
17.00 ± 0.49
19.43 ± 0.75
19.65 ± 0.25
24.09 ± 1.29

−
-8.57 ± 0.29
-3.04 ± 0.27
-0.61 ± 0.85
-0.39 ± 0.34
4.05 ± 0.93

−
0.90 ± 0.29
-0.91 ± 0.27
-2.53 ± 0.85
3.66 ± 0.34
4.38 ± 0.93

−
1.95 ± 0.38*
0.55 ± 0.09*
0.24 ± 0.13*
13.32 ± 2.78*
28.60 ± 11.84

ΔCT = CTgene - CTGapdh.
-ΔΔCT = -(ΔCTsample – ΔCTcontrol).
Positive –ΔΔCT value = increased gene expression relative to control at day 14.
Negative –ΔΔCT value = decreased gene expression relative to control at day 14.
Results represent mean ± SEM of absolute values from at least three independent experiments.
*p ≤ 0.05 relative to control at each time point.

121

Table 10. Effects of withdrawal of FGF2 on the intensity of GFP transgene expression in
primary dental pulp cultures.

Day 21

Day 14

Transgene
(wavelength)
3.6-GFP
(500 nm)
2.3-GFP
(483 nm)
DMP1-GFP
(500 nm)
DSPP-Cerulean
(500 nm)
3.6-GFP
(500 nm)
2.3-GFP
(483 nm)
DMP1-GFP
(500 nm)
DSPP-Cerulean
(500 nm)

VH

FGF2
(3-21)

FGF2
(3-14)

33142.5 ± 847.8

24740.0 ± 922.6*

28268.2 ± 1070.6

Fold changes
FGF2
(3-21)

FGF2
(3-14)

24740.0 ± 922.6*

~0.75

~0.75

15679.7 ± 805.4*

15679.7 ± 805.4*

~0.55

~0.55

19207.8 ± 549.0

4719.3 ± 684.7*

4719.3 ± 684.7*

~0.25

~0.25

4.20 ± 0.29

1.63 ± 0.12*

1.63 ± 0.12*

~0.39

~0.39

37521.3 ± 956.6

23651.3 ± 938.6*

46028.3 ± 2988.4*

~0.63

~1.23

34364.0 ± 442.4

22673.3 ± 418.7*

36032.3 ± 770.2

~0.66

~1.05

23202.0 ± 537.1

9953.0 ± 1814.8*

37128.3 ± 1321.2*

~0.43

~1.60

25.99 ± 1.52

10.60 ± 0.48*

61.46 ± 1.66*

~0.40

~2.36

Cultures were treated with VH or FGF2 between days 3-14. At day 14 FGF2 was withdrawn and
cells were grown under the control culture conditions (without FGF2) for additional 7 days till
day 21.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point. Fold changes represent FGF2 value divided by the control value for
each time point.
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Table 11. Effects of continuous exposure to FGF2 on expression of markers of
mineralization and dentinogenesis in FACS-sorted 2.3-GFP+ and 2.3-GFP– populations.

-ΔΔCT

Fold change

20.56 ± 0.33
26.64 ± 0.15
32.69 ± 0.35
38.02 ± 0.74
21.49 ± 0.04

−

−

−

5.81 ± 0.22
12.13 ± 0.55
16.34 ± 0.92
0.67 ± 0.31

0
0

1
1

−

N.D.

0

1

Gapdh
Bsp
Dmp1
Dspp
Osteocalcin

20.33 ± 0.19
22.18 ± 1.01
24.86 ± 1.72
31.07 ± 0.29
18.82 ± 0.05

−

−

−

1.62 ± 0.78
4.53 ± 1.68
10.39 ± 0.27
-1.74 ± 0.25

4.19 ± 0.78
7.60 ± 1.56
0
2.41 ± 0.46

24.98 ± 14.28
1020.06 ± 677.10
1
5.88 ± 1.88

Gapdh
Bsp
Dmp1
Dspp
Osteocalcin

20.77 ± 0.18
19.90 ± 0.16
22.23 ± 0.52
30.37 ± 0.40
16.72 ± 0.09

−

−

−

-0.84 ± 0.14
1.46 ± 0.43
8.84 ± 0.46
-4.02 ± 0.33

6.65 ± 0.32
10.67 ± 0.62
1.37 ± 0.19
4.69 ± 0.64

105.93 ± 24.02
2461.83 ± 855.23
3.20 ± 0.49
31.98 ± 1.21

-ΔΔCT

Fold change

7

Gapdh
Bsp
Dmp1
Dspp
Osteocalcin

10

ΔCT

14

Control (2.3-GFP+ population)
Day of
Gene
CT
culture

7

Gapdh
Bsp
Dmp1
Dspp
Osteocalcin

21.22 ± 0.30
25.71 ± 0.49
25.92 ± 1.49
31.62 ± 0.50
20.50 ± 0.04

10

Gapdh
Bsp
Dmp1
Dspp
Osteocalcin

20.12 ± 0.21
22.93 ± 0.85
26.07 ± 0.40
31.13 ± 1.01
19.21 ± 0.20

14

FGF2-treated between days 3-14 (2.3-GFP+ population)
Day of
Gene
CT
ΔCT
culture

Gapdh
Bsp
Dmp1
Dspp
Osteocalcin

20.81 ± 0.07
22.51 ± 0.57
23.78 ± 1.45
31.02 ± 0.24
19.43 ± 0.11

Control (2.3-GFP− population)
Day of
Gene
CT
culture

−

−

−

5.03 ± 0.45
4.70 ± 1.45
10.26 ± 0.26
-0.18 ± 0.14

0.78 ± 0.27
7.43 ± 1.14
0.33 ± 0.34
0.86 ± 0.41

1.77 ± 0.30
332.97 ± 87.31
1.19 ± 0.40
1.97 ± 0.61

−

−

−

2.81 ± 0.89
5.96 ± 0.54
11.02 ± 0.94
-0.91 ± 0.40

3.01 ± 0.76
5.29 ± 1.02
-0.63 ± 0.33
1.58 ± 0.36

10.16 ± 4.22
59.59 ±32.95
0.88 ± 0.48
3.17 ± 0.69

−

−

−

1.71 ± 0.61
2.97 ± 1.39
10.21 ± 0.21
-1.38 ± 0.17

4.11 ± 0.80
8.28 ± 0.70
0.17 ± 0.32
2.05 ± 0.38

23.78 ± 13.51
376.36 ± 133.04
1.19 ± 0.27
4.45 ± 1.21

ΔCT

-ΔΔCT

Fold change
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21.59 ± 0.18
27.36 ± 0.31
34.10 ± 0.13
38.61 ± 0.90
23.94 ± 0.03

−

−

−

7

Gapdh
Bsp
Dmp1
Dspp
Osteocalcin

5.77 ± 0.13
12.51 ± 0.05
17.02 ± 0.89
2.35 ± 0.21

0.04 ± 0.35
-1.26 ± 0.67
–
-1.68 ± 0.25

1.09 ± 0.23
0.52 ± 0.26
N.D.
0.32 ± 0.03

20.21 ± 0.37
26.99 ± 0.39
33.62 ± 0.22
39.13 ± 0.87
23.13 ± 0.10

−

−

−

10

Gapdh
Bsp
Dmp1
Dspp
Osteocalcin

5.78 ± 0.02
12.41 ± 0.60
17.92 ± 0.76
1.92 ± 0.47

0.03 ± 0.24
-1.16 ± 0.71
–
-1.25 ± 0.38

1.05 ± 0.16
0.54 ± 0.19
N.D.
0.45 ± 0.05

20.26 ± 0.08
22.11 ± 0.30
23.29 ± 0.76
31.58 ± 0.13
20.06 ± 0.16

−

−

−

14

Gapdh
Bsp
Dmp1
Dspp
Osteocalcin

-0.16 ± 0.21
1.03 ± 0.71
9.32 ± 0.22
-2.21 ± 0.07

5.97 ± 0.07
10.21 ± 0.13
1.07 ± 0.31
2.87 ± 0.27

62.81 ± 1.80
1197.60 ± 107.62
2.19 ± 0.46
7.61 ± 1.29

-ΔΔCT

Fold change

14

10

7

FGF2-treated between days 3-14 (2.3-GFP− population)
Day of
Gene
CT
ΔCT
culture
Gapdh
Bsp
Dmp1
Dspp
Osteocalcin

20.62 ± 0.14
28.04 ± 0.23
29.69 ± 0.19
38.79 ± 0.76
23.90 ± 0.12

−

−

−

7.42 ± 0.37
9.08 ± 0.30
18.17 ± 0.76
3.29 ± 0.25

-1.61 ± 0.17
2.17 ± 0.63
–
-2.61 ± 0.26

0.33 ± 0.03
5.40 ± 2.16

Gapdh
Bsp
Dmp1
Dspp
Osteocalcin

20.24 ± 0.31
27.56 ± 0.32
29.97 ± 0.64
38.61 ± 0.90
23.30 ± 0.13

−

−

−

7.31 ± 0.63
9.73 ± 0.96
18.37 ± 0.90
3.06 ± 0.44

-1.50 ± 0.42
1.52 ± 0.93
–
-2.39 ± 0.36

0.39 ± 0.10
3.99 ± 1.88

Gapdh
Bsp
Dmp1
Dspp
Osteocalcin

22.21 ± 0.58
22.86 ± 0.94
24.73 ± 0.71
33.93 ± 0.73
22.57 ± 0.09

−

−

−

0.65 ± 0.36
2.51 ± 0.71
11.72 ± 0.15
0.36 ± 0.67

5.17 ± 0.16
8.74 ± 0.58
-1.33 ± 0.21
2.87 ± 0.27

N.D.

0.17 ± 0.01

N.D.

0.20 ± 0.02

36.43 ± 2.61
488.42 ± 148.56
0.40 ± 0.05
1.69 ± 0.77

ΔCT = CTgene - CTGapdh
-ΔΔCT = -(ΔCTsample – ΔCTcontrol)
Positive –ΔΔCT value = increased gene expression relative to control.
Negative –ΔΔCt value = decreased gene expression relative to control.
Expression of Bsp, Dmp1 and Osteocalcin in both 2.3-GFP+ and 2.3-GFP– populations is
normalized to GFP+ VH at day 7.
Expression of Dspp in both 2.3-GFP+ and 2.3-GFP– populations is normalized to GFP+ VH at
day 10.
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Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point.
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Table 12. Effects of continuous exposure to FGF2 on expression of markers of
mineralization and dentinogenesis in primary BMSC cultures.

Day 14

Day 10

Day 7

Control
Gene
Gapdh
Type I collagen
Runx2
Bsp
Osteocalcin
Dmp1
Dspp

CT

ΔCT

-ΔΔCT

Fold change

19.85 ± 0.37
15.99 ± 0.45
29.51 ± 0.28
19.13 ± 0.32
22.25 ± 0.91
29.56 ± 0.94
–

−

−

−

-4.02 ± 0.26
9.51 ± 0.41
-0.87 ± 0.20
2.24 ± 0.69
9.55 ± 0.84
–

0
0
0
0
0
–

1
1
1
1
1
N.D.

Gapdh
Type I collagen
Runx2
Bsp
Osteocalcin
Dmp1
Dspp

19.95 ± 0.18
14.81 ± 0.08
28.11 ± 0.17
17.63 ± 0.17
19.77 ± 0.29
23.51 ± 0.24
–

−

−

−

-5.21 ± 0.20
8.09 ± 0.33
-2.40 ± 0.41
-0.25 ± 0.22
3.49 ± 0.30

1.20 ± 0.38
1.42 ± 0.64
1.52 ± 0.32
2.50 ± 0.68
6.06 ± 0.80

–

–

N.D.

Gapdh
Type 1 collagen
Runx2
Bsp
Osteocalcin
Dmp1
Dspp

20.74 ± 0.22
14.69 ± 0.16
28.71 ± 0.18
17.16 ± 0.07
19.38 ± 0.30
23.35 ± 0.31
–

−

−

−

-5.95 ± 0.25
8.07 ± 0.25
-3.48 ± 0.20
-1.26 ± 0.17
2.71 ± 0.25

1.93 ± 0.42
1.44 ± 0.64
2.61 ± 0.14
3.51 ± 0.55
6.84 ± 0.79

4.51 ± 1.27
2.86 ± 0.48
6.21 ± 0.63
15.33 ± 6.00
204.12 ± 98.9

–

–

N.D.

ΔCT

-ΔΔCT

Fold change

−

−

−

0.53 ± 0.41
9.51 ± 0.41
5.87 ± 0.41
4.79 ± 0.29
4.69 ± 0.62

-4.55 ± 0.49
-1.01 ± 0.46
-6.74 ± 0.30
-2.55 ± 0.78
4.86 ± 0.43

0.05 ± 0.02
0.58 ± 0.14
0.01 ± 0.002
0.27 ± 0.10
34.68 ± 10.30

–

–

N.D.

−

−

−

-0.20 ± 0.64
9.90 ± 0.46
5.88 ± 0.25
3.54 ± 0.38
7.18 ± 0.10

-3.81 ± 0.85
-0.39 ± 0.17
-6.75 ± 0.20
-1.30 ± 0.32
2.37 ± 0.85

0.14 ± 0.07
0.84 ± 0.17
0.01 ± 0.001
0.45 ± 0.10
9.64 ± 4.66

Day 10

Day 7

FGF2-treated (20 ng/ml between days 3-14)
Gene
CT
19.93 ± 0.29
Gapdh
20.48 ± 0.33
Type I collagen
30.47 ± 0.59
Runx2
25.82 ± 0.42
Bsp
24.74 ± 0.21
Osteocalcin
24.64 ± 0.70
Dmp1
–
Dspp
Gapdh
Type I collagen
Runx2
Bsp
Osteocalcin
Dmp1

20.37 ± 0.11
20.13 ± 0.63
30.23 ± 0.44
26.22 ± 0.20
23.88 ± 0.41
27.52 ± 0.18
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2.66 ± 0.79
2.86 ± 0.52
3.17 ± 0.72
8.80 ± 4.00
125.33 ± 68.0

Day 14

Dspp
Gapdh
Type I collagen
Runx2
Bsp
Osteocalcin
Dmp1
Dspp

–

–

–

N.D.

20.25 ± 0.13
19.37 ± 0.18
30.51 ± 0.16
25.82 ± 0.81
24.00 ± 0.70
29.39 ± 1.14
–

−

−

−

-0.84 ± 0.11
10.31 ± 0.20
5.62 ± 0.98
3.80 ± 0.62
9.19 ± 1.04

-3.18 ± 0.37
-0.80 ± 0.36
-6.49 ± 0.79
-1.55 ± 0.56
0.37 ± 0.83

0.13 ± 0.03
0.62 ± 0.12
0.02 ± 0.01
0.49 ± 0.24
2.33 ± 1.12

–

–

N.D.

ΔCT = CTgene - CTGapdh.
-ΔΔCT = -(ΔCTsample – ΔCTcontrol).
Positive –ΔΔCT value = increased gene expression relative to control at day 7.
Negative –ΔΔCt value = decreased gene expression relative to control at day 7.
All results are normalized to VH at day 7.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point.
N.D. = not detected.
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CHAPTER V

EFFECTS OF EARLY EXPOSURE OF PRIMARY DENTAL PULP CULTURES TO
FGF2 ON DENTINOGENESIS.

Abstract.

Odontoblast differentiation and reparative dentinogenesis are dependent on multiple
signaling molecules sequestrated in the dentin matrix and pulp-supportive tissues, including
members of Fibroblast Growth Factor (FGF) family. Previous studies have demonstrated that
FGF2 exerted both positive and negative effects on odontoblast differentiation. However the
underlying cellular and molecular mechanisms of these conflicting results are largely unclear.
Results outlined in Chapter IV demonstrated that continuous exposure of pulp cells to FGF2
markedly decreased mineralization and exerted biphasic effects on the expression of markers of
mineralization and dentinogenesis and expression of various transgenes. Exposure of dental pulp
cells to FGF2 during the proliferation phase of in vitro growth resulted in increased levels of
expression

of

Dmp1

and

Dspp,

however

additional

exposure

during

the

differentiation/mineralization phase of in vitro growth resulted in decreased expression of these
genes. These observations suggested that the effects of FGF2 on dentinogenesis may depend on
the stage of differentiation/maturity of cells and/or are mediated through distinct signaling
pathways. In the present study we have examined the underlying mechanisms and the signaling
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pathways involved in the transient stimulatory effects of FGF2 on dentinogenesis of pulp cells.
Our results showed that exposure of pulp cells to FGF2 during the proliferation phase of in vitro
growth did not have significant effects on proliferation of pulp cells but affected their
differentiation. FGF2 induced significant increases in the expression of Dmp1, Dspp, and the
number of DMP1-GFP+ and DSPP-Cerulean+ odontoblasts. Analysis of FACS-sorted 2.3-GFP–
(progenitors) and 2.3-GFP+ (cells at early stages of odontoblast differentiation) populations
showed that FGF2 stimulated differentiation of both populations. Finally, our results showed that
the

stimulatory

effects

of

FGF2

on

dentinogenesis

were

mediated

through

the

FGFR/MEK/Erk1/2 and BMP/BMPR signaling pathways. These results provide critical
information for the development of improved treatments for vital pulp therapy and dentin
regeneration.
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Introduction.

Odontoblasts differentiate from the neural crest-derived dental papilla. The formation of
dental papilla cells and their differentiation into odontoblasts are regulated by signals derived
from the primary and secondary enamel knots and basement membrane (21, 378, 379). During
this process dental papilla cells give rise to preodontoblasts, which undergo the minimum
number of cell divisions to become competent to respond to additional signals from dental
epithelium. The final cell division is asymmetric and generates two daughter cells. The cell
adjacent to the basement membrane differentiates into preodontoblasts, whereas the other cell
remains undifferentiated and incorporates into subodontoblastic layer of Höhl, which serves as a
reservoir of odontoprogenitor cells during reparative dentinogenesis (6-9). During subsequent
stages, preodontoblasts undergo specific morphological changes giving rise to polarizing
odontoblasts secreting Type I collagen. Polarizing odontoblasts differentiate further into
functional/secretory odontoblasts engaged in secretion of mineralized predentin, which consists
primarily of collagen and biochemically is similar to osteoid. Finally, functional odontoblasts
differentiate into fully differentiated/mature odontoblasts engaged in the production of
mineralized dentin. Mineralization of predentin into dentin occurs as various NCPs, such as BSP,
DMP1 and DPP, are incorporated at the mineralization front.

The dentin-pulp complex has a regenerative potential leading to the formation of tertiary
dentin. Two types of tertiary dentin are distinguished based on the intensity and duration of
stimuli. In response to mild and short stimuli that do not lead to the cell death reactionary dentin
is formed by pre-existing postmitotic primary odontoblasts. The formation of reactionary dentin

130

involves the upregulation of the secretory activity of odontoblasts and is referred to as
odontoblast-mediated tertiary dentinogenesis (18-20). Trauma of greater intensity leading to the
death of the pre-existing odontoblasts results in the formation of reparative dentin. Reparative
dentinogenesis is different from reactionary dentinogenesis and involves the recruitment and
proliferation of progenitor/stem cells to the site of injury, and their differentiation into a second
generation of odontoblasts or “odontoblast-like” cells and is referred to as progenitor-mediated
tertiary dentinogenesis (11, 21).

The differentiation of odontoblast-like cells during reparative dentinogenesis depends on
the availability of progenitor/stem cells and inductive signals for their differentiation (104, 105).
Despite many similarities between the primary and reparative dentinogenesis, the latter occurs in
the absence of signals from the dental epithelium and is dependent on multiple signaling
molecules, such as members of various families of growth factors including Fibroblast Growth
Factors (FGFs), Bone Morphogenetic Proteins (BMPs), Wingless/Integrated (Wnt), Vascular
Endothelial Growth Factor (VEGF), which are sequestrated in the dentin matrix and pulpsupportive tissues (106, 108, 110). These factors are released from injured dentin and/or pulp and
regulate various aspects of healing and repair, including proliferation and migration of the
progenitor cells and their differentiation into odontoblast-like cells (23).

FGF2, a member of the FGF family, plays essential roles in proliferation, migration and
homing of undifferentiated dental pulp cells during reparative dentinogenesis (125, 126, 146, 339,
341-343, 348). FGF2 has also been shown to increase the expression of markers of mesenchymal
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stem cells (MSCs), including Oct4, Nanog and Rex1 (344, 348), and the percentage of STRO-1+
cells in the dental pulp (342, 348).

However, the available literature reports conflicting results on the roles of FGF2 on
differentiation of pulp cells into odontoblasts. Several studies reported the inhibitory effects of
FGF2 on dentinogenesis and the expression of Dspp (126, 146, 339-341, 345, 349). On the other
hand, others have shown the stimulatory effects of FGF2 on the formation of osteodentin in vivo
(137, 146, 338) and expression of Dspp in vitro (345).

Most of the reported results are based on observations in whole primary dental pulp
cultures, which are composed of a heterogeneous population of cells made up fibroblasts,
macrophages, endothelial cells and lymphocytes and contain nodules at various stages of
differentiation/mineralization (90, 351, 352, 374). The heterogeneity of these cultures and the
lack of suitable markers for lineage stages have hampered better understanding of mechanisms
underlying the positive and negative effects of FGF signaling on odontoblast differentiation.

We have recently used a series of GFP reporter transgenic mice that display stagespecific activation of transgenes during odontoblast differentiation for lineage analysis and to
gain a better understanding of the progression of progenitor cells into odontoblasts (90, 351).

Using these transgenic animals we have demonstrated stage-specific effects of FGF2 on
differentiation of progenitor cells into odontoblasts (see Chapter IV). Exposure to FGF2 initially
increased levels of expression of markers of mineralization and dentinogenesis, including Dspp
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and Dmp1, and expression of DMP1-GFP transgene, a marker of cells at advanced stages of
odontoblast differentiation. However, these increases were transient and additional exposure to
FGF2 decreased expression of these markers, the extent of mineralization and expression of
various transgenes during the differentiation/mineralization phase of in vitro growth. These
observations suggested that the effects of FGF2 on pulp cells are dependent on the stage of
differentiation/maturity of cells. FGF2 initially promoted the formation of functional
odontoblasts but inhibited further differentiation of these cells at later time points, suggesting
that limited and early exposure of pulp cells to FGF2 leads to increases in dentinogenesis.

The purpose of the study outlined in this chapter was to test this possibility and to gain
further insight into cellular and molecular mechanisms regulating the stimulatory effects of
FGF2 on odontoblast differentiation in primary dental pulp cultures.
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Results.

Effects of early exposure to FGF2 on mineralization and dentinogenesis in primary dental
pulp cultures.

Results outlined in Chapter IV of this dissertation demonstrated that continuous exposure
of primary dental pulp cultures to FGF2 inhibited mineralization and dentinogenesis. In addition
we showed the biphasic effects of FGF2 on the expression of markers of mineralization and
dentinogenesis, suggesting stage-specific response of pulp cultures to FGF2. Our study showed
that exposure of pulp cells to FGF2 during the proliferation phase of in vitro growth increased
levels of Dmp1, Dspp and DMP1-GFP+ cells, whereas additional exposure to FGF2 during the
differentiation/mineralization phase of in vitro growth resulted in marked decreases in the
expression of all markers of mineralization and dentinogenesis.

The purpose of the study outlined in this chapter is to examine the cellular and molecular
mechanisms, by which early exposure of pulp cells to FGF2 stimulates their dentinogenic
differentiation. In this study, pulp cultures were exposed to 20 ng/ml FGF2 during only the
proliferation phase of in vitro growth (between days 3-7, referred to as early exposure). Starting
day 7 all cultures were grown in the mineralization-inducing medium without FGF2 for
additional 7-14 days.

XO and von Kossa staining showed the appearance of the mineralized matrix in both
control and FGF2-treated cultures around day 10 with increases thereafter (Figure 15 and Table
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13). The extent of mineralization in FGF2-treated cultures at days 10 and 14 were similar to that
in the control, and slightly higher than that in the control at day 21 (Figure 15 and Table 13).

Quantitative PCR analysis showed increases in the levels of expression of all markers of
mineralization and dentinogenesis at day 7 in FGF2-treated cultures as compared to control
(Figure 16 and Tables 14 and 15). On the other hand, FGF2-treated cultures showed marked
changes in the expression of Osteocalcin, Dmp1 and Dspp as compared to control at later time
points (Figure 16A and Table 14). Levels of Osteocalcin were ~1.2-1.8-fold higher in FGF2treated cultures as compared to those in the control (Figure 16A and Table 14). Expression of
Dmp1 in FGF2-treated cultures was significantly higher than that in the control at day 7 (~270fold) and similar to that in the control between days 10-21 (Figure 16A and Table 14).
Expression of Dspp in FGF2-treated cultures was detected earlier (at day 7) and at significantly
higher levels (~3.4-7.3-fold) at all time points as compared to control (Figure 16A and Table 14).
Further analysis showed that increases in the expression of Dmp1 and Dspp in FGF2-treated
cultures were detected as early as 12 and 24 hrs after treatment, respectively (Figure 16B and
Table 15).

These observations showed that early and limited exposure of pulp cells to FGF2 during
the proliferation phase of in vitro growth resulted in rapid and significant increases in the
expression of all markers of mineralization and dentinogenesis. This treatment did not affect the
expression of Type I collagen, Bsp, Osteocalcin and Dmp1 at later time points during the
differentiation/mineralization phase of in vitro growth. However, this treatment resulted in
significant increases in the expression of Dspp and slight increases in the extent of mineralization.
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The

effects

of

early

exposure

of

dental

pulp

cells

to

FGF2

during

the

differentiation/mineralization phase of in vitro growth are different from the effects of
continuous exposure of dental pulp to FGF2 that resulted in decreases in the expression of
markers of mineralization and dentinogenesis (see Figure 16A) as well as the extent of
mineralization. These observations suggest that early exposure of pulp cells to FGF2 stimulated
dentinogenesis but decreased osteogenesis in primary dental pulp cultures.

Effects of early exposure to FGF2 on cell proliferation.

To examine if the increases in the expression of Dmp1 and Dspp in these cultures were
related to increases in the cell number, the effects of FGF2 on cell proliferation in the whole
culture were examined by the WST-1 assay 24-96 hrs after exposure to FGF2 (days 4-7 of the
culture). Cell proliferation in the control and FGF2-treated cultures peaked around 48-72 hrs and
declined at 96 hrs. FGF2-treated cultures showed up to ~1.6-fold increase in proliferation at 2496 hrs as compared to control (Figures 17A and 17B). These observations showed that FGF2 did
not have marked stimulatory effects on cell proliferation as compared to control.

Effects of early exposure to FGF2 on expression of 3.6-GFP and 2.3-GFP transgenes in
primary dental pulp cultures.

To gain further insight into underlying mechanisms of the stimulatory effects of FGF2,
we cultured pulp cells from 3.6-GFP and 2.3-GFP transgenic mice. Our previous studies showed
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that these transgenes are good markers for identification of cells at early stages of odontoblast
differentiation (polarizing odontoblasts that lack the expression of Dmp1 and Dspp) (351).

In these experiments primary pulp cultures from these transgenic mice were exposed to
VH or FGF2 during the proliferation phase of in vitro growth. Epifluorescence analysis of
cultures from 3.6-GFP and 2.3-GFP transgenic mice showed slight (~1.5-fold) increases in the
intensity of both transgenes at day 7 as compared to control. The intensity of the expression of
3.6-GFP and 2.3-GFP transgenes in FGF2-treated cultures at days 10-21 was similar to that in
respective control cultures (Figure 18 and Table 16).

To determine if increases in the intensity of 2.3-GFP transgene in FGF2-treated cultures
were related to increases in the number of 2.3-GFP+ cells, FACS analysis was performed 24-96
hrs after exposure to FGF2 (days 4-7 of the culture) (Figure 20). Control cultures displayed slight
increases in the percentage of 2.3-GFP+ cells and slight decreases in the percentage of 2.3-GFP–
cells (~1.15-fold) (Figure 19 and Table 17).

Flow cytometry experiments were performed to examine the effects of FGF2 on the
regulation of the cell cycle in the 2.3-GFP+ and 2.3-GFP– populations (Figure 20). In the control
2.3-GFP+ population, during days 4-7 of culture ~79-83% of cells were in G1 phase and ~1621% were in S+G2/M phases of the cell cycle (Table 18). In the 2.3-GFP+ population exposed to
FGF2, ~67-83% of cells were in G1 phase and ~17-34% were in S+G2/M phases of cell cycle
(Table 18). These observations indicated a slight increase (~1.3-2-fold) in rates of proliferation
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in the 2.3-GFP+ population exposed to FGF2 as compared to control. Similarly, there were slight
increases (~1.2-1.7-fold) in the rates of proliferation in the 2.3-GFP– population.

Thus, the early exposure of pulp cells to FGF2 did not have significant effects on cells at
early stages of odontoblast differentiation. The effects of early exposure of dental pulp cells to
FGF2 during the proliferation phase of in vitro growth are different from the effects of
continuous exposure of dental pulp to FGF2 that resulted in decreases in the expression of these
transgenes.

Effects of early exposure to FGF2 on expression of DMP1-GFP and DSPP-Cerulean
transgenes in primary dental pulp cultures.

We next examined the effects of FGF2 on the expression of DMP1-GFP and DSPPCerulean transgenes shown to be good markers for functional and fully differentiated
odontoblasts (cells at later stages of odontoblast differentiation). Functional odontoblasts were
also identified by high levels of expressing of Dmp1 and low levels of Dspp (90) and fully
differentiated odontoblasts by high levels of Dspp expression.

Our analysis of the pulp cultures from DMP1-GFP transgenic mice showed marked
increases (~38-fold) in the intensity of DMP1-GFP expression in FGF2-treated cultures at day 7
as compared to control. The intensity of the expression of the DMP1-GFP transgene in FGF2treated cultures at days 10-21 was similar to that in control cultures (Figure 21 and Table 19). In
addition, FACS analysis showed significant increases in the percentage of DMP1-GFP+ cells in
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FGF2-treated cultures as compared to control. These increases were evident as early as 24 hrs
after treatment (~4-fold) with additional increases (~7-8-fold) thereafter (Figure 22 and Table
20).

We have previously shown the lack of proliferation of DMP1-GFP+ cells in control
cultures (90). These observations suggest that the increases in the number of DMP1-GFP+ cells
in the control and FGF2-treated cultures in the present study are related to activation of this
transgene in new cells (which did not express DMP1-GFP transgene before). This was
demonstrated in our time-lapse live imaging, which showed that FGF2 did not stimulate
proliferation of preexisting DMP1-GFP+ cells but activated DMP1-GFP transgene in new
DMP1-GFP– cells (data not shown). The increases in the number of DMP1-GFP+ cells in FGF2treated culture as compared to control suggest accelerated differentiation in FGF2-treated
cultures.

Accelerated differentiation in pulp cultures by early exposure to FGF2 was further
examined using pulp cultures from DSPP-Cerulean transgenic mice (Figures 23A and 23B, and
Table 21). Pulp cultures from these mice showed the appearance of DSPP-Cerulean+
odontoblasts expressing high levels of DSPP-Cerulean transgene around day 10 with ~3.4-3.8fold increases thereafter. In addition, control cultures displayed ~8-29-fold increases in the
intensity of DSPP-Cerulean transgene between days 10-21. FGF2-treated cultures contained
significantly higher percentages of DSPP-Cerulean+ odontoblasts (~2-17-fold) and displayed
higher intensity of DSPP-Cerulean transgene (~2-6.5-fold) as compared to control at all time
points.
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These observations indicated that early exposure of pulp cultures to FGF2 resulted in
marked increases in the number of DMP1-GFP+ and DSPP-Cerulean+ cells at day 7 followed by
further

increases

in

the

number

of

DSPP-Cerulean+

odontoblasts

during

the

differentiation/mineralization phase of in vitro growth.

Involvement of FGFR signaling in stimulatory effects of FGF2 on expression of Dmp1 and
Dspp in primary dental pulp cultures.

Next we examined the roles of FGFRs in mediating the stimulatory effects of FGF2 on
the expression of Dmp1 and Dspp.

In the first set of experiments, we examined the expression of Fgfrs in primary pulp cells
grown in the presence or absence of FGF2 (Figure 24). RT-PCR analysis showed that control
cultures displayed low levels of Fgfr1c and Dmp1 and no expression of Dspp during days 3-7 (096 hrs after treatment). In contrast, expression of Fgfr2c in these cultures was high initially (24
and 48 hrs) and decreased at later time points (72 and 96 hrs). FGF2-treated cultures showed
increases in the levels of Fgfr1c, Dmp1 and Dspp as compared to control. In contrast, FGF2treated cultures displayed more pronounced gradual decreases in the Fgfr2c expression. FGF2
had no effect on the expression of Fgfr3 as compared to control, and no Fgfr4 expression was
detected in any sample (data not shown).
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Taken together, these results demonstrated that FGF2 stimulated expression of Fgfr1c
and decreased expression of Fgfr2c. The changes in the expression of Fgfr1c in FGF2-treated
cultures were similar to those of Dmp1 and Dspp. These results suggest that FGF2-induced
maturation and differentiation of pulp cells involved changes in the patterns of expression of
Fgfrs.

In the second set of experiments, we examined the roles of FGFRs in stimulatory effects
of FGF2 by using SU5402, a potent inhibitor of the tyrosine kinase activity of fibroblast growth
factor receptors (360, 361). In these experiments primary pulp cultures were treated with
SU5402 with or without FGF2 between days 3-7 (0-96 hrs after treatment). The expression of
Dmp1 and Dspp in these cultures was examined and compared to that in control by qPCR at
various time points.

Quantitative PCR analysis showed no significant changes in the basal expression of
Dmp1 and the lack of expression of Dspp in cultures exposed to various concentrations of
SU5402 alone at all time points (Figure 25A and Table 22). Analysis of FGF2-treated cultures
showed that SU5402 attenuated FGF2-induced increases in the expression of Dmp1 and Dspp in
a concentration-dependent manner at all time points (Figure 25B, and Tables 22 and 23). In
addition, as low as 5 µM of SU5402 decreased FGF2-induced formation of DSPP-Cerulean+
odontoblasts at 96 hrs (Figure 26A). The inhibitory effects of SU5402 on Dmp1 and Dspp
expression were not related to marked differences in the cellularity of the cultures indicated by
the lack of detectable differences in the intensity of crystal violet staining (Figure 26B).
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Although SU5402 downregulated FGF2-induced increases in the expression of Dmp1 and
Dspp, their levels did not reach those in control cultures. These observations suggest that FGF2mediated increases in the levels of Dmp1 and Dspp were partially mediated through FGFR
signaling and involved indirect effects through activation of other signaling pathways.

Involvement of MEK/Erk1/2 signaling in stimulatory effects of FGF2 on expression of
Dmp1 and Dspp in primary dental pulp cultures.

Effects of FGF/FGFR signaling are mediated primarily through activation of the MAPK,
PI3K and PLCγ signaling pathways (380). MAPK signaling regulates various cellular functions,
including proliferation and differentiation (381-383). PI3K pathway exerts mostly anti-apoptotic
effects, although its role in regulation of cell proliferation and differentiation has also been
reported (384-386). PLCγ regulates cell adhesion and migration, Ca2+ entry into the cells and
actin cytoskeletal reorganization (387-389).

Thus, MEK/Erk1/2 signaling is the primary pathway involved in mediating the effects of
FGF/FGFRs on cell proliferation and differentiation. In addition, previous studies have showed
that MEK/Erk1/2 mediated FGF2-induced upregulation of Dmp1, Bsp, Osteopontin and
Osteocalcin in osteoblasts (243, 244, 390, 391), thus raising a possibility that it could be
involved in mediating the stimulatory effects of FGF2 on pulp cells and expression of Dmp1 and
Dspp.

To test this possibility, we first examined the effects of FGF2 on phosphorylation of
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Erk1/2 using immunocytochemistry. Our results showed that, unlike its cytoplasmic localization
in the control cultures, FGF2 induced nuclear localization of phospho-Erk1/2 protein after 30
min (Figure 27). These results are consistent with studies that showed that activation of the
Erk1/2 protein resulted in its rapid translocation from the cytoplasm to the nucleus (392-394).

As the next step we examined the effects of U0126, a highly selective inhibitor of both
MEK1 and MEK2 (362, 363), on localization of phospho-Erk1/2. Our results showed that U0126
significantly decreased the intensity of phospho-Erk1/2 staining, especially in the cell nuclei
(Figure 27). This is in agreement with previous results, which demonstrated that U0126
markedly inhibited FGF2-induced levels of phospho-Erk1/2 (244).

Subsequently, we examined the effects of U0126 on expression of Dmp1 and Dspp. In
these experiments cultures were grown with U0126 in the presence and absence of FGF2
between days 3-7 (0-96 hrs after treatment). The expression of Dmp1 and Dspp in these cultures
was examined and compared to the control at various time points by qPCR.

Quantitative PCR analysis showed concentration-dependent decreases in the basal
expression of Dmp1 and the lack of expression of Dspp in cultures treated with U0126 alone at
all time points (Figure 28A and Table 24). Analysis of FGF2-treated cultures showed that U0126
markedly attenuated FGF2-mediated increases in Dmp1 and Dspp expression at all time points
(Figure 28B, and Tables 24 and 25), and inhibited the FGF2-mediated increases in DSPPCerulean+ odontoblasts at 96 hrs (Figure 29A). The inhibitory effects of U0126 on gene
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expression were not related to marked differences in the cellularity of the cultures evidenced by
the lack of detectable differences in the intensity of crystal violet staining (Figure 29B).

These observations suggest an important role of FGF/FGFR-MEK/Erk1/2 pathway in
mediating the stimulatory effects of FGF2 on dental pulp cells. Our results are in agreement with
previous studies, which demonstrated that inhibition of MEK/Erk1/2 signaling markedly
decreased the expression of markers of mineralization in response to various growth factors,
including FGF2 (240, 395).

In general, the inhibitory effects of U0126 on the expression of Dmp1 and Dspp were
more potent as compared to those of SU5402 (compare Tables 23 and 25). Similar to SU5402,
U0126 downregulated FGF2-induced increases in the expression of Dmp1 and Dspp, but levels
of their expression still did not reach those in the control cultures. These observations suggest
that FGF2-mediated increases in the levels of Dmp1 and Dspp were mediated through the
MEK/Erk1/2 signaling and involved indirect effects through activation of other signaling
pathways.

Involvement of BMP/BMPR signaling in stimulatory effects of FGF2 on Dmp1 and Dspp in
primary dental pulp cultures.

Although both SU5402 and U0126 downregulated FGF2-induced increases in the
expression of Dmp1 and Dspp, levels of their expression did not reach those in the control

144

cultures, suggesting that FGF2-mediated increases in the levels of Dmp1 and Dspp also involved
activation of other signaling pathways.

Among various signaling pathways, which activate MEK/Erk1/2 signaling, we focused
on BMP signaling, as it has been shown to positively regulate odontoblast differentiation and
expression of Dspp in vivo and in vitro (396-400). These stimulatory effects of BMP signaling
occur primarily through activation of Smads, Msx, Dlx, Runx2, Osx and Nf-y (canonical BMP
pathway) (397, 398, 401-406). In addition, MEK/Erk1/2 signaling has been reported to mediate
stimulatory effects of BMP signaling in SV F4 dental follicle cells, and U0126 markedly
decreased these effects in a concentration-dependent manner (407).

Furthermore, results outlined in Chapter VII of this dissertation showed that FGF2
rapidly and significantly increased the expression of components of BMP signaling (Bmp2, Dlx5,
Msx2, Osx) in dental pulp cultures, suggesting that the effects of FGF2 on odontoblast lineage
are also mediated through BMP signaling.

To explore this possibility, we first examined the effects of SU5402 and U0126 on the
expression of Bmp2 in the control and FGF2-treated cultures (Figure 30 and Table 26). FGF2induced increases in the expression of Bmp2 were reversed by SU5402 and U0126, indicating
the roles of FGFR/MEK/Erk1/2 signaling in increased expression of Bmp2.

Next we examined the roles of BMP/BMPR signaling in mediating the stimulatory
effects of FGF2 on Dmp1 and Dspp using noggin, a specific inhibitor of BMP/BMPR signaling
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(364-366).

QPCR analysis showed that cultures exposed to various concentrations of noggin alone
displayed slight decreases in the basal expression of Dmp1 at 96 hrs (Figure 31 and Table 27).
Expression of Dspp was not detected in the control cultures at any time point (Figure 31 and
Table 27). Noggin markedly decreased FGF2-mediated increases in expression of Dmp1 and
completely abolished FGF2-mediated increases in the expression of Dspp at all time points
(Figure 31 and Table 27). In addition, noggin inhibited FGF2-induced increases in DSPPCerulean+ odontoblasts at 96 hrs (Figure 32A). The inhibitory effects of noggin on gene
expression were not related to marked differences in the cellularity of the cultures evidenced by
the lack of detectable differences in the intensity of crystal violet staining (Figure 32B).

The higher magnitude of the inhibition of BMP signaling on Dmp1 and Dspp could result
not only from the effects of BMP/BMPR signaling on MEK/Erk1/2, but also from its effects on
FGF/FGFR signaling (negative feedback loop). Therefore, we examined the effects of BMP
signaling on expression of Fgfr1c and Fgfr2c in pulp cells exposed to FGF2. Addition of noggin
completely reversed the FGF2-induced changes in expression of Fgfr1c and Fgfr2c (Figure 31C
and Table 27).

Overall, these results provide evidence for the involvement of the FGFR/MEK/Erk1/2 in
increases in Bmp2 and the involvement of BMP signaling in mediating the stimulatory effects of
FGF2 on the expression of Dmp1 and Dspp.
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AP-1 is a possible downstream mediator of the effects of FGF2 on Dmp1 and Dspp.

Our studies showed the involvement of the FGFR and MEK/Erk1/2 signaling pathways
in mediating the stimulatory effects of FGF2 on Dmp1 and Dspp. We also showed that these
effects occurred rapidly, suggesting a direct interaction between downstream targets of Erk1/2
with regulatory elements of these genes. Therefore, as a next step, we aimed to gain some insight
into transcription factors involved in mediating the effects of FGFR/MEK/Erk1/2 signaling on
expression of Dmp1 and Dspp.

Erk1/2 interacts with almost 300 proteins (408), and this makes it difficult to identify
specific downstream transcription factors mediating its effects on Dmp1 and Dspp. Among the
interacting proteins, several lines of evidence suggest involvement of AP-1 transcription factor in
dentinogenesis (7, 409-412). AP-1 is composed of c-Fos, c-Jun, junB and junD, and binds to the
promoter and enhancer regions of target genes at AP-1 motifs [5’-TGA(C/G)TCA-3’] (413-415).
Thus, AP-1 acts as a terminal mediator of the effects of multiple signaling pathways, including
MEK/Erk1/2, on expression of target genes (416, 417). In addition, AP-1 can regulate expression
of its target genes by binding to the activating transcription factor (CRE) [5’-TGACGTCA-3’]
(418, 419) and CRE-like [5’-TGAGCTCA-3’] (416, 420) motifs. Furthermore, increased
expression of c-fos (7-fold) and c-jun (4-fold) by FGF2 in ROS17/2.8 osteoblast-like cells has
recently been reported (255).

Computer bioinformatics analysis of the 25.000 bp regulatory region (upstream of the
transcription start) identified AP-1 and CRE-like binding sites within promoters of Dspp and
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Dmp1. Within the Dspp promoter, four AP-1 and two CRE-like motifs were identified (Figure
33A). Within the Dmp1 promoter, three AP-1 and one CRE-like motifs were identified. We were
unable to identify CRE motifs within Dspp and Dmp1 promoters (Figure 33B).

The identification of AP-1 binding motifs in the regulatory regions of Dspp and Dmp1
are consistent with previous results (397, 421, 422). However, our analysis examined the more
extended region of the promoters, and in contrast to those studies, identified the presence of not
only canonical AP-1 motifs, but also CRE-like motifs.

Overall, our data suggest that AP-1 transcription factor could be a terminal mediator of
the effects of FGF signaling on expression of Dmp1 and Dspp.

Effects of early exposure to FGF2 on FACS-sorted 2.3-GFP+ and 2.3-GFP– populations.

To gain insight into specific cell populations responsive to the stimulatory effects of
FGF2, we utilized FACS-mediated cell isolation and enrichment shown to be a powerful
experimental tool for lineage studies. Our previous observations on FACS-sorted populations
showed that 2.3-GFP+ population represented proliferative cells enriched in polarizing
odontoblasts, whereas DMP1-GFP+ population represented postmitotic functional odontoblasts
(90, 351).

Based on these observations, we examined the effects of FGF2 on 2.3-GFP+ and 2.3GFP– populations. In these experiments, primary pulp cultures from 2.3-GFP transgenic mice

148

were first grown under control culture conditions supporting their proliferation and expansion in
the absence of FGF2. At day 7, FACS was used to separate relatively homogeneous populations
of 2.3-GFP+ and 2.3-GFP– cells, and reanalysis demonstrated a high purity of isolated
populations (≥ 98%) (Figure 34). Both populations were replated at the same density as unsorted
cells and cultured in the absence or presence of FGF2 between days 3-7 as described for unsorted
cultures.

In control cultures established from the 2.3-GFP+ population, GFP expression was
detected initially and was maintained throughout the entire culture period (Figure 36). The first
sign of mineralization in these cultures was around day 10 with significant increases thereafter
(Figure 35). In these cultures low levels of Type I collagen and Dmp1 were detected around day
7 with increases thereafter. Low levels of Dspp were detected only around day 10 with increases
thereafter (Figure 36 and Table 28).

Early exposure of 2.3-GFP+ cultures to FGF2 resulted in continuous and marked
increases in the expression of Type I collagen, Dmp1 and Dspp as compared to control (Figure
35). The levels of Dmp1 in FGF2-treated cultures at day 7 were ~380-fold higher than those in
the control (Figure 36 and Table 28). The expression of Dspp in FGF2-treated cultures was
detected earlier (at day 7) and at higher levels (~9-17-fold) as compared to control (Figure 36
and Table 28). These observations indicated that FGF2 stimulated expression of Dmp1 and Dspp
in the 2.3-GFP+ population and accelerated differentiation of polarizing odontoblasts.
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Our analysis of cultures established from the 2.3-GFP– population showed that the
expression of GFP was not detected initially, but appeared at day 7 in a few isolated cuboidal
cells and increased thereafter (Figure 35). Expression of Type I collagen and Dmp1 was detected
at day 7, and mineralization and expression of Dspp were detected only at day 14 (Figures 35
and 36, and Table 28). In cultures from the 2.3-GFP– population, mineralization was not over the
entire culture dish and had a nodular pattern. The levels of expression of Type I collagen, Dmp1
and Dspp and the extent of mineralization in cultures established from the 2.3-GFP– population
were lower than those in cultures from the 2.3-GFP+ population (~1.5-3.5-fold), indicating that
the 2.3-GFP– population contains cells at the early stage of differentiation. The early exposure of
the 2.3-GFP– cultures to FGF2 resulted in increases in the expression of Dmp1 and Dspp.

These results suggest that FGF2 accelerated dentinogenic differentiation in progenitors
(2.3-GFP–) and cells at early stages of differentiation (2.3-GFP+).

Effects of early exposure to FGF2 on expression of selected genes in primary dental pulp
cultures.

To further test the possibility that exposure to FGF2 accelerated differentiation of pulp
cells, we examined the effects of FGF2 on expression of a selected group of genes, which based
on previously published in vivo studies, are expressed at distinct stages of odontoblast
differentiation.
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Previous studies showed that Ameloblastin (Ambn) was transiently expressed by
preodontoblasts and polarizing odontoblasts (46). Expression of Ambn declined markedly in
more mature odontoblasts (46, 121, 403, 423, 424). On the other hand, similar to Dmp1 (425)
and Dspp (375), Bono1 was not expressed in undifferentiated cells and was detected in
functional and fully differentiated odontoblasts (423).

Furthermore, previous observations have shown changes in the expression of Fgfrs
during odontoblast differentiation. Fgfr2c was detected in the dental mesenchyme prior to
differentiation and not detected in differentiated odontoblasts. On the other hand, Fgfr1c was
expressed at low levels in dental papilla and follicle and at high levels in a differentiated
odontoblast layer (117, 288).

In the next set of experiments we examined the effects of FGF2 on expression of these
markers in unsorted cultures, and 2.3-GFP+ and 2.3-GFP– populations at day 7 (Figure 37).
Quantitative PCR analysis at day 7 showed that FGF2 significantly increased the expression of
markers of more mature odontoblasts (Dmp1, Dspp, Bono1 and Fgfr1c) and decreased the
expression of markers of less mature odontoblasts (Ambn and Fgfr2c) in both 2.3-GFP+ and 2.3GFP– populations as compared to the respective controls (Figure 38 and Table 29).

Overall, these results demonstrated that early exposure to FGF2 stimulated dentinogenic
differentiation of both progenitors (2.3-GFP– cells) and cells at early stages of odontoblast
differentiation (2.3-GFP+ cells), albeit more significantly affected 2.3-GFP+ cells. This exposure
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resulted in increased formation of functional odontoblasts expressing Dmp1, Dspp, Bono1 and
Fgfr1c, and decreased formation of less mature progenitors expressing Ambn and Fgfr2c.
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Discussion.

Reparative dentinogenesis during pulp healing requires recruitment of progenitor cells
and their differentiation into odontoblast-like cells. However, it is still not established exactly (i)
which cell type contributes to the formation of new odontoblast-like cells, and (ii) which cellular
and molecular mechanisms are involved in this process. Since primary odontoblasts are
postmitotic cells, they are unable to regenerate by cell division upon damage. This suggests that
the cells other than mature odontoblasts are involved in this process. Although the origin of these
cells still remains unclear, it is believed that formation of new odontoblast-like cells results from
proliferation and differentiation of a population of stem/progenitor cells residing within the
dental pulp (presumably, cells of the Höhl layer) (9, 15, 19). Some studies have also suggested
that dental pulp cells at the apex of the roots could serve as an important source of cells involved
in reparative dentinogenesis (25). In addition, other cell types, such as undifferentiated
mesenchymal cells in the pulp core or pericytes, could be involved in this process (8, 15).
Differences in the origin of these cells could influence the resulting cell phenotype and its
relationship to that of the odontoblast (27).

Our previous studies demonstrated biphasic effects of FGF2 on dental pulp cells,
including early stimulatory effects on the expression of Dmp1, Dspp and DMP1-GFP+ cells.
These transient stimulatory effects were followed by inhibitory effects on further differentiation
and maturation of cells of the odontoblast lineage. These results might indicate that FGF2 had a
biphasic effect on odontoprogenitors in the dental pulp: stimulatory during the proliferation
phase of in vitro growth, and inhibitory during the differentiation/mineralization phase of in vitro
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growth. Therefore, the goal of the study outlined in this chapter was to gain further insight into
the cellular and molecular mechanisms underlying the stimulatory effects of FGF2 on
mineralization and dentinogenesis.

Our results showed that early and limited exposure (between days 3-7) of pulp cells to
FGF2 accelerated differentiation of pulp cells leading to increased dentinogenesis.

This increase in dentinogenesis was evident in increases in the levels of Type I collagen,
Bsp, Osteocalcin, Dmp1, Dspp, Bono1 and Fgfr1c at day 7. There were also decreases in the
expression of Fgfr2c and Ambn, which are expressed in the undifferentiated but not
differentiated cells of the odontoblast lineage. The most significant increases were detected in the
expression of Dmp1 (~330-fold) followed by increases in the expression of Dspp, Bsp and Bono1
(~2-3 fold).

Our additional analysis of pulp cultures from various transgenic mice at early time points
showed that FGF2 did not affect the percentage of cells at early stages of differentiation (3.6GFP and 2.3-GFP transgenes, markers of polarizing odontoblasts), but caused rapid and marked
increases in the percentage of DMP1-GFP+ cells (~6.5-7.6-fold). FGF2 also increased the
percentage of DSPP-Cerulean+ odontoblasts (~17 fold) that expressed this transgene at low
levels.

The increases in the number of DMP1-GFP+ and DSPP-Cerulean+ odontoblasts, together
with changes in the profile of the gene expression at day 7, are consistent with accelerated

154

differentiation and the increases in number of functional odontoblasts in FGF2-treated pulp as
compared to control.

Additionally, our analysis at later time points in culture (between days 10-21) showed
that after withdrawal of FGF2, cells continued their differentiation program. The levels of Type I
collagen, Bsp, Osteocalcin and Dmp1 in these cultures were either similar or slightly higher than
those in the control cultures. Most notable were the continuous and significant increases in the
levels of Dspp, intensity of DSPP-Cerulean transgene and the percentage of DSPP-Cerulean+
odontoblasts between day 10-21 in cultures exposed to FGF2 as compared to control.

The profile of gene expression and increases in the intensity of the expression of various
transgenes between days 10-21 in cultures exposed to FGF2 during the proliferation phase of in
vitro growth are different from those in cultures exposed to FGF2 continuously that showed
marked decreases in levels of various markers and transgenes (submitted manuscript). These
differences indicate that, unlike its initial stimulatory effects on differentiation of functional
odontoblasts from early progenitors, FGF2 inhibited further differentiation of these cells into
fully differentiated odontoblasts. Together these results provide evidence for stage-specificity of
the effects of FGF2 on differentiation of pulp cells.

These observations, by providing evidence of stage-specific effects of FGF2 on pulp cells,
offer insight into the reported contradictory positive and negative effects of FGF2 on odontoblast
differentiation. In vitro exposure of dental pulp cells grown in collagen type I gel cultures, but
not plate-coated collagen type I, to FGF2 increased expression of Dspp in pulp cultures (343).
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Exposure of immortalized human dental pulp cells to FGF2 stimulated expression Dmp1 and
Dspp (345). Exposure of E17 (bell stage) tooth germs to FGF2 inhibited on dentinogenesis and
the expression of Dspp, whereas similar treatment at E15 (cap stage) stimulated dentinogenesis
and Dspp (349).

Our observations also provide some insight into the reported stimulatory effects of FGF2
on the formation of calcified dentinal bridge after pulp exposure (137, 146, 338). A recent study
showed that the calcified bridge was DSP+ and DMP1+ matrix that did not include cells
expressing Nestin, which is expressed by odontoblasts and not by osteoblasts (137). This
indicates the formation of osteodentin, which is a bone-like mineralized matrix enriched in
DMP1 (426). It has been shown that DMP-1, which is expressed in both bone and tooth, induces
the differentiation of dental pulp stem cells to odontoblasts (427), and that the subcutaneous
implantation of DMP1 with collagen scaffold and dental pulp stem cells induced the formation of
dental pulp-like tissue (428).

Our studies on FACS-sorted populations showed that FGF2 stimulated proliferation and
accelerated differentiation in both progenitors (2.3-GFP– cells) and cells at early stages of
differentiation (2.3-GFP+ cells).

The expression of specific receptors is critical for the ability of the cells to respond to
various growth factors, including FGFs. FGF receptors are transmembrane proteins, which bind
FGF ligands and mediate their effects onto various downstream targets (151). Therefore,
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interactions between FGFs and FGF receptors are critical for mediating intracellular biological
effects of FGFs.

Our results demonstrated a differential pattern of expression of Fgfr1c and Fgfr2c.
Expression of Fgfr1c was low in less differentiated pulp cells, and it increased in response to
FGF2, similar to expression of Dmp1 and Dspp. This suggests that expression of Fgfr1 increased
in more mature cells. In contrast, Fgfr2c was expressed at high levels in less differentiated pulp
cells, and its levels markedly decreased in response to FGF2. This suggests that expression of
Fgfr2c decreased in more mature cells. Increased and decreased expression of Fgfr1 and Fgfr2,
respectively, was further confirmed in FACS-sorted DMP1-GFP– and DMP1-GFP+ cells (data
not shown). These results suggest that DMP1-GFP+ functional odontoblasts could be a critical
stage of odontogenesis that determines which effects (positive or negative) FGF signaling exerts
on odontoblast differentiation.

These results are in agreement with previous studies, which showed that Fgfr1c was
expressed at high levels in the odontoblast layer, whereas Fgfr2 expression was detected only in
the undifferentiated pulp cells (117, 288).

Similar stage-specific pattern of expression of Fgfr1 and Fgfr2 has been demonstrated in
osteoblast lineage cells. Microarray studies showed that FACS-sorted DMP1-GFP+ osteocytes
expressed markedly lower levels of Fgfr2 as compared to those in DMP1-GFP– cells (429). In
cultured mouse ADSCs, expression of Fgfr1 was relatively low prior to induction of
mineralization, however it markedly increased after induction of mineralization. In contrast,
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expression of Fgfr2 was the highest in undifferentiated ADSCs, and it markedly decreased after
induction of mineralization (303). In calvaria, Fgfr1c was expressed by more mature osteoblasts
as compared to Fgfr2c, which was expressed by proliferating osteoblast cells (213, 286, 300).

Similar to our study, others have shown that FGF2 had opposite effects on expression of
Fgfr1 and Fgfr2 in osteoblasts. Implantations of FGF2-loaded beads stimulated expression of
Fgfr1 and downregulated expression of Fgfr2 in calvarial sutures (300, 430, 431). Exposure of
proliferating BMSCs to FGF2 markedly increased expression of Fgfr1 and decreased expression
of Fgfr2 (432). Additionally, increases in Fgfr1 and decreases in Fgfr2 became more pronounced
with the advanced stages of osteoblast differentiation (213).

High levels of Fgfr1c expression in functional odontoblasts suggest that it could be
involved in stimulatory effects of FGF2 on Dmp1 and Dspp. In contrast, high levels of Fgfr2c
expression in undifferentiated pulp cells prevented their differentiation into more mature cells.
The differential pattern of Fgfr1c and Fgfr2c expression suggests opposite functional roles of
these receptors during odontoblast differentiation.

Subsequent experiments demonstrated that the stimulatory effects of FGF2 on
dentinogenesis and expression of Dmp1 and Dspp were mediated by the FGFR and MEK/Erk1/2
signaling pathways. To the best of our knowledge, the roles of FGFRs in the expression of Dmp1
and Dspp in dental pulp cells have not been reported previously. However, the roles of
MEK/Erk1/2 signaling in regulating the expression of Dmp1 and Dspp during dentinogenesis are
consistent with previous observations (433-438).
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Our results also showed the involvement of BMP/BMPR signaling in mediating
stimulatory effects of FGF2 on Dmp1 and Dspp. Our observations showed involvement of
FGFR/MEK/Erk1/2 signaling in FGF2-induced rapid upregulation of Bmp2. Inhibition of
BMP/BMPR signaling decreased FGF2-induced expression of Dmp1, Dspp and appearance of
DSPP-Cerulean+ odontoblasts. The involvement of BMP/BMPR signaling in stimulatory effects
of FGF2 on Dspp expression in our studies is consistent with previous observations in the dental
pulp (343).

Several studies have indicated roles of canonical (Smad-mediated) BMP signaling on
Dspp expression and odontoblast differentiation (398, 399). Deletion of Bmp2 in early polarizing
odontoblasts by using 3.6Col1a1-Cre resulted in impaired odontoblast polarization, dentin
formation and dramatic decreases in Dspp expression (396). Cre-mediated inactivation of Smad4,
a downstream target of BMP/BMPR signaling, in dental mesenchyme resulted in impaired
polarization of odontoblasts and the absence of Dspp and dentin (221).

However, in addition to canonical signaling, BMP/BMPR signaling is also mediated by
non-canonical (Smad-independent) pathway, which includes MEK/Erk1/2 (395, 439-441). It has
been shown that MEK/Erk1/2 is involved in BMP2-induced dentinogenic differentiation of SV
F4 dental follicle cells (407). These observations together with our results suggest a role for
canonical and non-canonical BMP-mediated pathways in FGF2-induced acceleration of
differentiation of dental pulp cells.
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Since we have demonstrated the role of the FGF/FGFR, MEK/Erk1/2 and BMP/BMPR
signaling pathways in regulation of expression of Dmp1 and Dspp, we next aimed to gain better
understanding of the specific transcription factors involved in mediating these stimulatory effects.

It is known that upon activation, Erk1/2 translocate to the nucleus where they regulate
expression of various transcription factors, including AP-1, Elk1/2, ATF2, FRA-1, Ets1/2 and
others (442, 443). Among these molecules, we focused on the components of the AP-1
transcription factor, which include c-Fos, c-Jun, junB and junD (444). We hypothesized that AP1 could be involved in mediating the nuclear FGF2 signals that stimulate Dmp1 and Dspp
transcription. This assumption was based on the previous results in the literature suggesting that
AP-1 could be important during the commitment of undifferentiated progenitor cells to the
odontoblast lineage, and during early stages of odontoblast differentiation.

Previous studies have shown that c-Fos was expressed at high levels in the layer of
maturing odontoblasts in developing rodent teeth. Expression of c-Jun was not localized in dental
papilla, subodontoblastic cells or preodontoblasts but it increased along the gradient of
differentiation of odontoblasts in developing bovine tooth germs (409, 410). Similarly, c-jun
transcripts were not detected in undifferentiated pulp cells (411), but they were significantly
increased in dental pulp cells adjacent to the site of dentin injury, suggesting that c-jun could be
important for recruitment of uncommitted progenitors towards the odontoblast lineage (7).
Another component of the AP-1 complex, junB, was not expressed in the undifferentiated pulp
cells, but it was detected at high levels in differentiating odontoblasts, and declined in fully
differentiated odontoblasts (411). Similarly, junD was not expressed in intact dental pulp prior
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and immediately after cavity preparation, however its expression was transiently detected in the
odontoblast cells adjacent to the cavity during the first 1-3 days after cavity preparation. This
suggests that activation of junD could be associated with the increased functional activity of
odontoblasts during the early period of reactionary dentin formation (412). In addition, several
canonical AP-1 binding sites have been localized within the Dmp1 and Dspp promoters (397,
421, 445), and expression of Dmp1 could be regulated by c-Jun and c-Fos (422). Taken together,
these results suggest that AP-1 transcription factor (c-Fos, c-Jun, junB and junD) could be
involved in regulation of various stages of odontoblast differentiation during normal and
reparative dentinogenesis, including commitment of undifferentiated progenitors towards
odontoblast lineage and secretory activity of differentiating and mature odontoblasts.

Our bioinformatics analysis demonstrated the presence of several AP-1 and AP-1-like
binding sites within both Dmp1 and Dspp promoters. In our study we were unable to locate any
CRE motifs within Dmp1 and Dspp promoters, but we demonstrated the presence of CRE-like
motifs within promoters of these genes. This suggests that AP-1 components could be activated
by FGF/FGFR – MEK/Erk1/2 signaling and mediate its stimulatory effects on Dmp1 and Dspp.

Although few previous reports demonstrated presence of these sites within Dmp1 and
Dspp promoters (397, 421, 422, 445), these studies identified only canonical AP-1/TRE binding
motifs within a short distance to the transcription start of these genes. However, as mentioned
above, AP-1 can bind not only to the canonical AP-1 motifs, but also to CRE [5’-TGACGTCA3’] and CRE-like [5’-TGAGCTCA-3’] motifs. In addition, regulatory elements controlling
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transcriptional activity of a gene can be located at distant (up to ~150 kb) locations from the
transcription start (446, 447) or even within the introns (448).

These results extend our knowledge about the regulatory elements within Dmp1 and
Dspp promoters and suggest that AP-1 could act as a transcriptional regulator of FGF/FGFR –
MEK/Erk1/2 signaling on Dmp1 and Dspp expression.

Effects of FGF signaling on osteogenesis vs. dentinogenesis.

Our observation on the effects of FGF2 on dental pulp cells shares many similarities with
the reported effects of FGF2 on osteogenesis and expression of Dmp1 in osteogenic cells.

Several studies have shown that short and limited exposure of osteoprogenitor cells to
FGF2 during the proliferation phase of in vitro growth results in significant increases in the
extent of mineralization and expression of markers of mineralization (including Type I collagen,
Alp, Bsp and Osteocalcin) (249, 251-253). It has been suggested that FGF2 increases the pool of
osteoprogenitors and MSCs leading to increased osteogenesis (247, 248).

FGF2 also markedly and rapidly (within ~2-8 hrs) increased the expression of Dmp1 in
cultured ROS17/2.8 osteoblast-like cells (255), MC-4 osteoblast-like cells, MLO-Y4 osteocytelike cells (244) and BMSCs (254). In our previous study we showed that FGF2 increased
expression of Dmp1 and the percentage of DMP1-GFP+ cells in BMSC cultures at day 7
(submitted manuscript).
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The role of FGFR/MEK/Erk1/2 signaling in the expression of Dmp1 in dental pulp cells
is similar to its role during osteogenesis. Inhibition of FGFR signaling decreased expression of
Dmp1 in MLO-Y4 osteocyte-like cells and primary calvarial osteoblasts (244). Tissue-specific
inactivation of Erk1/2 in Erk1–/–/Erk2flox/flox;Prx1-Cre mice markedly decreased expression of
Dmp1 in developing bone (244).

Crosstalk between the FGFR and BMP signaling pathways in our study is similar to
reported crosstalk during osteogenesis (217, 218, 449). Inhibition of FGFR signaling in calvarial
osteoblasts dramatically decreased expression of Bmp2 (213, 215), whereas activation of FGFR
signaling had an opposite effect (215). Inhibition of MEK/Erk1/2 signaling decreased Bmp2
levels in control and FGF2-treated calvarial osteoblast cultures (216).

These similarities suggest that our observations in dental pulp may reflect the effects of
FGF2 on osteoprogenitors and not odontoprogenitors. However, several lines of evidence
suggest that our studies reflect the stimulatory effects of early and limited exposure of FGF2 on
odontoprogenitors.

Our recent study showed significant differences between the early effects of FGF2 in
dental pulp and BMSC cultures. In pulp cultures at day 7, FGF2 induced increases in the
expression of various markers of mineralization and dentinogenesis, whereas in BMSC FGF2
caused significant decreases in the expression of these markers, except Dmp1.
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Furthermore, we and others (248) have shown that continuous exposure to FGF2
completely inhibited the expression of 3.6-GFP and 2.3-GFP transgenes in BMSC cultures
(submitted manuscript), indicating that inhibition of osteogenesis by FGF2 was mediated by
blocking the onset of preosteoblast differentiation (248). On the other hand, our studies on dental
pulp cells showed that FGF2 initially did not have significant effects on the expression of 3.6GFP and 2.3-GFP transgenes, and at later time points reduced (but did not inhibit) the expression
of these transgenes.

Furthermore, the rapid and almost complete recovery of mineralization in pulp cultures
after withdrawal of FGF2 in our study was different from that in BMSC cultures. Upon
withdrawal of FGF2 full osteoblast differentiation and mineralization did not appear in vitro and
was detected only after subcutaneous implantation of FGF2-treated cells in SCID/Beige mice in
vivo (248).

It is important to note that, unlike in osteogenesis, in which Dmp1 is expressed by
osteocytes, terminally differentiated cells, in dentinogenesis Dmp1 is expressed by functional
odontoblasts, a cell population that is formed transiently and gives rise to fully differentiated
odontoblasts. Several lines of evidence suggest that DMP1 regulates Dspp expression during
dentinogenesis. In developing teeth the expression of Dmp1 is detected earlier than that of Dspp
(425). Both Dmp1 and Dspp knockout mice display dentin hypomineralization with reduced
dentin thickness (68, 85). Dspp expression is reduced in the dentin of Dmp1 knockout mice
compared with that of wild-type mice (85). However, Dspp knockout mice did not show
alteration in the expression of Dmp1, and transgenic expression of Dspp rescued the tooth and
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alveolar bone defects of the Dmp1 knockout mice (99). In vitro analyses showed that Dmp1
markedly upregulated the Dspp promoter activities in a mesenchymal cell line (99).

Our study showed that early exposure of pulp cells to FGF2 initially led to significant
increases in the expression of Dmp1 and the number of DMP1-GFP+ cells and subsequently to
increases in the expression of Dspp and the number of DSPP-Cerulean+ odontoblasts. However,
unlike similar studies using osteogenic cells, early exposure of pulp cells to FGF2 did not result
in significant increases in the amount of mineralization as compared to control. These
observations suggest that in dental pulp, FGF2 inhibits osteogenesis and promotes dentinogenic
differentiation. This may be due to differences in the response of odontoprogenitors and
osteoprogenitors to FGF2 and/or differences in osteoprogenitors residing in dental pulp vs.
BMSC.

These observations provide strong evidence that increases in the expression of Dmp1 and
DMP1-GFP+ cells in dental pulp cultures in our study reflect the formation of functional
odontoblasts that will differentiate into fully differentiated odontoblasts.
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Summary and conclusions.

In summary, our results showed that early and limited exposure of dental pulp cells to
FGF2 during the proliferation phase of in vitro growth resulted in increased/accelerated
differentiation of pulp cells into functional odontoblasts, leading to an increased number of
mature odontoblasts in these cultures. In addition, we showed that the stimulatory effects of
FGF2 on dentinogenesis were mediated through the FGFR, MEK/Erk1/2 and BMP/BMPR
signaling pathways. The results presented in this study provide insight into the effects of FGF
signaling on dentinogenesis and would be useful in improved strategies for the clinical use of
FGF2 in dentin regeneration applications.
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Figures.

Figure 15. Effects of early exposure to FGF2 on the extent of mineralization in primary
dental pulp cultures. Primary dental pulp cultures derived from 5-7-day-old pups were treated
with VH or FGF2 between days 3-7 as described in the Materials and Methods. Starting day 7 all
cultures were grown under the mineralization-inducing culture conditions in the absence of
FGF2 for additional 7 to 14 days.
A. Representative images of the same areas in cultures at different time points analyzed under
brightfield (upper row), and epifluorescent light using TRITC Red filter for detection of XO
staining (middle row). Scale bar is 400 µm. Representative images of von Kossa staining of fixed
cultures are shown on the bottom row.
B. The intensity of fluorescence of XO staining at various time points.
C. Quantification of the area of von Kossa staining at various time points.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point.
N.D. = not detected.
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Early exposure to FGF2 did not have marked effects on the extent of mineralization as compared
to control.
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Figure 16. Effects of early exposure to FGF2 on expression of markers of mineralization
and dentinogenesis in primary dental pulp cultures. Pulp cultures were prepared as described
in Figure 15 and processed for qPCR analysis at different time points.
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A. Expression of markers of mineralization and dentinogenesis in the control and FGF2-treated
cultures was analyzed at days 7, 10, 14 and 21. Expression levels of Type I collagen, Bsp,
Osteocalcin and Dmp1 were normalized to VH at day 7, which is arbitrarily set to 1 and is
indicated by the dashed line. Expression levels of Dspp were normalized to VH at day 10, which
is arbitrarily set to 1 and is indicated by the dashed line.
B. Cultures were treated with VH or FGF2 starting day 3 (0 hrs) and processed for qPCR
analysis for Dmp1 and Dspp at various time points. Expression of Dmp1 and Dspp at 12-96 hrs
after exposure to FGF2 is shown. Expression of Dmp1 was normalized to VH at 12 hrs, which is
arbitrarily set to 1 and is indicated by the dashed line. Expression of Dspp was normalized to
FGF2-treated culture at 96 hrs, which is arbitrarily set to 1 and is indicated by the dashed line.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point.
N.D. = not detected.
Early exposure to FGF2 did not have marked effects on expression of Type I collagen, Bsp and
Osteocalcin but significantly increased expression of Dmp1 (at days 7 and 10) and Dspp (at all
time points) as compared to control.
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A.

B.
Hours after
treatment

VH

FGF2

Fold change

24

0.56 ± 0.01

0.62 ± 0.01*

~1.11

48

0.82 ± 0.05

1.04 ± 0.07*

~1.27

72

0.77 ± 0.03

1.18 ± 0.03*

~1.53

96

0.61 ± 0.03

1.00 ± 0.05*

~1.64

Figure 17. Effects of early exposure to FGF2 on proliferation and viability of primary
dental pulp cells. Cultures were treated with VH or FGF2 starting at day 3 (0 hrs) and processed
for WST-1 proliferation and viability assay at various time points as described in the Materials
and Methods.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point. Fold changes represent FGF2 value divided by the control value for
each time point.
Early exposure to FGF2 exerted modest stimulatory effects on proliferation and viability of
dental pulp cells as compared to control.
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Figure 18. Effects of early exposure to FGF2 on expression of 3.6-GFP and 2.3-GFP
transgenes in primary dental pulp cultures. Primary dental pulp cultures derived from 5-7day-old 3.6-GFP and 2.3-GFP transgenic mice were treated with VH or FGF2 between days 3-7
as described in Materials and Methods.
A. Representative images of the same areas in cultures at different time points analyzed under
brightfield (upper rows) and epifluorescent light using GFPtpz filter for detection of 3.6-GFP
(middle row). The lower row shows representative scanned composite 5x images of a larger area
of the wells, which were taken using GFPtpz filter. Scanned area is 1.24 cm2 (31% of the total
area of the well).
B. Representative images of the same areas in cultures at different time points analyzed under
brightfield (upper row) and epifluorescent light using GFPemd filter for detection of 2.3-GFP
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(middle row), as described in Panel A. Scale bar in the upper and middle rows is 200 µm, and in
the lower row is 2 mm.
C. The epifluorescence intensity of 3.6-GFP and 2.3-GFP transgenes at various time points.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point.
Early exposure to FGF2 slightly increased the intensity of expression of 3.6-GFP and 2.3-GFP at
day 7 as compared to control and had no effects at later time points.
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Figure 19. Effects of early exposure to FGF2 on formation of 3.6-GFP+ and 2.3-GFP+ cells
in primary dental pulp cultures. Primary dental pulp cultures derived from 5-7-day-old 3.6and 2.3-GFP pups were treated with VH or FGF2 between days 3-7, and subjected to FACS
analysis 24-96 hrs after treatment as described in Materials and Methods.
Representative FACS analysis of cultures at different time points is shown. Dot plots were gated
on live cells based on their forward- (FSC) and side- (SSC) scatter properties and exclusion of PI.
P4, P5 and P6 gates represent populations of cells expressing no GFP (GFP−), intermediate and
high levels of GFP (GFP+), respectively. Cells from GFP-negative littermates served as a
negative control at each time point (Neg. ctrl).
Early exposure to FGF2 did not have marked effects on the percentage of 3.6-GFP+ and 2.3GFP+ cells as compared to control.
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Figure 20. Effects of early exposure to FGF2 on proliferation of 2.3-GFP+ and 2.3-GFP–
cells in primary dental pulp cultures. Cultures derived from 5-7-day-old 2.3-GFP transgenic
mice were treated with VH or FGF2 starting day 3 (0 hrs). Proliferation of 2.3-GFP+ (cells at
early stages of differentiation) and 2.3-GFP– (progenitors) populations was determined at
different time points by FACS-based cell cycle analysis using Hoechst 33342 nuclear dye as
described in the Materials and Methods.
Early exposure to FGF2 did not have marked effects on the percentage of proliferating 2.3-GFP+
and 2.3-GFP– populations as compared to control.
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Figure 21. Effects of early exposure to FGF2 on expression of DMP1-GFP transgene in
primary dental pulp cultures. Primary dental pulp cultures derived from 5-7-day-old DMP1GFP transgenic mice were treated with VH or FGF2 between days 3-7 as described in Materials
and Methods.
Representative images of the same areas in cultures at different time points analyzed under
brightfield (upper rows) and epifluorescent light using GFPtpz filter for detection of GFP
(middle row). Scale bar is 200 µm.
The lower row shows representative scanned composite 5x images of a larger area of the well,
which were taken using GFPtpz filter. Scanned area is 1.24 cm2 (31% of the total area of the
well). Scale bar is 2 mm.
Graph represents the intensity of GFP epifluorescence at various time points.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point.
Early exposure to FGF2 significantly increased expression of DMP1-GFP transgene at days 7
and 10 as compared to control.
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Figure 22. Effects of early exposure to FGF2 on formation of DMP1-GFP+ cells in primary
dental pulp cultures. Primary dental pulp cultures derived from 5-7-day-old DMP1-GFP
transgenic mice were treated with VH or FGF2 between days 3-7, and subjected to FACS
analysis 24-96 hrs after exposure as described in the Materials and Methods.
Representative FACS analysis of cultures at different time points is shown. Dot plots were gated
on live cells based on their forward- (FSC) and side- (SSC) scatter properties and exclusion of PI.
P4, P5 and P6 gates represent populations of cells expressing no GFP (GFP–), intermediate and
high levels of GFP (GFP+), respectively. Cells from GFP-negative littermates served as a
negative control at each time point (Neg. ctrl).
Early exposure to FGF2 markedly increased the formation of DMP1-GFP+ cells as compared to
control.
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Figure 23. Effects of early exposure to FGF2 on percentage of DSPP-Cerulean+ odontoblasts in primary dental pulp
cultures. Cultures derived from 5-7-day-old DSPP-Cerulean transgenic mice were treated with VH
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or FGF2 between days 3-7 and processed by immunocytochemistry at various time
points as described in the Materials and Methods. Percentage of DSPP-Cerulean+
odontoblasts was calculated as a ratio between Cerulean+ cells and the total number of
Hoechst+ cells. Bone marrow stromal cell cultures (day 14) derived from DSPPCerulean littermates and stained with anti-GFP antibody served as a negative control
(BMSC).
A. Representative images of the same area in cultures taken under brightfield (BF),
epifluorescent light using GFPtpz (GFP) and Hoechst/GFP (DAPI/GFP) filters. Scale
bar is 200 µm.
B. Representative scanned composite 5x images of a larger area of the well. Scanned
area is 1.08 cm2 (27% of the total area of the well). Scale bar is 2 mm.
Early exposure to FGF2 significantly increased the percentage of DSPP-Cerulean+
odontoblasts at all time points as compared to control.
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Figure 24. Effects of early exposure to FGF2 on expression of Fgfr1c, Fgfr2c, Dmp1 and
Dspp in primary dental pulp cultures. Pulp cultures were established and treated with VH or
FGF2 between days 3-7 (0-96 hrs after treatment) as described in the Materials and Methods.
Expression levels of Fgfr1c, Fgfr2c, Dmp1 and Dspp were determined at 0, 24, 48, 72 and 96 hrs
after exposure. Gapdh served as an endogenous loading control. C = control; F = FGF2; DP =
Dental pulp culture at day 14 (positive control for Fgfr1c, Dmp1 and Dspp); Calv. = Calvaria
from 6-day-old pups (positive control for Fgfr2c and Dmp1); NC = Negative control (omission
of cDNA).
Early exposure to FGF2 increased expression of Fgfr1c, Dmp1 and Dspp, and decreased
expression of Fgfr2c as compared to control.
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Figure 25. Effects of SU5402 on expression of Dmp1 and Dspp in primary dental pulp
cultures. Pulp cells were treated with VH or FGF2 between days 3-7 as described in the
materials and Methods. FGF/FGFR signaling was inhibited by addition of various concentrations
of SU5402. Expression of Dmp1 and Dspp was measured by qPCR analysis at 48, 72 and 96 hrs
after exposure.
A. Effects of SU5402 on basal expression of Dmp1 and Dspp in the absence of FGF2.
Expression of Dmp1 was normalized to VH at 48 hrs, which is arbitrarily set to 1 and is indicated
by the dashed line. Expression of Dspp was not detected in any sample at any time point (N.D.).
B. Effects of SU5402 on FGF2-mediated increases in Dmp1 and Dspp.
The expression of Dmp1 was normalized to VH at 48 hrs, and the expression of Dspp was
normalized to FGF2-treated cultures at 96 hrs, which are arbitrarily set to 1 and are indicated by
the dashed line.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control.
N.D. = not detected.
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In the absence of FGF2, SU5402 had no effects on basal expression of Dmp1 (no Dspp was
detected in any sample). In the presence of FGF2, SU5402 decreased expression of Dmp1 and
Dspp in a concentration-dependent manner.
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Figure 26. Effects of SU5402 on formation of DSPP-Cerulean+ odontoblasts and viability of
primary dental pulp cells. Cultures derived from 5-7-day-old DSPP-Cerulean transgenic mice
were treated with VH or FGF2 alone or in combination with various concentrations of SU5402
between days 3-7, and processed by immunocytochemistry at day 7 as described in the Materials
and Methods.
A. Effects of SU5402 on formation of DSPP-Cerulean+ odontoblasts were examined by
immunocytochemistry using anti-GFP antibody. Addition of 5 µM SU5402 inhibited FGF2stimulated formation of DSPP-Cerulean+ odontoblasts. Scale bar is 200 µm.
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B. Pulp cultures derived from 5-7-day-old pups were exposed to FGF2 alone or in the presence
of various concentrations of SU5402 starting day 3 (0 hrs). At 48, 72 and 96 hrs after exposure
cells were fixed and stained with 0.1% crystal violet to visualize cellularity of the culture.
SU5402 decreased FGF2-induced formation of DSPP-Cerulean+ odontoblasts, and had no
effects on the cellularity of the cultures.
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Figure 27. Effects of early exposure to FGF2 and U0126 on phosphorylation of Erk1/2 in
primary dental pulp cultures. Pulp cultures derived from 5-7-day-old pups were exposed to
FGF2 alone or in the presence of 5, 10 or 20 µM U0126 at day 3 for 30 minutes as described in
the Materials and Methods. Negative control included dental pulp cells with omission of primary
antibody (No Ab). Scale bar is 100 µm.
U0126 decreased FGF2-induced phosphorylation of Erk1/2.
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Figure 28. Effects of U0126 on expression of Dmp1 and Dspp in the control and FGF2treated primary dental pulp cultures. Pulp cells were treated with VH or FGF2 starting day 3
(0 hrs). MEK/Erk1/2 signaling was inhibited by addition of various concentrations of U0126.
Expression of Dmp1 and Dspp was measured by qPCR analysis at various time points.
A. Effects of U0126 on basal expression of Dmp1 and Dspp in the absence of FGF2.
Expression of Dmp1 was normalized to VH at 48 hrs, which is arbitrarily set to 1 and is indicated
by the dashed line. Expression of Dspp was not detected in any culture at any time point (N.D.).
B. Effects of U0126 on FGF2-mediated increases in Dmp1 and Dspp.
Expression of Dmp1 was normalized to VH at 48 hrs, whereas Dspp was normalized to FGF2 at
96 hrs, which are arbitrarily set to 1 and indicated by the dashed line.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
respective controls.
N.D. = not detected.
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In the absence of FGF2, U0126 decreased basal expression of Dmp1 (no Dspp expression was
detected in any sample). In the presence of FGF2, U0126 decreased expression of Dmp1 and
Dspp in a concentration-dependent manner.
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Figure 29. Effects of U0126 on formation of DSPP-Cerulean+ odontoblasts and viability of
primary dental pulp cells. Cultures derived from 5-7-day-old DSPP-Cerulean transgenic mice
were treated with VH or FGF2 alone or in combination with various concentrations of U0126
between days 3-7, and processed by immunocytochemistry at day 7 as described in the Materials
and Methods.
A. Effects of U0126 on FGF2-stimulated formation of DSPP-Cerulean+ odontoblasts were
examined by immunocytochemistry using anti-GFP antibody to enhance visualization of DSPPCerulean transgene. Addition of 5 µM U0126 inhibited FGF2-stimulated formation of DSPPCerulean+ odontoblasts. Scale bar is 200 µm.
B. Pulp cultures derived from 5-7-day-old pups were exposed to FGF2 alone or in the presence
of 5, 10 or 20 µM U0126 starting day 3 (0 hrs). At various time points after treatment cells were
fixed and stained with 0.1% crystal violet to visualize cellularity of the culture.
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U0126 prevented FGF2-induced formation of DSPP-Cerulean+ odontoblasts, and did not affect
the cellularity of cultures.
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Figure 30. Effects of SU5402 and U0126 on expression of Bmp2 in primary dental pulp
cultures. Cultures were treated with VH or FGF2 starting day 3 (0 hrs). The FGFR and
MEK/Erk1/2 signaling pathways were inhibited by various concentrations of SU5402 (Panel A)
and U0126 (Panel B), respectively, as described in Materials and Methods. Expression of Bmp2
was measured by qPCR analysis at various time points after exposure. Expression levels of
Bmp2 were normalized to VH at 48 hrs after treatment, which is arbitrarily set to 1 and is
indicated by the dashed line.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point.
In the absence of FGF2, SU5402 had no effects on expression of Bmp2, whereas in the presence
of FGF2 SU5402 decreased expression of Bmp2 in a concentration-dependent manner as
compared to control.
In the absence and presence of FGF2, U0126 decreased expression of Bmp2 in a concentrationdependent manner as compared to control.
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Figure 31. Effects of noggin on expression of Dmp1, Dspp, Fgfr1c and Fgfr2c in primary
dental pulp cultures. Pulp cells were treated with VH or FGF2 starting day 3 (0 hrs).
BMP/BMPR signaling was inhibited by addition of various concentrations of noggin, a specific
BMP/BMPR inhibitor. Expression of Dmp1, Dspp, Fgfr1c and Fgfr2c was measured by qPCR
analysis at various time points after exposure.
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A. Effects of noggin on basal expression of Dmp1 and Dspp in the absence of FGF2.
Expression of Dmp1 was normalized to VH at 48 hrs, which is arbitrarily set to 1 and is indicated
by the dashed line. No expression of Dspp was detected in any sample at any time point (N.D.).
B. Effects of noggin on FGF2-mediated increases in expression of Dmp1 and Dspp. Expression
of Dmp1 was normalized to VH at 48 hrs, whereas Dspp was normalized to FGF2-treated
cultures at 96 hrs, which are arbitrarily set to 1 and indicated by the dashed line.
C. Effects of noggin on FGF2-mediated changes in expression of Fgfr1c and Fgfr2c. Expression
of both Fgfr1c and Fgfr2c was normalized to VH at 48 hrs, which is arbitrarily set to 1 and is
indicated by the dashed line.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
respective controls.
N.D. = not detected.
In the absence of FGF2, noggin decreased expression of Dmp1 at 96 hrs after exposure (no Dspp
expression was detected in any sample). In the presence of FGF2, noggin markedly decreased
expression of Dmp1 and abolished expression of Dspp. In addition, noggin reversed effects of
FGF2 on expression of Fgfr1c and Fgfr2c.
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Figure 32. Effects of noggin on formation of DSPP-Cerulean+ odontoblasts and viability of
primary dental pulp cells. Cultures derived from 5-7-day-old DSPP-Cerulean transgenic mice
were treated with VH or FGF2 alone or in combination with various concentrations of noggin
between days 3-7, and processed by immunocytochemistry at day 7 as described in the Materials
and Methods.
A. Effects of noggin on FGF2-induced formation of DSPP-Cerulean+ odontoblasts were
examined by immunocytochemistry using anti-GFP antibody to enhance visualization of DSPPCerulean transgene. Exposure to 100 ng/ml noggin inhibited FGF2-stimulated formation of
DSPP-Cerulean+ odontoblasts. Scale bar is 200 µm.
B. Pulp cultures derived from 5-7-day-old pups were exposed to FGF2 alone or in the presence
of 100, 200 or 300 ng/ml noggin, a specific BMP/BMPR inhibitor, starting day 3 (0 hrs). At
various time points after exposure, cells were fixed and stained with 0.1% crystal violet to
visualize cellularity of the culture.
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Noggin prevented FGF2-induced formation of DSPP-Cerulean+ odontoblasts, and had no effects
on cellularity of cultures.
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Figure 33. Mapping of potential binding sites for AP-1 transcription complex within the
Dspp and Dmp1 promoter regions. Potential AP-1, CRE and CRE-like binding sites for AP-1
were identified and mapped as described in the Materials and Methods.
A. Within the Dspp promoter region, we identified four sequences corresponding to the AP-1
binding sites (at positions -20316, -13405, -12328 and -8799) and two sequences corresponding
to the CRE-like binding site (at positions -14980 and -11689). Similar to the Dmp1 promoter, no
sequences corresponding to the CRE binding sites were identified within the Dspp promoter.
B. Within the Dmp1 promoter region, we identified three sequences corresponding to the AP-1
binding sites (at positions -17040, -4890 and -1094) and one sequence corresponding to the
CRE-like binding site (at position -11517). No sequences corresponding to the CRE binding sites
were identified.
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Bioinformatics analysis demonstrated the presence of AP-1 and CRE-like motifs within the
promoter regions of Dmp1 and Dspp.
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Figure 34. Isolation of 2.3-GFP– and 2.3-GFP+ populations by FACS. Cells derived from 57-day-old 2.3-GFP transgenic mice were grown under control culture conditions. At day 7, cells
were FACS sorted to isolate relatively homogeneous populations of 2.3-GFP+ and 2.3-GFP–
cells, which were then cultured as described in the Materials and Methods.
Dot plots from a representative 2.3-GFP-based FACS sorting experiment. Reanalysis of both
2.3-GFP− and 2.3-GFP+ populations demonstrated high (≥ 98%) purity of the FACS sorting. Q1,
Q2, Q3 and Q4 represent PI+/GFP−, PI+/GFP+, PI−/GFP− and PI−/GFP+ populations,
respectively. Negative control for FACS-sorting experiments included GFP– littermates (neg.
control).
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Figure 35. Effects of early exposure to FGF2 on the extent of mineralization and expression
of 2.3-GFP transgene in FACS-sorted 2.3-GFP+ and 2.3-GFP– populations. Primary pulp
cultures were established from 2.3-GFP transgenic mice and processed for GFP-based FACSsorting at day 7 as described in the Materials and Methods. Representative brightfield (BF) and
epifluorescent light using GFPemd and TRITC Red filters for detection of 2.3-GFP and XO
staining, respectively. Images of the same area in live cultures were taken at different time points.
In addition, von Kossa staining was performed on fixed cultures.
Early exposure to FGF2 did not decrease the extent of mineralization in both 2.3-GFP+ and 2.3GFP– populations as compared to respective controls.
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Figure 36. Effects of early exposure to FGF2 on expression of markers of mineralization
and dentinogenesis in FACS-sorted 2.3-GFP+ and 2.3-GFP– populations. Cultures were
established and treated with VH or FGF2 between days 3-7 as described for unsorted cultures. At
days 7, 10 and 14 cells were harvested and processed for RNA isolation and qPCR analysis as
described in the Materials and Methods.
In both 2.3-GFP– and 2.3-GFP+ populations, expression levels of Type I collagen and Dmp1
were normalized to GFP+ VH at day 7, which is arbitrarily set to 1 and is indicated by the dashed
line. Expression levels of Dspp in both 2.3-GFP– and 2.3-GFP+ populations were normalized to
GFP+ VH at day 10, which is arbitrarily set to 1 and is indicated by the dashed line.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point.
N.D. = not detected.
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Early exposure to FGF2 increased expression of Type I collagen, Dmp1 and Dspp in 2.3-GFP+
population as compared to control. In 2.3-GFP– population, early exposure to FGF2 stimulated
expression of Dmp1 and Dspp as compared to control.
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Figure 37. Isolation of 2.3-GFP+ and 2.3-GFP– populations for RNA isolation. Cells derived
from 5-7-day-old 2.3-GFP transgenic mice were treated with VH or FGF2 between days 3-7 as
described in the Materials and Methods. At day 7, cells were FACS sorted to isolate relatively
homogeneous populations of 2.3-GFP+ and 2.3-GFP– populations as described in the Materials
and Methods.
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Dot plots from a representative 2.3-GFP-based FACS sorting experiment. Negative control
samples were derived from GFP-negative wild-type littermates and used to establish the settings
for PI and GFP gates. Reanalysis of both 2.3-GFP− and 2.3-GFP+ populations demonstrated
high (≥ 98%) purity of the FACS sort. Q1, Q2, Q3 and Q4 represent PI+/GFP−, PI+/GFP+,
PI−/GFP− and PI−/GFP+ populations, respectively.
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Figure 38. Expression of a select group of genes in the control and FGF2-treated 2.3-GFP+
and 2.3-GFP– populations. Cells derived from 5-7-day-old 2.3-GFP transgenic mice were
treated with VH or FGF2 between days 3-7. At day 7, cells were FACS-sorted to isolate
homogeneous populations of 2.3-GFP+ and 2.3-GFP– cells as described in the Materials and
Methods. Immediately after FACS, sorted cells were processed for RNA isolation followed by
qPCR analysis.
Pattern of expression of Ambn, Dmp1, Dspp, Bono1, Fgfr1c and Fgfr2c in FGF2-treated
unsorted, 2.3-GFP+ and 2.3-GFP− sorted populations. Expression levels of Ambn, Dmp1 and
Bono1 were normalized to VH of unsorted culture, which is arbitrarily set to 1 and is indicated
by the dashed line. Expression levels of Dspp were normalized to FGF2 of unsorted culture,
which is arbitrarily set to 1 and is indicated by the dashed line.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point.
N.D. = not detected.
In unsorted cultures, and 2.3-GFP+ and 2.3-GFP– populations, early exposure to FGF2 increased
expression of markers of odontoblasts at relatively mature stages of differentiation (Dmp1, Dspp,
Bono1 and Fgfr1c) and decreased expression of markers of odontoblasts at early stages of
differentiation (Fgfr2c and Ambn).
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Tables.
Table 13. Effects of early exposure to FGF2 on the extent of mineralization in primary
dental pulp cultures.

von Kossa
(mm2)

Xylenol
Orange
(at 570 nm)

Assay

Day of the
culture

VH

FGF2

Fold change

7

N.D.

N.D.

−

10

221.2 ± 7.5

193.3 ± 30.3

~0.87

14

323.3 ± 33.7

326.6 ± 25.8

~1.01

21

796.3 ± 28.9

921.3 ± 39.4*

~1.16

7

N.D.

N.D.

−

10

60.9 ± 5.1

46.5 ± 14.9

~0.76

14

207.8 ± 11.8

193.1 ± 31.6

~0.93

21

334.1 ± 5.1

365.2 ± 3.4*

~1.09

Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point. Fold changes represent FGF2 value divided by the control value for
each time point.
N.D. = not detected.
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Table 14. Effects of early exposure to FGF2 on expression of markers of mineralization and
dentinogenesis in primary dental pulp cultures.
Day of
the
culture

Gene

CT

ΔCT

-ΔΔCT

Fold change

7

Gapdh
Bsp
Dmp1
Dspp
Osteocalcin
Type I collagen

19.68 ± 0.39
26.14 ± 0.63
31.04 ± 0.26
37.03 ± 0.91
22.69 ± 0.59
16.04 ± 0.28

−
5.80 ± 0.54
11.30 ± 0.46
−
2.32 ± 0.59
-4.10 ± 0.16

−
0
0
−
0
0

−
1
1
N.D.
1
1

10

Gapdh
Bsp
Dmp1
Dspp
Osteocalcin
Type I collagen

19.90 ± 0.50
20.34 ± 0.45
22.74 ± 0.38
31.26 ± 0.59
20.41 ± 0.88
14.64 ± 0.36

−
-0.36 ± 0.42
3.15 ± 0.89
11.13 ± 0.78
-0.45 ± 0.74
-5.91 ± 0.33

−
6.15 ± 0.82
7.73 ± 0.30
0
2.77 ± 0.41
1.71 ± 0.33

−
127.72 ± 52.69
237.97 ± 50.67
1
8.38 ± 2.52
4.06 ± 1.04

14

Gapdh
Bsp
Dmp1
Dspp
Osteocalcin
Type I collagen

20.91 ± 0.37
18.17 ± 0.96
21.65 ± 0.56
29.18 ± 0.49
18.24 ± 0.48
13.49 ± 0.28

−
-3.11 ± 0.86
0.57 ± 0.24
8.43 ± 0.44
-2.87 ± 0.32
-7.46 ± 0.24

−
8.90 ± 1.18
9.59 ± 0.13
2.22 ± 0.49
0.66 ± 0.51
5.19 ± 0.48

−
1015.83 ± 316.26
783.33 ± 69.49
6.12 ± 2.27
27.63 ± 4.55
11.54 ± 2.82

21

Control

Gapdh
Bsp
Dmp1
Dspp
Osteocalcin
Type I collagen

18.70 ± 0.45
15.57 ± 0.12
19.40 ± 0.36
26.34 ± 0.76
16.42 ± 0.26
11.53 ± 0.14

−
-5.27 ± 0.29
0.70 ± 0.17
7.64 ± 0.76
-2.28 ± 0.40
-7.17 ± 0.58

−
11.10 ± 0.29
10.54 ± 0.17
3.49 ± 0.76
4.60 ± 0.40
3.07 ± 0.58

−
2285.60 ± 482.46
1512.50 ± 182.92
14.69 ± 7.23
26.29 ± 7.75
9.71 ± 3.21

Day of
the
culture

Gene

CT

ΔCT

-ΔΔCT

Fold change

7

FGF2-treated between d3-7

Gapdh
Bsp
Dmp1
Dspp
Osteocalcin
Type I collagen

19.77 ± 0.39
24.87 ± 0.33
23.85 ± 0.68
30.69 ± 0.65
21.98 ± 0.21
15.73 ± 0.16

−
4.74 ± 0.52
4.08 ± 0.83
10.99 ± 0.98
13.12 ± 0.31
16.55 ± 0.50

−
1.24 ± 0.25
7.23 ± 0.68
0.65 ± 0.53
0.63 ± 0.27
0.47 ± 0.17

−
2.77 ± 0.39
328.25 ± 68.75
2.35 ± 0.69
1.72 ± 0.39
1.44 ± 0.19
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10

Gapdh
Bsp
Dmp1
Dspp
Osteocalcin
Type I collagen

19.66 ± 0.47
20.23 ± 0.29
23.13 ± 0.57
28.26 ± 0.88
20.57 ± 0.08
19.66 ± 0.47

−
-0.07 ± 0.24
3.47 ± 0.93
8.60 ± 1.23
14.34 ± 0.88
19.31 ± 0.68

−
6.27 ± 1.42
8.58 ± 0.62
2.83 ± 0.18
3.24 ± 0.44
1.92 ± 0.19

−
146.12 ± 79.15
639.19 ± 213.88
7.31 ± 0.84
10.27 ± 2.75
3.86 ± 0.54

14

Gapdh
Bsp
Dmp1
Dspp
Osteocalcin
Type I collagen

20.77 ± 0.41
17.37 ± 0.56
21.97 ± 0.81
27.19 ± 0.79
17.97 ± 0.12
20.77 ± 0.41

−
-3.40 ± 0.51
1.20 ± 0.95
6.42 ± 0.61
12.47 ± 0.25
16.52 ± 0.34

−
10.56 ± 0.16
10.00 ± 0.46
4.24 ± 0.49
5.56 ± 0.26
3.27 ± 0.12

−
1523.93 ± 170.34
1130.47 ± 348.08
20.94 ± 5.72
48.80 ± 8.20
9.71 ± 0.82

21

Gapdh
Bsp
Dmp1
Dspp
Osteocalcin
Type I collagen

18.93 ± 0.49
15.42 ± 0.11
19.38 ± 0.31
23.87 ± 1.43
16.06 ± 0.61
11.46 ± 0.04

−
-3.51 ± 0.58
0.45 ± 0.26
4.94 ± 1.00
-2.87 ± 0.80
-7.46 ± 0.47

−
9.31 ± 0.58
9.94 ± 0.26
6.20 ± 1.00
6.88 ± 0.80
3.27 ± 0.47

−
748.59 ± 301.86
1834.52 ± 295.5
107.22 ± 53.09
40.93 ± 14.40
11.49 ± 3.82

ΔCT = CTgene - CTGapdh.
-ΔΔCT = -(ΔCTsample – ΔCTcontrol).
Positive –ΔΔCT value = increased gene expression relative to control.
Negative –ΔΔCT value = decreased gene expression relative to control.
All fold changes are relative to control at day 7, except for Dspp, which is relative to VH at day
10.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point.
N.D. = not detected.
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Table 15. Effects of early exposure to FGF2 on expression of Dmp1 and Dspp in primary
dental pulp cultures.
Control
CT

ΔCT

-ΔΔCT

Fold change

12

Gapdh
Dmp1
Dspp

19.27 ± 0.60
32.45 ± 0.43
39.13 ± 0.72

−
12.63 ± 0.27
19.31 ± 0.68

−
0
−

−
1
N.D.

24

Gapdh
Dmp1
Dspp

19.73 ± 0.58
32.70 ± 0.51
36.75 ± 0.45

−
12.47 ± 0.25
16.52 ± 0.34

−
0.17 ± 0.44
−

−
1.22 ± 0.30
N.D.

36

Gapdh
Dmp1
Dspp

19.95 ± 0.33
33.43 ± 0.91
39.37 ± 0.31

−
13.20 ± 1.09
19.15 ± 0.08

−
-0.57 ± 1.27
−

−
1.46 ± 1.15
N.D.

48

Gapdh
Dmp1
Dspp

19.29 ± 0.23
33.19 ± 0.56
39.40 ± 0.33

−
13.70 ± 0.41
19.91 ± 0.47

−
-1.07 ± 0.64
−

−
0.56 ± 0.18
N.D.

72

Gapdh
Dmp1
Dspp

19.75 ± 0.36
34.19 ± 0.74
38.86 ± 0.59

−
14.19 ± 1.01
18.86 ± 0.70

−
-1.55 ± 1.13
−

−
0.59 ± 0.39
N.D.

96

Gapdh
Dmp1
Dspp

19.43 ± 0.28
32.15 ± 0.10
37.63 ± 0.73

−
12.90 ± 0.24
18.38 ± 0.75

−
-0.27 ± 0.36
−

−
0.89 ± 0.24
N.D.

CT

ΔCT

-ΔΔCT

Fold change

12

Gapdh
Dmp1
Dspp

19.19 ± 0.53
29.98 ± 0.53
34.93 ± 0.73

−
10.32 ± 0.55
15.27 ± 0.56

−
2.31 ± 0.29
-9.27 ± 0.42

−
5.16 ± 0.94
0.002 ± 0.001

24

Gapdh
Dmp1
Dspp

19.62 ± 0.54
29.40 ± 1.39
33.22 ± 0.87

−
9.33 ± 1.20
13.16 ± 0.90

−
3.30 ± 1.03
-7.56 ± 0.58

−
15.86 ± 10.03
0.006 ± 0.003

36

Gapdh
Dmp1
Dspp

19.03 ± 0.22
26.56 ± 0.20
30.67 ± 0.74

−
7.32 ± 0.30
11.43 ± 0.85

−
5.31 ± 0.25
-5.00 ± 0.48

−
40.85 ± 6.77
0.03 ± 0.01

4
8

Hours
after
treatment

Gene

Gapdh

19.43 ± 0.43

−

−

−

FGF2-treated between d3-7
Hours
after
treatment

Gene
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Dmp1
Dspp

26.26 ± 0.43
28.86 ± 0.28

6.44 ± 0.23
9.04 ± 0.47

6.20 ± 0.45
-3.20 ± 0.42

79.95 ± 20.69
0.12 ± 0.03

72

Gapdh
Dmp1
Dspp

19.71 ± 0.48
25.68 ± 0.21
27.99 ± 0.33

−
5.62 ± 0.59
7.92 ± 0.77

−
7.01 ± 0.70
-2.33 ± 0.14

−
163.3 ± 77.4
0.20 ± 0.02

96

Gapdh
Dmp1
Dspp

19.68 ± 0.27
22.10 ± 0.37
25.66 ± 0.34

−
2.39 ± 0.35
5.95 ± 0.70

−
10.24 ± 0.61
0

−
1458.1 ± 640.4
1

ΔCT = CTgene - CTGapdh.
-ΔΔCT = -(ΔCTsample – ΔCTcontrol).
Positive –ΔΔCT value = increased gene expression relative to control.
Negative –ΔΔCT value = decreased gene expression relative to control.
Expression of Dmp1 was normalized to untreated sample at 0 hrs, whereas Dspp was normalized
to FGF2-treated cultures at 96 hrs.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point.
N.D. = not detected.
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Table 16. Effects of early exposure to FGF2 on expression of 3.6-GFP and 2.3-GFP
transgenes in primary dental pulp cultures.

2.3-GFP
(483 nm)

3.6-GFP
(500 nm)

Transgene
(wavelength)

Day of the
culture

VH

7

5348.6 ± 158.1

10

FGF2

Fold changes

6175.2 ± 304.2*

~1.15

16227.3 ± 1015.4

11869.0 ± 726.8*

~0.73

14

33184.1 ± 630.6

33772.8 ± 1580.1

~1.01

21

37521.3 ± 1199.2

39627.7 ± 494.9

~1.06

7

3022.2 ± 245.0

4444.0 ± 275.3*

~1.47

10

16352.1 ± 1806.2

13436.0 ± 1417.3

~0.82

14

28268.2 ± 1070.6

30304.0 ± 3174.0

~1.07

21

36601.4 ± 1404.9

36560.2 ± 3178.3

~1.00

Results are expressed in absolute values and represent mean ± SEM of at least three independent
experiments; *p ≤ 0.05 relative to control at each time point. Fold changes represent FGF2 value
divided by the control value for each time point.
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Table 17. Effects of early exposure to FGF2 on the percentage of 3.6-GFP and 2.3-GFP
cells in the primary dental pulp cultures.
VH
Hours after
treatment

% GFP– cells

FGF2

% GFP+ cells

% GFP– cells

% GFP+ cells

3.6-GFP
24

36.57 ± 0.61

63.43 ± 0.60

31.97 ± 0.35

68.03 ± 0.41

48

21.28 ± 0.14

78.72 ± 0.14

19.57 ± 0.13

80.43 ± 0.10

72

19.48 ± 0.07

80.52 ± 0.07

17.28 ± 0.12

82.72 ± 0.12

96

17.31 ± 0.19

82.69 ± 0.14

15.62 ± 0.35

84.38 ± 0.40

2.3-GFP
24

26.63 ± 0.75

73.37 ± 0.65

26.09 ± 0.41

73.91 ± 0.45

48

22.36 ± 0.81

77.64 ± 0.69

23.49 ± 0.38

76.51 ± 0.37

72

18.62 ± 0.26

81.38 ± 0.29

16.78 ± 0.11

83.22 ± 0.13

96

15.10 ± 0.80

84.90 ± 0.77

12.57 ± 0.64

87.43 ± 0.66

Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point.
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Table 18. Effects of early exposure to FGF2 on proliferation of 2.3-GFP+ and 2.3-GFP–
cells in the primary dental pulp cultures (cell cycle analysis).

VH

FGF2

VH

FGF2

24 hrs

G0/G1
S
G2/M
S + G2/M

83.19 ± 0.38
7.81 ± 0.39
9.06 ± 0.05
16.88 ± 0.35

83.03 ± 2.41
4.56 ± 2.10
12.41 ± 1.13
16.97 ± 2.41

85.01 ± 0.08
7.50 ± 0.18
7.50 ± 0.21
15.00 ± 0.08

80.67 ± 1.16*
9.97 ± 0.64*
9.36 ± 0.60
19.33 ± 1.16*

48 hrs

G0/G1
S
G2/M
S + G2/M

83.65 ± 0.59
5.85 ± 1.60
10.51 ± 1.03
16.36 ± 0.59

79.16 ± 0.61*
8.66 ± 1.83
12.19 ± 1.23
20.85 ± 0.61*

85.93 ± 1.06
5.37 ± 1.30
8.70 ± 0.98
14.07 ± 1.06

80.97 ± 0.84*
9.95 ± 1.30
9.09 ± 0.66
19.03 ± 0.83*

72 hrs

2.3-GFP– cells

Cell cycle
phase

G0/G1
S
G2/M
S + G2/M

79.14 ± 0.51
0.04 ± 0.03
20.82 ± 0.54
20.86 ± 0.51

67.00 ± 0.49*
0.05 ± 0.88
32.95 ± 0.52*
33.00 ± 0.49*

77.89 ± 1.42
11.12 ± 2.69
11.00 ± 1.46
22.11 ± 1.42

61.90 ± 0.73*
10.21 ± 0.31*
27.89 ± 0.47
38.10 ± 0.74*

96 hrs

2.3-GFP+ cells

Time
point

G0/G1
S
G2/M
S + G2/M

80.34 ± 2.09
0
19.65 ± 2.56
19.65 ± 2.56

67.09 ± 2.35*
0
33.93 ± 1.78*
33.93 ± 1.78*

79.48 ± 1.38
7.17 ± 2.61
13.35 ± 2.18
20.52 ± 1.38

70.28 ± 2.20*
15.71 ± 2.32
14.02 ± 4.51
29.72 ± 2.20*

Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point.
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Table 19. Effects of early exposure to FGF2 on expression of DMP1-GFP transgene in
primary dental pulp cultures.
Day of the
culture

VH

FGF2

Fold changes

7

69.0 ± 13.01

2579.1 ± 161.8*

~37.38

10

9590.4 ± 614.3

11563.5 ± 313.4*

~1.21

14

19207.8 ± 508.3

23485.3 ± 1063.1*

~1.27

21

23202.0 ± 502.4

18358.3 ± 512.1*

~0.79

Results are expressed in absolute values and represent mean ± SEM of at least three independent
experiments; *p ≤ 0.05 relative to control at each time point. Fold changes represent FGF2 value
divided by the control value for each time point.
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Table 20. Effects of early exposure to FGF2 on the percentage of DMP1-GFP cells in
primary dental pulp cultures.
VH

FGF2

Hours after
treatment

% GFP– cells

% GFP+ cells

% GFP– cells

% GFP+ cells

24

97.40 ± 0.17

2.60 ± 0.17

89.20 ± 0.61*

10.80 ± 0.61*

48

97.50 ± 0.72

2.50 ± 0.72

80.90 ± 0.29*

19.10 ± 0.29*

72

96.40 ± 0.29

3.56 ± 0.29

74.50 ± 0.55*

25.50 ± 0.55*

96

94.60 ± 0.27

5.40 ± 0.27

64.60 ± 2.98*

35.40 ± 2.98*

Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point.
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Table 21. Effects of early exposure to FGF2 on the percentage of DSPP-Cerulean+
odontoblasts and epifluorescence intensity of DSPP-Cerulean transgene in primary dental
pulp cultures.

Epifluorescence
intensity of
DSPP-Cerulean

Percentage of
DSPP-Cerulean+
odontoblasts

Parameter

Day of the
culture

VH

FGF2

Fold change

7

0.11 ± 0.05

1.91 ± 0.25*

~17.4

10

1.94 ± 0.08

12.18 ± 0.31*

~6.5

14

6.57 ± 0.18

13.47 ± 0.40*

~2.1

21

7.51 ± 0.17

16.00 ± 0.54*

~2.1

7

0

0.46 ± 0.17*

−

10

0.71 ± 0.20

4.64 ± 0.25*

~6.5

14

5.58 ± 0.31

11.06 ± 0.53*

~2.0

21

20.33 ± 0.77

40.46 ± 1.70*

~2.0

Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point. Fold changes represent FGF2 value divided by the control value for
each time point.
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Table 22. Effects of SU5402 on expression of Dmp1 and Dspp in the control and FGF2treated primary dental pulp cultures.
Control
CT

ΔCT

-ΔΔCT

Fold change

48

Gapdh
Dmp1
Dspp

19.59 ± 0.36
32.18 ± 0.72
38.70 ± 0.39

−
12.59 ± 0.48
18.11 ± 0.44

−
0
−

−
1
N.D.

72

Gapdh
Dmp1
Dspp

19.37 ± 0.30
32.21 ± 0.38
36.05 ± 0.34

−
12.84 ± 0.23
16.98 ± 0.41

−
-0.25 ± 0.50
−

−
1.08 ± 0.28
N.D.

96

Gapdh
Dmp1
Dspp

19.62 ± 0.35
31.92 ± 0.20
37.73 ± 0.11

−
12.31 ± 0.28
17.79 ± 0.40

−
0.28 ± 0.57
−

−
1.68 ± 0.51
N.D.

CT

ΔCT

-ΔΔCT

Fold change

48

Gapdh
Dmp1
Dspp

20.26 ± 0.21
34.29 ± 0.23
37.85 ± 0.92

−
14.03 ± 0.43
17.59 ± 0.72

−
-0.53 ± 0.27
−

−
0.72 ± 0.14
N.D.

72

Gapdh
Dmp1
Dspp

19.77 ± 0.06
32.93 ± 0.14
35.93 ± 0.57

−
13.16 ± 0.15
16.16 ± 0.58

−
0.33 ± 0.02
−

−
1.26 ± 0.02
N.D.

96

Gapdh
Dmp1
Dspp

20.09 ± 0.17
33.33 ± 0.21
38.98 ± 0.51

−
13.24 ± 0.10
18.88 ± 0.34

−
0.26 ± 0.26
−

−
1.24 ± 0.23
N.D.

CT

ΔCT

-ΔΔCT

Fold change

48

Gapdh
Dmp1
Dspp

20.16 ± 0.02
34.00 ± 0.12
38.24 ± 0.13

−
13.84 ± 0.10
18.08 ± 0.11

−
-0.34 ± 0.24
−

−
0.81 ± 0.13
N.D.

72

Hours
after
treatment

Gene

Gapdh
Dmp1
Dspp

19.78 ± 0.04
33.22 ± 0.12
37.02 ± 1.20

−
13.44 ± 0.10
17.24 ± 1.17

−
0.05 ± 0.26
−

−
1.07 ± 0.20
N.D.

5 µM SU5402
Hours
after
treatment

Gene

10 µM SU5402
Hours
after
treatment

Gene
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−
12.80 ± 0.29
17.66 ± 0.20

−
0.70 ± 0.44
−

−
1.77 ± 0.46
N.D.

CT

ΔCT

-ΔΔCT

Fold change

48

Gapdh
Dmp1
Dspp

20.56 ± 0.43
35.08 ± 0.06
39.41 ± 0.12

−
14.53 ± 0.16
18.85 ± 0.21

−
-1.03 ± 0.33
−

−
0.52 ± 0.12
N.D.

72

Gapdh
Dmp1
Dspp

19.88 ± 0.08
34.49 ± 0.55
36.53 ± 1.06

−
14.61 ± 0.50
16.65 ± 1.12

−
-1.11 ± 0.40
−

−
0.50 ± 0.13
N.D.

96

Gapdh
Dmp1
Dspp

20.20 ± 0.04
33.63 ± 0.06
36.66 ± 1.19

−
13.43 ± 0.10
16.46 ± 1.17

−
0.07 ± 0.17
−

−
1.07 ± 0.13
N.D.

CT

ΔCT

-ΔΔCT

Fold change

48

Gapdh
Dmp1
Dspp

18.11 ± 0.41
28.14 ± 0.25
30.23 ± 0.52

−
10.02 ± 0.25
12.12 ± 0.41

−
1.66 ± 0.48
-1.19 ± 0.22

−
3.56 ± 1.31
0.45 ± 0.07

72

Gapdh
Dmp1
Dspp

18.53 ± 0.43
22.85 ± 0.22
29.84 ± 0.61

−
4.32 ± 0.61
11.31 ± 0.85

−
7.36 ± 0.40
-0.38 ± 0.38

−
178.36 ± 52.77
0.86 ± 0.29

96

Gapdh
Dmp1
Dspp

18.46 ± 0.45
22.03 ± 0.17
29.39 ± 0.57

−
3.57 ± 0.48
10.93 ± 0.58

−
8.11 ± 0.10
0

−
277.16 ± 19.12
1

CT

ΔCT

-ΔΔCT

Fold change

48

Gapdh
Dmp1
Dspp

18.39 ± 0.41
31.54 ± 0.12
30.92 ± 0.17

−
13.14 ± 0.32
12.53 ± 0.35

−
-1.46 ± 0.35
-1.60 ± 0.38

−
0.39 ± 0.10
0.35 ± 0.08

72

Gapdh
Dmp1
Dspp

18.38 ± 0.45
24.06 ± 0.22
31.46 ± 0.91

−
5.68 ± 0.65
13.08 ± 0.86

−
6.00 ± 0.19
-2.15 ± 0.30

−
65.10 ± 8.42
0.24 ± 0.07

Gapdh
Dmp1

19.02 ± 0.60
25.20 ± 1.25

−
6.18 ± 1.33

−
5.50 ± 0.81

−
58.27 ± 23.03

96

20.01 ± 0.04
32.81 ± 0.25
37.67 ± 0.23

96

Gapdh
Dmp1
Dspp

20 µM SU5402
Hours
after
treatment

Gene

FGF2-treated between 0-96 hrs
Hours after
treatment

Gene

FGF2 + 5 µM SU5402
Hours after
treatment

Gene
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Dspp

30.82 ± 0.55

11.80 ± 0.57

-0.87 ± 0.39

0.59 ± 0.14

FGF2 + 10 µM SU5402
CT

ΔCT

-ΔΔCT

Fold change

48

Gapdh
Dmp1
Dspp

18.77 ± 0.45
33.24 ± 0.16
32.99 ± 0.57

−
14.47 ± 0.48
14.22 ± 0.92

−
-2.78 ± 0.23
-3.29 ± 0.74

−
0.15 ± 0.02
0.13 ± 0.07

72

Gapdh
Dmp1
Dspp

18.58 ± 0.72
25.17 ± 1.20
32.65 ± 1.27

−
6.60 ± 1.48
14.07 ± 1.05

−
5.08 ± 0.96
-3.13 ± 0.40

−
47.25 ± 20.21
0.13 ± 0.04

96

Gapdh
Dmp1
Dspp

19.02 ± 0.65
26.63 ± 0.10
32.19 ± 0.91

−
7.61 ± 0.75
13.17 ± 0.28

−
4.07 ± 0.37
-2.24 ± 0.82

−
17.85 ± 4.22
0.30 ± 0.18

CT

ΔCT

-ΔΔCT

Fold change

48

Gapdh
Dmp1
Dspp

18.75 ± 0.53
34.04 ± 0.22
34.21 ± 0.90

−
15.29 ± 0.65
15.46 ± 1.38

−
-3.61 ± 0.14
-2.66 ± 1.61

−
0.08 ± 0.01
0.07 ± 0.06

72

Gapdh
Dmp1
Dspp

18.81 ± 0.42
25.68 ± 1.57
33.76 ± 1.53

−
6.88 ± 1.86
14.96 ± 1.35

−
5.08 ± 0.96
-2.15 ± 1.26

−
49.20 ± 22.49
0.10 ± 0.07

96

Hours after
treatment

Gene

Gapdh
Dmp1
Dspp

18.74 ± 0.46
28.14 ± 0.25
33.51 ± 0.82

−
9.39 ± 0.32
14.76 ± 0.38

−
4.07 ± 0.37
-2.18 ± 1.28

−
0.97 ± 0.16
0.09 ± 0.07

FGF2 + 20 µM SU5402
Hours after
treatment

Gene

ΔCT = CTgene - CTGapdh.
-ΔΔCT = -(ΔCTsample – ΔCTcontrol).
Positive –ΔΔCT value = increased gene expression relative to control.
Negative –ΔΔCT value = decreased gene expression relative to control.
All fold changes are relative to control at 48 hrs, except Dspp, which is relative to FGF2-treated
cultures at 96 hrs.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point.
N.D. = not detected.
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48

FGF2
FGF2 + 5 µM SU5402
FGF2 + 10 µM SU5402
FGF2 + 20 µM SU5402

Fold change
(Dmp1)
1
0.11
0.04
0.02

Fold change
(Dspp)
1
0.78
0.29
0.16

72

FGF2
FGF2 + 5 µM SU5402
FGF2 + 10 µM SU5402
FGF2 + 20 µM SU5402

1
0.37
0.27
0.28

1
0.28
0.15
0.12

96

Table 23. The extent of attenuation of FGF2-mediated increases in Dmp1 and Dspp by
SU5402 in primary dental pulp cultures.
Hours after
treatment

Treatment

FGF2
FGF2 + 5 µM SU5402
FGF2 + 10 µM SU5402
FGF2 + 20 µM SU5402

1
0.21
0.06
0.004

1
0.59
0.10
0.09

Results are expressed as a fold change relative to FGF2 at each time point. Fold changes
represent FGF2+inhibitor value divided by FGF2 alone value for each time point.
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Table 24. Effects of U0126 on expression of Dmp1 and Dspp in the control and FGF2treated primary dental pulp cultures.
Control
CT

ΔCT

-ΔΔCT

Fold change

48

Gapdh
Dmp1
Dspp

19.90 ± 0.15
31.41 ± 0.40
35.92 ± 0.46

–
11.51 ± 0.34
16.03 ± 0.41

–
0
–

–
1
N.D.

72

Gapdh
Dmp1
Dspp

19.78 ± 0.38
31.66 ± 0.43
36.05 ± 0.30

–
11.88 ± 0.36
16.27 ± 0.51

–
-0.37 ± 0.41
–

–
0.94 ± 0.50
N.D.

96

Gapdh
Dmp1
Dspp

20.21 ± 0.48
30.52 ± 0.82
36.42 ± 0.56

–
10.32 ± 0.72
16.22 ± 0.52

–
1.19 ± 0.74
–

–
2.81 ± 1.23
N.D.

CT

ΔCT

-ΔΔCT

Fold change

48

Gapdh
Dmp1
Dspp

20.31 ± 0.38
34.29 ± 0.69
36.72 ± 0.61

–
13.98 ± 0.42
16.41 ± 0.24

–
-2.11 ± 0.62
–

–
0.27 ± 0.09
N.D.

72

Gapdh
Dmp1
Dspp

19.56 ± 0.14
32.85 ± 0.30
36.15 ± 0.36

−
13.30 ± 0.15
16.60 ± 0.49

−
-1.43 ± 0.36
−

−
0.39 ± 0.08
N.D.

96

Gapdh
Dmp1
Dspp

19.82 ± 0.17
31.26 ± 0.57
37.35 ± 1.08

–
13.30 ± 0.15
17.53 ± 1.12

–
0.43 ± 0.42
–

–
1.46 ± 0.43
N.D.

CT

ΔCT

-ΔΔCT

Fold change

48

Gapdh
Dmp1
Dspp

20.09 ± 0.24
34.72 ± 0.53
37.42 ± 0.39

–
14.63 ± 0.52
17.33 ± 0.48

–
-2.76 ± 0.73
–

–
0.18 ± 0.06
N.D.

72

Gapdh
Dmp1
Dspp

20.05 ± 0.32
34.14 ± 0.30
39.01 ± 0.12

–
14.09 ± 0.19
18.96 ± 0.32

–
-2.23 ± 0.13
–

–
0.22 ± 0.02
N.D.

96

Hours after
treatment

Gene

Gapdh
Dmp1
Dspp

20.16 ± 0.16
31.78 ± 0.69
37.91 ± 1.06

–
11.62 ± 0.73
17.75 ± 1.13

–
0.24 ± 0.49
–

–
1.33 ± 0.46
N.D.

5 µM U0126
Hours after
treatment

Gene

10 µM U0126
Hours after
treatment

Gene
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20 µM U0126
CT

ΔCT

-ΔΔCT

Fold change

48

Gapdh
Dmp1
Dspp

20.77 ± 0.36
35.36 ± 0.84
38.56 ± 0.34

–
14.59 ± 0.72
17.79 ± 0.70

–
-2.73 ± 0.95
–

–
0.21 ± 0.08
N.D.

72

Gapdh
Dmp1
Dspp

19.99 ± 0.28
34.38 ± 0.21
39.77 ± 0.23

–
14.38 ± 0.13
19.78 ± 0.06

–
-2.52 ± 0.16
–

–
0.18 ± 0.02
N.D.

96

Gapdh
Dmp1
Dspp

20.28 ± 0.22
32.06 ± 0.91
39.15 ± 0.44

–
11.78 ± 0.83
18.87 ± 0.64

–
0.08 ± 0.61
–

–
1.24 ± 0.42
N.D.

CT

ΔCT

-ΔΔCT

Fold change

48

Gapdh
Dmp1
Dspp

20.51 ± 0.41
29.46 ± 0.22
31.26 ± 0.37

–
8.95 ± 0.58
10.76 ± 0.61

–
2.20 ± 0.07
-2.13 ± 0.99

–
4.62 ± 0.22
0.32 ± 0.14

72

Gapdh
Dmp1
Dspp

19.62 ± 0.37
24.08 ± 0.53
29.19 ± 0.30

–
4.46 ± 0.41
9.57 ± 0.43

–
6.70 ± 0.23
-0.95 ± 0.17

–
106.93 ± 17.57
0.52 ± 0.06

96

Gapdh
Dmp1
Dspp

19.51 ± 0.12
22.34 ± 0.82
28.13 ± 0.49

–
2.83 ± 0.69
8.62 ± 0.57

–
8.33 ± 0.07
0

–
322.51 ± 16.35
1

CT

ΔCT

-ΔΔCT

Fold change

48

Gapdh
Dmp1
Dspp

19.87 ± 0.29
32.04 ± 0.42
33.22 ± 0.54

–
12.17 ± 0.70
13.36 ± 0.26

–
-1.02 ± 0.90
-4.74 ± 0.52

–
0.66 ± 0.26
0.04 ± 0.01

72

Gapdh
Dmp1
Dspp

19.78 ± 0.13
26.83 ± 0.87
32.96 ± 0.28

–
7.05 ± 0.86
13.18 ± 0.18

–
4.11 ± 0.31
-4.55 ± 0.42

–
18.17 ± 4.23
0.05 ± 0.01

96

Hours after
treatment

Gene

Gapdh
Dmp1
Dspp

19.65 ± 0.14
24.60 ± 0.63
31.55 ± 0.07

–
4.95 ± 0.52
11.90 ± 0.18

–
6.21 ± 0.14
-3.28 ± 0.44

–
74.69 ± 7.48
0.11 ± 0.04

CT

ΔCT

-ΔΔCT

Fold change

FGF2-treated between 0-96 hrs
Hours after
treatment

Gene

FGF2 + 5 µM U0126
Hours after
treatment

Gene

FGF2 + 10 µM U0126
Hours after
treatment

Gene
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48

Gapdh
Dmp1
Dspp

19.91 ± 0.10
32.67 ± 0.90
35.75 ± 0.47

–
12.76 ± 0.80
15.83 ± 0.57

–
-1.60 ± 0.41
–

–
0.36 ± 0.11
N.D.

72

Gapdh
Dmp1
Dspp

19.66 ± 0.25
28.00 ± 0.87
34.64 ± 0.71

–
8.34 ± 0.88
14.98 ± 0.75

–
2.82 ± 0.71
-6.35 ± 0.76

–
8.66 ± 3.28
0.02 ± 0.007

96

Gapdh
Dmp1
Dspp

19.91 ± 0.24
25.51 ± 0.64
33.10 ± 0.46

–
5.60 ± 0.44
13.19 ± 0.22

–
5.56 ± 0.23
-4.56 ± 0.77

–
48.31 ± 7.84
0.06 ± 0.03

CT

ΔCT

-ΔΔCT

Fold change

48

Gapdh
Dmp1
Dspp

20.12 ± 0.16
33.38 ± 0.81
37.38 ± 0.70

–
13.27 ± 0.97
17.26 ± 0.79

–
-2.11 ± 1.14
–

–
0.36 ± 0.16
N.D.

72

Gapdh
Dmp1
Dspp

20.31 ± 0.21
30.26 ± 1.08
36.61 ± 0.70

–
9.95 ± 0.95
16.30 ± 0.53

–
1.21 ± 1.28
–

–
3.92 ± 1.86
N.D.

96

Gapdh
Dmp1
Dspp

20.10 ± 0.10
26.59 ± 1.26
36.26 ± 1.14

–
6.49 ± 1.15
16.17 ± 1.05

–
4.66 ± 0.53
-7.55 ± 1.37

–
28.44 ± 8.15
0.005 ± 0.005

FGF2 + 20 µM U0126
Hours after
treatment

Gene

ΔCT = CTgene - CTGapdh.
-ΔΔCT = -(ΔCTsample – ΔCTcontrol).
Positive –ΔΔCT value = increased gene expression relative to control.
Negative –ΔΔCT value = decreased gene expression relative to control.
All fold changes are relative to VH at 48 hrs, except Dspp, which is relative to FGF2-treated
cultures at 96 hrs.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point.
N.D. = not detected.
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48

FGF2
FGF2 + 5 µM U0126
FGF2 + 10 µM U0126
FGF2 + 20 µM U0126

Fold change
(Dmp1)
1
0.14
0.08
0.08

Fold change
(Dspp)
1
0.13
–
–

72

FGF2
FGF2 + 5 µM U0126
FGF2 + 10 µM U0126
FGF2 + 20 µM U0126

1
0.17
0.08
0.04

1
0.10
0.04
–

96

Table 25. The extent of attenuation of FGF2-mediated increases in Dmp1 and Dspp by
U0126 in primary dental pulp cultures.
Hours after
treatment

FGF2
FGF2 + 5 µM U0126
FGF2 + 10 µM U0126
FGF2 + 20 µM U0126

1
0.23
0.15
0.09

1
0.11
0.06
0.005

Treatment

Results are expressed as a fold change relative to FGF2 at each time point. Fold changes
represent FGF2+inhibitor value divided by FGF2 alone value for each time point.
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Table 26. Effects of SU5402 and U0126 on expression of Bmp2 in the control and FGF2treated primary dental pulp cultures.
Day of
the
culture

Gene
(Gapdh)

CT

ΔCT

-ΔΔCT

Fold change

48

VH
5 µM SU5402
10 µM SU5402
20 µM SU5402
FGF2
FGF2 + 5 µM SU5402
FGF2 + 10 µM SU5402
FGF2 + 20 µM SU5402

16.53 ± 0.22
15.95 ± 0.30
15.58 ± 0.02
16.15 ± 0.12
16.35 ± 0.13
16.88 ± 0.24
17.15 ± 0.24
17.26 ± 0.20

−
−
−
−
−
−
−
−

−
−
−
−
−
−
−
−

−
−
−
−
−
−
−
−

72

VH
5 µM SU5402
10 µM SU5402
20 µM SU5402
FGF2
FGF2 + 5 µM SU5402
FGF2 + 10 µM SU5402
FGF2 + 20 µM SU5402

16.47 ± 0.33
15.85 ± 0.21
15.40 ± 0.15
15.73 ± 0.08
16.88 ± 0.39
16.51 ± 0.25
16.45 ± 0.48
16.49 ± 0.32

−
−
−
−
−
−
−
−

−
−
−
−
−
−
−
−

−
−
−
−
−
−
−
−

96

VH
5 µM SU5402
10 µM SU5402
20 µM SU5402
FGF2
FGF2 + 5 µM SU5402
FGF2 + 10 µM SU5402
FGF2 + 20 µM SU5402

16.47 ± 0.33
15.85 ± 0.21
15.85 ± 0.13
16.03 ± 0.27
17.35 ± 0.08
16.84 ± 0.38
16.87 ± 0.09
16.91 ± 0.33

−
−
−
−
−
−
−
−

−
−
−
−
−
−
−
−

−
−
−
−
−
−
−
−

Day of
the
culture

Gene
(Bmp2)

CT

ΔCT

-ΔΔCT

Fold change

48

SU5402

VH
5 µM SU5402
10 µM SU5402
20 µM SU5402
FGF2
FGF2 + 5 µM SU5402
FGF2 + 10 µM SU5402

25.97 ± 0.38
25.41 ± 0.34
25.38 ± 0.11
26.22 ± 0.97
25.06 ± 0.52
26.41 ± 0.41
27.08 ± 0.35

9.44 ± 0.22
9.46 ± 0.24
9.80 ± 0.10
10.07 ± 0.85
8.71 ± 0.57
9.53 ± 0.63
9.92 ± 0.28

0
-0.30 ± 0.60
-0.64 ± 0.30
-0.91 ± 1.10
1.01 ± 0.49
0.19 ± 0.56
-0.20 ± 0.36

1
0.96 ± 0.38
0.67 ± 0.14
0.80 ± 0.34
2.23 ± 0.64
1.32 ± 0.48
0.92 ± 0.23
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FGF2 + 20 µM SU5402

27.17 ± 0.39

9.91 ± 0.19

-0.19 ± 0.17

0.89 ± 0.10

72

VH
5 µM SU5402
10 µM SU5402
20 µM SU5402
FGF2
FGF2 + 5 µM SU5402
FGF2 + 10 µM SU5402
FGF2 + 20 µM SU5402

26.53 ± 0.58
25.32 ± 0.24
25.47 ± 0.02
26.68 ± 0.83
26.09 ± 0.40
26.90 ± 0.13
27.20 ± 0.45
27.49 ± 0.12

10.24 ± 0.22
9.74 ± 0.37
10.07 ± 0.17
10.96 ± 0.80
9.22 ± 0.34
10.39 ± 0.20
10.75 ± 0.47
11.00 ± 0.31

-0.70 ± 0.22
-0.58 ± 0.55
-0.91 ± 0.45
-1.80 ± 1.14
0.50 ± 0.26
-0.67 ± 0.26
-1.03 ± 0.43
-1.28 ± 0.32

0.59 ± 0.06
0.76 ± 0.22
0.58 ± 0.16
0.47 ± 0.26
1.46 ± 0.24
0.65 ± 0.11
0.54 ± 0.17
0.43 ± 0.08

96

VH
5 µM SU5402
10 µM SU5402
20 µM SU5402
FGF2
FGF2 + 5 µM SU5402
FGF2 + 10 µM SU5402
FGF2 + 20 µM SU5402

27.02 ± 0.56
26.00 ± 0.31
26.19 ± 0.14
26.74 ± 1.24
26.13 ± 0.52
26.56 ± 0.32
27.82 ± 0.19
27.76 ± 0.18

10.55 ± 0.28
10.15 ± 0.14
10.34 ± 0.26
10.71 ± 1.03
8.78 ± 0.59
9.71 ± 0.66
10.96 ± 0.25
10.85 ± 0.50

1.00 ± 0.85
1.00 ± 0.51
-1.18 ± 0.65
-1.55 ± 1.31
0.94 ± 0.67
0.01 ± 0.72
-1.24 ± 0.33
-1.13 ± 0.59

0.57 ± 0.20
0.57 ± 0.20
0.54 ± 0.25
0.60 ± 0.28
2.42 ± 1.20
1.28 ± 0.61
0.45 ± 0.11
0.55 ± 0.24

Day of
the
culture

Gene
(Gapdh)

CT

ΔCT

-ΔΔCT

Fold change

16.96 ± 0.47
17.97 ± 0.15
18.19 ± 0.28
18.84 ± 0.12
15.77 ± 0.23
15.77 ± 0.09
15.88 ± 0.06
16.25 ± 0.09

–
–

–
–

–
–

48

VH
5 µM U0126
10 µM U0126
20 µM U0126
FGF2
FGF2 + 5 µM U0126
FGF2 + 10 µM U0126
FGF2 + 20 µM U0126

–
–
–
–
–
–

–
–
–
–
–
–

–
–
–
–
–
–

72

VH
5 µM U0126
10 µM U0126
20 µM U0126
FGF2
FGF2 + 5 µM U0126
FGF2 + 10 µM U0126
FGF2 + 20 µM U0126

16.83 ± 0.54
18.00 ± 0.32
17.98 ± 0.04
18.04 ± 0.37
15.58 ± 0.08
15.53 ± 0.12
15.96 ± 0.12
16.13 ± 0.06

–
–
–
–
–
–
–
–

–
–
–
–
–
–
–
–

–
–
–
–
–
–
–
–

96

VH
5 µM U0126

17.29 ± 0.58
18.03 ± 0.26

–
–

–
–

–
–

U0126
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–
–
–
–
–
–

–
–
–
–
–
–

CT

ΔCT

-ΔΔCT

Fold change

Day of
the
culture

Gene
(Bmp2)

48

–
–
–
–
–
–

VH
5 µM U0126
10 µM U0126
20 µM U0126
FGF2
FGF2 + 5 µM U0126
FGF2 + 10 µM U0126
FGF2 + 20 µM U0126

26.74 ± 0.18
27.20 ± 0.12
27.41 ± 0.26
27.88 ± 0.04
25.09 ± 0.10
25.31 ± 0.41
25.20 ± 0.31
25.66 ± 0.23

9.78 ± 0.64
9.23 ± 0.11
9.23 ± 0.06
9.03 ± 0.08
9.33 ± 0.14
9.55 ± 0.49
9.32 ± 0.37
9.41 ± 0.27

0
-0.41 ± 0.23
-0.41 ± 0.13
-0.22 ± 0.18
1.43 ± 0.09
1.21 ± 0.29
1.44 ± 0.15
1.34 ± 0.14

1
0.77 ± 0.13
0.76 ± 0.07
0.87 ± 0.11
3.38 ± 0.07
2.40 ± 0.44
2.74 ± 0.29
2.56 ± 0.26

72

18.06 ± 0.04
17.67 ± 0.22
16.05 ± 0.19
15.74 ± 0.16
15.86 ± 0.10
16.00 ± 0.04

VH
5 µM U0126
10 µM U0126
20 µM U0126
FGF2
FGF2 + 5 µM U0126
FGF2 + 10 µM U0126
FGF2 + 20 µM U0126

26.60 ± 0.19
27.64 ± 0.07
27.57 ± 0.05
28.41 ± 0.14
24.78 ± 0.09
25.40 ± 0.31
25.84 ± 0.27
26.10 ± 0.24

9.77 ± 0.62
9.64 ± 0.29
9.60 ± 0.08
10.37 ± 0.49
9.20 ± 0.10
9.87 ± 0.42
9.88 ± 0.23
9.97 ± 0.23

0.02 ± 0.13
-0.83 ± 0.25
-0.79 ± 0.18
-1.56 ± 0.57
1.55 ± 0.15
0.88 ± 0.50
0.88 ± 0.44
0.78 ± 0.25

1.03 ± 0.10
0.58 ± 0.10
0.59 ± 0.08
0.39 ± 0.12
3.16 ± 0.32
2.10 ± 0.79
2.01 ± 0.56
1.78 ± 0.33

96

10 µM U0126
20 µM U0126
FGF2
FGF2 + 5 µM U0126
FGF2 + 10 µM U0126
FGF2 + 20 µM U0126

VH
5 µM U0126
10 µM U0126
20 µM U0126
FGF2
FGF2 + 5 µM U0126
FGF2 + 10 µM U0126
FGF2 + 20 µM U0126

26.88 ± 0.21
27.74 ± 0.08
27.99 ± 0.16
27.81 ± 0.22
24.63 ± 0.08
25.24 ± 0.23
25.54 ± 0.10
25.78 ± 0.11

9.59 ± 0.67
9.71 ± 0.19
9.93 ± 0.16
10.14 ± 0.07
8.58 ± 0.27
9.51 ± 0.21
9.68 ± 0.14
9.77 ± 0.10

0.20 ± 0.13
-0.90 ± 0.22
-1.12 ± 0.28
-1.33 ± 0.19
1.25 ± 0.36
1.25 ± 0.36
1.07 ± 0.10
0.98 ± 0.32

1.17 ± 0.11
0.55 ± 0.08
0.48 ± 0.10
0.41 ± 0.06
3.59 ± 0.54
2.52 ± 0.59
2.11 ± 0.14
2.07 ± 0.42

The extent of attenuation of FGF2-mediated increases in Bmp2 by SU5402 and U0126.

48

Hours after
treatment

Treatment
FGF2
FGF2 + 5 µM SU5402
FGF2 + 10 µM SU5402

Fold change
1
0.59
0.41
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FGF2 + 20 µM SU5402

0.40

72

FGF2
FGF2 + 5 µM SU5402
FGF2 + 10 µM SU5402
FGF2 + 20 µM SU5402

1
0.45
0.37
0.29

96

FGF2
FGF2 + 5 µM SU5402
FGF2 + 10 µM SU5402
FGF2 + 20 µM SU5402

1
0.53
0.19
0.23

48

Fold change

FGF2
FGF2 + 5 µM U0126
FGF2 + 10 µM U0126
FGF2 + 20 µM U0126

1
0.71
0.81
0.76

72

Treatment

FGF2
FGF2 + 5 µM U0126
FGF2 + 10 µM U0126
FGF2 + 20 µM U0126

1
0.66
0.64
0.56

96

Hours after
treatment

FGF2
FGF2 + 5 µM U0126
FGF2 + 10 µM U0126
FGF2 + 20 µM U0126

1
0.70
0.59
0.58

ΔCT = CTBmp2 - CTGapdh.
-ΔΔCT = -(ΔCTsample – ΔCTcontrol).
Positive –ΔΔCT value = increased gene expression relative to control.
Negative –ΔΔCT value = decreased gene expression relative to control.
Fold changes are relative to VH at 48 hrs.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point. Fold changes represent FGF2 value divided by the control value for
each time point.
N.D. = not detected.
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Table 27. Effects of noggin on effects of FGF2 on expression of Dmp1, Dspp, Fgfr1c and
Fgfr2c in primary dental pulp cultures.
Hours after
treatment

Gene

CT

ΔCT

-ΔΔCT

Fold change

48

Gapdh (TaqMan)
Dmp1
Dspp
Gapdh (SYBR Green)
Fgfr1c
Fgfr2c

19.86 ± 0.13
32.87 ± 0.42
37.21 ± 0.31
16.96 ± 0.47
18.76 ± 0.29
23.38 ± 0.26

–
13.00 ± 0.40
17.34 ± 0.32
−
2.35 ± 0.49
6.97 ± 0.49

–
0
–
−
0
0

–
1
N.D.
−
1
1

72

Gapdh (TaqMan)
Dmp1
Dspp
Gapdh (SYBR Green)
Fgfr1c
Fgfr2c

19.82 ± 0.54
32.38 ± 0.23
36.65 ± 0.90
16.83 ± 0.54
18.37 ± 0.06
23.32 ± 0.54

–
12.56 ± 0.43
16.83 ± 0.73
−
2.45 ± 0.42
7.40 ± 0.42

–
0.44 ± 0.32
–
−
-0.10 ± 0.13
-0.44 ± 0.52

–
1.52 ± 0.30
N.D.
−
0.94 ± 0.09
0.83 ± 0.26

96

Gapdh (TaqMan)
Dmp1
Dspp
Gapdh (SYBR Green)
Fgfr1c
Fgfr2c

20.01 ± 0.45
31.11 ± 0.21
37.09 ± 0.72
17.29 ± 0.58
18.24 ± 0.05
23.86 ± 0.30

–
11.10 ± 0.49
17.08 ± 0.47
−
2.13 ± 0.60
7.75 ± 0.28

–
2.95 ± 0.38
–
−
0.22 ± 0.18
-0.79 ± 0.28

–
4.52 ± 1.42
N.D.
−
1.18 ± 0.14
0.60 ± 0.10

CT

ΔCT

-ΔΔCT

Fold change

48

Gapdh (TaqMan)
Dmp1
Dspp

20.67 ± 0.45
33.31 ± 0.22
38.96 ± 0.59

–
12.65 ± 0.33
18.30 ± 0.47

–
0.46 ± 0.44
–

–
1.52 ± 0.50
N.D.

72

Gapdh (TaqMan)
Dmp1
Dspp

20.19 ± 0.19
32.62 ± 0.24
39.64 ± 0.36

–
12.43 ± 0.05
19.44 ± 0.26

–
0.68 ± 0.23
–

–
1.64 ± 0.24
N.D.

96

Control

Gapdh (TaqMan)
Dmp1
Dspp

20.81 ± 0.51
32.07 ± 0.51
40.00 ± 0.00

–
11.26 ± 0.33
19.19 ± 0.51

–
1.85 ± 0.30
–

–
3.77 ± 0.81
N.D.

CT

ΔCT

-ΔΔCT

Fold change

20.62 ± 0.38
34.40 ± 0.96
38.78 ± 0.66

–
13.78 ± 0.60
18.16 ± 0.36

–
-0.67 ± 0.64
–

–
0.78 ± 0.38
N.D.

100 ng/ml noggin
Hours after
treatment

Gene

200 ng/ml noggin

48

Hours after
treatment

Gene
Gapdh (TaqMan)
Dmp1
Dspp
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72

Gapdh (TaqMan)
Dmp1
Dspp

20.40 ± 0.14
33.35 ± 0.94
39.37 ± 0.63

–
12.95 ± 0.80
18.97 ± 0.50

–
0.16 ± 0.85
–

–
1.63 ± 1.01
N.D.

96

Gapdh (TaqMan)
Dmp1
Dspp

20.44 ± 0.29
32.24 ± 0.46
39.16 ± 0.84

–
11.81 ± 0.27
18.72 ± 0.69

–
1.30 ± 0.32
–

–
2.60 ± 0.62
N.D.

CT

ΔCT

-ΔΔCT

Fold change

48

Gapdh (TaqMan)
Dmp1
Dspp

20.11 ± 0.40
34.48 ± 1.07
39.88 ± 0.12

–
14.37 ± 1.02
19.77 ± 0.53

–
-1.26 ± 1.01
–

–
0.68 ± 0.45
N.D.

72

Gapdh (TaqMan)
Dmp1
Dspp

20.15 ± 0.25
34.48 ± 1.31
38.35 ± 1.31

–
14.33 ± 1.27
18.20 ± 1.21

–
-1.22 ± 1.29
–

–
0.96 ± 0.78
N.D.

96

Gapdh (TaqMan)
Dmp1
Dspp

20.47 ± 0.29
32.92 ± 0.37
38.56 ± 0.77

–
12.44 ± 0.38
18.09 ± 0.53

–
0.66 ± 0.30
–

–
1.65 ± 0.33
N.D.

300 ng/ml noggin
Hours after
treatment

Gene

Hours after
treatment

Gene

CT

ΔCT

-ΔΔCT

Fold change

48

Gapdh (TaqMan)
Dmp1
Dspp
Gapdh (SYBR Green)
Fgfr1c
Fgfr2c

18.72 ± 0.77
31.00 ± 0.24
32.73 ± 0.82
15.77 ± 0.23
17.57 ± 0.11
24.60 ± 0.32

–
12.29 ± 1.01
14.01 ± 0.48
−
1.77 ± 0.37
8.80 ± 0.07

–
0.61 ± 0.30
-2.70 ± 0.56
−
0.57 ± 0.16
-1.83 ± 0.42

–
1.59 ± 0.35
0.18 ± 0.07
−
1.51 ± 0.16
0.31 ± 0.09

72

Gapdh (TaqMan)
Dmp1
Dspp
Gapdh (SYBR Green)
Fgfr1c
Fgfr2c

18.62 ± 0.86
25.33 ± 0.55
31.32 ± 0.55
15.58 ± 0.08
17.34 ± 0.08
24.97 ± 0.18

–
6.71 ± 1.24
12.70 ± 0.61
−
1.58 ± 0.34
9.21 ± 0.25

–
6.19 ± 0.56
-1.39 ± 0.31
−
0.77 ± 0.28
-2.24 ± 0.25

–
85.10 ± 34.27
0.40 ± 0.09
−
1.76 ± 0.32
0.22 ± 0.04

96

FGF2-treated between 0-96 hrs

Gapdh (TaqMan)
Dmp1
Dspp
Gapdh (SYBR Green)
Fgfr1c
Fgfr2c

18.85 ± 0.93
23.20 ± 0.40
30.16 ± 0.64
16.05 ± 0.19
17.60 ± 0.07
26.16 ± 0.31

–
4.35 ± 1.02
11.31 ± 0.87
−
1.00 ± 0.46
9.56 ± 0.08

–
8.54 ± 0.23
0
−
1.34 ± 0.37
-2.60 ± 0.45

–
382.30 ± 63.25
1
−
2.71 ± 0.70
0.18 ± 0.05
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Hours after
treatment

Gene

CT

ΔCT

-ΔΔCT

Fold change

48

Gapdh (TaqMan)
Dmp1
Dspp
Gapdh (SYBR Green)
Fgfr1c
Fgfr2c

18.89 ± 0.83
32.20 ± 0.32
37.17 ± 0.53
15.77 ± 0.09
17.89 ± 0.23
24.59 ± 0.34

–
13.31 ± 1.09
18.28 ± 0.63
−
2.19 ± 0.30
8.89 ± 0.58

–
-0.42 ± 0.26
–
−
0.16 ± 0.45
-1.93 ± 0.44

–
0.77 ± 0.14
N.D.
−
1.22 ± 0.32
0.29 ± 0.09

72

Gapdh (TaqMan)
Dmp1
Dspp
Gapdh (SYBR Green)
Fgfr1c
Fgfr2c

18.70 ± 0.86
26.92 ± 0.90
39.06 ± 0.60
15.53 ± 0.12
17.57 ± 0.09
24.33 ± 0.28

–
8.21 ± 1.60
20.36 ± 0.18
−
1.61 ± 0.41
8.37 ± 0.18

–
4.68 ± 0.26
–
−
0.73 ± 0.20
-1.40 ± 0.31

–
35.87 ± 20.99
N.D.
−
1.69 ± 0.23
0.40 ± 0.09

96

FGF2 + 100 ng/ml noggin

Gapdh (TaqMan)
Dmp1
Dspp
Gapdh (SYBR Green)
Fgfr1c
Fgfr2c

18.71 ± 0.69
24.20 ± 0.21
38.17 ± 0.96
15.74 ± 0.16
17.87 ± 0.06
24.62 ± 0.43

–
5.49 ± 0.87
19.46 ± 0.45
−
2.27 ± 0.48
9.01 ± 0.29

–
7.41 ± 0.08
–
−
0.08 ± 0.13
-2.04 ± 0.47

–
170.26 ± 9.62
N.D.
−
1.06 ± 0.10
0.27 ± 0.07

Hours after
treatment

Gene

CT

ΔCT

-ΔΔCT

Fold change

48

Gapdh (TaqMan)
Dmp1
Dspp
Gapdh (SYBR Green)
Fgfr1c
Fgfr2c

18.65 ± 0.76
32.79 ± 0.97
38.29 ± 0.86
15.88 ± 0.06
17.90 ± 0.24
24.16 ± 0.26

–
14.15 ± 1.38
19.64 ± 0.16
−
1.85 ± 0.51
8.11 ± 0.59

–
-1.25 ± 0.78
–
−
0.49 ± 0.25
-1.14 ± 0.25

–
0.56 ± 0.30
N.D.
−
1.45 ± 0.26
0.47 ± 0.09

72

Gapdh (TaqMan)
Dmp1
Dspp
Gapdh (SYBR Green)
Fgfr1c
Fgfr2c

18.78 ± 0.99
27.15 ± 0.98
39.16 ± 0.84
15.96 ± 0.12
18.41 ± 0.43
23.79 ± 0.25

–
8.37 ± 1.83
20.38 ± 0.18
−
2.23 ± 0.53
7.60 ± 0.19

–
4.53 ± 1.00
–
−
0.12 ± 0.44
-0.64 ± 0.38

–
36.82 ± 23.76
N.D.
−
1.18 ± 0.33
0.69 ± 0.16

96

FGF2 + 200 ng/ml noggin

Gapdh (TaqMan)
Dmp1
Dspp
Gapdh (SYBR Green)
Fgfr1c
Fgfr2c

18.77 ± 0.73
25.00 ± 0.70
39.62 ± 0.20
15.86 ± 0.10
17.78 ± 0.02
24.27 ± 0.26

–
6.24 ± 1.00
20.85 ± 0.91
−
2.11 ± 0.34
8.60 ± 0.14

–
6.66 ± 0.63
–
−
0.23 ± 0.15
-1.64 ± 0.40

–
118.77 ± 39.06
N.D.
−
1.19 ± 0.12
0.35 ± 0.10

FGF2 + 300 ng/ml noggin
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Hours after
treatment

Gene

CT

ΔCT

-ΔΔCT

Fold change

48

Gapdh (TaqMan)
Dmp1
Dspp
Gapdh (SYBR Green)
Fgfr1c
Fgfr2c

18.87 ± 0.86
33.96 ± 0.37
38.44 ± 0.96
16.25 ± 0.09
18.91 ± 0.73
23.64 ± 0.53

–
15.08 ± 0.52
19.56 ± 1.32
−
2.92 ± 0.29
7.65 ± 0.56

–
-2.18 ± 0.47
–
−
-0.57 ± 0.69
-0.68 ± 0.34

–
0.24 ± 0.07
N.D.
−
0.81 ± 0.28
0.66 ± 0.17

72

Gapdh (TaqMan)
Dmp1
Dspp
Gapdh (SYBR Green)
Fgfr1c
Fgfr2c

19.29 ± 0.67
27.91 ± 1.21
40.00 ± 0.00
16.13 ± 0.06
18.32 ± 0.27
23.10 ± 0.13

–
8.62 ± 1.81
20.71 ± 0.67
−
2.63 ± 0.46
7.41 ± 0.55

–
4.28 ± 1.11
–
−
-0.29 ± 0.27
-0.44 ± 0.06

–
36.02 ± 26.97
N.D.
−
0.85 ± 0.15
0.74 ± 0.03

96

Gapdh (TaqMan)
Dmp1
Dspp
Gapdh (SYBR Green)
Fgfr1c
Fgfr2c

18.45 ± 0.69
25.13 ± 1.05
39.01 ± 0.31
16.00 ± 0.04
17.77 ± 0.06
23.72 ± 0.49

–
6.68 ± 1.08
20.56 ± 0.69
−
2.00 ± 0.34
7.95 ± 0.86

–
6.22 ± 0.79
–
−
0.34 ± 0.20
-0.98 ± 0.52

–
94.39 ± 39.06
N.D.
−
1.30 ± 0.19
0.57 ± 0.19

Hours after
treatment

Treatment

Fold change
(Dmp1)

Fold change
(Dspp)

48

FGF2
FGF2 + 100 ng/ml noggin
FGF2 + 200 ng/ml noggin
FGF2 + 300 ng/ml noggin

1
0.48
0.35
0.15

1
N.D.
N.D.
N.D.

72

FGF2
FGF2 + 100 ng/ml noggin
FGF2 + 200 ng/ml noggin
FGF2 + 300 ng/ml noggin

1
0.42
0.43
0.42

1
N.D.
N.D.
N.D.

96

The extent of attenuation of FGF2-mediated increases in Dmp1 and Dspp by noggin.

FGF2
FGF2 + 100 ng/ml noggin
FGF2 + 200 ng/ml noggin
FGF2 + 300 ng/ml noggin

1
0.45
0.31
0.25

1
N.D.
N.D.
N.D.

ΔCT = CTgene - CTGapdh.
-ΔΔCT = -(ΔCTsample – ΔCTcontrol).
Positive –ΔΔCT value = increased gene expression relative to control.
Negative –ΔΔCT value = decreased gene expression relative to control.
All fold changes are relative to VH at 48 hrs, except Dspp, which is relative to FGF2-treated
cultures at 96 hrs.
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Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point. Fold changes represent FGF2 value divided by the control value for
each time point.
N.D. = not detected.
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Table 28. Effects of early exposure to FGF2 on expression of markers of mineralization and
dentinogenesis in FACS-sorted 2.3-GFP+ and 2.3-GFP– populations.

-ΔΔCT

Fold change

20.31 ± 0.64
32.50 ± 0.09
38.87 ± 0.23
16.56 ± 0.07

Gapdh
Dmp1
Dspp
Type I collagen

20.11 ± 0.27
23.62 ± 0.73
32.12 ± 0.70
15.09 ± 0.31

Gapdh
Dmp1
Dspp
Type I collagen

20.80 ± 0.26
22.38 ± 0.31
30.19 ± 0.23
13.88 ± 0.41

−

−

−

1.58 ± 0.50
9.39 ± 0.32
-6.92 ± 0.67

10.62 ± 0.24
2.62 ± 0.17
3.18 ± 0.47

1640.67 ± 283.38
6.26 ± 0.70
9.99 ± 3.01

-ΔΔCT

Fold change

7

Gapdh
Dmp1
Dspp
Type I collagen

10

ΔCT

14

Control (2.3-GFP+ population)
Day of
Gene
CT
the
culture

−

−

−

12.20 ± 0.62
18.57 ± 0.36
-3.75 ± 0.60

0

1

−

N.D.

0

1

−

−

−

3.51 ± 0.63
12.01 ± 0.41
-5.02 ± 0.34

8.68 ± 0.33
0
1.28 ± 0.86

444.23 ± 91.18
1
3.41 ± 1.90

21.76 ± 0.39
25.57 ± 0.15
32.30 ± 0.61
16.69 ± 0.14

−

−

−

7

Gapdh
Dmp1
Dspp
Type I collagen

3.80 ± 0.21
10.54 ± 0.19
-5.07 ± 0.38

8.40 ± 0.45
1.47 ± 0.44
1.32 ± 0.23

383.29 ± 98.58
3.15 ± 0.81
2.57 ± 0.42

21.21 ± 0.46
23.71 ± 0.30
29.13 ± 0.26
14.40 ± 0.34

−

−

−

10

Gapdh
Dmp1
Dspp
Type I collagen

2.50 ± 0.54
7.92 ± 0.42
-6.81 ± 0.71

9.70 ± 0.19
4.09 ± 0.02
3.07 ± 0.61

855.99 ± 115.62
17.07 ± 0.18
9.95 ± 3.96

Gapdh
Dmp1
Dspp
Type I collagen

22.68 ± 0.88
23.52 ± 0.22
28.87 ± 0.87
14.82 ± 0.60

−

−

−

14

FGF2-treated between d3-7 (2.3-GFP+ population)
Day of
Gene
CT
ΔCT
the
culture

0.84 ± 0.56
6.19 ± 0.29
-7.86 ± 0.50

11.36 ± 0.06
5.82 ± 0.13
4.11 ± 0.37

2627.31 ± 112.37
57.04 ± 5.10
18.52 ± 4.95

ΔCT

-ΔΔCT

Fold change

Control (2.3-GFP– population)
Day of
the
culture

Gene

CT
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7

Gapdh
Dmp1
Dspp
Type I collagen

20.54 ± 0.09
33.88 ± 0.54
37.70 ± 0.76
17.70 ± 0.31

−
13.34 ± 0.48
17.15 ± 0.64
-2.84 ± 0.25

−
-1.14 ± 0.57
−
-0.90 ± 0.55

−
0.52 ± 0.16
N.D.
0.60 ± 0.07

10

Gapdh
Dmp1
Dspp
Type I collagen

22.35 ± 0.52
26.61 ± 0.33
35.79 ± 0.15
16.99 ± 0.07

−
4.26 ± 0.21
13.43 ± 0.53
-5.36 ± 0.59

−
7.93 ± 0.68
−
1.61 ± 0.81

−
295.65 ± 106.01
N.D.
4.08 ± 1.44

14

Gapdh
Dmp1
Dspp
Type I collagen

21.77 ± 0.54
25.24 ± 1.19
32.33 ± 0.77
16.59 ± 0.05

−
3.47 ± 0.75
10.57 ± 0.19
-5.17 ± 0.55

−
8.73 ± 0.49
1.44 ± 0.23
1.43 ± 0.89

−
472.27 ± 144.75
2.82 ± 0.55
3.69 ± 1.10

FGF2-treated between d3-7 (2.3-GFP– population)
CT

ΔCT

-ΔΔCT

Fold change

7

Gapdh
Dmp1
Dspp
Type I collagen

20.44 ± 0.07
28.48 ± 0.05
38.27 ± 0.39
17.49 ± 0.20

−
8.04 ± 0.03
17.83 ± 0.27
-2.95 ± 0.14

−
4.16 ± 0.76
−
-0.80 ± 0.57

−
22.91 ± 10.39
N.D.
0.67 ± 0.19

10

Gapdh
Dmp1
Dspp
Type I collagen

22.41 ± 0.19
25.32 ± 0.25
31.28 ± 0.37
16.64 ± 0.16

−
2.91 ± 0.40
8.87 ± 0.33
-5.77 ± 0.34

−
9.29 ± 0.55
3.14 ± 0.43
2.03 ± 0.49

−
732.22 ± 305.91
9.86 ± 2.81
4.62 ± 1.46

14

Day of
the
culture

Gene

Gapdh
Dmp1
Dspp
Type I collagen

21.77 ± 0.54
23.39 ± 0.63
32.33 ± 0.77
15.23 ± 0.20

−
1.70 ± 0.74
7.83 ± 0.37
-6.46 ± 0.26

−
10.50 ± 0.14
4.18 ± 0.30
2.72 ± 0.35

−
1459.06 ± 149.96
19.30 ± 4.89
6.96 ± 1.04

ΔCT = CTgene - CTGapdh
-ΔΔCT = -(ΔCTsample – ΔCTcontrol)
Positive –ΔΔCT value = increased gene expression relative to control.
Negative –ΔΔCt value = decreased gene expression relative to control.
Expression of Type I collagen and Dmp1 in both 2.3-GFP+ and 2.3-GFP– populations was
normalized to GFP+ VH at day 7. Expression of Dspp in both 2.3-GFP+ and 2.3-GFP–
populations was normalized to GFP+ VH at day 10.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point.
N.D. = not detected.
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Table 29. Expression of a select group of genes in control and FGF2-treated 2.3-GFP+
and 2.3-GFP– populations.
Unsorted (control)
Gene
Gapdh (SYBR Green)
Ambn
Bono1
Fgfr1c
Fgfr2c
Gapdh (TaqMan)
Dmp1
Dspp

CT
18.57 ± 0.46
29.42 ± 0.82
28.43 ± 0.64
20.57 ± 0.19
24.42 ± 0.05
21.03 ± 0.79
31.68 ± 0.32
37.41 ± 0.94

ΔCT
−
10.85 ± 0.51
9.76 ± 1.25
1.89 ± 0.48
5.74 ± 0.64
−
11.15 ± 1.03
16.89 ± 1.23

-ΔΔCT
−
0
0
0
0
−
0
−

Fold change
−
1
1
1
1
−
1
N.D.

ΔCT
−
9.86 ± 0.73
9.51 ± 1.30
1.34 ± 0.56
7.23 ± 0.42
−
10.17 ± 0.89
15.73 ± 0.90

-ΔΔCT
−
0.98 ± 0.66
0.25 ± 0.20
0.55 ± 0.08
-1.48 ± 0.27
−
0.98 ± 0.27
−

Fold change
−
2.56 ± 0.16
1.21 ± 0.17
1.47 ± 0.08
0.37 ± 0.06
−
2.05 ± 0.37
N.D.

ΔCT
−
9.86 ± 0.73
11.24 ± 0.69
3.93 ± 0.53
4.53 ± 0.85
−
12.39 ± 0.91
17.14 ± 1.18

-ΔΔCT
−
0.04 ± 0.22
-1.48 ± 0.57
-2.04 ± 0.54
1.21 ± 0.21
−
-1.24 ± 0.19
−

Fold change
−
1.01 ± 0.15
0.42 ± 0.18
0.28 ± 0.10
2.36 ± 0.32
−
0.43 ± 0.05
N.D.

-ΔΔCT
−
-2.13 ± 0.91
0.93 ± 0.26
0.62 ± 0.11
-2.03 ± 0.58
−
8.60 ± 0.36

Fold change
−
0.36 ± 0.16
1.98 ± 0.38
1.55 ± 0.12
0.28 ± 0.10
−
414.11 ± 110.84

2.3-GFP+ population (control)
Gene
Gapdh (SYBR Green)
Ambn
Bono1
Fgfr1c
Fgfr2c
Gapdh (TaqMan)
Dmp1
Dspp

CT
18.90 ± 0.52
28.77 ± 1.10
28.04 ± 0.82
20.36 ± 0.50
26.24 ± 0.30
21.34 ± 0.64
31.24 ± 0.25
37.12 ± 1.08

2.3-GFP– population (control)
Gene
Gapdh (SYBR Green)
Ambn
Bono1
Fgfr1c
Fgfr2c
Gapdh (TaqMan)
Dmp1
Dspp

CT
19.60 ± 0.42
30.48 ± 0.91
30.65 ± 0.21
22.86 ± 0.36
23.46 ± 0.55
22.30 ± 0.74
34.05 ± 0.35
38.58 ± 0.66

Unsorted (FGF2-treated between days 3-7)
Gene
Gapdh (SYBR Green)
Ambn
Bono1
Fgfr1c
Fgfr2c
Gapdh (TaqMan)
Dmp1

CT
18.72 ± 0.61
31.69 ± 1.46
27.04 ± 1.01
19.49 ± 0.10
25.99 ± 0.76
20.80 ± 0.49
23.02 ± 0.10

ΔCT
−
12.98 ± 1.07
8.82 ± 1.46
1.28 ± 0.42
7.77 ± 1.21
−
2.55 ± 0.72
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Dspp

29.52 ± 0.39

9.05 ± 0.98

0

1

-ΔΔCT
−
-1.30 ± 0.48
1.51 ± 0.44
1.48 ± 0.08
-2.03 ± 0.34
−
9.04 ± 0.70
2.64 ± 0.11

Fold change
−
0.47 ± 0.13
3.15 ± 1.04
2.79 ± 0.16
0.26 ± 0.06
−
652.64 ± 269.08
5.57 ± 0.66

2.3-GFP+ population (FGF2-treated between days 3-7)
Gene
Gapdh (SYBR Green)
Ambn
Bono1
Fgfr1c
Fgfr2c
Gapdh (TaqMan)
Dmp1
Dspp

CT
18.22 ± 0.11
30.36 ± 0.84
26.40 ± 0.72
18.57 ± 0.28
25.93 ± 0.29
21.47 ± 0.51
23.64 ± 0.66
28.15 ± 0.34

ΔCT
−
12.15 ± 0.76
8.25 ± 0.82
0.42 ± 0.40
7.78 ± 0.35
−
2.11 ± 0.43
7.32 ± 0.86

2.3-GFP– population (FGF2-treated between days 3-7)
Gene
Gapdh (SYBR Green)
Ambn
Bono1
Fgfr1c
Fgfr2c
Gapdh (TaqMan)
Dmp1
Dspp

CT
19.45 ± 0.40
32.29 ± 1.04
29.87 ± 0.79
22.84 ± 0.47
24.45 ± 1.26
22.34 ± 0.50
34.27 ± 0.31
33.42 ± 1.09

ΔCT
−
12.84 ± 1.13
10.42 ± 0.54
3.38 ± 0.16
4.99 ± 0.76
−
11.72 ± 0.53
9.77 ± 1.21

-ΔΔCT
−
-2.00 ± 0.78
-0.66 ± 0.98
-1.49 ± 0.58
0.75 ± 0.15
−
-0.57 ± 0.96
0.19 ± 0.23

Fold change
−
0.39 ± 0.20
0.96 ± 0.56
0.41 ± 0.14
1.70 ± 0.17
−
0.95 ± 0.41
0.79 ± 0.33

ΔCT = CTgene - CTGapdh.
-ΔΔCT = -(ΔCTsample – ΔCTcontrol).
Positive –ΔΔCT value = increased gene expression relative to control.
Negative –ΔΔCT value = decreased gene expression relative to control.
All fold changes are relative to the unsorted control sample, except Dspp, which is relative to
unsorted FGF2-treated sample.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point.
N.D. = not detected.
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CHAPTER VI

EFFECTS OF LATE EXPOSURE OF PRIMARY DENTAL PULP CULTURES TO FGF2
ON DENTINOGENESIS.

Abstract.

Odontoblast differentiation during physiological and reparative dentinogenesis depends
upon multiple signaling molecules, including Fibroblast Growth Factors (FGFs), which are
sequestrated in the dentin matrix and pulp-supportive tissues. Previous studies have
demonstrated that FGF2 exerted both positive and negative effects on odontoblast differentiation,
however the underlying cellular and molecular mechanisms of these conflicting results are still
unclear. Our recent studies suggested that the effects of FGF2 on pulp cells are dependent on the
stage of differentiation/maturity of cells in that FGF2 initially promoted the formation of
functional odontoblasts from progenitors. In the present study we have examined the underlying
mechanisms and the signaling pathways involved in the inhibitory effects of FGF2 on
dentinogenesis by exposure of pulp cells to FGF2 during the mineralization/differentiation phase
of in vitro growth. We showed that this treatment resulted first in increases in the expression of
Dmp1, Dspp and DMP1-GFP and DSPP-Cerulean transgenes, indicating the stimulatory effects
of FGF2 on the differentiation of functional odontoblasts. Further exposure of cells to FGF2
prevented their differentiation into mature odontoblasts. Our studies on the FACS-sorted
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populations showed that in the 2.3-GFP+ population, FGF2 first increased the expression of both
Dmp1 and Dspp followed by their decreases as compared to control. In contrast, in the 2.3-GFP–
population, which is enriched in undifferentiated cells, FGF2 increased expression of both Dmp1
and Dspp at days 10 and 14 as compared to control. Finally, our results suggest that inhibitory
effects of FGF2 on further differentiation of functional odontoblasts into mature odontoblasts
and the expression of Dmp1 and Dspp were mediated by re-activation of the FGFR/MEK/Erk1/2
signaling pathways and downregulation of the activity of the BMP/BMPR signaling pathway.
These findings provide valuable information for development of improved strategy for dentin
regeneration by FGF2.
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Introduction.

Dentinogenesis is regulated by odontoblasts, which are highly specialized cells
originating from the neural crest-derived cells of the dental papilla. The differentiation of
odontoblasts from the neural crest cells is a long process involving several intermediate steps that
are dependent on and regulated by epithelial signals (378, 450). During this process at the bell
stage of tooth development, dental papilla underneath the secondary enamel knots differentiates
into preodontoblasts. Further differentiation of preodontoblasts into secretory/functional
odontoblasts and finally fully differentiated/mature odontoblasts proceeds in a graded fashion
from cusp tips towards the intercuspal areas and cervical loops. In mice the steps between the
formation of preodontoblasts and mature odontoblasts are completed within 6–10 hrs (451).

Secretory/functional odontoblasts (also called young odontoblasts) are engaged in the
secretion of unmineralized predentin matrix, which is composed primarily of Type I collagen
(451). As these odontoblasts continue their differentiation, they secrete various NCPs, which are
essential for mineralization of collagen fibers and crystal growth (452). The NCPs in dentin
belong to the SIBLING (small integrin-binding ligand, N-linked glycoprotein) family that
includes osteopontin (OPN), bone sialoprotein (BSP), dentin matrix protein 1 (DMP1), dentin
sialophosphoprotein (DSPP) and matrix extracellular phosphoglycoprotein (MEPE) (452).
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Among SIBLING proteins, Dmp1 and Dspp are the most abundant and essential NCPs in
dentin (54, 83). The Dspp gene encodes a single large precursor protein DSPP, which in
mineralized tissues undergoes proteolytic cleavage forming two fragments: dentin sialoprotein
(DSP) and dentin phosphoprotein (DPP) (11, 54, 61). Cleavage of DSPP protein is a critical and
initial step in promoting mineralization (64). Furthermore, important roles of Dspp in
biomineralization have been demonstrated in gene knockout animal studies (68-70) and in
human diseases, where multiple mutations of Dspp have been linked to the dentinogenesis
imperfecta and dentin dysplasia, two most common hereditary disorders affecting dentin (30, 71,
72). High levels of expression of Dspp and DSP are the hallmark of odontoblast differentiation
and are routinely used to distinguish differentiated odontoblasts from undifferentiated
progenitors and osteoblasts.

Similarly, important roles of Dmp1 during mineralization have been demonstrated in
animal models. Mice with deletion of Dmp1 displayed decreased levels of Dspp in teeth and
tooth abnormalities that were similar to those in Dspp knockout mice (85, 99). In addition,
DMP1 has been shown to bind to the Dspp promoter region, suggesting its role in regulation of
Dspp (100). Dmp1 together with Dspp are first detected in secretory odontoblasts and then in
fully differentiated odontoblasts.

Thus, odontoblast differentiation involves changes in the morphology and transcriptional
profile of cells. Recent studies identified genes belonging to the p38 MAPK pathway to display
more significant changes during odontoblast differentiation (453-455). These genes were
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abundantly expressed in odontoblasts during primary dentinogenesis and active secretion of
dentin, while being significantly downregulated during secondary dentinogenesis deposited at a
much slower rate than primary (453-455).

The dentin-pulp complex has a regenerative potential leading to the formation of
reparative dentin. Reparative dentinogenesis involves the recruitment and proliferation of
progenitor/stem cells to the site of injury, and their differentiation into a second generation of
odontoblasts or “odontoblast-like” cells (11, 21). The differentiation of odontoblast-like cells
during reparative dentinogenesis depends on the availability of progenitor/stem cells, inductive
signals released from the dentin matrix and pulp-supportive tissues (106, 108, 110) and
reactivation of p38 MAPK pathway (453-455)

Fibroblast growth factors (FGFs) are a family of signaling molecules shown to play essential
roles in primary dentinogenesis, reparative dentinogenesis as well as development and repair of
cartilage and bone (151, 156, 277, 367, 368). Currently, FGF family contains 22 members, which
elicit their effects through interaction with four highly conserved transmembrane tyrosine kinase
receptors (FGFR1, FGFR2, FGFR3, and FGFR4) in concert with heparin or heparan sulfate
proteoglycans (184, 367). FGFRs contain an extracellular ligand-binding domain with three
immunoglobulin-like domains (IgI, II and III), a transmembrane domain and a split intracellular
tyrosine kinase domain (151, 184). Three major downstream pathways, which mediate effects of
FGF/FGFR signaling on bone and osteoblasts tissues, include MAPK, PI3K/Akt and PLCγ (151,
277).
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FGF also plays important roles in primary and reparative dentinogenesis. FGF2 exerts
mitogenic effects on dental pulp cells (126, 339, 341-343, 348) and stimulates homing and
migration of dental pulp cells, resulting in recellularization of dental pulp (125). FGF2 increases
the expression of markers of mesenchymal stem cells Oct4, Nanog and Rex1 (344, 348) and the
percentage of STRO-1+ cells in the dental pulp (342, 348). Studies using stem cells from
inflamed primary teeth (iSHFD) showed that FGF2 increased their proliferation and migration
potential (146).

Available literature also provides evidence for both positive and negative effects of FGF2
on dentinogenesis and mineralization. Several studies reported inhibitory effects of FGF2 on
dentinogenesis and the expression of Dspp (126, 146, 339-341, 345, 349). On the other hand,
others have shown stimulatory effects of FGF2 on the formation of osteodentin in vivo (137, 146,
338) and expression of Dspp in vitro (345).

The mechanisms underlying the positive and negative effects of FGF signaling on
dentinogenesis are not well understood and most likely involve multiple intra- and extracellular
mediators and differential responses of various cell populations (373).

Using a series of GFP reporter transgenic mice that display stage-specific activation of
transgenes during odontoblast differentiation, we recently reported that the effects of FGF2 on
pulp cells are dependent on the stage of differentiation/maturity of cells in that FGF2 initially
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promoted the formation of functional odontoblasts and prevented their further differentiation
(submitted manuscript).

We showed that continuous exposure of primary dental pulp cultures to FGF2 resulted in
decreased mineralization and biphasic effects on the expression of markers of mineralization and
dentinogenesis as well as expression of various transgenes. We also showed that despite these
inhibitory effects in long-term cultures, FGF2 promoted differentiation of pulp cells into
functional odontoblasts (submitted manuscript), and that these stimulatory effects were mediated
by interactions between the FGFR/MEK/Erk1/2 and BMP/BMPR signaling pathways.

The purpose of the study outlined in this chapter was to gain insight into underlying
mechanisms regulating the inhibitory effects of FGF2 on odontoblast differentiation in primary
dental pulp cultures.
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Results.

Effects of late exposure to FGF2 on mineralization and dentinogenesis in primary dental
pulp cultures.

Previous studies in our laboratory showed that when placed in primary cultures, pulp
cells from unerupted molars proliferated rapidly and reached confluence around day 7
(proliferation phase of in vitro growth). Following addition of the mineralization-inducing
medium at day 7, these cells underwent differentiation and gave rise to an extensive amount of
mineralized matrix (differentiation/mineralization phase of in vitro growth). The first sign of
mineralization appeared around day 10 with significant increases in the extent of mineralization
thereafter. At day 21 almost the entire culture dish was covered with a sheet of the mineralized
tissue (352).

Using this well-characterized dental pulp culture system, we examined the effects of
limited and late exposure to FGF2 on mineralization and dentinogenesis. In these experiments,
primary

pulp

cultures

were

exposed

to

VH

(control)

or

FGF2

during

only

differentiation/mineralization phase of in vitro growth.

XO and von Kossa staining showed that late exposure to FGF2 markedly decreased the
extent of mineralization as compared to control (Figure 39A-C and Table 30). These decreases
were evident as early as day 10 (Figure 39A-C and Table 30) and not related to marked
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differences in the cellularity of the cultures evidenced by the lack of detectable differences in the
intensity of crystal violet staining (Figure 39A).

Quantitative PCR analysis showed continuous increases in the expression of markers of
mineralization and dentinogenesis in the control cultures (Figure 40 and Table 31). On the other
hand, late exposure to FGF2 resulted in decreases in the levels of expression of all markers at
days 14 and 21 as compared to control (Figure 40 and Table 31). FGF2-treated cultures also
showed transient increases in the levels of expression of Dmp1 and Osteocalcin (~2-fold) as well
as Dspp (~3-fold) at day 10 as compared to control (Figure 40 and Table 31).

These observations showed that exposure of pulp cultures to FGF2 during the
differentiation/mineralization phase of in vitro growth resulted in transient increases in the levels
of expression of Dmp1, Osteocalcin and Dspp at day 10 followed by decreases in the expression
of these and other markers of mineralization at days 14 and 21 as compared to control. Despite
changes relative to control, levels of expression of all transcripts in FGF2-treated cultures
between days 10-21 remained relatively constant (Figure 40 and Table 31).

Effects of late exposure to FGF2 on expression of various transgenes in primary dental
pulp cultures.

To gain further insight into underlying mechanisms of FGF2-induced changes, we
examined the effects of late exposure to FGF2 on expression of various transgenes that display
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stage-specific activation during odontoblast differentiation in vivo and in vitro (90, 351, 375). In
these studies 3.6-GFP and 2.3-GFP transgenes were used as markers for cells at early stages of
odontoblast differentiation (polarizing odontoblasts that lack expression of Dmp1 and Dspp)
(351). The expression of DMP1-GFP (90) and DSPP-Cerulean (unpublished data) transgenes
were used as markers for cells at later stages of odontoblast differentiation (functional and fully
differentiated odontoblasts). Functional odontoblasts were also identified by high levels of
expression of Dmp1 and low levels of Dspp (90), and fully differentiated odontoblasts by high
levels of Dspp expression.

Epifluorescence analysis showed continuous increases in the intensity of expression of
3.6-GFP, 2.3-GFP, DMP1-GFP and DSPP-Cerulean transgenes and the percentage of DSPPCerulean+ odontoblasts between days 7-21 in the control cultures (Figures 41A-C and 42, and
Table 32). FGF2-treated cultures showed decreases in the intensity of expression of 3.6-GFP and
2.3-GFP transgenes at all time points as compared to control (Figure 41A-C and Table 32). At
day 21, the intensity of expression of 3.6-GFP and 2.3-GFP transgenes in FGF2-treated cultures
was approximately half of that in the respective control cultures (Figure 41A-C and Table 32).

Analysis of cultures from DMP1-GFP and DSPP-Cerulean transgenic mice showed
increases in the intensity of both transgenes (~3-fold) at day 10 followed by decreases at days 14
and 21 as compared to control (Figures 41A-C and 42, and Table 32). Immunocytochemical
analysis also showed ~2.5-fold increase in the percentage of DSPP-Cerulean+ odontoblasts at
day 10 followed by decreases at days 14 and 21 as compared to control (Table 33).
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The increases in the intensity of expression of DMP1-GFP at day 10 can be related to
increases in the number of DMP1-GFP+ cells and/or increases in the intensity of expression in a
similar number of DMP1-GFP+ cells. The lack of proliferation of DMP1-GFP+ cells shown in
our previous studies (90) indicated that increases in the intensity of DMP1-GFP transgene is due
to its activation in a new population (which did not express DMP1-GFP transgene before) and
not due to proliferation of the existing DMP1-GFP+ population. These observations indicated
that late exposure to FGF2 initially accelerated differentiation of pulp cells.

Relatively constant intensity of various transgenes and the percentage of DSPPCerulean+ odontoblasts in FGF2-treated cultures indicated that cells were maintained at a
specific stage of maturation. The decreases in the expression of all transgenes and percentage of
DSPP-Cerulean+ odontoblasts at later time points (days 14 and 21) in FGF2-treated cultures
relative to control indicated that additional exposure to FGF2 prevented further differentiation of
these cells.

Recovery of differentiation and expression of various GFP transgenes in FGF2-treated
cultures.

The lack of significant changes in the expression of various transcripts, intensity of
various transgenes and the percentage of DSPP-Cerulean+ odontoblasts in FGF2-treated cultures
between days 10-14 suggested that FGF2 maintained cells at a specific stage of maturation.
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To test this possibility, we examined the reversibility of the inhibitory effects of FGF2 on
differentiation of pulp cells. In these experiments dental pulp cells were exposed to FGF2
between days 7-14 and then grown in the control medium (without FGF2) for additional 7 days.
The effects of withdrawal of FGF2 on the extent of mineralization and dentinogenesis in these
cultures were examined and compared to those in the control cultures and cultures continuously
exposed to FGF2 between days 7-21.

XO and von Kossa staining demonstrated that withdrawal of FGF2 for 7 days allowed
almost complete (~90%) recovery of mineralization (Figure 43A and Table 34). The intensity of
XO staining and the extent of mineralization measured by von Kossa staining at day 21 in these
cultures were similar to those in the control cultures (Figure 43 and Table 34).

Analysis of pulp cultures from various transgenic mice showed that at day 21 the
intensity of expression of 3.6-GFP, 2.3-GFP, DMP1-GFP and DSPP-Cerulean transgenes
reached or exceeded that in the respective controls (Figures 43B-D and 44, and Table 35). The
percentages of DSPP-Cerulean+ odontoblasts in these cultures were also higher (~1.4-fold) than
in control cultures (Figure 44).

The levels of expression of Type I collagen, Bsp and Osteocalcin at day 21 following
withdrawal of FGF2 for 7 days were higher than those in cultures exposed to FGF2 between days
7-21, but did not reach their expression levels in the control cultures (Figure 45 and Table 36).
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On the other hand, the levels of Dmp1 and Dspp in these cultures were similar and slightly
higher (~1.4 fold), respectively, than those in the control cultures (Figure 45 and Table 36).

The rapid recovery of mineralization, expression of markers of mineralization and
dentinogenesis and various transgenes in the cultures following withdrawal of FGF2 indicated
that late exposure of pulp cells to FGF2 prevented their further differentiation. The increases in
the expression of Dspp and the number of DSPP-Cerulean+ odontoblasts in these cultures
suggested increased dentinogenesis.

The increases in the number of DSPP-Cerulean+ odontoblasts and increases in the
intensity of expression of DMP1-GFP and DSPP-Cerulean transgenes after withdrawal of FGF2
provided additional evidence that late exposure of pulp cells to FGF2 prevented their further
differentiation that upon withdrawal of FGF2 gave rise to fully differentiated odontoblasts.

Effects of late exposure to FGF2 on FACS-sorted 2.3-GFP+ and 2.3-GFP– populations.

To gain insight into specific cell populations responsive to the effects of FGF2, we
utilized FACS-mediated cell isolation and enrichment shown to be a powerful experimental tool
for lineage studies. Our previous observations on FACS-sorted populations showed that 2.3GFP+ population represented proliferative cells enriched in polarizing odontoblasts, whereas
DMP1-GFP+ population represented postmitotic functional odontoblasts (90, 351).
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Based on these observations, we examined the effects of FGF2 on 2.3-GFP+ and 2.3GFP– populations. In these experiments, primary pulp cultures from 2.3-GFP transgenic mice
were first grown in culture conditions supporting their proliferation and expansion in the absence
of FGF2. At day 7, FACS was used to separate relatively homogeneous populations of the 2.3GFP+ and 2.3-GFP– cells, and reanalysis demonstrated a high (≥ 98%) purity of isolated
populations (Figure 46). Both populations were replated at the same density as unsorted cells and
cultured in the absence or presence of FGF2 as described for unsorted cultures.

In cultures established from the 2.3-GFP+ population, GFP expression was detected
initially and was maintained throughout the entire culture period (Figure 47). The first sign of
mineralization appeared around day 10 with marked increases thereafter (Figure 47). In these
cultures low levels of Type I collagen, Bsp, Osteocalcin, Dmp1 and Phex were detected around
day 7, whereas expression of Dspp was detected around day 10. Expression of these markers of
mineralization and dentinogenesis increased with more advanced stages of differentiation (Figure
48 and Table 37).

Late exposure of the 2.3-GFP+ population to FGF2 resulted in marked decreases in the
extent of mineralization at days 10 and 14 (Figure 47). In these cultures FGF2 decreased
expression of Type I collagen, Bsp, Osteocalcin and Phex at days 10 and 14 as compared to
control (Figure 48 and Table 37). In contrast, FGF2 increased the levels of expression of Dmp1
and Dspp at day 10 followed by decreases in levels of their expression at day 14 as compared to
control (Figure 48 and Table 37). Similar to our observations in unsorted cultures, despite
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decreases relative to control, the levels of Dmp1 and Dspp in FGF2-treated cultures remained
relatively unchanged at days 10 and 14.

Thus, late exposure of the 2.3-GFP+ population to FGF2 resulted in accelerated
differentiation at day 10. Additional exposure of this population to FGF2 prevented further
differentiation of these cells.

Our analysis of cultures established from the 2.3-GFP– population showed that
expression of GFP was not detected initially, but appeared at day 7 in a few isolated cuboidal
cells and increased thereafter (Figure 47). In these cultures low levels of Type I collagen, Bsp,
Osteocalcin, Dmp1 and Phex were detected at day 7, and mineralization and expression of Dspp
were detected only at day 14 (Figures 47 and 48, and Table 37), indicating delayed
differentiation as compared to the 2.3-GFP+ population. In these cultures mineralization was not
over the entire culture dish and had a nodular pattern. The levels of expression of all markers of
mineralization and dentinogenesis and the extent of mineralization in these cultures were lower
than those in the cultures established from the 2.3-GFP+ population, indicating that the 2.3GFP– population contained less differentiated cells (Figures 47 and 48, and Table 37). These
observations are similar to those observed in unsorted cultures (Figure 40).

Late exposure of the 2.3-GFP– population to FGF2 prevented mineralization as shown by
the lack of XO staining at day 21 (Figure 47). Quantitative PCR analysis showed that FGF2
decreased expression of Type I collagen, Bsp, Osteocalcin and Phex as compared to control
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(Figure 48 and Table 37). However FGF2-treated cultures showed increases in the levels of
Dmp1 and Dspp at days 10 and 14 as compared to control (Figure 48 and Table 37). The
increases in the levels of Dmp1 and Dspp at day 14 in FGF2-treated 2.3-GFP– cultures are
different from decreases in their levels of expression as compared to control in the 2.3-GFP+
population. These differences are most likely related to differences in the stage of maturity of
cells in the two populations.

Involvement of FGFR/MEK/Erk1/2 signaling in the effects of FGF2 on primary dental
pulp cultures.

Next we examined the signaling pathways involved in mediating the effects of late
exposure of pulp cells to FGF2 on their differentiation and expression of Dmp1 and Dspp.
Several studies indicated that interactions between FGFR and MEK/Erk1/2 pathways are
involved in mediating the effects of FGF2 on proliferation, differentiation and expression of
markers of mineralization in osteoblasts (243, 244, 390, 391). Our previous studies demonstrated
that FGFR/MEK/Erk1/2 signaling was essential for mediating the stimulatory effects of FGF2 on
dental pulp cells during the proliferation phase of in vitro growth (submitted manuscript).
Therefore we examined the role of the FGFR/MEK/Erk1/2 signaling in mediating the effects of
FGF2 during the differentiation/mineralization phase of in vitro growth.

In these experiments, the roles of FGFR in FGF2-induced changes in mineralization and
the expression of Dmp1 and Dspp in primary pulp cultures were examined by using SU5402, a
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potent inhibitor of the tyrosine kinase activity of FGF receptors (360, 361). The roles of
MEK/Erk1/2 signaling were examined by using U0126, a highly selective inhibitor of kinase
activity of both MEK1 and MEK2 (362, 363). Primary pulp cultures were treated with inhibitors
(SU5402 and U0126) in the absence or presence of FGF2 between days 7-14.

XO and von Kossa staining showed that inhibition of FGFR signaling reversed the FGF2induced decreases in mineralization in a concentration-dependent manner (Figure 49 and Table
38). In addition, inhibition of FGFR signaling almost completely reversed intensity of 2.3-GFP
transgene (Figure 50 and Table 39). Furthermore, 5 µM of SU5402 completely reversed
expression of Dmp1 and Dspp (Figure 51 and Table 40), the intensity of DSPP-Cerulean
transgene (Figure 52, and Table 41) and the percentage of DSPP-Cerulean+ cells (Figure 52).
The levels of Dmp1 in cultures treated with FGF2 and 5 µM of SU5402 reached those in control
cultures at days 10 and 14 (Figure 51 and Table 40). The levels of Dspp in these cultures reached
those in control at day 10 and were markedly higher than those in control at day 14. The
increases in the levels of Dspp in cultures treated with SU5402 alone or SU5402 in combination
with FGF2 at day 14 are suggestive of negative roles of FGFR signaling in the expression of
Dspp at late stages of odontoblast differentiation (Figure 51 and Table 40).

Control cultures exposed to various concentrations of U0126 alone displayed slight
increases in the extent of mineralization (Figure 53 and Table 42). On the other hand, control
cultures exposed to only 5 µM of U0126 alone displayed marked increases in the levels of Dmp1,
Dspp (Figure 54 and Table 43), the intensity of DSPP-Cerulean transgene (Table 44) and the
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percentage of DSPP-Cerulean+ odontoblasts (Figure 54) at day 14 but not at day 10. These
observations are suggestive of negative roles of MEK/Erk1/2 signaling on expression of Dmp1
and Dspp at late stages of odontoblast differentiation.

The levels of Dmp1 and Dspp (Figure 54 and Table 43), the intensity of DSPP-Cerulean
(Figure 55) and the percentage of DSPP-Cerulean+ odontoblasts (Figure 55 and Table 44) in
cultures treated with FGF2 and 5 µM of U0126 at day 10 reached those in control cultures and
significantly exceeded those in control cultures and cultures treated with U0126 alone at day 14.
Together, these observations indicated that the inhibitory effects of FGF2 on differentiation of
cells at late stages of odontoblast differentiation were mediated through the FGFR/MEK/Erk1/2
signaling.

Involvement of BMP/BMPR signaling in the effects of FGF2 on primary dental pulp
cultures.

Crosstalk between FGFR pathway and other signaling cascades, including BMP signaling,
controls the differentiation during normal bone development and contributes to craniosynostosis
(217, 218, 449, 456). Our previous study showed that the stimulatory effects of FGF2 on
odontoblast differentiation during the proliferation phase of in vitro growth were mediated
through interactions between the FGF/FGFR and BMP/BMPR signaling pathways (manuscript
in press).

253

Therefore, as the next step we examined the roles of BMP signaling in mediating the
effects of late exposure of pulp cells to FGF2 on their differentiation and expression of Dmp1
and Dspp. These effects were examined by using noggin, a specific inhibitor of BMP/BMPR
signaling (364-366). Primary pulp cultures were treated with noggin in the absence or presence
of FGF2 between days 7-14.

XO and von Kossa staining showed that inhibition of BMP/BMPR signaling in the
control cultures did not have marked effects on the extent of mineralization at days 10 and 14
(Figure 56 and Table 45). In addition, inhibition of BMP/BMPR signaling decreased expression
of Dmp1 and Dspp at both days 10 and 14 as compared to control (Figure 57 and Table 46).

Quantitative PCR analysis showed that 100 ng/ml of noggin reversed FGF2-induced
changes in the expression of Dmp1 and Dspp at day 10 but not at day 14 (Figure 57 and Table
46). Furthermore, noggin did not reverse FGF2-induced changes in the intensity of DSPPCerulean transgene and the percentage of DSPP-Cerulean+ odontoblasts at day 14 (Figure 58
and Table 47).

These observations indicated that the stimulatory effects of FGF2 on differentiation of
pulp cells during early stages of odontoblast differentiation include crosstalk with BMP/BMPR
signaling. However, the inhibitory effects of FGF2 on more mature odontoblasts (functional and
fully differentiated odontoblasts) do not include BMP/BMR signaling.
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Discussion.

We have recently used a series of GFP reporter transgenic mice that display stagespecific activation of transgenes during odontoblast differentiation to gain further insight into the
effects of FGF2 on dental pulp mineralization and dentinogenesis. These studies showed that
continuous

exposure

of

pulp

cells

to

FGF2

during

both

proliferation

and

differentiation/mineralization phases of in vitro growth resulted in marked decreases in the extent
of mineralization and biphasic effects on the expression of markers of mineralization and
dentinogenesis and expression of various transgenes (submitted manuscript). Our further analysis
showed that during the proliferation phase of in vitro growth, FGF2 caused continuous increases
in the expression of Dmp1, Dspp, and the number of DMP1-GFP+ and DSPP-Cerulean+ cells
(submitted manuscript).

However, these increases were transient and additional exposure of dental pulp to FGF2
during the differentiation/mineralization phase of in vitro growth resulted in decreases in the
expression of these markers, the extent of mineralization and expression of various transgenes.
These studies indicated that exposure of dental pulp cells to FGF2 initially increased/accelerated
differentiation of cells into functional odontoblasts. Our studies also suggested that FGF2
inhibited further differentiation of functional odontoblasts into mature odontoblasts.

The goal of the study outlined in this chapter was to gain further insight into the cellular
and molecular mechanisms underlying the inhibitory effects of FGF2 on mineralization and
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dentinogenesis. Our results showed that exposure of dental pulp cells to FGF2 during the
differentiation/mineralization phase of in vitro growth also first led to accelerated differentiation
of pulp cells into functional odontoblasts. Our resulted showed increases in the expression of
Dmp1, Dspp, the intensity of DMP1-GFP and DSPP-Cerulean transgenes, and the percentages of
DSPP-Cerulean+ odontoblasts in FGF2-treated cultures as compared to control at day 10 (i.e.,
three days after addition of FGF2).

However, unlike the transient increases in the levels of expression of all markers of
mineralization at day 7 following continuous exposure of dental pulp to FGF2, exposure during
the differentiation/mineralization phase of in vitro growth resulted in transient increases in the
expression of Dmp1, Dspp and Osteocalcin only. Furthermore, the fold increases in the levels of
Dmp1 following continuous exposure of dental pulp to FGF2 (~310-fold) are significantly higher
than fold increases (~2-fold) following exposure during the differentiation/mineralization phase
of in vitro growth. These differences indicate that the effects of FGF2 on pulp cells are
dependent on the stage of maturity and differentiation.

Our results showed that additional exposure of these cells to FGF2 prevented their
differentiation into mature odontoblasts, which is indicated by marked decreases in the extent of
mineralization and expression of markers of mineralization and dentinogenesis at days 14 and 21.
The inhibitory effects of FGF2 on mineralization and dentinogenesis are consistent with previous
observations on the effects of late exposure of pulp cells to FGF2 (126, 344, 457).
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In addition, our observations showed that decreases in the extent of mineralization and
expression of markers of mineralization and dentinogenesis in FGF2-treated cultures at days 14
and 21 were accompanied by decreases in the intensity of expression of 2.3-GFP, DMP1-GFP
and DSPP-Cerulean transgenes and the percentage of DSPP-Cerulean+ odontoblasts as
compared to control. However, despite these decreases relative to the respective controls, levels
of expression of various markers of mineralization and dentinogenesis, the intensity of
expression of various transgenes and the percentage of DSPP-Cerulean+ odontoblasts between
days 10-21 in FGF2-treated cultures remained relatively constant. These observations suggested
that additional exposure of functional odontoblasts in these cultures to FGF2 maintained these
cells at this stage of differentiation. The rapid and almost complete recovery of mineralization,
expression of markers of mineralization and dentinogenesis (except Osteocalcin) and the
expression of various transgenes 7 days after withdrawal of FGF2 indicated that FGF2 prevented
further maturation of functional odontoblasts into fully differentiated odontoblasts.

Our studies on the FACS-sorted populations showed that in the 2.3-GFP+ population,
which is enriched in cells at early stages of odontoblast differentiation (polarizing odontoblasts)
as compared to the 2.3-GFP– population, FGF2 first increased the expression of both Dmp1 and
Dspp followed by their decreases as compared to control. In contrast, in the 2.3-GFP– population,
which is enriched in progenitors, FGF2 increased expression of both Dmp1 and Dspp at days 10
and 14 as compared to control, indicating continuous differentiation of progenitors into
functional odontoblasts. The differences in the response of these two populations at day 14 are
related to differences in the state of differentiation of cells and suggest that additional exposure
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of the 2.3-GFP– population to FGF2 (beyond day 14) will prevent further differentiation of
functional odontoblasts in these cultures.

These results are consistent with our previous observations and indicate the stagespecificity of the effects of FGF2 on dental pulp cells. These observations together provide
evidence that FGF2 increases/accelerates differentiation of cells of the dentinogenic lineage into
functional odontoblasts, whereas it inhibits differentiation of functional odontoblasts into fully
differentiated/mature odontoblasts.

Signaling pathways involved in the stimulatory effects of FGF2 on differentiation of early
progenitors into functional odontoblasts.

In our studies, which examined the effects of FGF2 during the proliferation phase of in
vitro growth, we showed that the stimulatory effects of FGF2 on the expression of Dmp1 and
Dspp were mediated through FGFR/MEK/Erk1/2 pathways and indirectly through activation of
BMP/BMPR pathway (submitted manuscript).

Our present study confirms these observations and indicates that the stimulatory effects
of FGF2 on the expression of Dmp1, Dspp and DSPP-Cerulean+ odontoblasts during the
differentiation/mineralization

phase

of

in vitro

growth

are

also

mediated

through

FGFR/MEK/Erk1/2 and BMP/BMPR pathways. Inhibition of the FGFR, MEK/Erk1/2 and BMP
signaling restored FGF2-induced increases in the expression of Dmp1 and Dspp and the
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percentage of DSPP-Cerulean+ odontoblasts at day 14 in a concentration-dependent manner.
These observations are consistent with other reports indicating the roles of FGFR/MEK/Erk1/2
signaling in mediating the effects of FGF2 on dentinogenesis (433-437).

In addition, inhibition of the FGFR and MEK/Erk1/2 signaling pathways restored FGF2induced decreases in mineralization. Furthermore, pulp cultures exposed only to the inhibitors of
these pathways showed concentration-depended increases in the extent of mineralization,
indicating the negative roles of FGFR and MEK/Erk1/2 signaling on mineralization.

The negative roles of the FGFR and MEK/Erk1/2 signaling pathways on mineralization
in our studies are consistent with previous studies, which demonstrated that activation of these
signaling pathways during the mineralization/differentiation phase of in vitro growth resulted in
marked decreases in the extent of mineralized matrix, whereas inhibition of these signaling
pathways resulted in increases in the extent of mineralized matrix. (126, 240, 266, 344, 457-461).
Exposure of SHED cells to PD98059, an inhibitor of the MEK/Erk1/2 signaling pathway,
resulted in significant increases in the extent of mineralized matrix in vitro and after
transplantation of these cells in vivo (462). Exposure of SHED cells to both FGF2 and PD98059
during the differentiation/mineralization phase of in vitro growth completely recovered the
extent of mineralization as compared to control (457). In addition, PD98059 enhanced BMP9induced increases in the extent of mineralization in dental follicle cells (463), indicating the
involvement of MEK/Erk1/2 signaling in BMP-mediated increases in mineralization.
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Signaling pathways involved in the inhibitory effects of FGF2 on differentiation of
functional odontoblasts into fully differentiated odontoblasts.

Our results also reveal the negative roles of the FGFR and MEK/Erk1/2 signaling
pathways during advanced stages of odontoblast differentiation. Addition of SU5402 or U0126
alone resulted in marked increases in the basal levels of expression of Dmp1 and Dspp
transcripts and in the percentage of DSPP-Cerulean+ odontoblasts at day 14.

These observations suggest that in dental pulp cells, inhibition of differentiation of
functional odontoblasts into fully differentiated odontoblasts by FGF2 is related to re-activation
of FGFR/MEK/Erk1/2 signaling with negative roles in odontoblast differentiation.

The reduced levels of Dmp1 and Dspp, and decreases in the percentage of DSPPCerulean+ odontoblasts in cultures treated with noggin alone at day 14 as compared to control
are consistent with well established positive roles of the BMP/BMPR signaling pathway during
odontoblast differentiation. In vitro studies have shown the positive roles of the canonical
BMP/BMPR signaling in the expression of Dspp and odontoblast differentiation (398, 399).
Deletion of Bmp2 in early polarizing odontoblasts by using 3.6Col1a1-Cre resulted in
abnormalities in dentin and dramatic decreases in Dspp expression (396). Cre-mediated
inactivation of Smad4, a downstream target of BMP/BMPR signaling, in dental mesenchyme
resulted in impaired dentinogenesis and absence of Dspp expression (221).
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The additional decreases in the expression of Dmp1, Dspp and the percentage of DSPPCerulean+ odontoblasts in cultures treated with FGF2 and noggin at day 14 suggest that
inhibitory effects of FGF2 on differentiation may also involve reduced activity of this positive
signaling pathway.

The opposite roles of these signaling pathways on the expression of Dmp1 and Dspp
during the differentiation of pulp cells into functional odontoblasts and at more advanced stages
of odontoblast differentiation are similar to the contrasting expression of Runx2/Cbfa1, a
downstream target of these pathways (217, 218, 243, 464, 465), and Osterix (Osx), a downstream
effector of Runx2/Cbfa1 (466, 467). Previous studies showed that Runx2/Cbfa1 was expressed at
high levels during early stages of odontoblast differentiation (prior to functional odontoblasts)
and at very low levels during later stages of odontoblast differentiation (functional and fully
differentiated odontoblasts) (405, 468-471). On the other hand, Osx expression was high during
early and later stages of odontoblast differentiation (405). The Runx2/Cbfa1 null mice displayed
significant decreases in Dspp expression (472). Overexpression of Runx2/Cbfa1 in MD10-F2
mouse preodontoblast cell line induced increases in the expression of DSPP protein, whereas its
overexpression in odontoblast cell lines (MO6-G3 and MDPC-23) resulted in downregulation of
Dspp and DSPP protein (406). Overexpression of Osx in MO6-G3 cells increased Dspp
transcription (405).

Taken together, these observations suggest that stimulatory and inhibitory effects of
FGF2 on Dmp1 and Dspp during early and later stages of odontoblast differentiation are related
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to stage-specific changes in the expression of Runx2 and phospho-Runx2. This possibility is
supported by studies in the osteogenic cells. During bone formation, Runx2 protein is expressed
at high levels at early and intermediate stages of osteoblast differentiation and its expression
declines during terminal differentiation (473). Exposure of MC3T3-E1 osteoblast-like cells to
FGF2 stimulated levels of phospho-Runx2 in a concentration-dependent manner, and inhibition
of MEK/Erk1/2 signaling by U0126 markedly decreased the levels of phospho-Runx2 (474).

Although the roles of MEK/Erk1/2 signaling in expression of Dmp1 and Dspp are not
well studied, recent results have shown that components of the p38 MAPK pathway, were
expressed abundantly in odontoblasts during primary dentinogenesis and active secretion of
dentin, while being significantly downregulated in secondary dentinogenesis deposited at much
slower rate than primary dentinogenesis (453-455).

Comparison with bone.

Our observation on the effects of late exposure of dental pulp cells to FGF2 shares many
similarities with the reported effects of FGF2 on osteogenesis. Several studies have shown that
late exposure of cells of the osteoblast lineage to FGF2 markedly decreased their ability to
produce mineralized matrix and decreased expression of markers of mineralization (256, 265,
267-269). It has also been shown that the inhibitory effects of FGF2 on mineralization of
osteogenic cells were mediated by MEK/Erk1/2 signaling, as U0126 completely reversed FGF2mediated inhibition of mineralization in BMSC and MC3T3-E1 osteoblast-like cultures (266,
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458). BMSC cultures from Col3.6-HMWFgf2 transgenic mice, with overexpression of high
molecular weight FGF2, displayed significant decreases in the extent of mineralization and
expression of markers of mineralization. However, inhibition of MEK/Erk1/2 in these cultures
significantly increased the extent of mineralization and expression of markers of mineralization.
Interestingly, similar effects were also observed in the control (non-transgenic) cultures, which
did not overexpress Fgf2, suggesting that inhibitory effects of MEK/Erk1/2 did not require active
FGF/FGFR signaling (240).

These similarities suggest that our present study may reflect the effects of FGF2 on
osteogenic

lineage.

Our

results

showed

that

exposure

to

FGF2

during

the

differentiation/mineralization phase of in vitro growth resulted in increases in the Dmp1, Dspp
and Osteocalcin but not Bsp and Type 1 collagen. Further we demonstrated the lack of recovery
in the levels of expression of Osteocalcin, which is expressed by osteoblasts at later stages of
differentiation and osteocytes (475, 476), following withdrawal of FGF2 for 7 days. These
observations, together with slight increases in the intensity of DSPP-Cerulean transgene, the
percentage of DSPP-Cerulean+ odontoblasts and expression of Dspp in cultures following
withdrawal of FGF2 as compared to the respective controls, provide evidence for differences in
the response of osteogenic vs. dentinogenic cells in dental pulp to FGF2 and that FGF2 promoted
dentinogenic differentiation and inhibited the osteogenic differentiation in pulp cultures.
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Summary and conclusions.
In conclusion, our results demonstrated that exposure of dental pulp cells to FGF2 during
the differentiation/mineralization phase of in vitro growth resulted in biphasic effects on
odontoblast differentiation. Stimulatory effects were observed during early odontoblast
differentiation (days 7-10) and prior to formation of functional odontoblasts. In contrast,
inhibitory effects were observed during late stages of odontoblast differentiation (days 14-21)
and after formation of functional odontoblasts. Effects of late exposure of dental pulp cells to
FGF2 on odontoblast differentiation were mediated by FGFR and MEK/Erk1/2 signaling, but not
by BMP/BMPR signaling. The results presented in this chapter provide an explanation of the
conflicting results in the literature of FGFR signaling on dentinogenesis and odontoblast
differentiation. Thus, these results would be useful for development of improved strategy for
applications of FGF2 for dentin regeneration applications.
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Figures.

Figure 39. Effects of late exposure to FGF2 on the extent of mineralization in primary
dental pulp cultures. Primary dental pulp cultures derived from 5-7-day-old pups were treated
with VH orFGF2 between days 7-21 as described in the Materials and Methods.
A. Representative images of the same areas in cultures at various time points analyzed under
brightfield (upper row) and epifluorescent light using TRITC Red filter for detection of XO
staining (second top row). Scale bar is 200 µm.
Representative images of von Kossa (third top row) and crystal violet staining (bottom row) at
various time points.
B. The intensity of epifluorescence of XO staining at various time points.
C. Quantification of the area of von Kossa staining at various time points.
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Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point.
N.D. = not detected.
Late exposure to FGF2 markedly decreased the extent of mineralization as compared to control,
and did not affect cellularity of cultures.
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Figure 40. Effects of late exposure to FGF2 on expression of markers of mineralization and
dentinogenesis in primary dental pulp cultures. Cultures were treated with VH or FGF2
between days 7-21 followed by RNA isolation and qPCR as described in the Materials and
Methods. Expression of all genes, except Dspp, was normalized to VH at day 7, which is
arbitrarily set to 1 and indicated by the dashed line. Expression of Dspp was normalized to VH at
day 10, which is arbitrarily set to 1 and indicated by the dashed line.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point.
N.D. = not detected.
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Late exposure to FGF2 decreased expression of markers of mineralization and dentinogenesis at
days 14-21 as compared to control. These decreases were preceded by transient increases in
Dmp1 and Dspp at day 10.
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Figure 41. Effects of late exposure to FGF2 on expression of various GFP transgenes in
primary dental pulp cultures. Primary dental pulp cultures derived from 5-7-day-old 3.6-GFP,
2.3-GFP or DMP1-GFP transgenic mice were treated with VH or FGF2 between days 7-21 as
described in the Materials and Methods.
A. Representative images of the same areas in cultures at different time points analyzed under
brightfield (upper rows) and epifluorescent light using filter for GFPtpz for detection of 3.6-GFP
and DMP1-GFP (middle row), and filter for GFPemd for detection of 2.3-GFP (middle row).
Scale bar is 200 µm.
B. Representative scanned composite 5x images of a larger area of the wells which were taken
using respective filters as described in Panel A. Scanned area is 1.24 cm2 (31% of the total area
of the well). Scale bar is 2 mm.
C. The epifluorescence intensity of 3.6-GFP, 2.3-GFP and DMP1-GFP transgenes at various
time points.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point.
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Late exposure to FGF2 decreased intensity of expression of 3.6-GFP and 2.3-GFP transgenes at
all time points as compared to control. Intensity of expression of DMP1-GFP transgene was
decreased by FGF2 at days 14-21 but transiently increased at day 10 as compared to control.
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Figure 42. Effects of late exposure to FGF2 on the percentage of DSPP-Cerulean+
odontoblasts in primary dental pulp cultures. Cultures derived from DSPP-Cerulean
transgenic mice were treated with VH or FGF2 between days 7-21. Cells were processed for
immunocytochemical analysis using anti-GFP antibody at days 7, 10, 14 and 21. To visualize
nuclei, cells were stained with 1.0 µg/ml Hoechst 33342 dye prior to mounting.
Representative images of the same areas in cultures analyzed under brightfield (upper row),
epifluorescent light using GFPtpz filter (middle row) and overlaid Hoechst/GFP filters (lower
row). Primary BMSC cultures established from DSPP-Cerulean transgenic mice and processed
for immunocytochemistry without addition of anti-GFP antibody served as a negative control
(BMSC). Scale bar is 200 µm.
Late exposure to FGF2 increased the percentage of DSPP-Cerulean+ odontoblasts at day 10, and
then decreased it at days 14-21 as compared to control.
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Figure 43. Effects of withdrawal of FGF2 on the extent of mineralization and expression of
various GFP transgenes in primary dental pulp cultures. Cultures were established from 3.6GFP, 2.3-GFP and DMP1-GFP transgenic mice as described in the Materials and Methods.
Cultures were treated with VH or FGF2 between days 7-14. At day 14 FGF2 was withdrawn
from the culture and cells were grown under the control culture conditions (without FGF2) for
additional 7 days.
A. Images of the same areas in cultures at different time points analyzed under brightfield (upper
row) and epifluorescent light using TRITC Red filter for detection of XO staining (middle row).
Scale bar is 200 µm. The lower row represents scanned wells processed for von Kossa staining
assay.
B. Images of the same areas in cultures at different time points analyzed under brightfield (upper
row) and epifluorescent light using filter for GFPtpz for detection of 3.6-GFP (middle row).
Scale bar is 200 µm. Lower row is representative scanned composite 5x images of a larger area
of the well. Scanned area is 0.93 cm2 (23% of the total area of the well). Scale bar is 4 mm.
Graph represents the intensity of 3.6-GFP at various time points.
C. Images of the same areas in cultures at different time points analyzed under brightfield (upper
row) and epifluorescent light using filter for GFPemd for detection of 2.3-GFP (middle row).
Scale bar is 200 µm. Lower row is representative scanned composite 5x images of a larger area
of the well. Scanned area is 0.93 cm2 (23% of the total area of the well). Scale bar is 4 mm.
Graph represents the intensity of 2.3-GFP at various time points.
D. Images of the same areas in cultures at different time points analyzed under brightfield (upper
row) and epifluorescent light using filter for GFPtpz for detection of DMP1-GFP (middle row).
Scale bar is 200 µm. Lower row is representative scanned composite 5x images of a larger area
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of the well. Scanned area is 0.93 cm2 (23% of the total area of the well). Scale bar is 4 mm.
Graph represents the intensity of DMP1-GFP at various time points.
Results in all graphs represent mean ± SEM of at least three independent experiments; *p ≤ 0.05
relative to control of each time point.
Withdrawal of FGF2 almost completely recovered the extent of mineralization, and expression
of 3.6-GFP, 2.3-GFP and DMP1-GFP transgenes as compared to control.
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Figure 44. Effects of withdrawal of FGF2 on the percentage of DSPP-Cerulean+
odontoblasts in primary dental pulp cultures. Cultures were established from DSPP-Cerulean
transgenic mice and treated with VH or FGF2 between days 7-14. At day 14 FGF2 was
withdrawn from the culture and cells were grown under the control culture conditions (without
FGF2) for additional 7 days. Cultures were processed for immunocytochemical analysis using
anti-GFP antibody at days 14 and 21. To visualize nuclei, cells were stained with 1.0 µg/ml
Hoechst 33342 dye prior to mounting.
Representative images of the same areas in cultures analyzed under brightfield (upper row),
epifluorescent light using filters for GFPtpz detection (middle row) and overlaid images
(Hoechst/GFP) filters (lower row). Hoechst staining was visualized using filters for DAPI.
Primary dental pulp cultures without antibody served as a negative control. Scale bar is 200 µm.
Withdrawal of FGF2 increased the percentage of DSPP-Cerulean+ odontoblasts as compared to
control.
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Figure 45. Effects of withdrawal of FGF2 on expression of markers of mineralization and
dentinogenesis in primary dental pulp cultures. Cultures were established as described in
Figure 43. Expression of Type I collagen, Runx2, Bsp, Osteocalcin, Dmp1 and Dspp was
analyzed by qPCR analysis at days 14 and 21. Expression levels of all genes was normalized to
VH at day 14, which is arbitrarily set to 1 and is indicated by the dashed line
Results represent mean ± SEM of values from at least three independent experiments; *p ≤ 0.05
relative to control at each time point.
Withdrawal of FGF2 recovered expression of Type I collagen, Bsp, Runx2 and Dmp1 as
compared to control. Expression of Dspp was increased upon withdrawal of FGF2 as compared
to control, whereas expression of Osteocalcin remained significantly lower as compared to
control.
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Figure 46. Isolation of 2.3-GFP– and 2.3-GFP+ populations by FACS. Cultures were
established from 2.3-GFP transgenic mice and grown for 7 days in culture medium promoting
their proliferation. At day 7, cells were prepared for GFP-based FACS sorting. Cells were gated
based on FSC and SSC (P1), PI (P2) and GFP (P4 and 5). Reanalysis demonstrated a high (≥
98%) purity of isolated populations of 2.3-GFP– (Reanalysis P5) and 2.3-GFP+ cells (Reanalysis
P6).
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Figure 47. Effects of late exposure to FGF2 on the extent of mineralization of FACS-sorted
2.3-GFP+ and 2.3-GFP– populations. Cultures derived from 2.3-GFP transgenic mice were
grown for 7 days in culture medium promoting their proliferation. At day 7, cells were prepared
for GFP-based FACS sorting. Homogeneous populations of 2.3-GFP– and 2.3-GFP+ cells were
grown and treated with VH or FGF2 between days 7-14 as described for unsorted cultures.
Each panel represents images of the same areas in cultures at different time points analyzed
under brightfield (upper row) and epifluorescent light using filters for GFPemd and TRITC Red
for detection of GFP (middle row) and XO (lower row), respectively. Scale bar is 200 µm.
In both 2.3-GFP+ and 2.3-GFP– populations, late exposure to FGF2 decreased the extent of
mineralization as compared to respective controls.
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Figure 48. Effects of late exposure to FGF2 on expression of markers of mineralization and
dentinogenesis in FACS-sorted 2.3-GFP+ and 2.3-GFP– populations. Cultures were
established and treated with VH or FGF2 between days 7-14 as described in the Materials and
Methods. At days 7, 10 and 14 cells were harvested and processed for RNA isolation and qPCR
analysis. In both 2.3-GFP+ and 2.3-GFP– populations, expression of Type I collagen, Bsp,
Osteocalcin, Dmp1 and Phex was normalized to GFP+ VH at day 7, which is arbitrarily set to 1
and is indicated by the dashed line. Expression of Dspp in both 2.3-GFP+ and 2.3-GFP–
populations was normalized to GFP+ VH at day 10, which is arbitrarily set to 1 and is indicated
by the dashed line.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point.
N.D. = not detected.
In 2.3-GFP+ population, expression of Type I collagen, Bsp, Osteocalcin and Phex decreased in
FGF2-treated cultures at days 10 and 14 as compared to control. Expression of Dmp1 and Dspp
was higher in FGF2-treated cultures at day 10, and was lower at day 14 as compared to control.
In 2.3-GFP– population, expression of Type I collagen, Bsp, Osteocalcin and Phex decreased in
FGF2-treated cultures at days 10 and 14 as compared to control. Expression of Dmp1 and Dspp
was significantly increased by FGF2 at both days 10 and 14 as compared to control.
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Figure 49. Effects of inhibition of FGFR signaling by SU5402 on the extent of
mineralization in primary dent al pulp cultures. Primary dental pulp cultures were established

282

and grown as described in the Materials and Methods. Cells were treated with VH orFGF2
between days 7-14 in the absence or presence of SU5402 (5, 10 and 20 µM).
A. Representative images of the same areas in cultures analyzed under brightfield (upper
row) and epifluorescent light using TRITC Red filter for detection of XO staining
(second row) at days 10 and 14. Scale bar is 200 µm. The third row shows representative
cultures stained with von Kossa for each time point. The lower row shows representative
cultures stained with crystal violet for each time point.
B. Histogram showing the changes in the intensity of epifluorescence of XO staining (in
absolute values) at days 10 and 14. Results are expressed in absolute values and represent
mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to control at
each time point.
In the absence of FGF2, SU5402 had no marked effects on the extent of mineralization as
compared to control. In the presence of FGF2, SU5402 increased FGF2-induced decreases in the
extent of mineralization in a concentration-dependent manner as compared to control.
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Figure 50. Effects of SU5402 on the intensity of 2.3-GFP transgene in the control
and FGF2-treated primary dental pulp cultures. Primary dental pulp cultures were
established from 2.3-GFP transgenic mice and grown as described in Figure 49.
A. Representative images of the same areas in cultures at different time points analyzed
under brightfield (upper row), epifluorescent light using TRITC Red filter for detection
of XO staining (second row) and GFPemd for detection of 2.3-GFP (lower row). Scale
bar is 200 µm.
B. Quantification of epifluorescence intensity of 2.3-GFP transgene at different time
points.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05
relative to control at each time point.
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In the absence of FGF2, SU5402 had no marked effects on the intensity of 2.3-GFP
transgene as compared to control. In the presence of FGF2, SU5402 almost completely
recovered FGF2-induced decreases in the intensity of 2.3-GFP transgene as compared to
control.
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Figure 51. Effects of SU5402 on expression of Dmp1 and Dspp in the control and
FGF2-treated primary dental pulp cultures. Primary dental pulp cultures were
established as described in the Materials and Methods. Cells were treated with 5 µM
SU5402 in the absence or presence of FGF2 between days 7-14, and processed for
qPCR analysis for Dmp1 and Dspp at days 10 and 14. Expression of Dmp1 and Dspp
was normalized to VH at day 10, which is arbitrarily set to 1 and is indicated by the
dashed line
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05
relative to control at each time point.
In the absence or presence of FGF2, SU5402 decreased expression of Dmp1 and Dspp at
day 10 as compared to control. In contrast, SU5402 increased expression of Dmp1 and
Dspp at day 14 as compared to control.
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Figure 52. Effects of SU5402 on the percentage of DSPP-Cerulean+ odontoblasts in the control and FGF2-treated
primary dental pulp cultures. Cultures were established from 5-7-day-old DSPP-Cerulean transgenic mice and grown as
described in Figure 49. Cultures were processed for immunocytochemistry at day 14 as described in the Materials and
Methods. Percentage of DSPP-Cerulean+ odontoblasts was calculated as a ratio between Cerulean+ cells and the total number
of Hoechst+ cells. Dental pulp cultures established from DSPP-Cerulean transgenic mice and processed for
immunocytochemistry without addition of antibody served as a negative control (Dental pulp, without Ab).
Representative images of the same area taken under brightfield (BF, upper row), epifluorescent light using filters for GFPtpz
(GFP, middle row) and overlaid Hoechst/GFP (DAPI/GFP, lower row) filters. Scale bar is 200 µm.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to control at each time point.
In the absence or presence or FGF2, SU5402 increased the percentage of DSPP-Cerulean+ odontoblasts in a concentrationdependent manner at day 14 as compared to control.
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Figure 53. Effects of inhibition of MEK/Erk1/2 signaling by U0126 on the extent of
mineralization in primary dental pulp cultures. Primary dental pulp cultures were
established and grown as described in the Materials and Methods. Cells were treated
with VH or FGF2 between days 7-14 in the absence or presence of U0126 (5, 10 and 20
µM).
A. Representative images of the same areas in cultures analyzed under brightfield
(upper row) and epifluorescent light using TRITC Red filter for detection of XO
staining (second row) at days 10 and 14. Scale bar is 200 µm. The third row
shows representative cultures stained with von Kossa for each time point. The
lower row shows representative crystal violet staining.
B. Histogram showing the changes in the intensity of epifluorescence of XO
staining (in absolute values) at days 10 and 14. Results are expressed in absolute
values and represent mean ± SEM of at least three independent experiments; *p
≤ 0.05 relative to control at each time point.
In the absence of FGF2, U0126 has slight stimulatory effects on the extent of
mineralization as compared to control. In the presence of FGF2, U0126 increased FGF2induced decreases in the extent of mineralization in a concentration-dependent manner
as compared to control.
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Figure 54. Effects of U0126 on expression of Dmp1 and Dspp in the control and
FGF2-treated primary dental pulp cultures. Primary dental pulp cultures were
established as described in the Materials and Methods. Cells were treated with 5 µM
U0126 in the absence or presence of FGF2 between days 7-14, and processed for qPCR
analysis for Dmp1 and Dspp at days 10 and 14. Expression of Dmp1 and Dspp was
normalized to VH at day 10, which is arbitrarily set to 1 and is indicated by the dashed
line
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05
relative to control at each time point.
In the absence of presence of FGF2, U0126 decreased expression of Dmp1 and Dspp at
day 10 as compared to control. At day 14, U0126 markedly increased expression of
Dmp1 and Dspp as compared to control.
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Figure 55. Effects of U0126 on the percentage of DSPP-Cerulean+ odontoblasts in the control and FGF2-treated primary
dental pulp cultures. Cultures derived from 5-7-day-old DSPP-Cerulean transgenic mice were treated with VH or FGF2 between
days 7-14. MEK/Erk1/2 signaling was inhibited by addition of various concentrations of U0126. Cultures were processed for
immunocytochemistry at day 14 as described in the Materials and Methods. Percentage of DSPP-Cerulean+ odontoblasts was
calculated as a ratio between Cerulean+ cells and the total number of Hoechst+ cells. Dental pulp cultures established from DSPPCerulean transgenic mice and processed for immunocytochemistry without addition of antibody served as a negative control (Dental
pulp, without Ab).
Representative images of the same area taken under brightfield (BF, upper row), epifluorescent light using filters for GFPtpz (GFP,
middle row) and overlaid Hoechst/GFP (DAPI/GFP, lower row) filters. Scale bar is 200 µm.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to control at each time point.
In the absence or presence of FGF2, U0126 increased the percentage of DSPP-Cerulean+ odontoblasts in a concentration-dependent
manner at day 14 as compared to control.
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Figure 56. Effects of inhibition of BMP/BMPR signaling by noggin on the extent of
mineralization in primary dental pulp cultures. Primary dental pulp cultures were
established and grown as described in the Materials and Methods. Cells were treated
with VH (control) or 20 ng/ml FGF2 between days 7-14 in the absence or presence of
noggin (100, 200 and 300 ng/ml).
A. Representative images of the same areas in cultures analyzed under brightfield
(upper row) and epifluorescent light using TRITC Red filter for detection of XO
staining (second row) at days 10 and 14. Scale bar is 200 µm. The third row
shows representative cultures stained with von Kossa for each time point. The
lower row shows representative cultures stained with crystal violet for each time
point.
B. Histogram showing the changes in the intensity of epifluorescence of XO
staining (in absolute values) at days 10 and 14. Results are expressed in absolute
values and represent mean ± SEM of at least three independent experiments; *p
≤ 0.05 relative to control at each time point.
In the absence of presence of FGF2, noggin did not have effects on the extent of
mineralization as compared to control.
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Figure 57. Effects of noggin on expression of Dmp1 and Dspp in the control and
FGF2-treated primary dental pulp cultures. Primary dental pulp cultures were
established as described in the Materials and Methods. Cells were treated with 100
ng/ml noggin in the absence or presence of FGF2 between days 7-14, and processed for
qPCR analysis for Dmp1 and Dspp at days 10 and 14. Expression of Dmp1 and Dspp
was normalized to VH at day 10, which is arbitrarily set to 1 and is indicated by the
dashed line
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05
relative to control at each time point.
In the absence of presence of FGF2, noggin decreased expression of Dmp1 and Dspp at
both days 10 and 14 as compared to control.
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Figure 58. Effects of noggin on the percentage of DSPP-Cerulean+ odontoblasts in the control and FGF2-treated primary
dental pulp cultures. Cultures derived from 5-7-day-old DSPP-Cerulean transgenic mice were treated with VH or FGF2 between
days 7-14. BMP/BMPR signaling was inhibited by addition of various concentrations of noggin. Cultures were processed for
immunocytochemistry at day 14 as described in the Materials and Methods. Percentage of DSPP-Cerulean+ odontoblasts was
calculated as a ratio between Cerulean+ cells and the total number of Hoechst+ cells. Dental pulp cultures established from DSPPCerulean transgenic mice and processed for immunocytochemistry without addition of antibody served as a negative control (Dental
pulp, without Ab).
Representative images of the same area taken under brightfield (BF, upper row), epifluorescent light using filters for GFPtpz (GFP,
middle row) and overlaid Hoechst/GFP (DAPI/GFP, lower row) filters. Scale bar is 200 µm.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to control at each time point.
In the absence or presence of FGF2, noggin had no significant effects on the percentage of DSPP-Cerulean+ odontoblasts at day 14 as
compared to control.
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Tables.
Table 30. Effects of late exposure to FGF2 on the extent of mineralization in
primary dental pulp cultures.

von Kossa
(mm2)

Xylenol Orange
(at 570 nm)

Assay

Day of the
culture

Control

FGF2

Fold change

7

N.D.

N.D.

−

10

221.2 ± 7.5

15.7 ± 15.7*

~14.1

14

323.3 ± 33.7

61.3 ± 18.7*

~5.3

21

761.1 ± 50.7

188.0 ± 3.8*

~4.1

7

N.D.

N.D.

−

10

62.5 ± 3.9

7.9 ± 6.0*

~7.9

14

207.8 ± 11.8

23.9 ± 8.0*

~8.7

21

334.1 ± 5.1

66.0 ± 6.4*

~5.1

Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05
relative to control at each time point.
N.D. = not detected.
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Table 31. Effects of late exposure to FGF2 on expression of markers of
mineralization and dentinogenesis in primary dental pulp cultures.

Gene

CT

ΔCT

-ΔΔCT

Fold change

7

Gapdh
Bsp
Dmp1
Dspp
Osteocalcin
Runx2
Type I collagen

19.68 ± 0.39
26.14 ± 0.63
31.06 ± 0.28
37.03 ± 0.91
22.69 ± 0.59
27.90 ± 0.48
16.04 ± 0.28

−
5.80 ± 0.54
11.25 ± 0.44
17.21 ± 0.80
2.32 ± 0.59
7.85 ± 0.17
-4.10 ± 0.16

−
0
0
−
0
0
0

−
1
1
N.D.
1
1
1

10

Gapdh
Bsp
Dmp1
Dspp
Osteocalcin
Runx2
Type I collagen

19.90 ± 0.50
20.34 ± 0.45
22.72 ± 0.32
31.26 ± 0.59
20.41 ± 0.88
26.86 ± 0.34
14.64 ± 0.36

−
-0.36 ± 0.42
2.71 ± 0.64
11.13 ± 0.78
-0.45 ± 0.74
6.45 ± 0.34
5.91 ± 0.33

−
4.43 ± 2.08
8.48 ± 0.44
0
2.77 ± 0.41
0.86 ± 0.42
1.35 ± 0.64

−
127.72 ± 52.69
495.13 ± 161.12
1
8.38 ± 2.52
2.83 ± 0.47
4.06 ± 1.04

14

Gapdh
Bsp
Dmp1
Dspp
Osteocalcin
Runx2
Type I collagen

20.91 ± 0.37
18.17 ± 0.96
21.94 ± 0.57
29.18 ± 0.49
18.24 ± 0.48
26.79 ± 0.29
13.49 ± 0.28

−
-3.11 ± 0.86
0.92 ± 0.40
8.43 ± 0.44
-2.87 ± 0.32
5.96 ± 0.31
-7.46 ± 0.24

−
5.84 ± 3.22
9.84 ± 0.18
2.22 ± 0.49
5.19 ± 0.48
0.26 ± 0.63
2.25 ± 1.16

−
1015.83 ± 315.26
952.42 ± 118.60
6.12 ± 2.27
51.08 ± 22.30
3.86 ± 0.49
11.54 ± 2.82

21

Control
Day of
the
culture

Gapdh
Bsp
Dmp1
Dspp
Osteocalcin
Runx2
Type I collagen

21.47 ± 0.10
16.39 ± 0.08
21.86 ± 0.32
25.81 ± 0.22
16.39 ± 0.30
28.25 ± 0.08
13.91 ± 0.13

−
-5.08 ± 0.03
0.39 ± 0.21
4.35 ± 0.19
-5.08 ± 0.26
6.78 ± 0.09
-7.55 ± 0.03

−
10.88 ± 0.03
10.85 ± 0.21
6.79 ± 0.19
7.40 ± 0.26
1.02 ± 0.09
3.46 ± 0.03

−
1884.13 ± 36.74
1891.53 ± 264.77
112.35 ± 15.18
174.48 ± 33.24
2.03 ± 0.12
10.99 ± 0.27

CT

ΔCT

-ΔΔCT

Fold change

19.68 ± 0.39
26.14 ± 0.63

−
5.80 ± 0.54

−
0

−
1

7

FGF2 (7-21)
Day of
the
Gene
culture
Gapdh
Bsp
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Dmp1
Dspp
Osteocalcin
Runx2
Type I collagen

31.06 ± 0.28
37.03 ± 0.91
22.69 ± 0.59
27.90 ± 0.48
16.04 ± 0.28

11.25 ± 0.44
17.21 ± 0.80
2.32 ± 0.59
7.85 ± 0.17
-4.10 ± 0.16

0
−
0
0
0

1
N.D.
1
1
1

10

Gapdh
Bsp
Dmp1
Dspp
Osteocalcin
Runx2
Type I collagen

20.68 ± 0.19
21.58 ± 0.39
22.09 ± 0.70
29.66 ± 0.43
20.25 ± 0.06
27.85 ± 0.30
16.10 ± 0.23

−
0.90 ± 0.44
1.42 ± 0.86
8.99 ± 0.63
-0.43 ± 0.25
7.18 ± 0.19
-4.57 ± 0.19

−
6.25 ± 0.72
9.79 ± 0.26
1.68 ± 0.30
2.93 ± 0.52
0.36 ± 0.03
0.70 ± 0.17

−
96.25 ± 43.76
914.00 ± 173.46
3.34 ± 0.64*
17.11 ± 5.08
1.28 ± 0.03
1.64 ± 0.19

14

Gapdh
Bsp
Dmp1
Dspp
Osteocalcin
Runx2
Type I collagen

20.68 ± 0.25
20.83 ± 0.12
22.21 ± 0.81
29.84 ± 0.56
19.53 ± 0.50
26.84 ± 0.20
15.64 ± 0.57

−
0.14 ± 0.37
1.53 ± 0.77
9.15 ± 0.31
-1.16 ± 0.25
6.16 ± 0.06
-5.04 ± 0.37

−
7.01 ± 0.44
9.68 ± 0.31
1.51 ± 0.25
4.66 ± 0.32
1.44 ± 0.11
1.17 ± 0.17

−
140.04 ± 34.91
859.11 ± 195.78*
2.94 ± 0.46
26.53 ± 5.60
2.74 ± 0.22
2.28 ± 0.28*

21

Gapdh
Bsp
Dmp1
Dspp
Osteocalcin
Runx2
Type I collagen

20.94 ± 0.14
19.72 ± 0.20
22.58 ± 0.16
29.24 ± 0.35
17.57 ± 0.33
28.63 ± 0.31
14.95 ± 0.29

-1.22 ± 0.34
1.64 ± 0.02
8.30 ± 0.29
-3.37 ± 0.45
7.69 ± 0.45
-6.00 ± 0.37

7.02 ± 0.34
9.61 ± 0.02
2.84 ± 0.29
5.69 ± 0.45
0.11 ± 0.45
1.90 ± 0.37

136.61 ± 30.13
780.16 ± 9.79
7.44 ± 0.62
57.22 ± 17.86
1.18 ± 0.31
3.96 ± 0.58

ΔCT = CTgene - CTGapdh.
-ΔΔCT = -(ΔCTsample – ΔCTcontrol).
Positive –ΔΔCT value = increased gene expression relative to control.
Negative –ΔΔCT value = decreased gene expression relative to control.
All fold changes are relative to control at day 7, except for Dspp, which is relative to
control at day 10.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05
relative to control at each time point.
N.D. = not detected.
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Table 32. Effects of late exposure to FGF2 on the intensity of the expression of
various GFP transgenes in primary dental pulp cultures.

DMP1-GFP
(500 nm)

2.3-GFP
(483 nm)

3.6-GFP
(500 nm)

Transgene
(wavelength)

Day of the
culture

Control

FGF2

Fold
changes

7

5338.2 ± 210.7

5338.2 ± 210.7

1

10

15061.3 ± 1266.2

11596.7 ± 935.1

~1.3

14

33142.5 ± 847.8

20824.8 ± 1592.3*

~1.6

21

37521.3 ± 1199.2

21735.3 ± 719.5*

~1.7

7

2368.8 ± 293.3

2368.8 ± 293.3

1

10

14506.9 ± 2297.6

9678.7 ± 1430.4

~1.5

14

28731.6 ± 1466.3

15219.6 ± 848.9*

~1.9

21

36601.4 ± 1404.9

21529.8 ± 1350.0*

~1.7

7

69.0 ± 12.6

69.0 ± 12.6

1

10

9590.4 ± 614.3

13924.0 ± 1100.3*

~0.7

14

19207.8 ± 549.0

17465.7 ± 1199.3*

~0.7

21

28400.0 ± 1024.2*

23202.0 ± 537.1

~1.2

Results are expressed in absolute values and represent mean ± SEM of at least three
independent experiments; *p ≤ 0.05 relative to control at each time point.
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Table 33. Effects of late exposure to FGF2 on percentage of DSPP-Cerulean+
odontoblasts and epifluorescence intensity of DSPP-Cerulean transgene in primary
dental pulp cultures.

Epifluorescence
intensity of
DSPP-Cerulean

Percentage of
DSPP-Cerulean+
odontoblasts

Parameter

Day of the
culture

Control

FGF2

Fold change

7

0.11 ± 0.05

0.11 ± 0.05

1

10

2.26 ± 0.12

4.18 ± 0.09

~1.8

14

8.33 ± 0.17

7.43 ± 0.25*

~0.9

21

8.42 ± 0.19

6.87 ± 0.22*

~0.8

7

0

0

−

10

1.64 ± 0.47

3.72 ± 0.18*

~6.5

14

4.63 ± 0.31

3.64 ± 0.32

~1.3

21

27.05 ± 0.59

11.02 ± 0.54*

~2.5

Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05
relative to control at each time point. Fold changes represent FGF2 value divided by the
control value for each time point.
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Table 34. Effects of withdrawal of FGF2 on the extent of mineralization in primary
dental pulp cultures.

21

14

Day of
the
culture

Parameter
Xylenol Orange
(570 nm)
von Kossa
(mm2)
Xylenol Orange
(570 nm)
von Kossa
(mm2)

Control

FGF2
(7-21)

FGF2
(7-14)

323.3 ± 33.7

61.3 ± 18.7*

207.8 ± 11.8

23.9 ± 8.0*

761.1 ± 50.7
334.1 ± 5.1

Fold changes
FGF2
(7-21)

FGF2
(7-14)

61.3 ± 18.7*

~0.19

~0.19

23.9 ± 8.0*

~0.12

~0.12

188.0 ± 3.8*

671.0 ± 43.4

~0.25

~0.88

66.0 ± 6.4*

337.9 ± 14.2

~0.20

~1.01

Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05
relative to control of each time points.
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Table 35. Effects of withdrawal of FGF2 on the intensity of the expression of various
transgenes in primary dental pulp cultures.

Day 21

Day 14

Transgene
(wavelength)
3.6-GFP
(500 nm)
2.3-GFP
(483 nm)
DMP1-GFP
(500 nm)
DSPP-Cerulean
(500 nm)
3.6-GFP
(500 nm)
2.3-GFP
(483 nm)
DMP1-GFP
(500 nm)
DSPP-Cerulean
(500 nm)

Control

FGF2
(7-21)

FGF2
(7-14)

33142.5 ± 847.8

20824.8 ± 1592.3*

28731.6 ± 1466.3

Fold changes
FGF2
(7-21)

FGF2
(7-14)

20824.8 ± 1592.3*

~1.6

~0.63

15219.5 ± 848.9*

15219.5 ± 848.9*

~1.9

~0.53

19207.8 ± 549.0

27465.7 ± 1199.3*

27465.7 ± 1199.3*

~0.7

~1.43

4.63 ± 0.31

3.64 ± 0.32

3.64 ± 0.32

~1.3

~1.3

37521.3 ± 1199.2

21735.3 ± 719.5*

33612.7 ± 981.1

~1.72

~1.1

36601.4 ± 1404.9

21529.8 ± 1350.0*

29655.0 ± 1651.1*

~1.7

~1.2

28400.0 ± 1024.2

23202.0 ± 537.1*

32442.8 ± 1477.2*

~1.2

~0.88

27.05 ± 0.59

11.02 ± 0.54*

38.96 ± 1.23*

~2.5

~0.70

Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05
relative to control of each time point.
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Table 36. Effects of withdrawal of FGF2 on expression of markers of mineralization
and dentinogenesis in primary dental pulp cultures.

Gene

CT

ΔCT

-ΔΔCT

Fold change

14

Gapdh
Bsp
Dmp1
Dspp
Osteocalcin
Runx2
Type I collagen

21.22 ± 0.58
17.65 ± 0.73
22.53 ± 0.80
28.86 ± 0.52
18.92 ± 0.31
25.53 ± 0.43
13.58 ± 0.29

−
-3.56 ± 0.38
1.32 ± 0.80
7.64 ± 0.13
-2.30 ± 0.27
5.31 ± 0.20
-7.64 ± 0.32

−
0
0
0
0
0
0

−
1
1
1
1
1
1

21

Control
Day of
the
culture

Gapdh
Bsp
Dmp1
Dspp
Osteocalcin
Runx2
Type I collagen

21.47 ± 0.10
19.04 ± 0.10
21.76 ± 0.36
25.81 ± 0.22
16.39 ± 0.30
28.25 ± 0.08
13.91 ± 0.13

−
-2.43 ± 0.11
0.30 ± 0.26
4.35 ± 0.19
-5.08 ± 0.26
6.78 ± 0.09
-7.55 ± 0.03

−
0.09 ± 0.32
-1.14 ± 0.38
1.02 ± 0.80
3.29 ± 0.13
2.78 ± 0.27
-1.48 ± 0.20

−
0.49 ± 0.13
2.70 ± 1.36
9.86 ± 0.90
7.11 ± 1.25
0.37 ± 0.05
0.99 ± 0.22

CT

ΔCT

-ΔΔCT

Fold change

20.68 ± 0.25
20.83 ± 0.12
21.21 ± 0.81
29.84 ± 0.56
19.53 ± 0.50
26.84 ± 0.20
15.64 ± 0.57

−
0.14 ± 0.37
1.53 ± 0.77
9.15 ± 0.31
-1.15 ± 0.25
6.16 ± 0.06
-5.05 ± 0.37

−
-2.60 ± 0.53
0.21 ± 0.09
0.88 ± 0.41
1.52 ± 0.36
-1.14 ± 0.51
-0.84 ± 0.15

−
0.09 ± 0.02*
0.87 ± 0.05
0.37 ± 0.09
0.51 ± 0.15
0.56 ± 0.06
0.19 ± 0.05*

Gapdh
Bsp
Dmp1
Dspp
Osteocalcin
Runx2
Type I collagen

20.94 ± 0.14
19.72 ± 0.20
22.85 ± 1.28
29.24 ± 0.35
17.57 ± 0.33
28.63 ± 0.31
14.95 ± 0.29

−
-1.22 ± 0.34
1.91 ± 1.19
8.30 ± 0.29
-3.37 ± 0.45
7.69 ± 0.45
-6.00 ± 0.37

−
-2.34 ± 0.38
-0.59 ± 0.80
-0.66 ± 0.13
1.07 ± 0.27
-2.38 ± 0.20
-1.65 ± 0.32

−
0.21 ± 0.06
0.88 ± 0.44
0.64 ± 0.06*
2.17 ± 0.38*
0.20 ± 0.03
0.34 ± 0.08

CT

ΔCT

-ΔΔCT

Fold change

21

14

FGF2 (7-21)
Day of
Gene
the
culture
Gapdh
Bsp
Dmp1
Dspp
Osteocalcin
Runx2
Type I collagen

FGF2 (7-14)
Day of

Gene
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14

Gapdh
Bsp
Dmp1
Dspp
Osteocalcin
Runx2
Type I collagen

20.68 ± 0.25
20.83 ± 0.12
21.21 ± 0.81
29.84 ± 0.56
19.53 ± 0.50
26.84 ± 0.20
15.64 ± 0.57

−
0.14 ± 0.37
1.53 ± 0.77
9.15 ± 0.31
-1.15 ± 0.25
6.16 ± 0.06
-5.05 ± 0.37

−
-2.60 ± 0.53
0.21 ± 0.09
0.88 ± 0.41
1.52 ± 0.36
-1.14 ± 0.51
-0.84 ± 0.15

−
0.09 ± 0.02*
0.87 ± 0.05
0.37 ± 0.09
0.51 ± 0.15
0.56 ± 0.06
0.19 ± 0.05*

21

the
culture

Gapdh
Bsp
Dmp1
Dspp
Osteocalcin
Runx2
Type I collagen

21.22 ± 0.19
18.56 ± 0.12
21.08 ± 0.33
25.10 ± 0.45
17.26 ± 0.30
28.18 ± 0.27
14.09 ± 0.10

−
-2.66 ± 0.31
-0.15 ± 0.17
3.88 ± 0.50
-3.96 ± 0.43
6.95 ± 0.41
-7.14 ± 0.10

−
-0.90 ± 0.38
1.47 ± 0.80
3.76 ± 0.13
1.67 ± 0.27
-1.64 ± 0.20
-0.51 ± 0.32

−
0.58 ± 0.16
3.68 ± 1.85
13.65 ± 1.25
3.28 ± 0.58*
0.33 ± 0.05
0.74 ± 0.17

ΔCT = CTgene - CTGapdh.
-ΔΔCT = -(ΔCTsample – ΔCTcontrol).
Positive –ΔΔCT value = increased gene expression relative to control.
Negative –ΔΔCT value = decreased gene expression relative to control.
All fold changes are relative to control at day 14.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05
relative to control at each time point.
N.D. = not detected.
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Table 37. Effects of late exposure to FGF2 on expression of markers of
mineralization and dentinogenesis in FACS-sorted 2.3-GFP+ and 2.3-GFP–
populations.

-ΔΔCT

Fold change

20.66 ± 0.57
24.53 ± 0.07
33.57 ± 0.48
38.71 ± 0.71
23.14 ± 0.27
31.95 ± 0.06
16.63 ± 0.22

Gapdh
Bsp
Dmp1
Dspp
Osteocalcin
Phex
Type I collagen

21.73 ± 1.07
21.29 ± 0.05
27.78 ± 1.70
33.06 ± 0.82
19.93 ± 0.77
29.00 ± 0.07
14.94 ± 0.37

Gapdh
Bsp
Dmp1
Dspp
Osteocalcin
Phex
Type I collagen

21.07 ± 0.04
19.44 ± 0.26
21.62 ± 0.06
30.61 ± 1.90
18.07 ± 0.40
25.45 ± 0.01
14.33 ± 0.17

–

–

–

-1.63 ± 0.24
0.55 ± 0.10
9.54 ± 1.90
-3.00 ± 0.42
4.38 ± 0.04
-6.83 ± 0.21

5.50 ± 0.83
12.36 ± 0.20
1.78 ± 0.34
5.57 ± 0.08
6.91 ± 0.56
2.52 ± 0.85

58.45 ± 22.13
5371.77 ± 739.33
3.64 ± 0.86
44.72 ± 1.50
137.95 ± 46.15
7.49 ± 2.86

7

Gapdh
Bsp
Dmp1
Dspp
Osteocalcin
Phex
Type I collagen

10

ΔCT

14

Control (2.3-GFP+ population)
Day of
Gene
CT
the
culture

–

–

–

3.87 ± 0.62
12.91 ± 0.27
18.05 ± 0.20
2.48 ± 0.41
11.29 ± 0.54
-4.31 ± 0.64

0
0

1
1

–

N.D.

0

1

0

1

0

1

–

–

–

-0.45 ± 1.08
6.04 ± 1.14
11.33 ± 1.87
-1.80 ± 0.37
7.27 ± 1.11
-7.10 ± 0.55

4.32 ± 0.47
6.87 ± 1.01
0
4.52 ± 0.20
4.02 ± 0.63
2.79 ± 0.12

22.33 ± 7.90
195.43 ± 136.59
1
19.67 ± 1.65
19.68 ± 8.72
6.98 ± 0.60

10

7

FGF2-treated between days 7-14 (2.3-GFP+ population)
Day of
Gene
CT
ΔCT
-ΔΔCT
the
culture
Gapdh
Bsp
Dmp1
Dspp
Osteocalcin
Phex
Type I collagen

20.66 ± 0.57
24.53 ± 0.07
33.57 ± 0.48
38.71 ± 0.71
23.14 ± 0.27
31.95 ± 0.06
16.63 ± 0.22

Gapdh
Bsp
Dmp1
Dspp

20.52 ± 1.12
20.60 ± 0.09
22.80 ± 0.88
30.59 ± 0.70

Fold change

–

–

–

3.87 ± 0.62
12.91 ± 0.27
18.05 ± 0.20
2.48 ± 0.41
11.29 ± 0.54
-4.31 ± 0.64

0
0

1
1

–

N.D.

0

1

0

1

0

1

–

–

–

0.08 ± 1.08
2.28 ± 0.39
10.08 ± 1.74

3.79 ± 0.47
10.63 ± 0.12
1.25 ± 0.23

15.47 ± 5.50
1599.96 ± 125.14
2.44 ± 0.40
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14

Osteocalcin
Phex
Type I collagen

19.95 ± 0.61
31.35 ± 0.18
15.66 ± 0.09

-0.57 ± 0.63
10.83 ± 0.95
-5.92 ± 0.52

-3.05 ± 0.24
0.46 ± 0.44
1.62 ± 0.13

8.52 ± 1.31
1.52 ± 0.49
3.09 ± 0.26

Gapdh
Bsp
Dmp1
Dspp
Osteocalcin
Phex
Type I collagen

20.83 ± 0.04
21.36 ± 0.17
23.69 ± 0.10
30.90 ± 1.43
19.49 ± 0.27
27.00 ± 0.08
15.58 ± 0.17

–

–

–

0.54 ± 0.16
2.86 ± 0.11
10.07 ± 1.49
-1.34 ± 0.34
6.17 ± 0.18
-5.21 ± 0.07

3.33 ± 0.47
10.05 ± 0.21
1.25 ± 0.41
-3.83 ± 0.52
5.12 ± 0.45
0.91 ± 0.71

11.06 ± 2.89
1084.93 ± 166.85
2.57 ± 0.67
16.02 ± 5.31
38.20 ± 11.78
2.27 ± 0.78

ΔCT

-ΔΔCT

Fold change

14

10

7

Control (2.3-GFP– population)
Day of
Gene
CT
the
culture
Gapdh
Bsp
Dmp1
Dspp
Osteocalcin
Phex
Type I collagen

20.93 ± 0.42
30.34 ± 0.53
35.05 ± 0.19
39.50 ± 0.26
26.40 ± 0.67
34.65 ± 0.25
18.00 ± 0.20

Gapdh
Bsp
Dmp1
Dspp
Osteocalcin
Phex
Type I collagen

22.04 ± 0.92
28.33 ± 0.45
34.36 ± 0.60
39.73 ± 0.27
25.50 ± 0.82
34.62 ± 0.13
17.58 ± 0.67

Gapdh
Bsp
Dmp1
Dspp
Osteocalcin
Phex
Type I collagen

21.16 ± 0.05
25.81 ± 0.38
24.92 ± 0.35
32.41 ± 1.07
20.15 ± 0.26
34.74 ± 0.13
16.04 ± 0.05

–

–

–

4.64 ± 0.33
3.76 ± 0.31
11.25 ± 1.03
-1.01 ± 0.22
13.58 ± 0.18
-5.13 ± 0.08

-0.77 ± 0.47
9.16 ± 0.03
-1.17 ± 0.75
3.50 ± 0.35
-2.29 ± 0.69
0.82 ± 0.72

0.65 ± 0.21
571.12 ± 12.94
0.56 ± 0.25
11.91 ± 2.62
0.25 ± 0.09
2.15 ± 0.75

–

–

–

9.41 ± 0.96
14.11 ± 0.62
18.57 ± 0.55
5.47 ± 1.09
13.71 ± 0.67
-3.13 ± 0.27

-5.54 ± 0.36
-1.20 ± 0.4

0.02 ± 0.006
0.48 ± 0.15

−

N.D.

-2.98 ± 0.69
-2.42 ± 0.30
-1.17 ± 0.41

0.16 ± 0.08
0.19 ± 0.03
0.48 ± 0.12

–

–

–

6.29 ± 1.36
12.32 ± 1.03
17.69 ± 1.18
3.46 ± 1.73
12.58 ± 0.81
-4.46 ± 0.25

-2.42 ± 0.74
0.59 ± 0.77

0.25 ± 0.14
1.95 ± 0.92

−

N.D.

-0.98 ± 1.34
-1.29 ± 0.30
0.15 ± 0.39

1.22 ± 1.01
0.43 ± 0.09
1.19 ± 0.27

7

FGF2-treated between days 7-14 (2.3-GFP– population)
Day of
Gene
CT
ΔCT
-ΔΔCT
the
culture
Gapdh
Bsp
Dmp1
Dspp

20.93 ± 0.42
30.34 ± 0.53
35.05 ± 0.19
39.50 ± 0.26

Fold change

–

–

–

9.41 ± 0.96
14.11 ± 0.62
18.57 ± 0.55

-5.54 ± 0.36
-1.20 ± 0.4

0.02 ± 0.006
0.48 ± 0.15

−

N.D.
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Osteocalcin
Phex
Type I collagen

26.40 ± 0.67
34.65 ± 0.25
18.00 ± 0.20

5.47 ± 1.09
13.71 ± 0.67
-3.13 ± 0.27

-2.98 ± 0.69
-2.42 ± 0.30
-1.17 ± 0.41

0.16 ± 0.08
0.19 ± 0.03
0.48 ± 0.12

21.59 ± 0.59
27.98 ± 0.03
30.43 ± 0.10
34.62 ± 0.20
25.28 ± 0.22
35.74 ± 0.18
17.32 ± 0.42

–

–

–

10

Gapdh
Bsp
Dmp1
Dspp
Osteocalcin
Phex
Type I collagen

6.39 ± 0.61
8.84 ± 0.63
13.03 ± 0.54
3.69 ± 0.81
14.15 ± 0.50
-4.27 ± 0.18

-2.52 ± 0.04
4.07 ± 0.47
-2.95 ± 1.22
-1.21 ± 0.46
–
-0.04 ± 0.47

0.17 ± 0.005
18.74 ± 6.27
0.21 ± 0.10
0.48 ± 0.15
N.D.
1.07 ± 0.28

20.77 ± 0.11
27.58 ± 0.29
23.37 ± 0.23
29.85 ± 1.60
22.92 ± 0.57
36.01 ± 0.18
16.30 ± 0.20

–

–

–

14

Gapdh
Bsp
Dmp1
Dspp
Osteocalcin
Phex
Type I collagen

6.80 ± 0.38
2.60 ± 0.15
9.08 ± 1.70
2.15 ± 0.66
15.24 ± 0.29
-4.47 ± 0.10

-2.93 ± 0.24
10.31 ± 0.20
-1.00 ± 0.16
0.33 ± 0.26

0.13 ± 0.02
1294.50 ± 168.05
2.02 ± 0.23
1.30 ± 0.25

–

N.D.

0.17 ± 0.69

1.35 ± 0.48

ΔCT = CTgene - CTGapdh
-ΔΔCT = -(ΔCTsample – ΔCTcontrol)
Positive –ΔΔCT value = increased gene expression relative to control.
Negative –ΔΔCt value = decreased gene expression relative to control.
Expression of all genes, except Dspp, in both 2.3-GFP+ and 2.3-GFP– populations was
normalized to GFP+ VH at day 7. Expression of Dspp in both 2.3-GFP+ and 2.3-GFP–
populations was normalized to GFP+ VH at day 10.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05
relative to control at each time point.
N.D. = not detected.
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Day of
the
culture

Control

FGF2

10

258.0 ± 5.8

14

Table 38. Effects of SU5402 treatment on the intensity of Xylenol Orange staining in the control and FGF2-treated primary
dental pulp cultures.

452.0 ± 13.4

SU5402 (µM)

FGF2 + SU5402 (µM)

5

10

20

19.0 ± 5.8*

245.0 ± 7.15

256.0 ± 6.8

351.0 ± 4.1*

76.0 ± 2.3*

455.0 ± 32.6

469.0 ± 33.5

531.0 ± 36.6

5

10

20

72.0 ± 10.3*

182.0 ± 18.7*

250.0 ± 23.3

143.0 ± 12.9*

270.0 ± 21.6*

353.0 ± 22.9*

Effects of SU5402 in the absence or presence of FGF2 on Xylenol Orange intensity in the control primary dental pulp cultures.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to control at each time point.
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Day of
the
culture

Control

SU5402

FGF2

FGF2 + SU5402

10

13972.0 ± 1765.0

15227.0 ± 1219.6

7184.0 ± 788.1

10485.0 ± 1731.1

14

Table 39. Effects of SU5402 on the epifluorescence intensity of 2.3-GFP transgene
in the control and FGF2-treated primary dental pulp cultures.

29987.0 ± 2081.8

32331.0 ± 1873.0

15772.0 ± 1359.9*

24678.0 ± 1823.4

Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05
relative to control at each time point.
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Table 40. Effects of SU5402 on expression of Dmp1 and Dspp in the control and FGF2treated primary dental pulp cultures.
Control
CT

ΔCT

-ΔΔCT

Fold change

10

Gapdh
Dmp1
Dspp

19.46 ± 0.35
21.87 ± 0.48
31.92 ± 1.15

−
2.41 ± 0.45
12.47 ± 0.80

−
0
0

−
1
1

14

Gapdh
Dmp1
Dspp

20.39 ± 0.45
21.76 ± 0.10
29.64 ± 1.44

−
1.38 ± 0.81
9.25 ± 1.16

−
1.03 ± 0.42
3.21 ± 0.36

−
4.21 ± 0.33
5.31 ± 1.24

CT

ΔCT

-ΔΔCT

Fold change

10

Gapdh
Dmp1
Dspp

19.28 ± 0.25
22.37 ± 0.73
33.19 ± 0.69

−
3.09 ± 0.77
13.91 ± 0.67

−
-0.68 ± 0.34
-1.45 ± 1.25

−
0.77 ± 0.15
0.17 ± 0.04

14

Day of
the
culture

Gene

Gapdh
Dmp1
Dspp

20.27 ± 0.48
21.42 ± 0.40
29.45 ± 1.61

−
1.15 ± 0.36
9.18 ± 1.21

−
1.26 ± 0.80
3.29 ± 0.43

−
4.72 ± 0.46
8.62 ± 0.04

5 µM SU5402
Day of
the
culture

Gene

FGF2 (7-14)
CT

ΔCT

-ΔΔCT

Fold change

10

Gapdh
Dmp1
Dspp

19.44 ± 0.28
20.81 ± 0.55
29.25 ± 0.81

−
1.36 ± 0.30
9.81 ± 0.53

−
1.05 ± 0.32
2.65 ± 0.52

−
2.33 ± 0.34
3.10 ± 0.52

14

Day of
the
culture

Gene

Gapdh
Dmp1
Dspp

19.91 ± 0.32
21.83 ± 0.86
30.20 ± 1.58

−
1.92 ± 0.61
10.29 ± 1.27

−
0.49 ± 0.22
2.17 ± 0.68

−
2.12 ± 0.30
2.79 ± 0.61

CT

ΔCT

-ΔΔCT

Fold change

19.36 ± 0.29
21.91 ± 0.60

−
2.55 ± 0.62

−
-0.14 ± 0.24

−
0.98 ± 0.19

FGF2 + 5 µM SU5402

10

Day of
the
culture

Gene
Gapdh
Dmp1
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14

Dspp

31.11 ± 1.99

11.75 ± 1.99

0.72 ± 2.11

4.86 ± 2.59

Gapdh
Dmp1
Dspp

19.68 ± 0.35
20.58 ± 0.62
28.17 ± 1.29

−
0.89 ± 0.29
8.49 ± 1.06

−
1.52 ± 0.24
3.98 ± 0.29

−
0.24 ± 0.11
25.47 ± 1.51

ΔCT = CTgene - CTGapdh.
-ΔΔCT = -(ΔCTsample – ΔCTcontrol).
Positive –ΔΔCT value = increased gene expression relative to control.
Negative –ΔΔCT value = decreased gene expression relative to control.
All fold changes are relative to control at day 10.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point.
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Table 41. Effects of SU5402 on the epifluorescence intensity of DSPP-Cerulean transgene in the control and FGF2treated primary dental pulp cultures.
Control

FGF2

7.05 ± 0.40

7.53 ± 1.75

5

SU5402 (µM)
10

20

14.39 ± 2.73

42.54 ± 6.2*

48.03 ± 8.0*

FGF2 + SU5402 (µM)
5
10
20.55 ± 3.05

40.50 ± 7.6*

20

45.20 ± 6.5*

Effects of SU5402 treatment in the absence or presence of FGF2 on epifluorescence intensity of DSPP-Cerulean transgene in
primary dental pulp cultures.
Results represent the percentage of the ratio between epifluorescence intensity of DSPP-Cerulean and DAPI measured at 500
and 343 nm wavelength, respectively. Ratio of DSPP-Cerulean/DAPI in BMSC cultures served as a negative control, and it
was subtracted from DSPP-Cerulean/DAPI ratio in the dental pulp cultures.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to control at each time point.
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Day of
the
culture

Control

FGF2

10

202.0 ± 2.8

14

Table 42. Effects of U0126 on the intensity of Xylenol Orange staining in the control and FGF2-treated primary dental pulp
cultures.

376.0 ± 32.8

U0126 (µM)

FGF2 + U0126 (µM)

5

10

20

42.0 ± 6.0*

232.0 ± 18.8

251.0 ± 6.7

261.0 ± 13.8

74.0 ± 1.8*

422.0 ± 18.6

475.0 ± 20.0

510.0 ± 9.8*

5

10

20

90.0 ± 10.3*

154.0 ± 20.6

188.0 ± 28.9

219.0 ± 25.1

288.0 ± 14.9

308.0 ± 14.3

Effects of U0126 treatment in the absence or presence of FGF2 on Xylenol Orange intensity in primary dental pulp cultures.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to control at each time point.
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Table 43. Effects of U0126 on expression of Dmp1 and Dspp in the control and
FGF2-treated primary dental pulp cultures.
Control
CT

ΔCT

-ΔΔCT

Fold change

10

Gapdh
Dmp1
Dspp

20.27 ± 0.24
24.66 ± 0.82
32.06 ± 0.33

−
4.39 ± 0.78
11.79 ± 0.36

−
0
0

−
1
1

14

Gapdh
Dmp1
Dspp

21.26 ± 0.16
22.71 ± 0.75
29.14 ± 0.42

−
1.46 ± 0.76
7.88 ± 0.29

−
2.93 ± 0.22
3.91 ± 0.26

−
4.21 ± 1.72
5.31 ± 1.32

CT

ΔCT

-ΔΔCT

Fold change

10

Gapdh
Dmp1
Dspp

21.03 ± 0.44
25.42 ± 1.21
33.37 ± 0.43

−
4.39 ± 1.61
12.33 ± 0.37

−
-1.29 ± 0.8
-0.21 ± 0.7

−
0.73 ± 0.51
0.86 ± 0.37

14

Day of
the
culture

Gene

Gapdh
Dmp1
Dspp

22.14 ± 0.27
21.32 ± 0.24
28.22 ± 0.70

−
-0.83 ± 0.10
6.08 ± 0.45

−
3.92 ± 0.86
6.05 ± 0.82

−
8.36 ± 5.91
63.15 ± 29.6

5 µM U0126
Day of
the
culture

Gene

FGF2 (7-14)
CT

ΔCT

-ΔΔCT

Fold change

10

Gapdh
Dmp1
Dspp

20.12 ± 0.53
24.60 ± 1.08
31.13 ± 0.37

−
4.47 ± 0.94
11.00 ± 0.74

−
1.21 ± 0.37
0.45 ± 0.20

−
2.33 ± 0.95
3.10 ± 0.52

14

Gapdh
Dmp1
Dspp

21.22 ± 0.33
24.08 ± 0.90
30.52 ± 0.57

−
2.86 ± 1.19
9.30 ± 0.42

−
2.82 ± 0.70
2.16 ± 0.87

−
2.12 ± 0.87
2.79 ± 0.61

CT

ΔCT

-ΔΔCT

Fold change

10

Gapdh
Dmp1
Dspp

20.40 ± 0.42
25.11 ± 0.28
31.59 ± 0.72

−
4.71 ± 0.70
11.20 ± 1.14

−
0.96 ± 0.90
0.26 ± 0.58

−
0.91 ± 0.64
1.07 ± 0.37

1
4

Day of
the
culture

Gene

Gapdh

21.24 ± 0.05

−

−

−

FGF2 + 5 µM U0126
Day of
the
culture

Gene
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Dmp1
Dspp

22.86 ± 1.02
25.77 ± 0.99

1.62 ± 1.02
4.53 ± 0.99

4.06 ± 0.30
6.93 ± 1.29

10.34 ± 7.31
325.01 ± 116.20

ΔCT = CTgene - CTGapdh.
-ΔΔCT = -(ΔCTsample – ΔCTcontrol).
Positive –ΔΔCT value = increased gene expression relative to control.
Negative –ΔΔCT value = decreased gene expression relative to control.
All fold changes are relative to control at day 10.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05
relative to control at each time point.
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Table 44. Effects of U0126 on the epifluorescence intensity of DSPP-Cerulean transgene in the control and FGF2-treated
primary dental pulp cultures.
Control

FGF2

6.54 ± 0.98

5.37 ± 0.73

5

U0126 (µM)
10

20

26.47 ± 2.5*

28.68 ± 3.5*

32.49 ± 2.5*

5

FGF2 + U0126 (µM)
10

34.50 ± 2.04*

45.19 ± 1.29*

20

47.99 ± 1.83*

Effects of U0126 in the absence or presence of FGF2 on epifluorescence intensity of DSPP-Cerulean transgene in primary dental pulp
cultures.
Results represent the percentage of the ratio between epifluorescence intensity of DSPP-Cerulean and DAPI measured at 500 and 343
nm wavelength, respectively. Ratio of DSPP-Cerulean/DAPI in BMSC cultures served as a negative control, and it was subtracted
from DSPP-Cerulean/DAPI ratio in the dental pulp cultures.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to control at each time point.
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Day of
the
culture

Control

FGF2

10

234.0 ± 7.9

14

Table 45 Effects of noggin on the intensity of Xylenol Orange staining in the control and FGF2-treated primary dental pulp
cultures.

448.0 ± 14.1

Noggin (ng/ml)

FGF2 + noggin (ng/ml)

100

200

300

25.0 ± 5.3*

223.0 ± 10.6

234.0 ± 14.0

225.0 ± 10.4

55.0 ± 9.3*

474.0 ± 15.4

502.0 ± 19.8

464.0 ± 13.9

100

200

300

19.0 ± 1.2*

30.0 ± 0.3*

25.0 ± 6.4*

72.0 ± 11.3*

74.0 ± 6.5*

65.0 ± 7.9*

Effects of noggin in the absence or presence of FGF2 on Xylenol Orange intensity in primary dental pulp cultures.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to control at each time point.

317

Table 46. Effects of noggin on expression of Dmp1 and Dspp in the control and
FGF2-treated primary dental pulp cultures.
Control
CT

ΔCT

-ΔΔCT

Fold change

10

Gapdh
Dmp1
Dspp

19.86 ± 0.16
24.69 ± 0.50
28.50 ± 1.59

−
4.83 ± 0.43
8.64 ± 1.73

−
0
0

−
1
1

14

Gapdh
Dmp1
Dspp

19.66 ± 0.01
22.43 ± 0.67
27.15 ± 1.63

−
2.78 ± 0.66
7.49 ± 1.68

−
2.05 ± 0.27
1.15 ± 0.08

−
4.21 ± 0.33
5.31 ± 1.32

CT

ΔCT

-ΔΔCT

Fold change

10

Gapdh
Dmp1
Dspp

19.92 ± 0.16
25.47 ± 0.46
29.63 ± 1.92

−
5.55 ± 0.35
9.71 ± 2.07

−
-0.72 ± 0.11
-1.07 ± 0.45

−
0.56 ± 0.004
0.52 ± 0.13

14

Day of the
culture

Gene

Gapdh
Dmp1
Dspp

19.67 ± 0.44
22.48 ± 1.13
27.38 ± 1.66

−
2.82 ± 1.07
7.71 ± 1.46

−
2.01 ± 0.67
0.93 ± 0.50

−
2.28 ± 0.27
1.53 ± 0.18

100 ng/ml noggin
Day of the
culture

Gene

FGF2 (7-14)
CT

ΔCT

-ΔΔCT

Fold change

10

Gapdh
Dmp1
Dspp

20.49 ± 0.16
24.37 ± 0.33
27.60 ± 1.70

−
3.88 ± 0.40
7.11 ± 1.79

−
0.95 ± 0.17
1.53 ± 0.09

−
2.33 ± 0.34
3.10 ± 0.52

14

Gapdh
Dmp1
Dspp

19.67 ± 0.18
23.11 ± 0.66
27.46 ± 1.67

−
3.44 ± 0.61
7.79 ± 1.62

−
1.39 ± 0.24
1.16 ± 0.17

−
2.12 ± 0.30
2.79 ± 0.61

CT

ΔCT

-ΔΔCT

Fold change

10

Gapdh
Dmp1
Dspp

19.92 ± 0.21
24.79 ± 0.37
27.99 ± 1.57

−
4.86 ± 0.24
8.06 ± 1.79

−
-0.03 ± 0.24
0.58 ± 0.31

−
0.84 ± 0.05
1.56 ± 0.31

14

Day of
the
culture

Gene

Gapdh
Dmp1
Dspp

19.43 ± 0.16
22.03 ± 1.14
27.28 ± 1.82

−
2.60 ± 1.10
7.85 ± 1.90

−
2.23 ± 0.68
0.79 ± 0.48

−
1.30 ± 0.07
1.01 ± 0.17

FGF2 + 100 ng/ml noggin
Day of
the
culture

Gene
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ΔCT = CTgene - CTGapdh.
-ΔΔCT = -(ΔCTsample – ΔCTcontrol).
Positive –ΔΔCT value = increased gene expression relative to control.
Negative –ΔΔCT value = decreased gene expression relative to control.
All fold changes are relative to control at day 10.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05
relative to control at each time point.
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Table 47. Effects of noggin on the epifluorescence intensity of DSPP-Cerulean transgene in the control and FGF2-treated
primary dental pulp cultures.
Control

FGF2

4.63 ± 0.31

3.64 ± 0.32

100

Noggin (ng/ml)
200

300

3.65 ± 0.69

3.15 ± 0.47

4.27 ± 0.80

FGF2 + noggin (ng/ml)
100
200
300
3.29 ± 1.21

4.26 ± 0.87

4.16 ± 0.98

Effects of noggin treatment in the absence or absence of 20 ng/ml FGF2 on epifluorescence intensity of DSPP-Cerulean transgene in
the control primary dental pulp cultures at day 14.
Results represent the percentage of the ratio between epifluorescence intensity of DSPP-Cerulean and DAPI measured at 500 and 343
nm wavelength, respectively. Ratio of DSPP-Cerulean/DAPI in BMSC cultures served as a negative control, and it was subtracted
from DSPP-Cerulean/DAPI ratio in the dental pulp cultures.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to the control at each time point.
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CHAPTER VII

BIPHASIC EFFECTS OF FGF2 ON ODONTOBLAST DIFFERENTIATION INVOLVE
CHANGES IN THE BMP AND WNT SIGNALING PATHWAYS.

Abstract.

Odontoblast differentiation during physiological and reparative dentinogenesis is
dependent upon multiple signaling molecules, including Fibroblast Growth Factors (FGFs), Bone
Morphogenetic Proteins (BMPs) and Wingless/Integrated (Wnt) ligands. Results reported in
Chapter IV of this dissertation demonstrated that continuous exposure of primary dental pulp
cultures to FGF2 exerted biphasic effects on the expression of markers of mineralization and
dentinogenesis. In the present chapter we examined the possible involvement of the BMP and
Wnt signaling pathways in mediating the effects of FGF2 on dental pulp cells. Our results
showed that stimulatory effects of FGF2 on dentinogenesis during the proliferation phase of in
vitro growth were associated with increased expression of the components of BMP (Bmp2, Dlx5,
Msx2, Osx) and Wnt (Wnt10a, Wisp2) pathways, and decreased expression of an inhibitor of Wnt
signaling, Nkd2. Further addition of FGF2 during the differentiation/mineralization phase of in
vitro growth resulted in decreased expression of components of BMP signaling (Bmp2, Runx2,
Osx) and increased expression of inhibitors of Wnt signaling (Nkd2, Dkk3). This suggests that
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both BMP and Wnt pathways may be involved in mediating the effects of FGF2 on dental pulp
cells.
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Introduction.

Fibroblast growth factors (FGFs) are a family of growth factors shown to play an
essential role in development, repair and regeneration of damaged skeletal tissues, including
cartilage, bone and tooth (151). The FGF family contains 22 members, which elicit their effects
through interaction with four highly conserved transmembrane tyrosine kinase receptors
(FGFR1-4) in concert with heparin or heparan sulfate proteoglycans (151). Among FGFs, FGF2
is widely expressed in the cells of the odontoblast lineage (118), suggesting a role in odontoblast
proliferation and differentiation.

Our recent studies have demonstrated that continuous exposure of primary dental pulp
cultures to FGF2 during both proliferation and differentiation/mineralization phases of in vitro
growth (days 3-14) decreased mineralization and expression of markers of mineralization and
dentinogenesis at days 10 and 14. However, these inhibitory effects were preceded by transient
stimulatory effects of FGF2 on expression of Dmp1 and Dspp at day 7, suggesting that FGF2
exerted biphasic effects on odontoblast differentiation in vitro.

In the present chapter we examined changes in the expression of components of the Bone
Morphogenetic Protein (BMP) and Wingless/Integrated (Wnt) signaling pathways, known
regulators of odontoblast differentiation, in response to FGF2 during proliferation and
differentiation/mineralization phases of in vitro growth.
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Results.

In control dental pulp cultures, mineralization and expression of markers of
mineralization and dentinogenesis increased after induction of mineralization at days 10 and 14
(data not shown). Our results demonstrated that control cultures also displayed increases in the
expression levels of Bmp2, Runx2 and Osx at days 10 and 14 (Figure 59A and Table 48). These
results suggest that BMP signaling could act as a positive regulator of early and intermediate
odontoblast differentiation. This is in agreement with multiple studies demonstrating the positive
role of BMP signaling on dentinogenesis in vivo and in vitro (396-399, 477, 478).

We next examined changes in the expression of selected components of BMP signaling
in response to FGF2. FGF2-treated cultures showed marked increases in the expression of Bmp2
and more modest increases in the expression of Runx2 and Osx at day 7 as compared to control.
Further exposure to FGF2 resulted in decreases in the expression of these transcripts at days 10
and 14 as compared to control (Figure 59A and Table 48).

To the best of our knowledge, effects of FGF2 on expression of these genes in the cells of
the odontoblast lineage have not been described. However, negative effects of FGF2 on Bmp2
(266), Runx2 (240) and Osx (240) have been reported in studies using differentiating cells of the
osteoblast lineage. These observations, together with the decreased expression of markers of
mineralization and dentinogenesis, suggest that BMP signaling could be involved in mediating
inhibitory effects of FGF2 on dentinogenesis during the differentiation/mineralization phase of in
vitro growth.
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To gain further insight into the possible roles of BMP/BMPR signaling in mediating
effects of FGF2 on odontoblast differentiation, we examined FGF2-induced changes in the
expression of components of BMP/BMPR pathway during the proliferation phase of in vitro
growth. Previous studies have demonstrated that within the odontoblast lineage, Fgf2 (115, 118)
and Bmp2 (122) were expressed at all stages of differentiation, including undifferentiated dental
pulp cells. This suggests that the FGF and BMP signaling pathways could cooperatively regulate
early commitment and differentiation of odontoprogenitor cells towards more mature
odontoblasts.

Examination of gene expression during the first 7 days showed that FGF2 markedly (~36-fold) and rapidly (within ~12 hrs after exposure) increased the levels of Bmp2 but not Bmp4.
Expression of Dlx5, Msx2 and Osx was increased around 48-96 hrs after exposure to FGF2.
There were no significant differences in the levels of Runx2 in the control vs. FGF2-treated
cultures (Figure 59B and Table 49).

Next we examined effects of FGF2 on expression of components of Wnt signaling.
Mineralization and dentinogenesis in the control cultures were associated with relatively constant
levels of expression of Wnt10a ligand (Figure 60A and Table 50). However, expression of Nkd2,
an inhibitor of Wnt signaling (479), and Dkk3 was significantly increased at more advanced
stages of culture differentiation (Figure 60A and Table 50). Exposure these cultures to FGF2
increased expression of Wnt10a and Dkk3 at day 7 as compared to control, but decreased
expression of Nkd2 (Figure 60A and Table 50). Further exposure to FGF2 resulted in increased
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expression of Wnt10a and decreased expression of Nkd2 and Dkk3 at days 10 and 14 as
compared to control (Figure 60A and Table 50). Although the role of Dkk3 in regulation of Wnt
signaling remains controversial (480), in our studies the pattern of its expression during the
differentiation/mineralization phase of in vitro growth was similar to that of Nkd2, suggesting
that Dkk3 may function as an inhibitor of Wnt signaling.

These results suggest that Wnt signaling could act as a negative regulator of odontoblast
differentiation. This is in agreement with multiple studies demonstrating the negative role of Wnt
signaling on intermediate and terminal odontoblast differentiation in vivo and in vitro (481-483).

Further analysis during the first 7 days (Figure 60B and Table 51) showed that FGF2
increased expression of Wnt10a and Wisp2, another component of Wnt signaling, at 48-96 hrs as
compared to control. Expression of Dkk3 also exhibited an increase at 48-96 hrs after treatment
that was not statistically significant (p ≥ 0.05). Expression of Nkd2 was decreased in FGF2treated cultures at 12-96 hrs as compared to control (Figure 60B and Table 51).
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Discussion.

Results outlined in Chapter IV of this dissertation demonstrated that continuous exposure
of dental pulp cells to FGF2 resulted in biphasic effects on odontoblast differentiation, including
stimulatory effects during the proliferation phase of in vitro growth, and inhibitory effects during
the differentiation/mineralization phase of in vitro growth. In the present chapter we examined
the possible involvement of the BMP and Wnt signaling pathways in FGF2-induced changes in
dentinogenic differentiation of pulp cells.

First we looked at BMP signaling, as it has been shown to positively regulate odontoblast
differentiation and dentinogenesis in vivo and in vitro. Conditional deletion of Bmp2 in early
polarizing odontoblasts resulted in hypomineralized dentin, impaired maturation of odontoblasts
and decreased expression of Dspp in vivo (396). In vitro studies showed that addition of BMP2
increased expression of Dmp1 and Dspp (396-399), whereas noggin, a specific inhibitor of
BMP/BMPR signaling, had an opposite effect (399, 400). In addition, BMP2 enhanced the
activity of Msx, Dlx5, Runx2, Osx and Nf-y (397, 398, 402-406) considered to be downstream
effectors of BMP signaling during odontoblast differentiation. Furthermore, several regulatory
sequences, including Runx2 (406, 484, 485) and Msx1 (486) binding sites, have been identified
within the Dspp promoter, suggesting roles of these transcription factors in regulation of Dspp.
Similarly, Runx2 (485) and Msx1 (445) binding sites have been identified within the Dmp1
promoter, suggesting their roles in regulation of Dmp1.

In addition, multiple studies indicated the possibility of crosstalk between FGF and BMP
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pathways. Implantation of beads loaded with FGF18 into the coronal sutures stimulated
osteogenesis and markedly increased expression of Bmp2, and noggin reversed these effects
(210). FGF2 antagonized retinoic acid-mediated upregulation of Bmpr-1b (211), and constitutive
activation of Bmpr-1b restored FGF2-mediated inhibition of mineralization (212). FGF2
treatment or constitutive activation of Fgfr2 markedly decreased expression of Noggin mRNA
and protein and resulted in significant increases in expression of Bmp2 (213-215). On the other
hand, dominant-negative Fgfr2 had a stimulatory effect on noggin (214) and markedly reduced
the expression of Bmp2 (213-215).

In addition to noggin, interactions between FGF and BMP pathways are mediated by
Erk1/2 (216), Runx2 (210, 217, 218) and Foxc1 (219).

Our results showed that progression of mineralization and dentinogenesis in control
cultures was associated with increases in the expression of Bmp2, Runx2 and Osx, suggesting
that BMP signaling could act as a positive regulator of odontoblast differentiation. We also
showed that decreases in mineralization and dentinogenesis by FGF2 were associated with
decreases in the expression of Bmp2, Runx2 and Osx at days 10 and 14.

In control cultures, expression of components of BMP signaling was relatively
unchanged during the first 7 days. In contrast, FGF2 rapidly upregulated expression of Bmp2
(~12 hrs after exposure), whereas expression levels of Dlx5, Msx2 and Osx were increased at
later time points. The increases in the expression of these genes during the first 7 days were
associated with increased expression of Dmp1 and Dspp by FGF2 (see Chapter V of this
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dissertation).

Taken together, these observations suggest that the stimulatory and inhibitory effects of
FGF2 on dentinogenic differentiation of dental pulp cells involved changes in BMP signaling.

Wnt is also one of the essential signaling pathways regulating tooth development and
odontoblast differentiation (487). High expression levels of Wnt10a (488) and Lef1 (482) were
detected during early stages of odontoblast differentiation, however they declined in fully
differentiated odontoblasts. Inactivation of Wnt10a or Lef1 led to inhibition of dentinogenic
differentiation, whereas their overexpression had a stimulatory effect on dentinogenesis (482,
489). Expression of inhibitors of Wnt signaling, Axin2, Dkk1 and Dkk2, decreased markedly in
fully differentiated odontoblasts (490, 491). Conditional inactivation of β-catenin in OCCre;Ctnnb1CO/CO mice resulted in the lack of dentin due to the absence of odontoblasts (492, 493).
These findings suggest that Wnt signaling acts as a positive regulator of early and intermediate
stages of odontoblast differentiation.

In contrast, other studies showed that Wnt signaling acted primarily as a negative
regulator of odontoblast differentiation. Transient transfection of human dental pulp cells with
Wnt1

or

β-catenin

Increases/stabilization

significantly
of

β-catenin

decreased
resulted

their
in

dentinogenic
reduced

differentiation

formation

of

(481).

dentin,

its

hypomineralization, and decreased expression of Dspp (221, 494).

Several studies have demonstrated that interactions between the FGF and Wnt signaling
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pathways might be important for proper tooth and skeletal development, and specification of the
cell fate (220-224). Expression levels of Wisp1, Wisp2 and Fxd4, downstream targets of Wnt
signaling, were markedly decreased in Apert and Crouzon osteoblasts, which express
constitutively active Fgfr2 (377). In addition, the cross-talk between the FGF and Wnt signaling
pathways could be mediated at the level of Lef1 (225), Atf4 (226), Erk1/2 (227, 228), p38 (229),
Runx2 (230) and β-catenin (231).

Considering the important roles of Wnt pathway in odontoblast differentiation, and
reported interactions between the FGF and Wnt signaling pathways, we examined the effects of
FGF2 treatment on some of the components of the Wnt signaling pathway.

These results suggest that in contrast to BMP signaling, effects of Wnt signaling include
stimulation of early odontoblast differentiation and inhibition of intermediate and terminal
odontoblast differentiation.

Our results showed that mineralization and dentinogenesis in control cultures were
associated with increases in the expression of Nkd2 and Dkk3, inhibitors of Wnt signaling, at
days 10 and 14. In addition, FGF2-induced decreases in mineralization and dentinogenesis at
days 10 and 14 were associated with lower levels of Nkd2 and Dkk3, but higher levels of Wnt10a.
Furthermore, Wnt10a and Wisp2 expression was increased and the expression of Nkd2 was
decreased by FGF2 during the first 7 days. This suggests that the increased activity of Wnt
signaling in response to FGF2 stimulates early odontoblast differentiation but inhibits late
odontoblast differentiation. This is in agreement with previous results showing that Wnt
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signaling stimulates formation of polarizing and functional odontoblasts, but inhibits their
terminal differentiation (483).
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Summary and conclusions.

In conclusion, our results suggest that the BMP and Wnt signaling pathways are involved
in mediating both stimulatory and inhibitory effects of FGF2 on dentinogenic differentiation of
dental pulp cells. Better understanding of the molecular mechanisms underlying these effects of
FGF2 on dentinogenesis could provide critical information for the development of improved
treatments for vital pulp therapy and dentin regeneration.
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Figures.

Figure 59. Effects of continuous exposure to FGF2 on expression of select components of
the BMP/BMPR signaling pathway in primary dental pulp cultures during the
proliferation and differentiation/mineralization phases of in vitro growth. Cultures were
established and grown in the presence of VH or FGF2 between days 3-14. Gene expression was
analyzed at various time points by TaqMan or SYBR Green qPCR.
A. Expression of components of the BMP/BMPR signaling pathway (Bmp2, Runx2 and Osx) at
days 7, 10 and 14. Expression of all genes was normalized to VH at day 7, which is arbitrarily set
to 1 and is indicated by the dashed line.
B. Expression of components of the BMP/BMPR signaling pathway (Bmp2, Bmp4, Dlx5, Msx2,
Runx2 and Osx) at 12-96 hrs after exposure to FGF2. Expression of all genes was normalized to
VH at 12 hrs, which is arbitrarily set to 1 and is indicated by the dashed line.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point.

333

During the differentiation/mineralization phase of in vitro growth, FGF2 decreased expression of
components of BMP signaling (Bmp2, Runx2, Osx) as compared to control. During the
proliferation phase of in vitro growth, FGF2 increased expression of Bmp2 as early as 12 hrs
after exposure, whereas expression of Osx and Msx2 was increased at later time points. FGF2
exerted no significant effects on expression of Runx2, Bmp4 and Dlx5 as compared to control.
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Figure 60. Effects of continuous exposure to FGF2 on expression of select components of
the Wnt signaling pathway in primary dental pulp cultures during the proliferation and
differentiation/mineralization phases of in vitro growth. Cultures were established and grown
in the presence of VH or FGF2 between days 3-7 (0-96 hrs after treatment). Gene expression was
analyzed at various time points by TaqMan or SYBR Green qPCR.
A. Expression of components of the Wnt signaling pathway (Wnt10a, Nkd2 and Dkk3) at days 7,
10 and 14. Expression of all genes was normalized to VH at day 7, which is arbitrarily set to 1
and is indicated by the dashed line.
B. Expression of components of the Wnt signaling pathway (Wnt10a, Wisp2, Nkd2 and Dkk3) at
12-96 hrs after exposure to FGF2. Expression of all genes was normalized to VH at 12 hrs,
which is arbitrarily set to 1 and is indicated by the dashed line.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point.
During the differentiation/mineralization phase of in vitro growth, FGF2 increased expression of
Wnt10a and decreased expression of Nkd2 and Dkk3, suggesting increased Wnt signaling.
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During the proliferation phase of in vitro growth, FGF2 increased expression of Wnt10a and
Wisp2 and decreased expression of Nkd2, suggesting increased Wnt signaling.
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Tables.
Table 48. Effects of continuous exposure to FGF2 on expression of select components of the
BMP/BMPR signaling pathway in primary dental pulp cultures during the
differentiation/mineralization phase of in vitro growth.

Day 14

Day 10

Day 7

Control
Gene
Gapdh (TaqMan)
Runx2
Osx
Gapdh (SYBR Green)
Bmp2

CT
20.07 ± 0.25
28.04 ± 0.44
24.63 ± 0.37
16.95 ± 0.24
28.20 ± 0.46

Gapdh (TaqMan)
Runx2
Osx
Gapdh (SYBR Green)
Bmp2

20.54 ± 0.10
27.01 ± 0.32
24.10 ± 0.30
17.49 ± 0.69
26.22 ± 0.72

Gapdh (TaqMan)
Runx2
Osx
Gapdh (SYBR Green)
Bmp2

20.41 ± 0.07
26.80 ± 0.24
23.63 ± 0.30
18.13 ± 0.69
25.57 ± 0.67

ΔCT

-ΔΔCT

Fold change

−

−

−

7.80 ± 0.18
4.65 ± 0.30

0
0

1
1

−

−

−

10.77 ± 0.57

0

1

−

−

−

6.45 ± 0.34
3.57 ± 0.20

1.35 ± 0.24
0.92 ± 0.27

2.73 ± 0.44
1.96 ± 0.33

−

−

−

8.73 ± 1.33

2.52 ± 0.38

6.18 ± 1.73

−

−

−

5.96 ± 0.31
13.79 ± 0.08

1.84 ± 0.19
1.27 ± 0.45

3.73 ± 0.45
2.66 ± 0.81

−

−

7.44 ± 0.89

3.82 ± 0.85

−

ΔCT

-ΔΔCT

−

−

−

7.17 ± 0.20
3.60 ± 0.55

0.63 ± 0.25
1.05 ± 0.36

1.7 ± 0.35*
2.43 ± 0.66

19.9 ± 11.3

Day 14

Day 10

Day 7

FGF2-treated between days 3-14
Gene
Gapdh (TaqMan)
Runx2
Osx
Gapdh (SYBR Green)
Bmp2

CT
20.65 ± 0.42
27.47 ± 0.28
23.50 ± 0.15
16.86 ± 0.34
25.82 ± 0.38

Gapdh (TaqMan)
Runx2
Osx
Gapdh (SYBR Green)
Bmp2

19.80 ± 0.23
27.58 ± 0.04
25.10 ± 1.31
17.12 ± 0.96
27.52 ± 0.67

Gapdh (TaqMan)
Runx2
Osx
Gapdh (SYBR Green)
Bmp2

20.54 ± 0.24
28.76 ± 0.23
24.53 ± 0.10
17.67 ± 0.11
26.89 ± 1.30

Fold change

−

−

−

8.94 ± 0.52

1.83 ± 0.24

3.81 ± 0.7*

−

−

−

7.72 ± 0.04
5.31 ± 1.20

0.31 ± 0.16
-0.82 ± 0.95

1.26 ± 0.17
0.78 ± 0.31

−

−

−

10.40 ± 1.24

0.85 ± 0.49

2.00 ± 0.6*

−

−

−

8.02 ± 0.19
4.00 ± 0.27

0.01 ± 0.29
0.49 ± 0.42

1.06 ± 0.2*
1.52 ± 0.41

−

−

−

9.22 ± 1.38

2.04 ± 0.57

4.77 ± 1.7*

ΔCT = CTgene - CTGapdh (for Runx2 and Osx - relative to Gapdh TaqMan; for Bmp2 – relative to
Gapdh SYBR Green).
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-ΔΔCT = -(ΔCTsample – ΔCTcontrol).
Positive –ΔΔCT value = increased gene expression relative to control.
Negative –ΔΔCt value = decreased gene expression relative to control.
All results were normalized to VH at day 7.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point.
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Table 49. Effects of continuous exposure to FGF2 on expression of select components of the
BMP/BMPR signaling pathway in primary dental pulp cultures during the proliferation
phase of in vitro growth.
Hours
after
treatment

Gene

CT

ΔCT

-ΔΔCT

Fold
change

12

Gapdh (SYBR Green)
Bmp2
Dlx5
Msx2
Gapdh (TaqMan)
Bmp4
Osx
Runx2

16.43 ± 0.48
27.69 ± 0.64
29.08 ± 0.30
25.48 ± 0.76
19.27 ± 0.60
25.97 ± 0.15
25.04 ± 0.27
27.66 ± 0.73

−
10.99 ± 0.14
12.38 ± 0.27
9.05 ± 0.43
−
6.71 ± 0.52
5.23 ± 0.13
8.40 ± 0.29

−
0
0
0
−
0
0
0

−
1
1
1
−
1
1
1

24

Gapdh (SYBR Green)
Bmp2
Dlx5
Msx2
Gapdh (TaqMan)
Bmp4
Osx
Runx2

16.42 ± 0.39
28.41 ± 0.14
28.58 ± 0.33
25.10 ± 0.73
19.73 ± 0.57
26.50 ± 0.09
25.24 ± 0.43
28.21 ± 0.35

−
11.77 ± 0.32
11.94 ± 0.20
8.64 ± 0.50
−
6.78 ± 0.49
5.01 ± 0.13
8.48 ± 0.26

−
-0.78 ± 0.45
0.43 ± 0.30
-0.42 ± 0.63
−
-0.07 ± 0.35
0.22 ± 0.16
-0.09 ± 0.39

−
0.64 ± 0.19
1.40 ± 0.25
1.73 ± 0.63
−
1.03 ± 0.21
1.18 ± 0.13
1.04 ± 0.25

36

Gapdh (SYBR Green)
Bmp2
Dlx5
Msx2
Gapdh (TaqMan)
Bmp4
Osx
Runx2

16.86 ± 0.36
29.32 ± 0.18
29.42 ± 0.47
25.50 ± 0.46
19.95 ± 0.33
27.20 ± 0.26
24.65 ± 0.28
27.83 ± 0.57

−
12.15 ± 0.18
12.25 ± 0.21
8.64 ± 0.27
−
7.24 ± 0.25
4.42 ± 0.16
7.87 ± 0.35

−
-1.17 ± 0.29
0.12 ± 0.38
-0.41 ± 0.16
−
-0.54 ± 0.30
0.81 ± 0.26
0.52 ± 0.25

−
0.46 ± 0.09
1.16 ± 0.26
1.36 ± 0.14
−
0.73 ± 0.15
1.80 ± 0.30
1.50 ± 0.24

48

Gapdh (SYBR Green)
Bmp2
Dlx5
Msx2
Gapdh (TaqMan)
Bmp4
Osx
Runx2

16.17 ± 0.18
28.61 ± 0.16
28.42 ± 0.40
25.34 ± 0.27
19.29 ± 0.23
26.97 ± 0.20
23.93 ± 0.20
27.31 ± 0.49

−
12.37 ± 0.09
12.17 ± 0.21
9.17 ± 0.25
−
7.68 ± 0.37
4.44 ± 0.34
8.03 ± 0.27

−
-1.38 ± 0.18
0.21 ± 0.42
-0.12 ± 0.36
−
-0.98 ± 0.22
0.79 ± 0.36
0.37 ± 0.45

−
0.39 ± 0.05
1.26 ± 0.40
1.01 ± 0.23
−
0.53 ± 0.08
1.84 ± 0.43
1.46 ± 0.35

72

Control

Gapdh (SYBR Green)
Bmp2
Dlx5
Msx2
Gapdh (TaqMan)

16.73 ± 0.33
29.06 ± 0.03
28.28 ± 0.31
25.06 ± 0.36
19.75 ± 0.36

−
12.17 ± 0.42
11.40 ± 0.32
8.33 ± 0.15
−

−
-1.19 ± 0.55
0.98 ± 0.09
0.72 ± 0.37
−

−
0.50 ± 0.17
1.98 ± 0.13
1.79 ± 0.36
−
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27.68 ± 0.14
24.23 ± 0.37
27.62 ± 0.22

7.93 ± 0.46
4.23 ± 0.40
7.86 ± 0.19

-1.23 ± 0.47
1.00 ± 0.36
0.53 ± 0.20

0.49 ± 0.14
2.14 ± 0.57
1.49 ± 0.22

Gapdh (SYBR Green)
Bmp2
Dlx5
Msx2
Gapdh (TaqMan)
Bmp4
Osx
Runx2

16.13 ± 0.31
29.23 ± 0.24
27.96 ± 0.15
24.60 ± 0.40
19.43 ± 0.28
27.60 ± 0.13
24.20 ± 0.31
27.43 ± 0.35

−
13.26 ± 0.14
11.98 ± 0.26
8.47 ± 0.26
−
8.17 ± 0.18
4.95 ± 0.39
8.00 ± 0.57

−
-2.27 ± 0.28
0.39 ± 0.23
0.59 ± 0.45
−
-1.47 ± 0.69
0.28 ± 0.35
0.40 ± 0.54

−
0.21 ± 0.04
1.34 ± 0.20
1.72 ± 0.48
−
0.52 ± 0.27
1.29 ± 0.34
1.66 ± 0.73

Hours
after
treatment

Gene

CT

ΔCT

-ΔΔCT

Fold
change

12

Gapdh (SYBR Green)
Bmp2
Dlx5
Msx2
Gapdh (TaqMan)
Bmp4
Osx
Runx2

16.43 ± 0.48
26.01 ± 0.22
28.50 ± 0.66
25.45 ± 0.67
19.19 ± 0.53
25.77 ± 0.26
24.78 ± 0.05
27.67 ± 0.67

−
9.54 ± 0.41
12.03 ± 0.22
9.13 ± 0.29
−
6.58 ± 0.31
5.12 ± 0.27
8.48 ± 0.26

−
1.44 ± 0.55
0.35 ± 0.41
-0.08 ± 0.23
−
0.12 ± 0.28
0.11 ± 0.18
-0.09 ± 0.15

−
3.09 ± 0.99
1.37 ± 0.34
0.98 ± 0.15
−
1.13 ± 0.18
1.10 ± 0.14
0.96 ± 0.10

24

Gapdh (SYBR Green)
Bmp2
Dlx5
Msx2
Gapdh (TaqMan)
Bmp4
Osx
Runx2

16.42 ± 0.39
26.73 ± 0.63
28.93 ± 0.47
24.66 ± 0.63
19.62 ± 0.54
26.36 ± 0.12
24.61 ± 0.34
27.89 ± 0.47

−
10.25 ± 0.23
12.46 ± 0.30
8.36 ± 0.24
−
6.74 ± 0.44
4.54 ± 0.18
8.27 ± 0.35

−
0.74 ± 0.30
-0.08 ± 0.32
0.69 ± 0.31
−
-0.03 ± 0.38
0.69 ± 0.27
0.13 ± 0.33

−
1.74 ± 0.37
0.99 ± 0.20
1.74 ± 0.38
−
1.07 ± 0.24
1.67 ± 0.32
1.20 ± 0.32

36

Gapdh (SYBR Green)
Bmp2
Dlx5
Msx2
Gapdh (TaqMan)
Bmp4
Osx
Runx2

16.86 ± 0.36
26.83 ± 0.25
28.47 ± 0.16
24.48 ± 0.79
19.03 ± 0.22
27.18 ± 0.19
23.93 ± 0.28
27.32 ± 0.51

−
10.42 ± 0.29
12.07 ± 0.23
8.26 ± 0.50
−
8.14 ± 0.14
4.70 ± 0.20
8.29 ± 0.39

−
0.56 ± 0.42
0.30 ± 0.04
0.80 ± 0.28
−
-1.44 ± 0.53
0.53 ± 0.30
0.11 ± 0.31

−
1.60 ± 0.43
1.24 ± 0.03
1.83 ± 0.31
−
0.45 ± 0.16
1.51 ± 0.32
1.15 ± 0.24

48

Gapdh (SYBR Green)
Bmp2
Dlx5
Msx2
Gapdh (TaqMan)

16.17 ± 0.18
27.01 ± 0.23
27.99 ± 0.47
24.05 ± 0.61
19.43 ± 0.43

−
10.34 ± 0.37
11.33 ± 0.19
7.61 ± 0.45
−

−
0.64 ± 0.48
1.04 ± 0.38
1.44 ± 0.28
−

−
1.72 ± 0.46
2.19 ± 0.51
2.88 ± 0.56
−

96

Bmp4
Osx
Runx2

FGF2
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Bmp4
Osx
Runx2

27.70 ± 0.17
24.01 ± 0.36
27.94 ± 0.22

8.27 ± 0.31
4.19 ± 0.11
8.51 ± 0.40

-1.57 ± 0.35
1.04 ± 0.05
-0.12 ± 0.49

0.37 ± 0.07
2.06 ± 0.07
1.13 ± 0.46

72

Gapdh (SYBR Green)
Bmp2
Dlx5
Msx2
Gapdh (TaqMan)
Bmp4
Osx
Runx2

16.73 ± 0.33
27.80 ± 0.32
28.30 ± 0.19
24.60 ± 0.58
19.71 ± 0.48
28.29 ± 0.27
24.11 ± 0.27
27.76 ± 0.41

−
11.09 ± 0.51
11.58 ± 0.38
8.19 ± 0.35
−
8.58 ± 0.35
4.05 ± 0.27
8.05 ± 0.26

−
-0.10 ± 0.64
0.79 ± 0.17
0.86 ± 0.21
−
-1.87 ± 0.60
1.18 ± 0.37
0.35 ± 0.35

−
1.12 ± 0.42
1.75 ± 0.21
1.88 ± 0.30
−
0.33 ± 0.10
2.41 ± 0.55
1.39 ± 0.36

96

Gapdh (SYBR Green)
Bmp2
Dlx5
Msx2
Gapdh (TaqMan)
Bmp4
Osx
Runx2

16.13 ± 0.31
27.93 ± 0.45
27.72 ± 0.20
23.59 ± 0.65
19.68 ± 0.27
27.99 ± 0.19
23.52 ± 0.61
26.99 ± 0.63

−
11.21 ± 0.49
11.01 ± 0.36
6.76 ± 0.40
−
8.31 ± 0.17
3.82 ± 0.27
7.31 ± 0.63

−
0.23 ± 0.50
1.36 ± 0.23
2.29 ± 0.32
−
-1.60 ± 0.57
1.41 ± 0.14
1.08 ± 0.65

−
0.97 ± 0.36
2.63 ± 0.43
5.29 ± 1.33
−
0.42 ± 0.17
2.69 ± 0.25
2.93 ± 1.41

ΔCT = CTgene - CTGapdh (for Bmp4, Runx2 and Osx - relative to Gapdh TaqMan; for Bmp2, Dlx5
and Msx2 – relative to Gapdh SYBR Green).
-ΔΔCT = -(ΔCTsample – ΔCTcontrol).
Positive –ΔΔCT value = increased gene expression relative to control.
Negative –ΔΔCT value = decreased gene expression relative to control.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point. All fold changes were relative to VH at 12 hrs.
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Table 50. Effects of continuous exposure to FGF2 on expression of select components of the
Wnt signaling pathway in primary dental pulp cultures during the
differentiation/mineralization phase of in vitro growth.

Day 7

Gapdh
Wnt10a
Nkd2
Dkk3

CT
16.95 ± 0.24
29.31 ± 0.58
30.92 ± 0.11
30.74 ± 0.49

Day 10

Gapdh
Wnt10a
Nkd2
Dkk3

17.49 ± 0.69
29.87 ± 0.26
28.39 ± 0.46
28.61 ± 0.45

Gapdh
Wnt10a
Nkd2
Dkk3

18.13 ± 0.69
29.67 ± 0.32
27.42 ± 0.27
27.38 ± 0.25

−

−

−

Day 14

Control
Gene

ΔCT

-ΔΔCT

Fold change

−

−

−

12.17 ± 0.50
13.91 ± 0.29
13.74 ± 0.53

0
0
0

1
1
1

−

−

−

12.38 ± 0.90
10.90 ± 0.78
11.12 ± 0.72

-0.81 ± 0.82
3.07 ± 0.59
3.43 ± 0.42

0.74 ± 0.29
9.84 ± 3.78
11.66 ± 3.0

11.54 ± 0.38
9.28 ± 0.79
9.25 ± 0.44

0.03 ± 0.52
4.68 ± 0.65
5.30 ± 0.37

1.17 ± 0.45
30.92 ± 3.1
42.2 ± 10.5

ΔCT

Fold change

−

−

−

Day 7

CT
16.86 ± 0.34
28.26 ± 0.38
29.99 ± 0.25
29.76 ± 0.31

-ΔΔCT

Gapdh
Wnt10a
Nkd2
Dkk3

11.47 ± 0.41
13.24 ± 0.53
13.10 ± 0.16

0.71 ± 0.35
0.67 ± 0.25
0.64 ± 0.45

1.93 ± 0.60
1.72 ± 0.31
1.88 ± 0.55

Day 10

Gapdh
Wnt10a
Nkd2
Dkk3

17.12 ± 0.96
28.11 ± 0.45
30.21 ± 0.12
29.85 ± 0.71

−

−

−

10.99 ± 0.74
13.10 ± 0.85
12.73 ± 0.72

0.58 ± 0.54
0.87 ± 0.48
1.83 ± 0.80

1.69 ± 0.50
2.06 ± 0.72
4.69 ± 2.28

Day 14

FGF2-treated between days 3-14
Gene

Gapdh
Wnt10a
Nkd2
Dkk3

17.67 ± 0.11
28.28 ± 0.33
29.08 ± 0.49
29.29 ± 0.28

−

−

−

10.60 ± 0.38
11.41 ± 0.40
11.62 ± 0.32

0.96 ± 0.49
2.56 ± 0.72
2.93 ± 0.61

2.20 ± 0.79
7.32 ± 3.1*
9.21 ± 4.1*

ΔCT = CTgene - CTGapdh
-ΔΔCT = -(ΔCTsample – ΔCTcontrol).
Positive –ΔΔCT value = increased gene expression relative to control.
Negative –ΔΔCt value = decreased gene expression relative to control
All results were normalized to VH at day 7.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point.
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Table 51. Effects of continuous exposure to FGF2 on expression of select components of the
Wnt signaling pathway in primary dental pulp cultures during the proliferation phase of in
vitro growth.
Control
CT

ΔCT

-ΔΔCT

Fold
change

12

Gapdh
Dkk3
Nkd2
Wisp2
Wnt10a

16.43 ± 0.48
32.13 ± 0.53
28.87 ± 0.71
31.19 ± 0.75
29.77 ± 0.52

−
15.43 ± 0.33
12.17 ± 0.30
14.48 ± 0.44
13.06 ± 0.21

−
0
0
0
0

−
1
1
1
1

24

Gapdh
Dkk3
Nkd2
Wisp2
Wnt10a

16.42 ± 0.39
30.98 ± 0.47
29.51 ± 0.30
30.80 ± 0.63
29.49 ± 0.41

−
14.34 ± 0.80
12.88 ± 0.67
14.17 ± 0.74
12.85 ± 0.29

−
1.09 ± 0.83
-0.71 ± 0.50
0.31 ± 0.30
0.21 ± 0.18

−
2.76 ± 1.10
0.68 ± 0.20
1.30 ± 0.28
1.18 ± 0.14

36

Gapdh
Dkk3
Nkd2
Wisp2
Wnt10a

16.86 ± 0.36
31.10 ± 0.40
29.81 ± 0.65
31.19 ± 0.65
29.75 ± 0.66

−
13.93 ± 0.63
12.64 ± 0.60
14.02 ± 0.37
12.59 ± 0.38

−
1.50 ± 0.58
-0.47 ± 0.47
0.46 ± 0.34
0.47 ± 0.35

−
3.24 ± 0.99
0.79 ± 0.21
1.46 ± 0.36
1.47 ± 0.33

48

Gapdh
Dkk3
Nkd2
Wisp2
Wnt10a

16.17 ± 0.18
30.12 ± 0.20
29.04 ± 0.47
30.04 ± 0.15
29.02 ± 0.19

−
13.87 ± 0.42
12.79 ± 0.42
13.79 ± 0.16
12.77 ± 0.10

−
1.56 ± 0.40
-0.63 ± 0.14
0.68 ± 0.54
0.29 ± 0.27

−
3.16 ± 0.78
0.65 ± 0.06
1.83 ± 0.61
1.26 ± 0.21

72

Gapdh
Dkk3
Nkd2
Wisp2
Wnt10a

16.73 ± 0.33
31.11 ± 0.48
29.65 ± 0.37
30.91 ± 0.14
29.84 ± 0.57

−
14.22 ± 0.52
12.76 ± 0.65
14.02 ± 0.49
12.95 ± 0.20

−
1.21 ± 0.40
-0.60 ± 0.51
0.46 ± 0.30
0.11 ± 0.35

−
2.48 ± 0.58
0.74 ± 0.22
1.44 ± 0.30
1.15 ± 0.30

96

Hours
after
treatment

Gapdh
Dkk3
Nkd2
Wisp2
Wnt10a

16.13 ± 0.31
30.25 ± 0.71
29.00 ± 0.53
30.22 ± 0.86
29.38 ± 0.53

−
14.28 ± 1.00
13.03 ± 0.56
14.25 ± 0.73
13.40 ± 0.16

−
1.15 ± 1.01
-0.86 ± 0.36
0.23 ± 0.53
0.34 ± 0.33

−
3.16 ±1.33
0.58 ± 0.13
1.34 ± 0.47
0.83 ± 0.20

CT

ΔCT

-ΔΔCT

Fold
change

16.43 ± 0.48

−

−

−

Gene

FGF2

1
2

Hours
after
treatment

Gene
Gapdh
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Dkk3
Nkd2
Wisp2
Wnt10a

29.61 ± 0.50
29.25 ± 0.77
30.79 ± 0.72
29.42 ± 0.34

13.60 ± 0.30
12.78 ± 0.46
14.32 ± 0.32
12.95 ± 0.29

1.83 ± 0.49
-0.61 ± 0.18
0.16 ± 0.24
0.11 ± 0.11

3.99 ± 1.44
0.66 ± 0.08
1.15 ± 0.19
1.08 ± 0.08

24

Gapdh
Dkk3
Nkd2
Wisp2
Wnt10a

16.42 ± 0.39
30.24 ± 0.72
29.90 ± 0.38
30.44 ± 0.63
29.34 ± 0.54

−
14.44 ± 0.79
13.43 ± 0.64
13.96 ± 0.15
12.86 ± 0.17

−
0.99 ± 0.86
-1.26 ± 0.57
0.52 ± 0.44
0.20 ± 0.14

−
2.65 ± 1.17
0.48 ± 0.15
1.56 ± 0.40
1.16 ± 0.11

36

Gapdh
Dkk3
Nkd2
Wisp2
Wnt10a

16.86 ± 0.36
29.04 ± 0.89
30.30 ± 0.74
30.34 ± 0.10
28.92 ± 0.18

−
13.51 ± 0.58
13.89 ± 0.66
13.93 ± 0.31
12.52 ± 0.22

−
1.91 ± 0.55
-1.72 ± 0.38
0.55 ± 0.56
0.55 ± 0.19

−
4.27 ± 1.27
0.33 ± 0.09
1.71 ± 0.69
1.49 ± 0.21

48

Gapdh
Dkk3
Nkd2
Wisp2
Wnt10a

16.17 ± 0.18
29.48 ± 0.53
30.18 ± 0.38
29.49 ± 0.31
28.49 ± 0.47

−
13.29 ± 0.34
13.52 ± 0.67
12.83 ± 0.17
11.83 ± 0.01

−
2.14 ± 0.37
-1.35 ± 0.44
1.65 ± 0.39
1.23 ± 0.20

−
4.70 ± 1.15
0.42 ± 0.13
3.37 ± 0.90
2.40 ± 0.32

72

Gapdh
Dkk3
Nkd2
Wisp2
Wnt10a

16.73 ± 0.33
29.11 ± 1.00
30.30 ± 0.45
29.73 ± 0.39
28.82 ± 0.43

−
13.39 ± 0.34
13.58 ± 0.59
13.01 ± 0.32
12.10 ± 0.18

−
2.04 ± 0.32
-1.42 ± 0.47
1.46 ± 0.23
0.96 ± 0.36

−
4.30 ± 0.91
0.41 ± 0.11
2.83 ± 0.48
2.05 ± 0.44

96

Gapdh
Dkk3
Nkd2
Wisp2
Wnt10a

16.13 ± 0.31
29.26 ± 0.52
30.36 ± 0.43
29.01 ± 0.52
28.80 ± 0.59

−
13.06 ± 0.54
13.65 ± 0.29
12.30 ± 0.09
12.09 ± 0.29

−
2.37 ± 0.56
-1.48 ± 0.09
2.18 ± 0.45
0.97 ± 0.26

−
5.90 ± 1.89
0.36 ± 0.02
4.94 ± 1.25
2.03 ± 0.36

ΔCT = CTgene - CTGapdh.
-ΔΔCT = -(ΔCTsample – ΔCTcontrol).
Positive –ΔΔCT value = increased gene expression relative to control.
Negative –ΔΔCT value = decreased gene expression relative to control.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point. All fold changes were relative to VH at 12 hrs.
N.D. = not detected.
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CHAPTER VIII

EFFECTS

OF

FGF2

ON

MINERALIZATION

AND

ODONTOBLAST

DIFFERENTIATION INVOLVE CHANGES IN THE EXPRESSION OF GENES
REGULATING LOCAL PHOSPHATE BALANCE.

Abstract.

Odontoblast differentiation during physiological and reparative dentinogenesis is
dependent upon multiple signaling molecules, including Fibroblast Growth Factors (FGFs),
sequestrated in the dentin matrix and pulp-supportive tissues. FGFs can be released from injured
dentin matrix or pulp cells, and they play an important role during reparative dentinogenesis by
affecting proliferation and differentiation of responding progenitor cells into odontoblast-like
cells and subsequent mineralization of the deposited matrix. Previous studies in our laboratory
showed that FGF2 exerted stage-specific effects on odontoblast differentiation and production of
mineralized dentin-like matrix in primary dental pulp cultures. Early exposure of pulp cells to
FGF2 did not markedly affect the extent of mineralization, whereas the continuous and late
exposure to FGF2 significantly decreased the extent of mineralization. In the present study we
examined changes in the expression of genes regulating local phosphate balance (Ank, Enpp1,
Tnap and Phex) in response to different exposures to FGF2. Our results demonstrated that the
expression of Ank and Enpp1 in the control cultures peaked during the intermediate stages of
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culture differentiation and then declined, whereas Tnap and Phex displayed continuous increases.
Early exposure to FGF2 did not significantly affect gene expression. Continuous and late
exposure to FGF2 increased the expression of Ank and Enpp1, and decreased the expression of
Tnap and Phex. Withdrawal of FGF2 reversed FGF2-induced effects on gene expression. These
results demonstrate that Ank, Enpp1, Tnap and Phex are functionally coupled to matrix
mineralization and suggest their involvement in stage-specific effects of FGF2 on mineralization
of primary dental pulp cultures. Better understanding of the effects of FGF2 on mineralization
would improve its applications for dentin regeneration.
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Introduction.

Dentin is a mineralized tissue secreted by odontoblasts. It is first deposited as predentin,
an unmineralized matrix composed primarily of Type I collagen (11, 15). Predentin gradually
undergoes mineralization, as various NCPs are incorporated into the mineralization front (15).
Mature dentin is composed of approximately 70% inorganic (mineral) material, 20% organic
material, and 10% water by weight.

The formation of mineralized matrix requires the presence and physicochemical
interactions between Ca2+ and inorganic phosphate (Pi) ions (12). Hydroxyapatite (HA) is the
major mineral crystal present in the extracellular matrix of bone and dentin (15), and is
composed of calcium (Ca2+) and inorganic phosphate (PO43–) ions.

Calcium ions can derive either from the cells or from local or circulating calcium-binding
proteins. There are four major sources of phosphate ions in the body: 1) intracellular
pyrophosphate (iPPi) is transported from the intracellular space outside the cell membrane. In the
ECM transported iPPi is called extracellular PPi (ePPi), which represents an abundant metabolic
product. Hydrolysis of ePPi in the ECM generates inorganic phosphate (Pi); 2) from hydrolysis
of other phosphate-containing proteins, such as phosphoesters or phosphoproteins; 3) from
circulating Pi, which is reabsorbed from the circulation in the kidneys, and 4) from phosphate
absorption in the intestinum (495, 496).
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Phosphate homeostasis is regulated by several transmembrane proteins, including
progressive ankylosis protein (ANK), plasma cell membrane glycoprotein (PC-1), tissuenonspecific alkaline phosphatase (TNAP), and phosphate-regulating gene with homologies to
endopeptidase on the X-chromosome (PHEX). The coordinate activity of these proteins
maintains the physiological ratio of local Pi and PPi levels inside and outside the cells. Both
odontoblasts and osteoblasts express these genes (497-502), and their deficiency results in
alteration of the Pi/PPi balance and development of severe mineral-related pathological
conditions (503-506).

ANK is encoded by the Ank gene and regulates transport of iPPi to extracellular space
that increases concentration of ePPi, thus inhibiting HA formation and mineralization (507). PC1 is encoded by the Enpp1 gene and hydrolyzes ATP that generates PPi, thus inhibiting HA
formation and mineralization (508, 509). PHEX is encoded by the Phex gene and acts as a
positive regulator of mineralization (510-512). TNAP is encoded by the Tnap (also called Alpl or
Akp2) gene and increases hydrolysis of ePPi and formation of Pi, thus promoting HA formation
and mineralization (513, 514). These observations indicate that decreased differentiation and
mineralization are associated with increased activity of ANK and PC-1, whereas increased
differentiation and mineralization is associated with increased activity of TNAP and PHEX.

Our recent observations have shown that FGF2 modulated differentiation of odontoblasts
and mineralization of dental pulp in a stage-dependent manner. Continuous exposure of dental
pulp to FGF2 during both proliferation and differentiation/mineralization phases of in vitro
growth, as well as exposure to FGF2 during only the differentiation phase of in vitro growth,
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inhibited and/or decreased the extent of mineralization and the levels of the expression of
markers of mineralization and dentinogenesis. On the other hand, early exposure of dental pulp
to FGF2 during the proliferation phase of in vitro growth resulted in increases in the expression
of Dspp but did not affect the extent of mineralization (submitted manuscripts).

Considering important roles of phosphate homeostasis in mineralization, we examined
the expression of changes in the expression of Ank, Enpp1, Tnap and Phex transcripts in dental
pulp cells grown in the absence or presence of FGF2.
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Results.

Previous studies in our laboratory showed that when placed in primary cultures, pulp
cells from unerupted molars proliferated rapidly and reached confluence around day 7
(proliferation phase of in vitro growth). Following addition of the mineralization-inducing
medium at day 7, these cells underwent differentiation and gave rise to an extensive amount of
mineralized matrix (differentiation/mineralization phase of in vitro growth). The first sign of
mineralization was around day 10 with significant increases in the extent of mineralization
thereafter. At day 21 almost the entire culture dish was covered with a sheet of the mineralized
tissue (352).

Using this well-characterized dental pulp culture system, we examined the expression of
Ank, Enpp1, Tnap and Phex during mineralization and dentinogenesis (Figure 61 and Table 52).
Expression of all transcripts was detected as early as day 7. Expression of Ank and Enpp1 peaked
at day 10 and 14, respectively, and decreased thereafter. In contrast, expression of Tnap and
Phex displayed continuous increases between days 7-21.

These observations indicated that mineralization in dental pulp cultures is associated with
continuous increases the levels of Tnap and Phex shown to be positive regulators of
mineralization (513, 514). The mineralization in dental pulp also included transient increases in
the expression of Ank and Enpp1 shown to be negative regulators of mineralization (504, 515522). However, increased mineralization in these cultures was associated with decreases in the
expression of Ank and Enpp1.
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Continuous exposure of dental pulp to FGF2 that resulted in marked decreases in
mineralization and dentinogenesis modulated the expression of these transcripts (Figure 62 and
Table 52). The inhibition of mineralization in FGF2-treated cultures was associated with
increases in the expression of Ank and Enpp1 and decreases in the expression of Tnap and Phex
at days 7 and 10. However, increased mineralization was associated with increases in the
expression of Tnap and Phex and decreases in the expression of Ank and Enpp1. Late exposure
of dental pulp to FGF2 that also resulted in marked decreases in mineralization and
dentinogenesis led to modulation of these transcripts very similar to what we observed during
continuous exposure (Figure 63 and Table 52).

Recovery of mineralization 7 days after withdrawal of FGF2 reversed FGF2-induced
changes on expression of Ank, Enpp1, Tnap and Phex (Figure 64 and Table 53). The levels of
expression of these transcripts reached those in the control cultures. Withdrawal of FGF2 from
cultures exposed to FGF2 during the differentiation/mineralization phase of in vitro growth led
to modulation of these transcripts very similar to what we observed during continuous exposure
(Figure 65 and Table 53).

Early exposure to FGF2 during the proliferation phase of in vitro growth did not have
significant effects on expression of these transcripts as compared to control and is consistent with
the lack of significant effects on the extent of differentiation (Figure 66 and Table 52).
Discussion.
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Biomineralization is a process of deposition of mineral into the physiologically healthy
biological tissues. In vertebrates, biomineralization is the cell-mediated process by which HA is
deposited in the ECM of skeletal structures, including dentin. In contrast to calcification, which
is a non-physiological event occurring in the soft tissue, mineralization is generally a
physiological process regulated by various ECM proteins and enzymes directing the entry and
fixation of mineral salts in the mineralized tissue (12). Thus, the mechanisms regulating the
deposition of HA and subsequent mineralization are complex and involve multiple regulators
with positive and negative effects.

Previous studies in our laboratory have demonstrated that FGF2 exerted stage-specific
effects on mineralization and dentinogenic differentiation of primary dental pulp cultures. Early
exposure to FGF2 during only the proliferation phase of in vitro growth did not markedly affect
the extent of mineralization as compared to control, whereas continuous or late exposure to
FGF2 significantly decreased the extent of mineralization at days 10-21 (submitted manuscripts).
These results indicate that FGF2-induced decreases in mineralization could involve changes in
the expression of genes that regulate phosphate homeostasis and formation of HA.

Therefore we examined the effects of FGF2 on expression of Ank, Enpp1, Tnap and Phex,
genes that coordinately maintain the physiological ratio of Pi and PPi levels inside and outside
the cells. Although to the best of our knowledge, roles of Ank and Enpp1 in odontoblast
differentiation have not been examined, several reports in the literature demonstrated their roles
in osteoblast differentiation and bone formation in vivo and in vitro. In vivo studies showed that
inactivation of the Ank gene results in progressive thickening of bones of appendicular and
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craniofacial skeleton (515-517), hyperostotic skull and mandibles (518) and severe joint
ankylosis due to ectopic crystal deposition in virtually all joints of the body (507, 523). In vitro
studies showed that expression of Ank in differentiating BMSC cultures peaked 4 days after
induction of mineralization and then gradually declined with advanced stages of culture
differentiation (524). Similarly, inactivation of Enpp1 in vivo resulted in accelerated bone
formation (519), hyperostosis (504, 520-522), and calcification of joints and other tissues (504,
525, 526). These results indicate that Ank and Enpp1 are negative regulators of terminal
osteoblast differentiation.

In contrast to Ank and Enpp1, both Tnap and Phex have been shown to act as positive
regulators of mineralization and differentiation. In developing teeth Phex is expressed in fully
differentiated odontoblasts in vivo and in vitro (527). In situ hybridization studies showed that
similar to Dspp, Phex expression was the highest in fully differentiated/mature odontoblasts
(500). In addition, immunohistochemical analysis demonstrated that PHEX protein, similar to
DSP and Nestin, was expressed in fully differentiated/mature odontoblasts but not in less mature
cells (492, 528). In bone, high levels of expression of Phex were detected in DMP1-GFP+
calvarial osteocytes, suggesting its regulatory role during terminal differentiation of osteoblast
(429). Similarly, expression of Tnap transcripts and protein in developing mouse tooth roots has
been localized to both differentiating and fully differentiated/mature odontoblasts (492, 528).
Taken together, these results suggest that Tnap and Phex act as positive regulators of
mineralization.
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Thus, considering important roles of these genes in phosphate homeostasis and
mineralization, we examined changes in their expression in dental pulp cells grown in the
absence or presence of FGF2 at various phases of culture growth.

We showed that increased differentiation and mineralization in primary pulp cultures
were associated with continuous increases in levels of expression of Tnap and Phex, whereas
Ank and Enpp1 peaked at days 10-14 and declined at day 21. These results suggest that Ank and
Enpp1 play roles during early and/or intermediate stages of odontoblast differentiation, however
they negatively regulate terminal odontoblast differentiation. In contrast, Tnap and Phex play
roles during intermediate and/or late odontoblast differentiation. These observations are in
agreement with studies on odontoblasts and osteoblasts, which showed that Ank and Enpp1 act as
negative regulators of terminal osteoblast differentiation, whereas Tnap and Phex act as positive
regulators of terminal osteoblast differentiation.

Our previous studies showed that both continuous and late exposure to FGF2 had marked
effects on the expression of the genes during the differentiation/mineralization phase of in vitro
growth. In our present study we showed that both treatments exerted a very similar pattern of
effects

during

this

phase.

Expression

of

both

Tnap

and

Phex

during

the

differentiation/mineralization phase of in vitro growth was decreased by both treatments as
compared to control. These results suggest that continuous and late exposure to FGF2 prevented
formation of fully differentiated/mature odontoblasts expressing high levels of Tnap and Phex
and producing mineralized dentin-like matrix. This is in agreement with previous studies that
demonstrated that exposure of calvarial osteoblast or BMSC cultures to FGF2 significantly
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decreased the expression of Tnap (529). Decreased levels of Tnap in our experiments are
consistent with previous reports using ADSC (211) and MC3T3-E1 (530, 531) cultures.
Similarly, BMSCs from Fgfr2C342Y mice, which express constitutively active Fgfr2, displayed
significantly lower levels of mineralization and expression of Tnap (328). Decreased expression
of Phex in cultures exposed to FGF2 in our studies is also consistent with previous reports using
MC3T3-E1 clone 4 (MC4) and primary BMSC cultures (254).

In contrast, both continuous and late exposure to FGF2 increased expression of Ank (at
days 14 and 21) and Enpp1 (at days 10 and 21), further confirming that FGF2 inhibited terminal
odontoblast differentiation in these cultures. These results are in agreement with previous studies,
which demonstrated that exposure of MLO-Y4 osteocyte-like cells to FGF2 significantly
increased expression of Ank and Enpp1 (244). In addition, despite the decreased extent of
mineralization, expression of both Ank and Enpp1 was markedly increased by FGF2 in MC3T3E1 osteoblast-like cells (531). Similarly, increased expression of Enpp1 and Ank expression in
response to FGF2 was demonstrated in other studies using calvarial osteoblast and BMSC
cultures (529).

Our previous studies have shown that withdrawal of FGF2 reversed FGF2-induced
decreases in the extent of mineralization and expression of markers of mineralization and
dentinogenesis. These results suggest that withdrawal of FGF2 resulted in increased
dentinogenesis and formation of fully differentiated/mature odontoblasts (manuscript in
preparation). In this chapter we demonstrated that withdrawal of FGF2 completely reversed
FGF2-induced changes in expression of Enpp1, Tnap and, to a lesser extent, Ank and Phex. This
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is in agreement with the increased formation of fully differentiated/mature odontoblasts observed
in these cultures (submitted manuscript).

Our previous studies demonstrated that early exposure to FGF2 did not have significant
effects on mineralization as compared to control. In this section we have demonstrated that early
exposure to FGF2 did not affect the expression of Ank, Tnap, Enpp1 and Phex during the
differentiation/mineralization phase of in vitro growth. However, we observed a significant
increase in the expression of Enpp1 and slight increases in Ank, Tnap and Phex in FGF2-treated
cultures at day 7. This is in agreement with the increased expression of Enpp1 by FGF2 in
undifferentiated MC3T3E1 (530), ROS17/2.8 (255), MLO-Y4 (244), and calvarial and BMSC
cultures (529). In addition, the lack of the effects of FGF2 on differentiated pulp cultures
correlates with the findings that FGF2 did not affect expression of Enpp1 in differentiated
osteoblasts (530). However, expression of Tnap was decreased by FGF2 in undifferentiated
preosteoblast cells (530), which is opposite to stimulatory effects of FGF2 on undifferentiated
pulp cells in our study.
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Summary and conclusions.

Taken together, our results demonstrated that FGF2-induced changes in the extent of
mineralization involved changes in the expression of Ank, Tnap, Enpp1 and Phex, thus
supporting that these genes are functionally coupled to matrix mineralization. Continuous and
late exposure to FGF2 markedly decreased mineralization, and our present study showed that
these decreases were associated with the decreased expression of Tnap and Phex, and increased
expression of Ank and Enpp1. In contrast, early exposure to FGF2 did not affect the extent of
mineralization and, in general, had no effects on expression of these genes.
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Figures.

Figure 61. Pattern of expression of Ank, Tnap, Enpp1 and Phex during the proliferation
and differentiation/mineralization phases of in vitro growth in the control primary dental
pulp cultures. Cultures were established and grown under the control culture conditions
(without FGF2) as described in the Materials and Methods. At various time points cells were
harvested and processed for RNA isolation and qPCR analysis. Expression levels of all genes are
normalized to VH at day 7, which is arbitrarily set to 1 and is indicated by the dashed line.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point.
During the differentiation/mineralization phase of in vitro growth, expression of Ank and Enpp1
peaked during the intermediate stages of differentiation and declined at late stages of
differentiation. Expression of Tnap and Phex continuously increased with advanced stages of
culture differentiation.
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Figure 62. Effects of continuous exposure to FGF2 on expression of Ank, Tnap, Enpp1 and
Phex during the proliferation and differentiation/mineralization phases of in vitro growth
in primary dental pulp cultures. Cultures were established and grown in the absence (VH) or
presence of FGF2 between days 3-21 as described in the Materials and Methods. At various time
points cells were harvested and processed for RNA isolation and qPCR analysis. Expression
levels of all genes were normalized to VH at day 7, which is arbitrarily set to 1 and is indicated
by the dashed line. Results represent mean ± SEM of at least three independent experiments; *p
≤ 0.05 relative to control at each time point.
Continuous exposure to FGF2 led to increased expression of Ank and Enpp1 as compared to
control, whereas expression of Tnap and Phex decreased as compared to control.
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Figure 63. Effects of late exposure to FGF2 on expression of Ank, Tnap, Enpp1 and Phex
during the proliferation and differentiation/mineralization phases of in vitro growth in
primary dental pulp cultures. Cultures were established and grown in the absence (VH) or
presence of FGF2 between days 7-21 as described in the Materials and Methods. At various time
points cells were harvested and processed for RNA isolation and qPCR analysis. Expression
levels of all genes were normalized to VH at day 7, which is arbitrarily set to 1 and is indicated
by the dashed line. Results represent mean ± SEM of at least three independent experiments; *p
≤ 0.05 relative to control at each time point.
Similar to continuous exposure, late exposure to FGF2 led to increased expression of Ank and
Enpp1 as compared to control, whereas expression of Tnap and Phex decreased as compared to
control.
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Figure 64. Effects of withdrawal of FGF2 on expression of Ank, Tnap, Enpp1 and Phex in
primary dental pulp cultures continuously exposed to FGF2. Cultures were exposed to FGF2
between days 3-14. At day 14 FGF2 was withdrawn from the cultures and cells were grown
under the control culture conditions (without FGF2) for additional 7 days. Expression of Ank,
Tnap, Enpp1 and Phex was analyzed by qPCR analysis at days 14 and 21. Expression levels of
all genes were normalized to those in VH at day 14, which is arbitrarily set to 1 and is indicated
by the dashed lines. Results represent mean ± SEM of values from at least three independent
experiments; *p ≤ 0.05 relative to control at each time point; #p ≤ 0.05 relative to FGF2 (3-21) at
day 21.
Withdrawal of FGF2 reversed FGF2-induced changes in the expression of Ank, Tnap, Enpp1 and
Phex.

361

Figure 65. Effects of withdrawal of FGF2 on expression of Ank, Tnap, Enpp1 and Phex in
primary dental pulp cultures exposed to FGF2 during the differentiation/mineralization
phase of in vitro growth. Cultures were exposed to FGF2 between days 7-14. At day 14 FGF2
was withdrawn from the cultures and cells were grown under the control culture conditions
(without FGF2) for additional 7 days. Expression of Ank, Tnap, Enpp1 and Phex was analyzed
by qPCR analysis at days 14 and 21. Expression levels of all genes were normalized to those in
VH at day 14, which is arbitrarily set to 1 and is indicated by the dashed lines. Results represent
mean ± SEM of values from at least three independent experiments; *p ≤ 0.05 relative to control
at each time point; #p ≤ 0.05 relative to FGF2 (3-21) at day 21.
Withdrawal of FGF2 reversed FGF2-induced changes in the expression of Ank, Tnap, Enpp1 and
Phex.

362

Figure 66. Effects of early exposure to FGF2 on expression of Ank, Tnap, Enpp1 and Phex
during the proliferation and differentiation/mineralization phases of in vitro growth in
primary dental pulp cultures. Cultures were established and grown in the absence (VH) or
presence of FGF2 between days 3-7 as described in the Materials and Methods. At various time
points cells were harvested and processed for RNA isolation and qPCR analysis. Expression
levels of all genes were normalized to VH at day 7, which is arbitrarily set to 1 and is indicated
by the dashed line. Results represent mean ± SEM of at least three independent experiments; *p
≤ 0.05 relative to control at each time point.
Early exposure to FGF2 had no significant effects on expression of Ank, Tnap, Enpp1 and Phex
as compared to control.

363

Tables.
Table 52. Effects of various FGF2 treatments on expression of Ank, Enpp1, Tnap and Phex
during the proliferation and differentiation/mineralization phase of in vitro growth in
primary dental pulp cultures.

CT

ΔCT

-ΔΔCT

Fold change

7

Gapdh
Ank
Enpp1
Tnap
Phex

17.69 ± 0.22
19.65 ± 0.18
29.20 ± 0.34
18.84 ± 0.06
22.12 ± 0.14

−
1.96 ± 0.31
11.50 ± 0.16
1.15 ± 0.26
4.43 ± 0.11

−
0
0
0
0

−
1
1
1
1

10

Gapdh
Ank
Enpp1
Tnap
Phex

17.26 ± 0.32
17.82 ± 0.06
29.08 ± 0.28
16.76 ± 0.34
21.22 ± 0.34

−
0.56 ± 0.38
11.82 ± 0.07
-0.50 ± 0.62
3.97 ± 0.09

−
1.40 ± 0.17
-0.32 ± 0.23
1.64 ± 0.38
0.46 ± 0.12

−
2.69 ± 0.33
0.83 ± 0.14
3.45 ± 0.83
1.39 ± 0.11

14

Gapdh
Ank
Enpp1
Tnap
Phex

17.75 ± 0.11
19.56 ± 0.14
28.71 ± 0.37
16.35 ± 0.25
18.46 ± 0.29

−
1.81 ± 0.13
10.96 ± 0.45
-1.40 ± 0.23
0.71 ± 0.26

−
0.14 ± 0.18
0.54 ± 0.36
2.55 ± 0.17
3.71 ± 0.37

−
1.13 ± 0.15
1.60 ± 0.42
5.97 ± 0.66
14.43 ± 3.56

21

Control
Day of
the
culture

Gene

Gapdh
Ank
Enpp1
Tnap
Phex

17.94 ± 0.09
19.25 ± 0.12
30.22 ± 0.28
15.99 ± 0.23
18.28 ± 0.12

−
1.31 ± 0.12
12.28 ± 0.30
-1.95 ± 0.15
0.34 ± 0.15

−
0.64 ± 0.37
-0.78 ± 0.21
3.10 ± 0.15
4.08 ± 0.23

−
1.73 ± 0.48
0.60 ± 0.10
8.73 ± 0.89
17.54 ± 2.50

CT

ΔCT

-ΔΔCT

Fold change

17.62 ± 0.31
19.22 ± 0.16
27.93 ± 0.25
17.83 ± 0.23
21.60 ± 0.19

−
1.60 ± 0.37
10.31 ± 0.18
0.21 ± 0.51
3.98 ± 0.14

−
0.36 ± 0.08
1.19 ± 0.20
0.93 ± 0.25
0.44 ± 0.11

−
1.29 ± 0.08
2.35 ± 0.31
1.99 ± 0.31
1.37 ± 0.10

17.38 ± 0.29

−

−

1
0

7

FGF2 (3-21)
Day of
the
Gene
culture
Gapdh
Ank
Enpp1
Tnap
Phex
Gapdh
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−

Ank
Enpp1
Tnap
Phex

18.82 ± 0.69
27.18 ± 0.32
16.96 ± 0.40
21.25 ± 0.64

1.44 ± 0.45
9.80 ± 0.61
-0.42 ± 0.14
3.87 ± 0.45

0.51 ± 0.21
1.71 ± 0.45
1.57 ± 0.13
0.56 ± 0.37

1.47 ± 0.22
3.72 ± 0.94
3.01 ± 0.27
1.63 ± 0.41

14

Gapdh
Ank
Enpp1
Tnap
Phex

17.34 ± 0.06
17.15 ± 0.21
28.15 ± 0.27
17.05 ± 0.34
18.72 ± 0.14

−
-0.19 ± 0.21
10.80 ± 0.29
-0.29 ± 0.28
1.38 ± 0.17

−
2.15 ± 0.49
0.70 ± 0.18
1.44 ± 0.41
3.04 ± 0.19

−
5.35 ± 1.98
1.66 ± 0.21
3.02 ± 0.70
8.46 ± 1.06

21

Gapdh
Ank
Enpp1
Tnap
Phex

18.02 ± 0.07
16.25 ± 0.12
27.63 ± 0.34
16.90 ± 0.04
20.15 ± 0.25

−
-1.77 ± 0.19
9.62 ± 0.32
-1.12 ± 0.10
2.13 ± 0.32

−
3.72 ± 0.22
1.89 ± 0.19
2.26 ± 0.17
2.29 ± 0.25

−
13.66 ± 1.89
3.80 ± 0.49
4.91 ± 0.62
5.12 ± 0.90

CT

ΔCT

-ΔΔCT

Fold change

17.69 ± 0.22
19.65 ± 0.18
29.20 ± 0.34
18.84 ± 0.06
22.12 ± 0.14

−
1.96 ± 0.31
11.50 ± 0.16
1.15 ± 0.26
4.43 ± 0.11

−
0
0
0
0

−
1
1
1
1

10

Gapdh
Ank
Enpp1
Tnap
Phex

16.81 ± 0.03
18.69 ± 0.16
27.07 ± 0.09
17.17 ± 0.48
20.09 ± 0.21

−
1.88 ± 0.15
10.25 ± 0.08
0.36 ± 0.45
3.27 ± 0.21

−
0.08 ± 0.18
1.25 ± 0.09
0.79 ± 0.26
1.15 ± 0.11

−
1.08 ± 0.14
2.39 ± 0.16
1.82 ± 0.35
2.24 ± 0.16

14

Gapdh
Ank
Enpp1
Tnap
Phex

16.82 ± 0.06
17.40 ± 0.20
27.58 ± 0.11
16.91 ± 0.27
17.89 ± 0.27

−
0.57 ± 0.23
10.75 ± 0.06
0.08 ± 0.32
1.07 ± 0.25

−
1.38 ± 0.17
0.75 ± 0.17
1.07 ± 0.23
3.36 ± 0.30

−
2.66 ± 0.30
1.72 ± 0.21
2.18 ± 0.34
10.91 ± 1.98

21

Gapdh
Ank
Enpp1
Tnap
Phex

17.60 ± 0.16
16.36 ± 0.10
27.20 ± 0.21
16.80 ± 0.05
19.66 ± 0.55

−
-1.24 ± 0.11
9.60 ± 0.26
-0.79 ± 0.12
2.06 ± 0.42

−
3.20 ± 0.40
1.91 ± 0.16
1.94 ± 0.38
2.37 ± 0.34

−
10.29 ± 2.79
3.82 ± 0.43
4.28 ± 1.21
5.63 ± 1.44

7

FGF2 (7-21)
Day of
Gene
the
culture
Gapdh
Ank
Enpp1
Tnap
Phex
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CT

ΔCT

-ΔΔCT

Fold change

7

Gapdh
Ank
Enpp1
Tnap
Phex

17.62 ± 0.31
19.22 ± 0.16
27.93 ± 0.25
17.83 ± 0.23
21.60 ± 0.19

−
1.60 ± 0.37
10.31 ± 0.18
0.21 ± 0.51
3.98 ± 0.14

−
0.36 ± 0.08
1.19 ± 0.20
0.93 ± 0.25
0.44 ± 0.11

−
1.29 ± 0.08
2.35 ± 0.31
1.99 ± 0.31
1.37 ± 0.10

10

Gapdh
Ank
Enpp1
Tnap
Phex

16.94 ± 0.15
18.87 ± 0.34
27.71 ± 0.51
16.53 ± 0.28
19.82 ± 0.21

−
1.93 ± 0.27
10.76 ± 0.38
-0.42 ± 0.40
2.88 ± 0.21

−
0.03 ± 0.34
0.75 ± 0.23
1.56 ± 0.20
1.55 ± 0.25

−
1.10 ± 0.25
1.74 ± 0.29
3.05 ± 0.46
3.05 ± 0.48

14

Gapdh
Ank
Enpp1
Tnap
Phex

18.11 ± 0.14
19.71 ± 0.19
30.12 ± 0.44
16.18 ± 0.32
18.51 ± 0.16

−
1.60 ± 0.26
12.02 ± 0.52
-1.93 ± 0.22
0.41 ± 0.11

−
0.36 ± 0.56
-0.51 ± 0.45
3.08 ± 0.39
4.02 ± 0.13

−
1.63 ± 0.67
0.82 ± 0.27
9.31 ± 2.22
16.42 ± 1.44

21

FGF2 (3-7)
Day of
the
culture

Gene

Gapdh
Ank
Enpp1
Tnap
Phex

17.99 ± 0.32
19.58 ± 0.16
31.20 ± 1.41
16.19 ± 0.11
18.22 ± 0.28

−
1.60 ± 0.46
13.21 ± 1.12
-1.80 ± 0.21
0.23 ± 0.09

−
0.36 ± 0.17
-1.71 ± 0.97
2.94 ± 0.10
4.20 ± 0.10

−
1.31 ± 0.16
0.49 ± 0.19
7.75 ± 0.53
18.44 ± 1.20

ΔCT = CTgene - CTGapdh.
-ΔΔCT = -(ΔCTsample – ΔCTcontrol).
Positive –ΔΔCT value = increased gene expression relative to control.
Negative –ΔΔCT value = decreased gene expression relative to control.
All fold changes are relative to VH at day 7.
Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point.
N.D. = not detected.
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Table 53. Effects of withdrawal of FGF2 on expression of Ank, Enpp1, Tnap and Phex in
primary dental pulp cultures.

CT

ΔCT

-ΔΔCT

Fold change

14

Gapdh
Ank
Enpp1
Tnap
Phex

17.75 ± 0.11
19.56 ± 0.14
28.71 ± 0.37
16.35 ± 0.25
18.46 ± 0.29

−
1.81 ± 0.13
10.96 ± 0.45
-1.40 ± 0.23
0.71 ± 0.26

−
0
0
0
0

−
1
1
1
1

21

Control
Day of
the
culture

Gene

Gapdh
Ank
Enpp1
Tnap
Phex

17.94 ± 0.09
19.25 ± 0.12
30.22 ± 0.28
15.99 ± 0.23
18.28 ± 0.12

−
1.31 ± 0.12
12.28 ± 0.30
-1.95 ± 0.15
0.34 ± 0.15

−
0.50 ± 0.20
-1.32 ± 0.15
0.55 ± 0.09
0.37 ± 0.17

−
1.46 ± 0.21
0.41 ± 0.04
1.48 ± 0.09
1.32 ± 0.14

CT

ΔCT

-ΔΔCT

Fold change

17.34 ± 0.06
17.15 ± 0.21
28.15 ± 0.27
17.05 ± 0.34
18.72 ± 0.14

−
-0.19 ± 0.21
10.80 ± 0.29
-0.29 ± 0.28
1.38 ± 0.17

−
2.00 ± 0.32
0.16 ± 0.49
-1.11 ± 0.25
-0.67 ± 0.30

−
4.34 ± 1.05
1.29 ± 0.33
0.48 ± 0.08
0.67 ± 0.12

18.02 ± 0.07
16.25 ± 0.12
27.63 ± 0.34
16.90 ± 0.04
20.15 ± 0.25

−
-1.77 ± 0.19
9.62 ± 0.32
-1.12 ± 0.10
2.13 ± 0.32

−
3.58 ± 0.14
1.35 ± 0.18
-0.29 ± 0.21
-1.42 ± 0.51

−
12.12 ± 1.19
2.60 ± 0.30
0.84 ± 0.11
0.43 ± 0.11

CT

ΔCT

-ΔΔCT

Fold change

17.34 ± 0.06
17.15 ± 0.21
28.15 ± 0.27
17.05 ± 0.34
18.72 ± 0.14

−
-0.19 ± 0.21
10.80 ± 0.29
-0.29 ± 0.28
1.38 ± 0.17

−
2.00 ± 0.32
0.16 ± 0.49
-1.11 ± 0.25
-0.67 ± 0.30

−
4.34 ± 1.05
1.29 ± 0.33
0.48 ± 0.08
0.67 ± 0.12

21

14

FGF2 (3-21)
Day of
the
Gene
culture
Gapdh
Ank
Enpp1
Tnap
Phex
Gapdh
Ank
Enpp1
Tnap
Phex

14

FGF2 (3-14)
Day of
the
Gene
culture
Gapdh
Ank
Enpp1
Tnap
Phex
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21

Gapdh
Ank
Enpp1
Tnap
Phex

21

14

FGF2 (7-21)
Day of
the
Gene
culture
Gapdh
Ank
Enpp1
Tnap
Phex
Gapdh
Ank
Enpp1
Tnap
Phex

21

14

FGF2 (7-14)
Day of
the
Gene
culture
Gapdh
Ank
Enpp1
Tnap
Phex
Gapdh
Ank
Enpp1
Tnap
Phex

18.63 ± 0.17
18.30 ± 0.15
31.11 ± 0.13
16.61 ± 0.12
19.60 ± 0.44

−
-0.33 ± 0.25
12.48 ± 0.18
-2.02 ± 0.06
0.97 ± 0.30

−
2.14 ± 0.34
-1.52 ± 0.32
0.62 ± 0.26
-0.26 ± 0.47

−
4.82 ± 1.21
0.37 ± 0.07
1.62 ± 0.30
0.97 ± 0.24

CT

ΔCT

-ΔΔCT

Fold change

−
1.24 ± 0.14
0.21 ± 0.49
-1.48 ± 0.09
-0.35 ± 0.23

−
2.40 ± 0.25
1.37 ± 0.44
0.36 ± 0.02
0.81 ± 0.13

16.82 ± 0.06
17.40 ± 0.20
27.58 ± 0.11
16.91 ± 0.27
17.89 ± 0.27

−
0.57 ± 0.23
10.75 ± 0.06
0.08 ± 0.32
1.07 ± 0.25

17.60 ± 0.16
16.36 ± 0.10
27.20 ± 0.21
16.80 ± 0.05
19.66 ± 0.55

−
-1.24 ± 0.11
9.60 ± 0.26
-0.79 ± 0.12
2.06 ± 0.42

−
3.05 ± 0.23
1.36 ± 0.20
-0.61 ± 0.33
-1.35 ± 0.67

−
8.61 ± 1.30
2.64 ± 0.35
0.71 ± 0.17
0.55 ± 0.26

CT

ΔCT

-ΔΔCT

Fold change

16.82 ± 0.06
17.40 ± 0.20
27.58 ± 0.11
16.91 ± 0.27
17.89 ± 0.27

−
0.57 ± 0.23
10.75 ± 0.06
0.08 ± 0.32
1.07 ± 0.25

−
1.24 ± 0.14
0.21 ± 0.49
-1.48 ± 0.09
-0.35 ± 0.23

−
2.40 ± 0.25
1.37 ± 0.44
0.36 ± 0.02
0.81 ± 0.13

18.26 ± 0.16
18.62 ± 0.07
30.53 ± 0.68
16.38 ± 0.03
19.55 ± 0.05

−
0.36 ± 0.09
12.17 ± 0.46
1.88 ± 0.13
1.29 ± 0.21

−
1.45 ± 0.22
-1.21 ± 0.07
0.48 ± 0.36
-0.58 ± 0.07

−
2.84 ± 0.44
0.43 ± 0.02
1.52 ± 0.37
0.67 ± 0.04

ΔCT = CTgene - CTGapdh.
-ΔΔCT = -(ΔCTsample – ΔCTcontrol).
Positive –ΔΔCT value = increased gene expression relative to control.
Negative –ΔΔCT value = decreased gene expression relative to control.
All fold changes are relative to VH at day 14.
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Results represent mean ± SEM of at least three independent experiments; *p ≤ 0.05 relative to
control at each time point.
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CHAPTER IX

GENERAL DISCUSSION.

Previous results in the literature have demonstrated that FGF2 exerted both positive and
negative effects on dentinogenic differentiation of pulp cells, mineralization and expression of
markers of mineralization and dentinogenesis. However, the cellular and molecular mechanisms
underlying these opposite effects of FGF2 on odontoblast differentiation have not been
elucidated. Using primary pulp cultures from various GFP reporter transgenic mice, which
display stage-specific activation of transgenes during odontoblast differentiation in vivo and in
vitro, we have gained further insights into stage-specific effects of FGF2 on mineralization and
dentinogenesis of dental pulp cells.

We showed that continuous exposure of pulp cells to FGF2 between days 3-21 resulted in
marked decreases in the extent of mineralization, expression of markers of mineralization and
dentinogenesis, and the expression of various transgenes and percentage of fully differentiated
odontoblasts identified by the expression of Dspp and DSPP-Cerulean transgene at days 10-21.
However, at day 7 FGF2-treated cultures showed increases in levels of expression of markers of
mineralization and dentinogenesis (Dmp1 and Dspp) and the expression of DMP1-GFP
transgene. These observations suggested that the effects of FGF2 on dentinogenesis are stagespecific in that FGF2 may stimulate/accelerate the differentiated of progenitors present during
the first 7 days in cultures, while inhibit the differentiation of cells at more advanced stages of
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differentiation, which appear in cultures between days 7-21 after addition of the mineralizationinducing medium.

These possibilities were examined by additional sets of experiments, in which the effects of
limited and early exposure vs. limited and late exposure of dental pulp to FGF2 were examined
and compared.

Limited and early exposure of pulp cells to FGF2 during only proliferation phase of in
vitro growth (between days 3-7) did not cause decreases in mineralization and expression of
markers of mineralization and various transgenes. Analysis at day 7 showed that FGF2 had no
significant effects on the percentage of cells at early stages of odontoblast differentiation (2.3GFP+ and 2.3-GFP– populations) but caused marked increases in the percentage of cells
expressing markers of more advanced stages of differentiation (Dmp1, Dspp, DMP1-GFP,
DSPP-Cerulean). These observations indicated that FGF2 accelerated differentiation of
progenitors into functional odontoblasts. Analysis at later time point showed increases in the
levels of Dmp1 and Dspp, intensity of DMP1-GFP and DSPP-Cerulean transgenes and the
percentage of DSPP-Cerulean+ odontoblasts in FGF2-treated cultures as compared to control.
Increased number of fully differentiated odontoblasts in FGF2-treated cultures suggested that
FGF2 stimulated odontoblast differentiation.

Limited and later exposure of pulp cells to FGF2 during the differentiation/mineralization
phase of in vitro growth (between days 7-21) caused changes that were similar to the changes
reported with continuous exposure of pulp cells to FGF2. FGF2 transiently increased the
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expression of Dmp1, Dspp, DMP1-GFP, DSPP-Cerulean and the percentage of DSPP-Cerulean+
odontoblasts at day 10 followed by significant decreases in the extent of mineralization, the
expression of markers of mineralization and the expression of various transgenes. These
observations

indicated

that

exposure

of

pulp

cultures

to

FGF2

during

the

differentiation/mineralization phase of in vitro growth also stimulated/accelerated differentiation
of cells at early stages of differentiation, which are present between days 7-10 into functional
odontoblasts. Further exposure to FGF2 inhibits their further differentiation into fully
differentiation odontoblasts.

We also showed that despite the decreases relative to control, levels of Dmp1 and Dspp in
FGF2-treated cultures remained relatively constant over time in culture. These observations
suggested that FGF2 initially stimulated formation of functional odontoblasts and additional
exposure to FGF2 maintained these cells at this stage of differentiation and prevented their
further differentiation into mature odontoblasts.

This possibility was tested by examining the effects of withdrawal of FGF2 on
differentiation of these cells. Our results showed that withdrawal of FGF2 for 7 days resulted in
complete recovery of mineralization and expression of Dmp1, Dspp, DMP1-GFP and DSPPCerulean, indicating that FGF2 prevented differentiation of functional odontoblasts into mature
odontoblasts.

We have also examined the signaling pathways that are involved in mediating the stagespecific stimulatory and inhibitory effects of FGF2 on pulp cells. Our results showed that the
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stimulatory effects of FGF2 on Dmp1 and Dspp were mediated through FGFR, MEK/Erk1/2
signaling pathways as well as BMP/BMPR signaling. Our studies also showed that the inhibitory
effects of FGF2 were mediated by re-activation of FGFR and MEK/Erk1/2 and inhibition of the
BMP/BMPR signaling pathway with negative and positive roles in cells at advanced stages of
odontoblast differentiation, respectively.

To gain further insight into the stage-specific effects of FGF2 and to examine which
specific subpopulations were affected by FGF2, we examined its effects on FACS-sorted 2.3GFP– (undifferentiated) and 2.3-GFP+ (polarizing odontoblasts) populations. Analysis of 2.3GFP– population showed that FGF2 caused increases in the levels of expression of Dmp1 and
Dspp at all time points except at day 14 in cultures exposed to FGF2 continuously, confirming
that FGF2 stimulated differentiation of progenitors and cells at early stages of differentiation.
Analysis of 2.3-GFP+ population showed that in this more committed population, various FGF2
treatments initially increased levels of expression of Dmp1 and Dspp. Further exposure to FGF2
decreased levels of expression of Dmp1 and Dspp.

We also showed that stage-specific stimulatory and inhibitory effects of FGF2 were
associated with changes in the expression of downstream targets of the BMP and Wnt signaling
pathways and genes regulating local phosphate homeostasis.

In addition, we demonstrated similarities and differences between the effects of FGF2 on
cells of the odontoblast vs. osteoblast lineages by using primary BMSC cultures. We showed that
unlike in pulp cells, in BMSC cultures FGF2 completely inhibited the extent of mineralization
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and the expression of 3.6-GFP and 2.3-GFP transgenes in BMSC cultures, indicating that
inhibition of osteogenesis by FGF2 was mediated by blocking the onset of preosteoblast
differentiation.

Furthermore, the rapid and almost complete recovery of mineralization in pulp cultures
after withdrawal of FGF2 in our study was different from that in BMSC cultures. Upon
withdrawal of FGF2 full osteoblast differentiation and mineralization did not appear in vitro and
was detected only after subcutaneous implantation of FGF2-treated cells in SCID/Beige mice in
vivo (248).

It is important to note that, unlike in osteogenesis, in which Dmp1 is expressed by
osteocytes, terminally differentiated cells, in dentinogenesis Dmp1 is expressed by functional
odontoblasts, a cell population that is formed transiently and gives rise to fully differentiated
odontoblasts. Several lines of evidence suggest that DMP1 regulates Dspp expression during
dentinogenesis. In developing teeth the expression of Dmp1 is detected earlier than that of Dspp
(425). Both Dspp and Dmp1 knockout mice display dentin hypomineralization with reduced
dentin thickness (68, 85). Dspp expression is reduced in the dentin of Dmp1 knockout mice
compared with that of wild-type mice (85). However, Dspp knockout mice did not show
alteration in the expression of Dmp1 and transgenic expression of Dspp rescued the tooth and
alveolar bone defects of the Dmp1 knockout mice (99). In vitro analyses showed that Dmp1
significantly upregulated the Dspp promoter activities in a mesenchymal cell line (99).
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Our study showed that early exposure of pulp cells to FGF2 initially led to significant
increases in the expression of Dmp1 and the number of DMP1-GFP+ cells and subsequently to
increases in the expression of Dspp and the number of DSPP-Cerulean+ odontoblasts. However,
unlike similar studies using osteogenic cells, early exposure of pulp cells to FGF2 did not result
in increased mineralization as compared to control. These observations suggest that in dental
pulp, FGF2 inhibits osteogenesis and promotes dentinogenic differentiation. This may be due to
differences in the response of odontoprogenitors and osteoprogenitors to FGF2 and/or
differences in osteoprogenitors residing in dental pulp vs. BMSC.

These observations provide strong evidence that increases in the expression of Dmp1 and
DMP1-GFP+ cells in dental pulp cells in our study reflect the formation of functional
odontoblasts that will differentiate into fully differentiated odontoblasts.

Taken together, these results demonstrated that in the dental pulp, FGF2 stimulated
differentiation of progenitors and cells at early stages of maturity into functional odontoblasts,
identified by high levels of Dmp1 and DMP1-GFP and low but detectable levels of Dspp and
DSPP-Cerulean. Further exposure of functional odontoblasts to FGF2 prevented their maturation
into fully differentiated odontoblasts identified by high levels of Dspp and DSPP-Cerulean.

Our results indicate that FGF2 is a useful growth factor for dentin regeneration. The stagespecific effects of FGF2 on pulp cells in our studies provide an explanation for the conflicting
positive and negative effects of FGF2 in previously reported results. Our results also suggest that
reparative dentinogenesis can be best formed by short and limited exposure of pulp cells to FGF2
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and that prolonged exposure of pulp cells to FGF2 may lead to the formation of unmineralized
dentin secreted by functional odontoblasts.
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